

=> d his full

(FILE 'HOME' ENTERED AT 09:54:00 ON 10 MAY 2006)

L numbers L1-L25 are for search of a different application. They are not applicable here.

FILE 'STNGUIDE' ENTERED AT 10:38:20 ON 10 MAY 2006

FILE 'CAPLUS' ENTERED AT 10:59:46 ON 10 MAY 2006

E US20 -432359/APPS  
L26 1 SEA AB: ON PLU=ON US2002-432359P/1 N  
D SCA  
SEL RN

FILE 'REGISTRY' ENTERED AT 11:00:46 ON 10 MAY 2006

L27 5 SEA AB: ON PLU=ON (110-89-4/BI OR 7043-39-6/BI OR 288-32-4/B  
I OR 70925-38-8/BI OR 98-92-0/BI)  
D SCA

FILE 'CAPLUS' ENTERED AT 11:01:58 ON 10 MAY 2006

D L26 ALL

FILE 'STNGUIDE' ENTERED AT 11:03:13 ON 10 MAY 2006

FILE 'REGISTRY' ENTERED AT 11:03:58 ON 10 MAY 2006

L28 1623130 SEA AB: ON PLU=ON NCNC2/ESS  
L\*\*\* DEL 0 S NCCN /ESS  
L29 989235 SEA AB: ON PLU=ON NC2NC2/ESS  
L30 73029 SEA AB: ON PLU=ON L28 AND L29  
L31 40839 SEA AB: ON PLU=ON L30 AND NRRS=2  
L32 19146 SEA AB: ON PLU=ON L28 (S) L29  
E "IMIDAZO(1,2-A)PYRAZIN-3-AMINE, N-(1,1-DIMETHYLETHYL)-2-(5-((  
L33 1 SEA AB: ON PLU=ON "IMIDAZO(1,2-A)PYRAZIN-3-AMINE, N-(1,1-DIME  
THYLETHYL)-2-(5-((3-(METHYLAMINO)PHENYL)ETHYNYL)-2-THIENYL)-"/C  
N  
D SCA  
D RSD  
L34 1794 SEA AB: ON PLU=ON 333.871.5/RID

FILE 'CAPLUS' ENTERED AT 11:09:09 ON 10 MAY 2006

L35 221 SEA AB: ON PLU=ON L34  
L36 520762 SEA AB: ON PLU=ON ?NEURO?/BI  
L37 13 SEA AB: ON PLU=ON L35 AND L36  
L38 39352 SEA AB: ON PLU=ON ALZHEIMER?/BI  
L39 28450 SEA AB: ON PLU=ON SCHIZO?/BI  
L40 0 SEA AB: ON PLU=ON "MENTAL AND BEHAVIORAL DISORDER"/CT  
L41 15699 SEA AB: ON PLU=ON "MENTAL AND BEHAVIORAL DISORDERS"/CT  
L42 12834 SEA AB: ON PLU=ON DEMENT?/BI  
L43 7220 SEA AB: ON PLU=ON NEUROGEN?/OBI OF NEURO GEN?/OBI  
L44 10303 SEA AB: ON PLU=ON ?PSYCHIAT?/BI  
L\*\*\* DEL 2 S L35 AND (L36 AND L38-L44)  
L45 22 SEA AB: ON PLU=ON L35 AND (L36 OR L38 OR L39 OR L40 OR L41  
OR L42 OR L43 OR L44))  
L46 184 SEA AB: ON PLU=ON KELLEHER J?/AU  
L47 0 SEA AB: ON PLU=ON JOHE K?/AU  
L48 16 SEA AB: ON PLU=ON JOHE K?/AU  
L49 0 SEA AB: ON PLU=ON L46 AND L48  
L50 1323 SEA AB: ON PLU=ON KELLEHER?/AU  
L51 1 SEA AB: ON PLU=ON L50 AND L48

```

          D SCA
L5          0 SEA ABB=ON  PLU  N  (L50 OR L48) AND L35
L5          20 SEA ABB=ON  PLU  N  (L50 OR L48) AND ((L38 OR L39 OR L40 OR
          L41 OR L42 OR L43 OR L44))
L5          20 SEA ABB=ON  PLU  N  L53 OR L51

```

FILE 'CAPLUS' ENTERED AT 1 20:34 ON 10 MAY 2006

```

          D QUE L51
          D QUE L53
L5          20 SEA ABB=ON  PLU  N  L51 OR L53
          D IBIB ABS HITI  L55 1-20

```

FILE 'REGISTRY' ENTERED AT 1:22:41 ON 10 MAY 2006

```

FILE 'CAPLUS' ENTERED AT 1 22:44 ON 10 MAY 2006
          D STAT QUE L37
          D STAT QUE L45
L5          22 SEA ABB=ON  PLU  N  L37 OR L45
L5          22 SEA ABB=ON  PLU  N  L56 NOT L55
          D IBIB ABS HITI  HITSTR L57 1-22

```

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: MAY 2006 HIGHEST RN 883631 57-0  
 DICTIONARY FILE UPDATES: MAY 2006 HIGHEST RN 883631 57-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```

*****
*
* The CA roles and document type information have been moved from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL is now *
* available and contains the CA role and document type information. *
*
*****

```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/ide/regprops.html>

FILE CAPLUS

Copyright of the articles which records in this database refer is

held by the publisher as listed in the PUBLISHER (field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information without the prior written consent of CAS, is  
strictly prohibited

FILE COVERS 1907 - May 2006 VOL 144 ISS 20

FILE LAST UPDATED: May 2006 (20060509/ED)

Effective October 1, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/fopolicy.html>

FILE STNGUIDE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May , 2006 (20060505/UP).

=>





=> file caplus  
FILE 'CAPLUS' ENTERED AT 11:20:34 ON 10 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996) unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 May 2006 VOL 144 ISS 20  
FILE LAST UPDATED: 9 May 2006 (20060509/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que L51

L48	16	SEA FILE=CAPLUS	ABB=ON	PLU=ON	JOHE K?/AU
L50	1323	SEA FILE=CAPLUS	ABB=ON	PLU=ON	KELLEHER?/AU
L51	1	SEA FILE=CAPLUS	ABB=ON	PLU=ON	L50 AND L48

=> d que L53

L38	39352	SEA FILE=CAPLUS	ABB=ON	PLU=ON	ALZHEIMER?/BI
L39	28450	SEA FILE=CAPLUS	ABB=ON	PLU=ON	SCHIZO?/BI
L40	0	SEA FILE=CAPLUS	ABB=ON	PLU=ON	"MENTAL AND BEHAVIORAL DISORDER"/CT
L41	15699	SEA FILE=CAPLUS	ABB=ON	PLU=ON	"MENTAL AND BEHAVIORAL DISORDERS"/CT
L42	12834	SEA FILE=CAPLUS	ABB=ON	PLU=ON	DEMENT?/BI
L43	7220	SEA FILE=CAPLUS	ABB=ON	PLU=ON	NEUROGEN?/OBI OR NEUROGEN?/OBI
L44	10303	SEA FILE=CAPLUS	ABB=ON	PLU=ON	?PSYCHIAT?/BI
L48	16	SEA FILE=CAPLUS	ABB=ON	PLU=ON	JOHE K?/AU
L50	1323	SEA FILE=CAPLUS	ABB=ON	PLU=ON	KELLEHER?/AU
L53	20	SEA FILE=CAPLUS	ABB=ON	PLU=ON	(L50 OR L48) AND ((L38 OR L39 OR L40 OR L41 OR L42 OR L43 OR L44))

=> s L51 or L53

L55 20 L51 OR L53

=> d ibib abs hitind L55 1-20

L55 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:242452 CAPLUS  
DOCUMENT NUMBER: 144:246387  
TITLE: Discovery of neurogenic, Alzheimer's disease therapeutics  
AUTHOR(S): Kelleher-Andersson, Judith

CORPORATE SOURCE: Dept. Neurobiology, Neuronascent, Inc., Clarksville,  
MD, 21029, USA  
SOURCE: Current Alzheimer Research (2006), 3(1), 55-62  
CODEN: CARUBY; ISSN: 1557-2050  
PUBLISHER: Bentham Science Publishers Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Many researchers have questioned whether new potential therapies aimed at reversing **Alzheimer's** disease (AD) are indeed scientifically feasible. A number of approved therapies already exist for **Alzheimer's** disease, yet these drugs only slow the disease progression for a period of time and treat the symptoms of this devastating disease. New therapies intended to reverse the disease would necessarily need to replace dead, dying, and dysfunctional neurons in affected regions of the brain. This complex drug discovery problem is further complicated by the knowledge that AD is mainly an aging disorder and that aging, though not considered a disease, causes biol. changes that may also need to be overcome. The requirement for new, functional neurons under neurodegenerative diseases, as seen in AD and stroke, suggests that an inhibitor of neuronal death, like Memantine, is insufficient to reverse the cognitive and phys. loss. New neurons, or neurogenesis, may be required for real improvement or reversal of the cognitive deficit. Adult neurogenesis, first described by Altman in the early 1960s, has more recently been observed as a response to injury or disease. Of interest was the finding that new neurons appear to migrate to disease/injury-affected areas in the brain not normally neurogenic in the adult. This pathol.-stimulation of neurogenesis does not appear sufficient to stave off the disease and subsequent behavioral decline. Therefore, the desire to amplify and improve upon the neurogenesis-response to neurodegenerative disease appears warranted, if not yet feasible. The key to doing so lies in identifying what signals are required to promote neurogenesis and neuron survival, either in injury and disease or under environmental stimuli. This could provide clues for how to pharmacol. induce neurogenesis under neurodegenerative conditions. Currently, progress in identifying therapeutics that appear to promote ameliorative neurogenesis for AD is lagging behind the pharmacol. induction of neurogenesis as a therapy for depression.

CC 1-0 (Pharmacology)  
Section cross reference(s): 14  
ST review **neurogenic Alzheimer** disease therapeutics drug  
discovery  
IT Nerve, disease  
Nervous system, disease  
(degeneration; discovery of **neurogenic and Alzheimer**  
's disease therapeutics)  
IT **Alzheimer's** disease  
Drug discovery  
**Neurogenesis**  
Signal transduction, biological  
Therapy  
(discovery of **neurogenic and Alzheimer's** disease  
therapeutics)

REFERENCE COUNT: 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:247717 CAPLUS

DOCUMENT NUMBER: 143:303220

TITLE: **Neurogenesis** as a potential therapeutic  
strategy for neurodegenerative disorders

AUTHOR(S): Kelleher-Andersson, J.  
CORPORATE SOURCE: Neuronascent, Inc., Clarksville, MD, USA  
SOURCE: Journal of Alzheimer's Disease (2004), 6(6, Suppl.), S19-S25  
CODEN: JADIF9; ISSN: 1387-2877  
PUBLISHER: IOS Press  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English  
AB A review. A review describes the potential of neurogenesis as a therapeutic strategy for neurodegenerative disorders. Great developments have been made in the field of adult neurogenesis, the goal of small mol. therapeutic that both increases the generation of nascent neurons and inhibits the region-specific neuronal loss, may still be years away. However, an agent that enhances all stages of neurogenesis, might not only halt the steep cognitive decline observed in **Alzheimer's** disease patients but might perhaps even reverse the disease outcome. Dual function, small mol. agents provide one promising source for such therapeutics.  
CC 14-0 (Mammalian Pathological Biochemistry)  
Section cross-reference(s): 1  
ST review **neurogenesis** neurodegenerative disorder **Alzheimer's** disease  
IT Nervous system, disease  
(degeneration; small mol. agents provide promising source for enhancing all stages of **neurogenesis** that might not only halt steep cognitive decline observed in **Alzheimer's** disease patients but might even reverse disease outcome)  
IT **Alzheimer's** disease  
Brain  
Drug targets  
Human  
**Neurogenesis**  
(small mol. agents provide promising source for enhancing all stages of **neurogenesis** that might not only halt steep cognitive decline observed in **Alzheimer's** disease patients but might even reverse disease outcome)  
REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT  
L55 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2005:60631 CAPLUS  
DOCUMENT NUMBER: 142:256470  
TITLE: Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro  
AUTHOR(S): Kelleher, Colleen; Kurth, Isabel; Lingner, Joachim  
CORPORATE SOURCE: Swiss Institute for Experimental Cancer Research, Epalinges, Switz.  
SOURCE: Molecular and Cellular Biology (2005), 25(2), 808-818  
CODEN: MCEBD4; ISSN: 0270-7306  
PUBLISHER: American Society for Microbiology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The telomeric single-strand DNA binding protein protection of telomeres 1 (POT1) protects telomeres from rapid degradation in **Schizosaccharomyces pombe** and has been implicated in pos. and neg. telomere length regulation in humans. Human POT1 appears to interact with telomeres both through direct binding to the 3' overhanging G-strand DNA and through interaction with the TRF1 duplex telomere DNA binding complex. The influence of POT1 on telomerase activity has not been studied at the

mol. level. We show here that POT1 neg. effects telomerase activity in vitro. We find that the DNA binding activity of POT1 is required for telomerase inhibition. Furthermore, POT1 is incapable of inhibiting telomeric repeat addition to substrate primers that are defective for POT1 binding, suggesting that in vivo, POT1 likely affects substrate access to telomerase.

CC 6-3 (General Biochemistry)

Section cross-reference(s): 7

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1007457 CAPLUS

DOCUMENT NUMBER: 142:273810

TITLE: Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study

AUTHOR(S): Bearn, Jennifer; Evans, Andrew; **Kelleher, Michael**; Turner, Kirsten; Lees, Andrew

CORPORATE SOURCE: National Addiction Centre, Institute of Psychiatry, London, SE58AF, UK

SOURCE: Drug and Alcohol Dependence (2004), 76(3), 305-310

CODEN: DADEDV; ISSN: 0376-8716

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Patients with Parkinson's disease may use Dopamine Replacement Therapy (DRT) in excess of therapeutic need. We investigate whether a group of 10 patients with Parkinson's disease, provisionally diagnosed with "Hedonistic Homeostatic Dysregulation" because of their excessive use of DRT, met established operational **psychiatric** criteria for substance dependence, compared with 10 patients with Parkinson's disease compliant with prescribed DRT. Using a semi-structured questionnaire designed to distinguish between adaptive therapeutic dependence on DRT and a maladaptive pathol. pattern of DRT use, in conjunction with the SCID-1, we found that seven of the patients deemed by their treating physicians to be misusing DRT fulfilled operational criteria for maladaptive dependence in contrast to none of the compliant group. The majority experienced dysphoric "withdrawal" symptoms in the "off" state and increased their dose of DRT in an effort to control their mood. They also continued to use high doses of DRT despite disabling dyskinesias and social difficulties. This study provides preliminary evidence that some patients with Parkinson's disease may become maladaptively dependent on DRT. This finding has both clin. relevance for the treatment of PD and further implicates dopaminergic pathways in the genesis of substance dependence.

CC 1-11 (Pharmacology)

Section cross-reference(s): 2

IT **Mental and behavioral disorders**

(depression; Parkinson's disease patient with HHD due to DRT showed long duration of disease, high dyskinesia, anxiety, dysphoric withdrawal symptoms resulting in more use of DRT indicating maladaptive therapy dependence than those compliant to DRT)

IT **Mental and behavioral disorders**

(psychosis; Parkinson's disease patient with HHD due to DRT showed long duration of disease, high dyskinesia, anxiety, dysphoric withdrawal symptoms resulting in more use of DRT indicating maladaptive therapy dependence than those compliant to DRT)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:515647 CAPLU;  
 DOCUMENT NUMBER: 141:47365  
 TITLE: Method for discovering neurogenic agents  
 INVENTOR(S): Kelleher-Andersson, Judith; Johe, Karl  
 K.  
 PATENT ASSIGNEE(S): Johe, Karl, K., USA  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004053071	A2	20040624	WO 2003-US38670	20031205
WO 2004053071	A3	20060330		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, AY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004185429	A1	20040923	US 2003-728652	20031205
EP 1576124	A2	20050921	EP 2003-790356	20031205
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, AE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPL. INFO.:			US 2002-432359P	P 20021209
			US 2003-493674P	P 20030808
			WO 2003-US38670	W 20031205

OTHER SOURCE(S): MARPAT 141:47365

AB A method for discovering neurogenic drugs is disclosed. The method allows for systematic screening of test agents such as libraries of compounds. The method consists of exposing test agents to cultures of differentiating neural progenitor cells and measuring their effects on increasing the overall cell number and/or the number of neurons.

IC ICM C12N

CC 1-11 (Pharmacology)

ST neurogenic agent screening neurodegenerative  
 neuropsychiatric disease stem cell

IT Cognitive disorders

(aged-related; method for discovering neurogenic agents)

IT Nervous system, disease

(amyotrophic lateral sclerosis; method for discovering  
 neurogenic agents)

IT Nervous system, disease

(degeneration; method for discovering neurogenic agents)

IT Mental and behavioral disorders

(dementia; method for discovering neurogenic  
 agents)

IT Central nervous system, disease

(demyelination; method for discovering neurogenic agents)

IT Mental and behavioral disorders

(depression; method for discovering neurogenic agents)

IT Sleep

(deprivation; method for discovering **neurogenic** agents)

IT Brain  
(hippocampus; method for discovering **neurogenic** agents)

IT Spinal column, disease  
(injury; method for discovering **neurogenic** agents)

IT Aging, animal  
  **Alzheimer's disease**  
  Amnesia  
  Analysis  
  Animal tissue culture  
  Anxiety  
  Brain  
  Cell differentiation  
  Central nervous system  
  Chemical library  
  Cognition enhancers  
  Cognitive disorders  
  Drug screening  
  Human  
  **Mental and behavioral disorders**  
  Multiple sclerosis  
  Nervous system agents  
  **Neurogenesis**  
  Neuroglia  
  Neuron  
  Parkinson's disease  
  **Schizophrenia**  
    (method for discovering **neurogenic** agents)

IT Stem cell  
(neural; method for discovering **neurogenic** agents)

IT Pain  
(neuropathic; method for discovering **neurogenic** agents)

IT Stress, animal  
(post-traumatic syndrome; method for discovering **neurogenic** agents)

IT Culture media  
(serum-free, mitogen-free; method for discovering **neurogenic** agents)

IT Brain, disease  
(stroke; method for discovering **neurogenic** agents)

IT Brain  
(subventricular zone; method for discovering **neurogenic** agents)

IT Injury  
(trauma; method for discovering **neurogenic** agents)

IT 98-92-0, Nicotinamide 110-89-4D, Piperidine, aryloxy derivs. 288-32-4,  
Imidazole, biological studies 27043-39-6, Amiopyrimidine  
705925-38-8D, derivs.  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(method for discovering **neurogenic** agents)

L55 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:368361 CAPLUS

DOCUMENT NUMBER: 140:355106

TITLE: Loss of presenilin function causes impairments of  
memory and synaptic plasticity followed by  
age-dependent neurodegeneration

AUTHOR(S): Saura, Carlos A.; Choi, Se-young; Beglopoulos,  
Vassilios; Malkani, Seema; Zhang, Dawei; Rao, B. S.

Shankaranarayana; Chattarji, Sumantra; Kelleher, Raymond J., III; Kandel, Eric R.; Duff, Karen; Kirkwood, Alfredo; Shen, Jie

CORPORATE SOURCE: Center for Neurologic Diseases, Brigham and Women's Hospital, Program in Neuroscience, Harvard Medical School, Boston, MA, 02115, USA

SOURCE: Neuron (2004), 42(1), 23-36  
CODEN: NERNET; ISSN: 0896-6273

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Mutations in presenilins are the major cause of familial Alzheimer's disease, but the pathogenic mechanism by which presenilin mutations cause memory loss and neurodegeneration remains unclear. Here the authors demonstrate that conditional double knockout mice lacking both presenilins in the postnatal forebrain exhibit impairments in hippocampal memory and synaptic plasticity. These deficits are associated with specific reductions in NMDA receptor-mediated responses and synaptic levels of NMDA receptors and  $\alpha$ CaMKII. Furthermore, loss of presenilins causes reduced expression of CBP and CREB/CBP target genes, such as c-fos and BDNF. With increasing age, mutant mice develop striking neurodegeneration of the cerebral cortex and worsening impairments of memory and synaptic function. Neurodegeneration is accompanied by increased levels of the Cdk5 activator p25 and hyperphosphorylated tau. These results define essential roles and molecular targets of presenilins in synaptic plasticity, learning and memory, and neuronal survival in the adult cerebral cortex.

CC 14-10 (Mammalian Pathological Biochemistry)

ST presenilin memory synaptic plasticity impairment age dependent neurodegeneration Alzheimer

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (14-3-3; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease and CBP and CREB/CBP-dependent gene expression)

IT Presenilins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (1; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease)

IT Presenilins  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (2; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CBP (CREB-binding protein); loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease and CBP and CREB/CBP-dependent gene expression)

IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (CREB (cAMP-responsive element-binding); loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease and CBP and CREB/CBP-dependent gene expression)

- expression)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Cdk5 activator protein p35; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease and)
- IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(Egr-1; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age dependent neurodegeneration in relation to familial Alzheimer's disease and CBP and CREB/DBP-dependent gene expression)
- IT Glutamate receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(NMDA-binding; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease and)
- IT Neurotrophic factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(brain-derived; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease and CBP and CREB/DBP-dependent gene expression)
- IT Transcription factors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(c-fos; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age dependent neurodegeneration in relation to familial Alzheimer's disease and CBP and CREB/DBP-dependent gene expression)
- IT Brain, disease  
(degeneration, cerebral cortex and hippocampus, loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease)
- IT Alzheimer's disease  
(familial; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease)
- IT Brain  
(hippocampus; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease)
- IT Tau factor  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hyperphosphorylated; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease and)
- IT Phosphorylation, biological  
(hyperphosphorylation, tau; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial Alzheimer's disease and)
- IT Synaptic plasticity  
(impairment; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent



neurodegeneration in relation to familial **Alzheimer's** disease)

- IT Aging, animal  
Development, mammalian postnatal  
Memory disorders  
(loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial **Alzheimer's** disease)
- IT Transcription, genetic  
(loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial **Alzheimer's** disease and CBP and CREB/CBP-dependent gene expression)
- IT Gene, animal  
Neurofibromin  
mRNA  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial **Alzheimer's** disease and CBP and CREB/CBP-dependent gene expression)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(synapsin I; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial **Alzheimer's** disease and CBP and CREB/CBP-dependent gene expression)
- IT 475489-73-7, Calcium/calmodulin-dependent protein kinase II  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$ ; loss of presenilin function causes impairments of hippocampal memory and synaptic plasticity followed by age-dependent neurodegeneration in relation to familial **Alzheimer's** disease and)

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 7 OF 2) CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:934393 CAPLUS

DOCUMENT NUMBER: 139:391229

TITLE: Oxcarbazepine: clinical experience with hospitalized **psychiatric** patients

AUTHOR(S): Centorrino, Franca; Albert, Matthew J.; Berry, Judith M.; Kelleher, James P.; Fellman, Veronica; Line, Gyorgy; Koukopoulos, Alexia E.; Kidwell, Jennifer E.; Fogarty, Kate V.; Baldessarini, Ross J.

CORPORATE SOURCE: Consolidated Department of Psychiatry, Harvard Medical School, Boston, MA, USA

SOURCE: Bipolar Disorders (2003), 5(5), 370-374

CODEN: BDIIAU; ISSN: 1398-5647

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Oxcarbazepine (10-keto-carbamazepine) appears to be better tolerated and simpler to use than carbamazepine. It has antimanic effects but, as its potential clin. usefulness and tolerability in broad samples of **psychiatric** patients remain to be tested, we reviewed both the pharmacol. of oxcarbazepine and our early experience with this new agent among **psychiatric** inpatients. We reviewed medical records of all inpatients given oxcarbazepine in the first 15 mo of its use at McLean Hospital. Data analyzed included dosing, presenting illnesses, other

medications, clin. changes, and adverse effects. Oxcarbazepine was given to 56 inpatients (1.3% of admissions; 31 women, 25 men) presenting with depression (n = 23), mania (n = 19), or psychosis (n = 14). The discharge daily dose for the 43 patients (76%) taking oxcarbazepine was 831 mg/day, 34% higher in men than women, and fell by 9 mg/yr of age. Oxcarbazepine was the only putative mood-stabilizing agent given at discharge in 19 of 43 cases (44%). It was discontinued in 20% of patients for apparent inefficacy, and 4% for adverse effects. Changes in CGI and GAF scores were similarly high across illnesses, and unrelated to days of use of oxcarbazepine or its dose. Oxcarbazepine was well tolerated and simpler to use clin. than its precursor carbamazepine. This agent should be studied in controlled trials to test its efficacy in specific types of major **psychiatric** disorders, and particularly for long-term maintenance treatment in bipolar disorder.

CC 1-11 (Pharmacology)

IT **Mental and behavioral disorders**

(bipolar disorder; oxcarbazepine in **psychiatric** patients)

IT **Mental and behavioral disorders**

(depression; oxcarbazepine in **psychiatric** patients)

IT Human

Psychotropics

(oxcarbazepine in **psychiatric** patients)

IT **Mental and behavioral disorders**

(psychosis; oxcarbazepine in **psychiatric** patients)

IT 28721-07-5, Oxcarbazepine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(oxcarbazepine in **psychiatric** patients)

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:419712 CAPLUS

DOCUMENT NUMBER: 137:27724

TITLE: Advances in atypical antipsychotics for the treatment of **schizophrenia**. New formulations and new agents

AUTHOR(S): Kelleher, James P.; Centorrino, Franca; Albert, Matthew J.; Baldessarini, Ross J.

CORPORATE SOURCE: Department of Psychiatry, Harvard Medical School, Boston, MA, USA

SOURCE: CNS Drugs (2002), 16(4), 249-267

CODEN: CNDREF; ISSN: 1172-7047

PUBLISHER: Adis International Ltd.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Innovation in atypical antipsychotic agents continues with new preps. of available drugs as well as novel agents. In this article, we provide an update on these novel products by reviewing information from a computerized literature search, recent abstrs. and discussions with industry representatives. A generic formulation of clozapine is now available. It may be less well absorbed and/or less effective than Clozaril, although evidence is conflicting. A fatty acid amide derivative of clozapine is in early development. A liquid formulation of risperidone is currently available, which may be a useful treatment for psychotic agitation as well as a preferable alternative to tablets for some patients. A depot formulation is in development for the long-term management of psychosis. An orally disintegrating tablet formulation of olanzapine is a useful alternative to standard tablets. A short-acting injectable formulation of the drug is in development for psychotic

agitation. Sacrets and slow-release formulations of quetiapine are in development. Ziprasidone, a recently launched agent, is available in tablet form for **schizophrenia/schizoaffective** disorder, psychotic depression and mania. A short-acting injectable formulation is in development for psychotic agitation. Aripiprazole (tablets) and iloperidone (tablets and depot injection) are two antipsychotics in development for **schizophrenia/schizoaffective** disorder (available information regarding iloperidone is very limited). These new formulations and agents should broaden options for the treatment of psychosis.

CC 1-0 (Pharmacology)

ST review atypical antipsychotic **schizophrenia**

IT Antipsychotics

Human

**Schizophrenia**

(advances in atypical antipsychotics for treatment of **schizophrenia**)

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:411993 CAPLUS

DOCUMENT NUMBER: 138:65824

TITLE: Nitrones as neuroprotectants and antiaging drugs

AUTHOR(S): Floyd, Robert A.; Hensley, Kenneth; Forster, Michael J.; Kelleher-Anderson, Judith A.; Wood, Paul L.

CORPORATE SOURCE: Free Radical Biology and Aging Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 73104, USA

SOURCE: Annals of the New York Academy of Sciences (2002), 959(Increasing Health Life Span), 321-329  
CODEN: ANYAA9; ISSN: 0077-8923

PUBLISHER: New York Academy of Sciences

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Specific nitrones have been used for more than 30 yr in anal. chemical and biochem. to trap and stabilize free radicals for the purpose of their identification and characterization. PBN ( $\alpha$ -phenyl-tert-Bu nitrone), one of the more widely used nitrones for this purpose, has been shown to have potent pharmacol. activities in models of a number of aging-related diseases, most notably the neurodegenerative diseases of stroke and **Alzheimer's** disease. Studies in cell and animal models strongly suggest that PBN has potent antiaging activity. A novel nitrone, CPI-1429, has been shown to extend the life span of mice when administration was started in older animals. It has also shown efficacy in the prevention of memory dysfunction associated with normal aging in a mouse model. Mechanistic studies have shown that the neuroprotective activity of nitrones is not due to mass-action free radical-trapping activity, but due to cessation of enhanced signal transduction processes associated with neuro-inflammatory processes known to be enhanced in several neurodegenerative conditions. Enhanced neuroinflammatory processes produce higher levels of neurotoxins, which cause death or dysfunction of neurons. Therefore, quelling of these processes is considered to have a beneficial effect allowing proper neuronal functioning. The possible antiaging activity of nitrones may reside in their ability to quell enhanced production of reactive oxygen species associated with age-related conditions. On the basis of novel ideas about the action of secretory products formed by senescent cells on bystander cells, it is postulated that nitrones will mitigate these processes and that this may be the

mechanism of their antiaging activity.  
CC 1-0 (Pharmacology)  
ST review nitrone neuroprotectant antiaging memory longevity  
**Alzheimer** stroke neurodegenerative  
IT Aging, animal  
**Alzheimer's** disease  
Longevity  
Memory, biological  
(nitrones as neuroprotectants and antiaging drugs)  
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2001:179318 CAPLUS  
DOCUMENT NUMBER: 134:299982  
TITLE: Analysis of a managed **psychiatric** disability  
program  
AUTHOR(S): McCulloch, Joyce; Ozminkowski, Ronald J.; Cuffel,  
Brian; Dunn, Rodney L.; Goldman, William;  
**Kelleher, Dolores**; Compatoro, Andrea  
CORPORATE SOURCE: Behavioral Health Sciences, The MEDSTAT Group, Inc,  
San Francisco, USA  
SOURCE: Journal of Occupational and Environmental Medicine  
(2001), 43(2), 101-109  
CODEN: JOEMFM; ISSN: 1076-2752  
PUBLISHER: Lippincott Williams & Wilkins  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The cost of mental illness to employers has been well documented; however,  
efforts to effectively reduce the costs of **psychiatric**  
disability are adversely affected by the fragmentation of health care  
services. This report is a case study of a program in which a managed  
behavioral health care organization managed the **psychiatric**  
disability of a telecommunications company. Compared with a non-random  
cohort of claimants not managed under the pilot, the duration of  
disability was reduced by 23% (17.1 days). Patient and provider  
satisfaction with the program was high. This study illustrates the  
potential for effectively reducing the cost of **psychiatric**  
disability and the challenges in coordinating health care.  
CC 59-5 (Air Pollution and Industrial Hygiene)  
ST **psychiatric** disability occupational health  
IT Mental disorder  
Occupational health  
(anal. of managed **psychiatric** disability program)

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2000:351555 CAPLUS  
DOCUMENT NUMBER: 133:3721  
TITLE: The CXC chemokine H174 and methods for preventing  
damage to the nervous system  
INVENTOR(S): Jacobs, Kenneth; McCoy, John M.; Lavallie, Edward R.;  
Collins-Racie, Lisa A.; Lu, Zhijian; Mi, Sha;  
**Kelleher, Kerry**; Carlin-Duckett, McKeough;  
Dorf, Martin E.  
PATENT ASSIGNEE(S): Genetics Institute, Inc., USA; President and Fellows  
of Harvard College  
SOURCE: PCT Int. Appl., 105 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000029439	A1	20000525	WO 1999 US27199	19991116
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2351146	AA	20000525	CA 1999 2351146	19991116
EP 1133521	A1	20010919	EP 1999 960408	19991116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1998 193092 A 19981116  
 WO 1999 US27199 W 19991116

AB This invention provides polynucleotides comprising sequences encoding the CXC chemokine H174 and modified forms thereof, the encoded CXC chemokine H174 and modified forms thereof, methods of identifying inhibitors of the interaction between H174 and receptors for H174, and methods of treating nervous system conditions involving H174.

IC ICM C07K014-52  
 ICS A61K038-19; C07H021-04

CC 15-5 (Immunochemistry)

IT AIDS (disease)

AIDS (disease)

(AIDS **dementia** complex; CXC chemokine H174 and methods for preventing damage to the nervous system)

IT Mental disorder

Mental disorder

(AIDS **dementia**, CXC chemokine H174 and methods for preventing damage to the nervous system)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:464292 CAPLUS

DOCUMENT NUMBER: 131:102188

TITLE: Preparation of thiophene nitron compounds for treatment of neurodegenerative, autoimmune, and inflammatory diseases

INVENTOR(S): Kelleher, Judith A.; Maples, Kirk R.; Zhang, Yong-Kang

PATENT ASSIGNEE(S): Centaur Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 9936420 A1 19990722 WO 1999-US786 19990114  
 W: AL, AM, AT, AU, AZ BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
 DK, EE, ES, FI, GB GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
 KE, KG, KP, KR, KZ LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,  
 MW, MX, NO, NZ, PL PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
 TR, TT, UA, UG, US UZ, VN, YU, ZW  
 RW: GH, GM, KE, LS, MW SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 ZA 9900255 A 19990714 ZA 1999-255 19990114  
 CA 2318555 AA 19990722 CA 1999-2318555 19990114  
 AU 9922269 A1 19990802 AU 1999-22269 19990114  
 US 6015831 A 20000118 US 1999-245126 19990114  
 EP 1047688 A1 20001102 EP 1999-902243 19990114  
 EP 1047688 B1 20021120  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI  
 JP 2002509147 T2 20020326 JP 2000-540136 19990114  
 AT 228123 E 20021215 AT 1999-902243 19990114  
 CN 1136211 B 20040128 CN 1999-803301 19990114  
 AU 2003227320 A1 20030904 AU 2003-227320 20030729  
 PRIORITY APPLN. INFO.: US 1998-72790P P 19980116  
 AU 1999-22269 A3 19990114  
 WO 1999-US786 W 19990114  
 OTHER SOURCE(S): MARPAT 131:102188  
 GI



AB The title compds. I [R1 = H, (un)substituted alkyl, halo, etc.; R2 = H, (un)substituted alkyl, etc.; R3 = H, (un)substituted alkyl, cycloalkenyl, etc.; W = SR4, etc.; R4 = (un)substituted alkyl, alkynyl, etc.; n = 0 - 2; m = 1 - 3; provided that m + n = 3] are prepared I are also useful as anal. reagents for detecting free radicals.  $\alpha$ -[2-(4-Methoxyphenylthio)-5-thienyl]-N-tert-butyl nitron (preparation given) inhibited  $\beta$ -amyloid-induced release of interleukin-1 $\beta$  by at least 30% compared to the controls.

IC ICM C07D333-34

ICS A61K031-38

CC 27-8 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 80

IT Alzheimer's disease

Rheumatoid arthritis

Septicemia

(preparation and therapeutic effect of thiophene nitron compds.)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L55 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:464287 CAPLUS

DOCUMENT NUMBER: 131:102186

TITLE: Preparation of phenylthiofurylalkylnitrones for

treatment of neurological, autoimmune, and inflammatory disease and as analytical reagents.

INVENTOR(S): Kelleher, Judith A.; Maples, Kirk R.; Zhang, Yong-Kang

PATENT ASSIGNEE(S): Centaur Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 59 pp.  
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9936415	A1	19990722	WO 1999-US785	19990114
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, EE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9900252	A	19990714	ZA 1999-252	19990114
CA 2318357	AA	19990722	CA 1999-2318357	19990114
AU 9923192	A1	19990802	AU 1999-23192	19990114
AU 742768	B2	20020110		
US 5998469	A	19991207	US 1999-245130	19990114
EP 1047683	A1	20001102	EP 1999-903086	19990114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002509143	T2	20020326	JP 2000-540131	19990114
NZ 505757	A	20020927	NZ 1999-505757	19990114
TW 446703	B	20010721	TW 1999-88100606	19990115
US 6127408	A	20001003	US 1999-408126	19990929
US 6310092	B1	20011030	US 2000-505716	20000217
PRIORITY APPLN. INFO.:			US 1998-71626P	P 19980116
			US 1999-245130	A3 19990114
			WO 1999-US785	W 19990114
			US 1999-408126	A1 19990929
OTHER SOURCE(S):			MARPAT 131:102186	
GI				



AB Title compds. [I; R1 = (substituted) alkyl, alkenyl, alkynyl, aralkyl, aryl, cycloalkyl, cycloalkylalkyl, cycloalkenyl; R2 = (substituted) alkyl, alkenyl, alkynyl, aralkyl, aryl, alkoxy, cycloalkyl, halo; R3 = H, (substituted) alkyl, alkenyl, alkynyl, aralkyl, aryl, cycloalkyl,

cycloalkylalkyl; R4 = (substituted) alkyl, alkenyl, alkynyl, aralkyl, aryl, cycloalkyl, cycloalkylalkyl, cycloalkenyl; n = 0-2], were prepared as therapeutics for preventing and/or treating neurodegenerative, autoimmune and inflammatory conditions in mammals and as anal. reagents for detecting free radicals. Thus, 2-(4-methoxyphenylthio)-5-furaldehyde (preparation given), N-tert-butylhydroxylamine (preparation given), mol sieves, and silica gel were refluxed overnight in CHCl<sub>3</sub> to give 78.8%  $\alpha$ -[2-(4-methoxyphenylthio)-5-furyl]-1-tert-butyl nitron. I inhibited A $\beta$ (1-42)  $\beta$ -pleated sheet formation and/or  $\beta$ -amyloid-induced increase of interleukin-1 $\beta$  and/or IL-1 $\beta$ -induced cell toxicity by  $\geq$ 30% compared to controls.

IC ICM C07D307-64  
ICS A61K031-34  
CC 27-6 (Heterocyclic Compounds (One Hetero Atom))  
Section cross-reference(s): 1, 80  
IT AIDS (disease)  
AIDS (disease)  
(AIDS **dementia** complex, treatment; preparation of phenylthiofurylalkylnitrones for treatment of neurol., autoimmune, and inflammatory disease and as anal. reagents)  
IT Mental disorder  
Mental disorder  
(AIDS **dementia**, treatment, preparation of phenylthiofurylalkylnitrones for treatment of neurol., autoimmune, and inflammatory disease and as anal. reagents)  
IT Anti-**Alzheimer's** agents  
Anti-inflammatory agents  
Antiarthritics  
Antiparkinsonian agents  
(preparation of phenylthiofurylalkylnitrones for treatment of neurol., autoimmune, and inflammatory disease and as anal. reagents)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:282195 CAPLUS

DOCUMENT NUMBER: 130:311617

TITLE: Preparation of  $\alpha$ -aryl-N-alkylnitrones for treatment of neurodegenerative, autoimmune, and inflammatory disease and as analytical reagents for detection of free radicals.

INVENTOR(S): Kelleher, Judith A.; Maples, Kirk R.; Dykman, Alina; Zhang, Yong-Kang; Wilcox, Allan L.; Levell, Julian

PATENT ASSIGNEE(S): Centaur Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 104 pp.

CODEN: P1XXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920601	A1	19990429	WO 1998-US21624	19981016
W: AL, AM, AT, AU, AZ, FA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, PO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				



RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

ZA 9809436	A	19990416	ZA 1998-9436	19981015
US 6046232	A	20000404	US 1998-172753	19981015
CA 2305798	IA	19990429	CA 1998-2305798	19981016
AU 9910833	A1	19990510	AU 1999-10833	19981016
EP 1025079	A1	20000809	EP 1998-953456	19981016
EP 1025079	E1	20050202		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

BR 9813256	A	20000829	BR 1998-13256	19981016
TR 200001023	T2	20001121	TR 2000-20001023	19981016
JP 2001520217	T2	20011030	JP 2000-516943	19981016
NZ 503910	A	20020927	NZ 1998-503910	19981016
RU 2225392	C2	20040310	RU 2000-112097	19981016
AT 288419	E	20050215	AT 1998-953456	19981016
ES 2235374	T3	20050701	ES 1998-953456	19981016
TW 226882	E1	20050121	TW 1998-87117185	19981017
NO 2000001914	A	20000602	NO 2000-1914	20000412
US 6433008	E1	20020813	US 2000-529555	20000718
US 6441032	E1	20020827	US 2000-635527	20000809
US 2003087957	A1	20030508	US 2002-74595	20020211
US 2005124691	A1	20050609	US 2004-792910	20040305


PRIORITY APPLN. INFO.:

US 1997-62324P	P	19971017
US 1997-63736P	P	19971029
US 1998-90475P	P	19980624
US 1998-172753	A1	19981015
WO 1998-US21524	W	19981016
US 2000-500650	A3	20000209
US 2002-74595	A1	20020211

OTHER SOURCE(S):

MARPAT 130:311617

GI



AB Title compds. [I; R1 = alkoxy, alkaryloxy, alkycycloalkoxy, aryloxy, cycloalkoxy; R2 = H, alkoxy, alkycycloalkoxy, cycloalkoxy, halo; adjacent R1R2 = alkylenedioxy; R3 = H, alkoxy, alkycycloalkoxy, cycloalkoxy, halo; R4 = H, alkyl; R5 = (substituted) alkyl, cycloalkyl; with provisos], were prepared. Thus, 4-hydroxybenzaldehyde was refluxed 30 min. with NaOH in EtOH; I(CH<sub>2</sub>)<sub>5</sub>CH<sub>3</sub> was added and the mixture was refluxed 68 h to give a residue which was kept 18 h with PrNO<sub>2</sub>, NH<sub>4</sub>Cl, and Zn in EtOH/H<sub>2</sub>O to give 12.4% α-4-hexyloxyphenyl-N-propylnitrone. Several I at 100 mg/kg orally in rats treated with M. tuberculosis in incomplete Freund's adjuvant reduced CNS inflammatory deficit.

IC ICM C07C291-02

ICS A61K031-135

CC 25-22 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1, 80

IT Mental disorder

(**dementia**, treatment of HIV **dementia**; preparation of  $\alpha$ -aryl-N-alkylnitrones for treatment of neurodegenerative autoimmune, and inflammatory disease and as anal. reagent: for detection of free radicals)

IT Anti-Alzheimer's agents

Antiarthritics

Antiparkinsonian agents

(preparation of  $\alpha$ -aryl-N-alkylnitrones for treatment of neurodegenerative, autoimmune, and inflammatory disease and as anal. reagents for detection of free radicals)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:751854 CAPLUS

DOCUMENT NUMBER: 130:192459

TITLE: Transient expression of  $\beta$ -galactosidase in differentiating sporozoites of *Eimeria tenella*

AUTHOR(S): Kelleher, Michelle; Tomley, Fiona M.

CORPORATE SOURCE: Division of Molecular Biology, The Institute for Animal Health, Compton, Berkshire, RG20 9NN, UK

SOURCE: Molecular and Biochemical Parasitology (1998), 97(1,2), 21-31

CODEN: MBIIDP; ISSN: 0166-6851

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A transient transfection system has been developed for a member of the Apicomplexa, *Eimeria tenella*, using  $\beta$ -galactosidase ( $\beta$ gal) from *Escherichia coli* as the reporter enzyme. Successfully expressed constructs contained sequences of the *E. tenella* microneme gene *Etmic-1* fused to the coding region of *lacZ*. Transfectants expressing  $\beta$ gal were able to invade host cells and proceed through part of the life-cycle, forming **schizonts** from which merozoites were released. This indicated that transfectants could differentiate at least to first generation **schizonts**. However, this differentiation was delayed compared with unelectroporated sporozoites by approx. 15 h. Some merozoites arising from transfected sporozoites also expressed  $\beta$ gal. These results are encouraging for the development of a stable transfection system for *E. tenella*, using  $\beta$ gal as a reporter enzyme.

CC 3-2 (Biochemical Genetics)

Section cross-reference(s): 10

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:87722 CAPLUS

DOCUMENT NUMBER: 128:140602

TITLE: Furan nitro compound

INVENTOR(S): Kelleher, Judith A.; Maples, Kirk R.;

Waterbury, Lowell David; Wilcox, Allan L.; Xu, Hong; Zhang, Yong-kang

PATENT ASSIGNEE(S): Centaur Pharmaceuticals, Inc., USA; Kelleher, Judith A.; Maples, Kirk R.; Waterbury, Lowell David; Wilcox, Allan L.; Xu, Hong; Zhang, Yong-Kang

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO	DATE
WO 9803496	A1	19980129	WO 1997-US11960	19970714
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2260825	AA	19980129	CA 1997-2260825	19970714
AU 9736555	A1	19980210	AU 1997-36555	19970714
AU 715226	B2	20000120		
EP 1021430	A1	20000726	EP 1997-933350	19970714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 333705	A	20000929	NZ 1997-333705	19970714
JP 2000514822	T2	20001107	JP 1998-506980	19970714
US 5942507	A	19990824	US 1997-895968	19970717
ZA 9706388	A	19980219	ZA 1997-6388	19970718
US 6040444	A	20000321	US 1999-317267	19990524
US 6051571	A	20000418	US 1999-317266	19990524
US 6376540	B1	20020423	US 1999-230065	19991217
PRIORITY APPLN. INFO.:			US 1996-22169P	P 19960719
			WO 1997-US11960	W 19970714
			US 1997-895968	A3 19970717

OTHER SOURCE(S): MARFAT 128:140602

AB Furan nitrones, e.g., N-isopropyl- $\alpha$ -(5-sulfo-2-furanyl)nitron (I), were prepared for treatment of neurodegenerative and/or autoimmune disorders. Thus, refluxing N-isopropylhydroxylamine and Na 5-formyl-2-furansulfonate in MeOH gave a 75% yield of I. In rats I reduced the mean infarct volume of a stroke by 32% when administered 3 h post stroke. Other tests of the nitrones included (1) inhibition of A $\beta$  beta-pleated sheet formation, (2) protection against A $\beta$ (25-35)-induced neuronal cell loss, (3) inflammation reduction, (4) reduction of  $\beta$ -amyloid-induced increased cytokine release, (5) reduction of locomotor impairment due to A $\beta$ -peptide, (6) reduction of spatial learning deficit, (7) prevention of MBP-induced exptl. allergic encephalomyelitis, (8) prevention of weight loss, (9) and reduction of learning deficit in autoimmune mice.

IC ICM C07D307-64

ICS A61K031-34

CC 27-6 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 63

IT **Alzheimer's disease**

Anti-inflammatory agents

Autoimmune disease

(furan nitron compounds for treatment of neurodegenerative and/or autoimmune disorders)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L55 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:657035 CAPLUS

DOCUMENT NUMBER: 126:14770

TITLE: Alkaline and acid phosphatase inhibitors in treatment of neurological disorders  
 INVENTOR(S): Kelleher, Judith A.; Eveleth, David D.  
 PATENT ASSIGNEE(S): Cortex Pharmaceuticals, Inc., USA  
 SOURCE: U.S., 11 pp., Cont.-in-part of U.S. Ser. No. 71,281, abandoned.  
 CODEN: USXXAP  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY A.C. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 567724	A	19961022	US 1994-252109	19940601
PRIORITY APPLN. INFO.:			US 1993-71281	B2 19930601

AB The present invention provides a method of inhibiting  $\beta$ -amyloid toxicity in brain cells. The method includes administering to the cells an amount of an alkaline phosphatase inhibitor which is pharmacol. effective to reduce degeneration in the cells. Methods of treatment of peripheral neuropathy are also provided using acid or alkaline phosphatase inhibitors.

IC ICM A61K031-38  
 INCL 514 68000  
 CC 1-1 (Pharmacology)  
 Section cross-reference(s): 63  
 IT Alzheimer's disease  
 Amyloidosis  
 Brain, disease  
 Down's syndrome  
 alkaline and acid phosphatase inhibitors in treatment of neurol. (disorders)

L55 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1995:364210 CAPLUS  
 DOCUMENT NUMBER: 122:123145  
 TITLE: Alkaline and acid phosphatase inhibitors in treatment of neurological disorders  
 INVENTOR(S): Kelleher, Judith A.; Eveleth, David D., Jr.  
 PATENT ASSIGNEE(S): Cortex Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 21 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY A.C. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427603	A1	19941208	WO 1994-US6186	19940601
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 163966	AA	19941208	CA 1994-2163966	19940601
AU 470506	A1	19941220	AU 1994-70506	19940601
AU 698101	B2	19981022		
EP 01441	A1	19960320	EP 1994-919323	19940601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1993-71281	A 19930601

WO 1994-US6186 W 19940601

AB A method is provided for inhibiting  $\beta$ -amyloid toxicity in brain cells. The method includes administering to the cells an amount of an alkaline phosphatase inhibitor which is pharmacol. effective in reduction of degeneration in the cells. Methods of treatment for peripheral neuropathy are also provided using acid or alkaline phosphatase inhibitors. Inhibition of  $\beta$ -amyloid peptide toxicity with e.g. levamisole is described.

IC ICM A61K031-425

ICS A61K031-305; A61K033 16; A61K031-225

CC 1-11 (Pharmacology)

IT Mental disorder

(Alzheimer's disease, alkaline and acid phosphatase inhibitors for treatment of neuro. disorders)

L55 ANSWER 19 OF 20 CAPLUS (COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:362498 CAPLUS

DOCUMENT NUMBER: 122:173146

TITLE: Use of metabotropic receptor agonists in treatment of progressive neurodegenerative diseases

INVENTOR(S): Eveleth, David D.; Kelleher, Judith A.;

Cotman, Carl W.

PATENT ASSIGNEE(S): Cortex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9427602	A1	19941208	WO 1994-US5751	19940520
W: AT, AU, BB, BG, BF, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SI, SE, SK, TJ, TT, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9468363	A1	19941220	AU 1994-68363	19940520
US 5622981	A	19970422	US 1995-418903	19950407
PRIORITY APPLN. INFO.:			US 1993-70518	A 19930601
			WO 1994-US5751	W 19940520

AB A pharmaceutical composition is disclosed which comprises a metabotropic receptor agonist, e.g. trans-aminocyclopentane-1,3-dicarboxylic acid (trans-ACPD) or 1S,3R-ACPD, for use in treating a mammal with a neurodegenerative disease which is caused at least in part by  $\beta$ -amyloid protein neurotoxicity. In a study using cultured embryonic rat hippocampal neurons, the inhibition of  $\beta$ -amyloid-induced neuronal death by ACPD is consistent with the concns. of ACPD known to be required to occupy the metabotropic receptor.

IC ICM A61K031-42

ICS A61K031-19; A61K031-66

CC 1-11 (Pharmacology)

Section cross-reference(s): 63

IT Mental disorder

(Alzheimer's disease, metabotropic receptor agonists for neurodegenerative disease treatment)

IT Mental disorder

(dementia, multi-infarct, metabotropic receptor agonists for neurodegenerative disease treatment)

IT Brain, disease

(multi-infarct dementia, metabotropic receptor agonists for  
neurodegenerative disease treatment)

L55 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:585706 CAPLUS

DOCUMENT NUMBER: 117:185706

TITLE: Simple derivation of TFIID-dependent RNA polymerase II  
transcription systems from **Schizosaccharomyces**  
**pombe** and other organisms, and factors required for  
transcriptional activation

AUTHOR(S): Flanagan, Peter M.; Kelleher, Raymond J., III  
; Tschochner, Herbert; Sayre, Michael H.; Kornberg,  
Roger D.

CORPORATE SOURCE: Sch. Med., Stanford Univ., Stanford, CA, 94305, USA

SOURCE: Proceedings of the National Academy of Sciences of the  
United States of America (1992), 89(16), 7659-63  
CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Resolution of whole cell extract through two chromatog. steps yields a single  
protein fraction requiring only the addition of TFIID for the initiation of  
transcription at RNA polymerase II promoters. This approach allows the  
convenient generation of RNA polymerase II transcription systems from  
*Saccharomyces cerevisiae*, human lymphocytes, and *S. pombe*. TFIIIs from  
all three organisms are interchangeable among all three systems. The *S.*  
*cerevisiae* and *S. pombe* systems support effects of acidic activator  
proteins, provided a further protein fraction from *S. cerevisiae* is  
supplied. This further fraction is distinct from the mediator of  
transcriptional activation described previously and represents a second  
component in addition to general initiation factors that may facilitate a  
response to acidic activators.

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 10

ST transcription initiation protein RNA polymerase TFIID;  
**Schizosaccharomyces** initiation factor invitro transcription  
initiation; evolution conservation transcription initiation factor

IT *Saccharomyces cerevisiae*

**Schizosaccharomyces pombe**

(TFIID-dependent RNA polymerase II in vitro transcription system  
derived from chromatog. isolated factors of)

IT Transcription, genetic

(TFIID-dependent RNA polymerase II in vitro,

**Schizosaccharomyces pombe**-derived factors for initiation of)

IT Gene

RL: B OL (Biological study)

(TFIID-dependent RNA polymerase II transcription system derived from  
**Schizosaccharomyces pombe** for in vitro transcription of,  
factors for)

IT Evolution

(conservation in, of transcription initiation factor of *Saccharomyces*  
*cerevisiae* and human lymphocyte and **Schizosaccharomyces**  
**pombe**)

IT Ribonucleic acid formation factors

RL: B OL (Biological study)

(**Schizosaccharomyces pombe** whole cell extract chromatog.  
derived, for in vitro gene transcription by TFIID-dependent RNA  
polymerase II)

IT Ribonucleic acid formation factors

RL: B OL (Biological study)

(TFIID (transcription factor IID , **Schizosaccharomyces pombe**

chromatog. isolated initiation factors and, for gene in vitro  
transcription)

Page 24



Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d stat que L37

```
L34      1794 SEA FILE=REGISTRY ABB=ON  PLU=ON  333.871.5/RID
L35      221 SEA FILE=CAPLUS ABB=ON  PLU=ON  L34
L36      520762 SEA FILE=CAPLUS ABB=ON  PLU=ON  ?NEURO?/BI
L37      13 SEA FILE=CAPLUS ABB=ON  PLU=ON  L35 AND L36
```

=> d stat que L45

```
L34      1794 SEA FILE=REGISTRY ABB=ON  PLU=ON  333.871.5/RID
L35      221 SEA FILE=CAPLUS ABB=ON  PLU=ON  L34
L36      520762 SEA FILE=CAPLUS ABB=ON  PLU=ON  ?NEURO?/BI
L38      39352 SEA FILE=CAPLUS ABB=ON  PLU=ON  ALZHEIMER?/BI
L39      28450 SEA FILE=CAPLUS ABB=ON  PLU=ON  SCHIZO?/BI
L40      0 SEA FILE=CAPLUS ABB=ON  PLU=ON  "MENTAL AND BEHAVIORAL
DISORDER"/CT
L41      15699 SEA FILE=CAPLUS ABB=ON  PLU=ON  "MENTAL AND BEHAVIORAL
DISORDERS"/CT
L42      12834 SEA FILE=CAPLUS ABB=ON  PLU=ON  DEMENT?/BI
L43      7220 SEA FILE=CAPLUS ABB=ON  PLU=ON  NEUROGEN?/OBI OR NEURO
GEN?/OBI
L44      10303 SEA FILE=CAPLUS ABB=ON  PLU=ON  ?PSYCHIAT?/BI
L45      22 SEA FILE=CAPLUS ABB=ON  PLU=ON  L35 AND (L36 OR (L38 OR L39 OR
L40 OR L41 OR L42 OR L43 OR L44))
```

=> s L37 or L45

L56 22 L37 OR L45

=> s L56 not L55

L57 22 L56 NOT L55

=> d bib abs hitind hitstr L57 1-20

L57 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:269420 CAPLUS

DOCUMENT NUMBER: 144:331435

TITLE: Preparation of imidazo[1,2-a]pyridin-3-amines and  
related compounds as mGluR5 receptor modulators

INVENTOR(S): Kuehnert, Sven; Oberboersch, Stefan; Sundermann,  
Corinna; Haurand, Michael; Jostock, Ruth; Schiene,  
Klaus; Tzschentke, Thomas; Christoph, Thomas;  
Kaulartz, Dagmar

PATENT ASSIGNEE(S): Gruenenthal GmbH, Germany

SOURCE: PCT Int. Appl., 227 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006029980	A1	20060323	WO 2005-EP54436	20050908


W: AI, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CI, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LI, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NJ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZI, ZW

RW: AC, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, CH, GN, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KC, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

DE 2004-102004044884A 20040914

GI



I

II

AB Title compds. I [A1 = N, CR1a; A2 = N, CR1b; A3 = N, CR1c; A4 = N, CR1d; R1a, R1b, R1c, R1d = H, halo, NO<sub>2</sub>, etc.; R2, R3 = H, COR<sub>20</sub>, COOR<sub>22</sub>, etc.; R<sub>20</sub>, R<sub>22</sub> = H, alkyl, aryl, etc.; M1 = aryl, heteroaryl with provisos; M2 = aryl, heteroaryl with provisos] and their pharmaceutically acceptable salts and formulations were prepared. For example, a one-pot condensation-cyclization of 2-aminopyrazine, cyclopentyl isocyanide and 5-phenylethynylthiophene-2-aldehyde afforded claimed imidazopyridinylamine II in 54% yield. In mGluR5 receptor binding assays, compds. I exhibited IC<sub>50</sub> values ranging from 0.0028-15.55 μM.

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT **Mental and behavioral disorders**

(attention deficit disorder, treatment of; preparation of imidazo[1,2-a]pyridin-3-amines and related compds. as mGluR5 receptor modulators)

IT **Mental and behavioral disorders**

(depression, treatment of; preparation of imidazo[1,2-a]pyridin-3-amines and related compds. as mGluR5 receptor modulators)

IT **Analgesics**

Anti-Alzheimer's agents

Anticonvulsants

Antidepressants

Antidiarrheals

Antidiuretics

Antimigraine agents

Antiobesity agents

Antiparkinsonian agents

Antipsychotics

Antitussives  
 Cognition enhancers  
 Combination chemotherapy  
 Human  
 Muscle relaxants  
 Nervous system agents  
 (preparation of imidazo[1,2-a]pyridin-3-amines and related compds. as mGluR5  
 receptor modulators)

IT **Alzheimer's disease**

Anorexia  
 Bulimia  
 Cachexia  
 Cardiovascular system, disease  
 Cognitive disorders  
 Cough  
 Diuresis  
 Drug withdrawal  
 Epilepsy  
 Multiple sclerosis  
 Obesity  
 Pain  
 Parkinson's disease  
 Pruritus

**Schizophrenia**

(treatment of; preparation of imidazo[1,2-a]pyridin-3-amines and related  
 compds. as mGluR5 receptor modulators)

IT **880250-84-0P**, N-tert-Butyl-2-[5-(6-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of imidazo[1,2-a]pyridin-3-amines and related compds. as mGluR5  
 receptor modulators)

IT **880238-42-6P**, Cyclopentyl[2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880238-59-5P 880238-72-2P  
 880238-86-8P 880239-02-1P 880239-08-7P 880239-25-8P  
**880239-39-4P** 880239-52-1P 880239-65-6P, (4-Methoxybenzyl)[5-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine  
 880239-77-0P, (4-Methoxybenzyl)[6-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880239-91-8P, (4-Methoxybenzyl)[7-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine  
 880240-04-0P, (4-Methoxybenzyl)[8-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880240-20-0P, [5,7-Dimethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl](4-methoxybenzyl)amine 880240-35-1P, [8-Benzyloxy-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl](4-methoxybenzyl)amine 880240-50-1P, (4-Methoxybenzyl)[2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine  
**880240-65-3P**, (4-Methoxybenzyl)[3-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine **880240-79-9P**, tert-Butyl[2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880240-95-9P, tert-Butyl[6-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880241-08-7P, [8-Benzyloxy-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl](3-methoxyphenyl)amine 880241-22-1P, (3-Methoxybenzyl)[5-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine  
 880241-38-3P, (3-Methoxybenzyl)[8-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880241-52-1P, [5,7-Dimethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl](3-methoxybenzyl)amine 880241-64-1P, [8-Benzyloxy-2-(5-

phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (3-methoxybenzyl)amine 880241-76-9P, (3-Methoxybenzyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine **880241-88-3P**, (3-Methoxybenzyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880242-03-5P, [6-Methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (1-phenylethyl)amine 880242-16-0P, [7-Methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (1-phenylethyl)amine 880242-30-8P, [5,7-Dimethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (1-phenylethyl)amine 880242-44-4P, [8-Benzoyloxy-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (1-phenylethyl)amine **880242-57-9P**, (1-Phenylethyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880242-70-6P, (2-Chlorobenzyl) [5,7-dimethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880242-84-2P, (3-Chloro-4-fluorophenyl) [7-phenyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880242-99-9P, (4-Methoxybenzyl) [7-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrimidin-3-yl]amine 880243-14-1P, [8-Methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (1-phenylethyl)amine 880243-28-7P, [7-Methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrimidin-3-yl] (1-phenylethyl)amine 880243-42-5P, (2-Methoxybenzyl) [7-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880243-56-1P, (2-Methoxybenzyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880243-70-9P, (2-Chlorobenzyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880243-85-6P, (2-Methoxybenzyl) [7-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrimidin-3-yl]amine 880243-99-2P, (3-Methoxyphenyl) [6-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880244-15-5P, [5,7-Dimethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (3-methoxyphenyl)amine **880244-30-4P**, (3-Methoxyphenyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880244-44-0P, [7-Ethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (2-methoxybenzyl)amine 880244-58-6P, (2-Chlorobenzyl) [7-ethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880244-72-4P, [7-tert-Butyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (3-chloro-4-fluorophenyl)amine 880244-86-0P, (3-Methoxybenzyl) [7-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrimidin-3-yl]amine 880245-01-2P, [7-Ethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (2-fluorophenyl)amine 880245-14-7P, [7-tert-Butyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (2-fluorophenyl)amine 880245-29-4P, (2,4-Difluorophenyl) [2-(5-phenylethynylthiophen-2-yl)-7-(3-phenylpropyl)imidazo[1,2-a]pyridin-3-yl]amine 880245-41-0P, (4-Fluorobenzyl) [7-methyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880245-53-4P, [5,7-Dimethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (4-fluorobenzyl)amine 880245-69-2P, [7-Ethyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (3-trifluoromethylbenzyl)amine 880245-83-0P, [7-Isopropyl-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (3-trifluoromethylbenzyl)amine **880245-97-6P**, tert-Butyl [2-(4-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine **880246-11-7P**, [2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl] (1,1,3,3-tetramethylbutyl)amine **880246-23-1P**, Butyl [2-(4-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880246-34-4P, [2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (1,1,3,3-tetramethylbutyl)amine **880246-48-0P**, [2-(5-Pyridinylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl] (1,1,3,3-tetramethylbutyl)amine **880246-61-7P**, 880246-76-4P, [6-Chloro-2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-

yl) (1,1,3,3-tetramethylbutyl)amine 880246-89-9P, [6,8-Dichloro 2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (1,1,3,3-tetramethylbutyl)amine 880247-03-0P 880247-16-5P, Dimethyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880247-31-4P, Methyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880247-45-0P, N-[2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]acetamide 880247-59-6P, Ethyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880247-73-4P, Propyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880247-82-5P, Butyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880247-83-6P, (2-Methylpropyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880247-84-7P, Pentyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880247-85-8P 880247-86-9P, Benzyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880247-87-0P, [2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-ylamino]acetic acid methyl ester 880247-88-1P 880247-89-2P 880247-90-5P, N-[2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]benzamide 880247-91-6P, [2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]pyridin-3-ylmethylamine 880247-92-7P, 2,2-Dimethyl-N-[2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]propionamide 880247-93-8P, 3-Methoxy-N-[2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]benzamide 880247-94-9P 880247-95-0P 880247-96-1P, Methyl 2-[5-(phenylethynyl)thiophen-2-yl]-3-(2,4,4-trimethylpentan-2-ylamino)imidazo[1,2-a]pyrazine-8-carboxylate 880247-97-2P, 2-[5-(phenylethynyl)thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrimidin-3-amine 880247-98-3P, 2-[5-[(6-Methylpyridin-2-yl)ethynyl]thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrazin-3-amine 880247-99-4P, N-Cyclohexyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-00-0P, 2-[5-(phenylethynyl)thiophen-2-yl]-3-(piperidin-1-yl)imidazo[1,2-a]pyrazine 880248-01-1P, N-tert-Butyl-N-methyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-02-2P, Methyl 2-[5-(phenylethynyl)thiophen-2-yl]-3-(2,4,4-trimethylpentan-2-ylamino)imidazo[1,2-a]pyridine-6-carboxylate 880248-03-3P, N-tert-Butyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-04-4P, 8-Bromo-N-cyclopentyl-6-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880248-05-5P, N,N-Diethyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-06-6P, N-tert-Butyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880248-07-7P, N-tert-Butyl-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-08-8P, 8-Bromo-N-tert-butyl-6-methyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880248-09-9P, N-tert-Butyl-8-methyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880248-10-2P, N-Methyl-2-[5-(phenylethynyl)thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-11-3P, 2-[5-(phenylethynyl)thiophen-2-yl]-3-(pyrrolidin-1-yl)imidazo[1,2-a]pyrazine Hydrochloride 880248-12-4P, N-tert-Butyl-2-[5-[(4-fluorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-13-5P, N-tert-Butyl-7-methyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880248-14-6P, N-tert-Butyl-5-methyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880248-15-7P, 8-Chloro-2-[3-(pyridin-2-ylethynyl)phenyl]-6-(trifluoromethyl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880248-16-8P,

N-tert-Butyl-2-[5-[(3-fluorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-17-9P**,  
 N-tert-Butyl-2-[5-[(2-fluorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-18-0P**, Methyl  
 3-(tert-butylamino)-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazine-8-carboxylate **880248-19-1P**, N-tert-Butyl-2-[5-(pyrazin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine  
**880248-20-4P**, 1-[5-[(4-Aminophenyl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine **880248-21-5P**,  
 N-Isopropyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-22-6P**, N-tert-Butyl-2-[5-(thiophen-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride  
**880248-23-7P**, N-tert-Butyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine **880248-24-8P**,  
 N-tert-Butyl-2-[5-[(2-methoxyphenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-25-9P**,  
 N-tert-Butyl-2-[5-[(3-methoxyphenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-26-0P**,  
 N-tert-Butyl-2-[5-[(4-methoxyphenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-27-1P** **880248-28-2P**,  
 N-tert-Butyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine **880248-29-3P**, N-tert-Butyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyrazin-3-amine **880248-30-6P**,  
 N-tert-Butyl-2-[2-methyl-6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-amine **880248-31-7P**, N-tert-Butyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-32-8P**,  
 3-(tert-butylamino)-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazine-8-carboxylic acid **880248-33-9P**, 4-[[5-[3-(tert-butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]phenol  
 Hydrochloride **880248-34-0P**, 3-[[5-[3-(tert-butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]phenol  
**880248-35-1P**, 1-[5-[(3-Aminophenyl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-36-2P**,  
 2-[5-[(2-Aminophenyl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-37-3P** **880248-38-4P**,  
 N-tert-Butyl-2-[6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-amine **880248-39-5P**, N-tert-Butyl-2-[5-(pyridin-4-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride  
**880248-40-8P**, 1-[5-[(6-Aminopyridin-3-yl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-41-9P**,  
 N-tert-Butyl-2-[5-(pyrimidin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-42-0P**,  
 N-tert-Butyl-2-[5-[(4-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-43-1P**,  
 N-tert-Butyl-2-[5-[(5-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-44-2P**, N-tert-Butyl-2-[5-(pyridin-4-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine Hydrochloride  
**880248-45-3P**, N-tert-Butyl-2-[5-(thiazol-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-46-4P**,  
 2-[5-(Pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-47-5P**, N-tert-Butyl-2-[5-[(5-methylthiophen-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride  
**880248-48-6P**, 1-[5-[(6-Aminopyridin-2-yl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-49-7P**,  
 N-tert-Butyl-2-[5-[(3-methylthiophen-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-50-0P**,  
 N-tert-Butyl-2-[4-(phenylethynyl)thiazol-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-51-1P**, N-tert-Butyl-2-[5-(m-tolylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-52-2P**,  
 3-[[5-[3-(tert-butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]

yl]ethynyl]benzonitrile Hydrochloride 880248-53-3P, N-tert-Butyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrimidin-3-amine  
 880248-54-4P, N-tert-Butyl-2-[6-(phenylethynyl)pyridin-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-55-5P,  
 N-tert-Butyl-N-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-56-6P, 4-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]benzonitrile  
 Hydrochloride 880248-57-7P, 2-[5-[(1H-Indol-6-yl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine  
 Hydrochloride 880248-58-8P, N-tert-Butyl-2-[2-(phenylethynyl)thiazol-5-yl]imidazo[1,2-a]pyrazin-3-amine  
 880248-59-9P 880248-60-2P, 2-[5-[[3-(1H-Pyrrol-1-yl)phenyl]ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine  
 Hydrochloride 880248-61-3P, 2-[5-[(1H-Indol-4-yl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine  
 Hydrochloride 880248-62-4P, N-tert-Butyl-2-[5-[(3-nitrophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine  
 Hydrochloride 880248-63-5P, N-tert-Butyl-2-[5-[(4-nitrophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine  
 Hydrochloride 880248-64-6P, N-tert-Butyl-2-[5-(thiazol-4-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride  
 880248-65-7P, 2-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]phenol 880248-66-8P,  
 2-[5-[[3-(Aminomethyl)phenyl]ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine 880248-67-9P,  
 2-[5-(Biphenyl-3-ylethynyl)thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-68-0P,  
 N-tert-Butyl-2-[5-(thiophen-3-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-69-1P,  
 N-tert-Butyl-2-[5-[[3-(dimethylamino)phenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-70-4P,  
 N-tert-Butyl-2-[5-[(6-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-71-5P,  
 N-tert-Butyl-2-[5-[(3-fluoropyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-72-6P,  
 N-tert-Butyl-2-[5-[[3-(methylamino)phenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-73-7P,  
 N-tert-Butyl-2-[5-(p-tolyethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-74-8P, N-tert-Butyl-2-[5-(o-tolyethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-75-9P,  
 N-tert-Butyl-2-[4-methyl-5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-76-0P,  
 N-tert-Butyl-2-[4-methyl-5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-77-1P,  
 N-tert-Butyl-2-[5-[(6-fluoropyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-78-2P, N-tert-Butyl-2-[5-[(2-nitrophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine  
 880248-79-3P, N-tert-Butyl-8-chloro-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-80-6P,  
 N-tert-Butyl-2-[5-[(6-methoxypyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-81-7P,  
 N-tert-Butyl-2-[5-[(5-fluoropyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-82-8P 880248-83-9P,  
 N-tert-Butyl-2-[5-[(5-methoxypyridin-3-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880248-84-0P,  
 5-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]nicotinonitrile Hydrochloride 880248-85-1P,  
 N-tert-Butyl-2-[5-[[3-(methylthio)phenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880248-86-2P, Methyl 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]benzoate

**880248-87-3P**, N-tert-Butyl-2-[5-[(3,5-difluoropyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine  
**880248-88-4P**, N-tert-Butyl-2-[5-(phenylethynyl)thiazol-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-89-5P**,  
 N-tert-Butyl-2-[2-(pyridin-4-ylethynyl)thiazol-5-yl]imidazo[1,2-a]pyrazin-3-amine **880248-90-8P**, 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]benzaldehyde **880248-91-9P**,  
 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]-4-fluorobenzonitrile **880248-92-0P**,  
 N-tert-Butyl-2-[5-[[3-(trifluoromethyl)phenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-93-1P**,  
 N-tert-Butyl-2-[2-(pyridin-2-ylethynyl)thiazol-5-yl]imidazo[1,2-a]pyrazin-3-amine **880248-94-2P**, N-tert-Butyl-2-[3-methyl-5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride  
**880248-95-3P**, N-tert-Butyl-2-[3-methyl-5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride  
**880248-96-4P**, N-tert-Butyl-2-[5-[(3-vinylphenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-97-5P**,  
 2-[5-[(1H-Imidazol-4-yl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-98-6P**,  
 N-tert-Butyl-2-[5-[(3-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-99-7P**, N,N-Dimethyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-00-3P**,  
 N-tert-Butyl-2-[5-[[2-(tert-butyl)diphenylsilyl]thiazol-5-yl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine **880249-01-4P**,  
 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyridin-2-yl]thiophen-2-yl]ethynyl]benzonitrile **880249-02-5P**, N-tert-Butyl-2-[5-(phenylethynyl)thiazol-2-yl]imidazo[1,2-a]pyridin-3-amine **880249-03-6P**,  
 N-tert-Butyl-2-[5-(thiazol-5-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine **880249-04-7P**, N-tert-Butyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine Hydrochloride **880249-05-8P**,  
 6-Chloro-N-cyclohexyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyridin-3-amine **880249-06-9P**,  
 5,7-Dimethyl-N-phenethyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrimidin-3-amine **880249-07-0P**, N-(3-Methoxyphenethyl)-5,7-dimethyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrimidin-3-amine  
**880249-08-1P**, N-(3-Methoxyphenethyl)-5,7-dimethyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrimidin-3-amine  
**880249-09-2P**, N-(3-Methoxyphenethyl)-5,7-dimethyl-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyrimidin-3-amine **880249-10-5P**,  
 N-(4-Chlorobenzyl)-8-methyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine **880249-11-6P**, N-(3-Methoxyphenethyl)-5-methyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine  
**880249-12-7P**, N-(2-Methylhexan-2-yl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-13-8P**,  
 N-Phenethyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-14-9P**, N-(3-Methoxyphenethyl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine  
**880249-15-0P**, 2-[4-(Phenylethynyl)thiophen-2-yl]-N-[2-(thiophen-2-yl)ethyl]imidazo[1,2-a]pyrazin-3-amine **880249-16-1P**,  
 N-(4-Chlorobenzyl)-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine **880249-17-2P**, N-(2-Methylpentan-2-yl)-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine  
**880249-18-3P**, N-(Cyclohexylmethyl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-19-4P**,  
 N-(2-Methoxybenzyl)-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-20-7P**, N-(Cyclohexylmethyl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine **880249-21-8P**, N-(2-Methylpentan-2-yl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine  
**880249-22-9P**, 8-Eromo-6-methyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]-



N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine  
 880249-23 0P, 8-Bromo-N-cyclopentyl-6-methyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880249-24-1P,  
 N-Cyclopentyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880249-25-2P, N-(1-Phenylethyl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine  
 880249-26-3P, N-(2-Methylpentan-2-yl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880249-27-4P, 8-Bromo-N-cyclohexyl-6-methyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine  
 880249-28-5P, N-Cyclopentyl-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine 880249-29-6P, N-(3-Methoxyphenethyl)-7-methyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrimidin-3-amine  
 880249-30 9P, 8-(Benzyloxy)-2-[5-(phenylethynyl)thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880249-31-0P,  
 8-(Benzyloxy)-N-cyclopentyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-32-1P, 8-(Benzyloxy)-N-(2-methylpentan-2-yl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine  
 880249-33-2P, 6-Chloro-N-(4-fluorobenzyl)-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-34-3P, 6-Bromo-N-butyl-5-methyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine  
 880249-35 4P, N-(Furan-2-yl)-8-methyl-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-36-5P, N-(Furan-2-yl)-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-37-0P,  
 N-(Furan-2-yl)-2-[5-(phenylethynyl)furan-2-yl]-7-propylimidazo[1,2-a]pyridin-3-amine 880249-38-7P, 5,7-Dimethyl-2-[4-(phenylethynyl)thiophen-2-yl]-N-[3-(trifluoromethyl)phenyl]imidazo[1,2-a]pyrimidin-3-amine 880249-39-8P, 6-Bromo-N-(4-chlorophenethyl)-8-methyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine  
 880249-40 1P, N-(4-Chlorophenethyl)-7-phenyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-41-2P, N-Phenethyl-7-phenyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine  
 880249-42-3P, N-(4-Chlorobenzyl)-5,7-dimethyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-43-4P, 6-Bromo-N-(4-chlorobenzyl)-5-methyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-44-5P, 8-Bromo-N-(4-chlorobenzyl)-6-methyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-45-6P,  
 N-(3-Methoxyphenethyl)-2-[4-(phenylethynyl)thiophen-2-yl]-5-propylimidazo[1,2-a]pyridin-3-amine 880249-46-7P, 6-Bromo-8-methyl-2-[4-(phenylethynyl)thiophen-2-yl]-N-[2-(thiophen-2-yl)ethyl]imidazo[1,2-a]pyridin-3-amine 880249-47-8P, 7-Phenyl-2-[4-(phenylethynyl)thiophen-2-yl]-N-[2-(thiophen-2-yl)ethyl]imidazo[1,2-a]pyridin-3-amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazo[1,2-a]pyridin-3-amines and related compds. as mGluR5 receptor modulators)

IT 880249-48-9P, 6,8-Dibromo-N-(2-methylpentan-2-yl)-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-49-0P, 6-Bromo-N-(2,6-dimethylphenyl)-8-methyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-50-3P,  
 N-Cyclohexyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine 880249-51-4P, 2-[3-(pyridin-2-ylethynyl)phenyl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrazin-3-amine 880249-52-5P,  
 N-Cyclopentyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine 880249-53-6P, 8-Chloro-2-[4-(pyridin-2-ylethynyl)phenyl]-6-trifluoromethyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880249-54-7P, N-4-Fluorophenyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine 880249-55-8P,  
 N-Cyclopentyl-2-[2-methyl-6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-amine 880249-56-9P, N-Cyclohexyl-2-[2-methyl-6-

(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-amine  
**880249-57-0P**, N-Cyclopentyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-58-1P**, 8-Bromo-N-cyclopentyl-6-methyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine  
**880249-59-2P**, N-Cyclohexyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-60-5P**, 2-[5-(Pyridin-2-ylethynyl)furan-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrazin-3-amine **880249-61-6P**, N-Cyclopentyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyrazin-3-amine **880249-62-7P**, 8-Bromo-N-cyclopentyl-6-methyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine  
**880249-63-8P**, N-Cyclohexyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyrazin-3-amine **880249-64-9P**, N-(4-Fluorophenyl)-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyrazin-3-amine **880249-65-0P**, 2-[5-(Pyridin-2-ylethynyl)thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine  
**880249-66-1P**, N-Cyclohexyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrimidin-3-amine **880249-67-2P**, 2-[3-(Pyridin-2-ylethynyl)phenyl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrimidin-3-amine  
**880249-68-3P**, 2-[6-(Phenylethynyl)pyridin-3-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrimidin-3-amine **880249-69-4P**, N-Cyclopentyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrimidin-3-amine  
**880249-70-7P**, N-tert-Butyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrimidin-3-amine **880249-71-8P**, N-Cyclopentyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyrimidin-3-amine  
**880249-72-9P**, N-Cyclopentyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine **880249-73-0P**, N-tert-Butyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine **880249-74-1P**, 2-[3-(Pyridin-2-ylethynyl)phenyl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine **880249-75-2P**, N-4-Fluorophenyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine **880249-76-3P**, N-tert-Butyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine  
**880249-77-4P**, N-Cyclopentyl-2-[2-methyl-5-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-amine **880249-78-5P**, N-(4-Fluorophenyl)-2-[2-methyl-6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-amine  
**880249-79-6P**, N-Cyclopentyl-6-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine **880249-80-9P**, N-tert-Butyl-6-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine  
**880249-81-0P**, N-Cyclohexyl-6-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine **880249-82-1P**, 6-Methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine **880249-83-2P**, 6-Methyl-2-[2-methyl-6-(phenylethynyl)pyridin-3-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine  
**880249-84-3P**, N-Cyclopentyl-6-methyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine **880249-85-4P**, N-Cyclohexyl-6-methyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyridin-3-amine **880249-86-5P**, N-Cyclohexyl-7-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine  
**880249-87-6P**, 7-Methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine **880249-88-7P**, N-tert-Butyl-7-methyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine **880249-89-8P**, N-4-Fluorophenyl-7-methyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine  
**880249-90-1P**, N-tert-Butyl-7-methyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine **880249-91-2P**, N-4-Fluorophenyl-7-methyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine  
**880249-92-3P**, N-Cyclohexyl-8-methyl-2-[6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-amine **880249-93-4P**, N-Cyclopentyl-2-[6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-amine  
**880249-94-5P**, N-tert-Butyl-2-[6-(phenylethynyl)pyridin-3-

yl]imidazo[1,2-a]pyridin-3-amine 880249-95-6P, N-Cyclohexyl-2-[6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-amine 880249-96-7P, 2-[6-(Phenylethynyl)pyridin-3-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880249-97-8P, N-tert-Butyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-98-9P, N-Cyclohexyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880249-99-0P, N-4-Fluorophenyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-00-0P, N-Cyclohexyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyridin-3-amine 880250-01-1P, 2-[3-[(6-Methylpyridin-2-yl)ethynyl]phenyl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880250-02-2P, N-tert-Butyl-5-methyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyridin-3-amine 880250-03-3P, 5-Methyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880250-04-4P, N-Cyclohexyl-5,7-dimethyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrimidin-3-amine 880250-05-5P, N-Cyclohexyl-5,7-dimethyl-2-[2-methyl-6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyrimidin-3-amine 880250-06-6P, N-Cyclopentyl-5,7-dimethyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrimidin-3-amine 880250-07-7P, N-tert-Butyl-5,7-dimethyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrimidin-3-amine 880250-08-8P, N-4-Fluorophenyl-8-methyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880250-09-9P, N-Cyclohexyl-8-methyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880250-10-2P, N-Cyclohexyl-7-ethyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-11-3P, 7-Ethyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880250-12-4P, N-Cyclohexyl-7-ethyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880250-13-5P, N-Cyclopentyl-7-ethyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880250-14-6P, N-Cyclopentyl-7-ethyl-2-[6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-amine 880250-15-7P, N-tert-Butyl-7-ethyl-2-[6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyridin-3-amine 880250-16-8P, N-tert-Butyl-7-ethyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-17-9P, 7-Isopropyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880250-18-0P, N-tert-Butyl-7-isopropyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880250-19-1P, N-tert-Butyl-7-isopropyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880250-20-4P, N-Cyclohexyl-7-isopropyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-21-5P, N-tert-Butyl-7-isopropyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyridin-3-amine 880250-22-6P, 6-Chloro-N-cyclopentyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-23-7P, N-tert-Butyl-6-chloro-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-24-8P, 6-Chloro-N-cyclohexyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880250-25-9P, 6-Chloro-2-[3-(pyridin-2-ylethynyl)phenyl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880250-26-0P, N-tert-Butyl-6-chloro-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880250-27-1P, 6-Chloro-N-cyclohexyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyridin-3-amine 880250-28-2P, N-tert-Butyl-6-chloro-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-29-3P, 6-Chloro-N-cyclohexyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-30-6P, 6-Chloro-2-[5-(pyridin-2-ylethynyl)furan-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyridin-3-amine 880250-31-7P, 6-Chloro-N-cyclopentyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyridin-3-amine 880250-32-8P,

N-tert-Butyl-6-chloro-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyridin-3-amine 880250-33-9P  
**880250-34-0P**, N-Methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine 880250-35-1P 880250-36-2P  
 880250-37-3P 880250-38-4P, tert-Butyl[2-(5-pyridin-2-ylethynylthiazol-2-yl)imidazo[1,2-a]pyridin-3-yl]amine 880250-39-5P tert-Butyl[2-(2-pyridin-2-ylethynylthiazol-5-yl)imidazo[1,2-a]pyridin-3-yl]amine 880250-40-8P, tert-Butyl[2-[5-(6-fluoropyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-yl]amine Hydrochloride 880250-41-9P, tert-Butyl[2-[5-(3-chloro-5-fluorophenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-yl]amine Hydrochloride 880250-42-0P 880250-43-1P  
**880250-44-2P**, tert-Butyl[2-[5-(3-trifluoromethoxyphenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-yl]amine 880250-45-3P 880250-46-4P, tert-Butyl[2-[5-(3,5-dimethylphenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-yl]amine Hydrochloride 880250-47-5P, tert-Butyl[2-[5-(3-fluoropyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-yl]amine Hydrochloride 880250-48-6P 880250-49-7P, tert-Butyl[2-[5-(5-chlorothiophen-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-yl]amine Hydrochloride 880250-50-0P, tert-Butyl[2-[5-(5-methylpyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-yl]amine Hydrochloride 880250-51-1P, 1-[3-[(3-tert-Butylaminoimidazo[1,2-a]pyridin-2-yl)thiophen-2-ylethynyl]phenyl]ethane Hydrochloride 880250-52-2P, [3-[5-(3-tert-Butylaminoimidazo[1,2-a]pyridin-2-yl)thiophen-2-ylethynyl]phenyl]methanol Hydrochloride 880250-53-3P, N-tert-Butyl-2-[5-[(3-methoxypyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-54-4P, N-tert-Butyl-2-[5-(thiophen-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine Hydrochloride 880250-55-5P, 5-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyridin-2-yl]thiophen-2-yl]ethynyl]-2-fluorobenzonitrile Hydrochloride 880250-56-6P, N-tert-Butyl-2-[5-[(3,4-difluorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-57-7P, N-tert-Butyl-2-[5-[[3-(methoxymethyl)phenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-58-8P, 2-[5-[(3-Aminophenyl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyridin-3-amine Hydrochloride 880250-59-9P, N-tert-Butyl-2-[5-[(4-fluoro-3-methylphenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine Hydrochloride 880250-60-2P, N-tert-Butyl-2-[5-[(3,5-difluorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-61-3P, N-tert-Butyl-2-[5-(thiophen-3-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine Hydrochloride 880250-62-4P, N-tert-Butyl-2-[5-[(3-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine Hydrochloride 880250-63-5P, 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyridin-2-yl]thiophen-2-yl]ethynyl]benzenesulfonamide Hydrochloride 880250-64-6P, 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyridin-2-yl]thiophen-2-yl]ethynyl]benzoic acid 880250-65-7P, 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyridin-2-yl]thiophen-2-yl]ethynyl]benzamide Hydrochloride 880250-66-8P, N-[3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyridin-2-yl]thiophen-2-yl]ethynyl]phenyl]acetamide 880250-67-9P, N-tert-Butyl-N-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-68-0P, N,N-Dimethyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-69-1P, N-tert-Butyl-N-methyl-2-[5-(pyridin-2-ylethynyl)thiazol-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-70-4P, [6-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyridin-2-yl]thiophen-2-yl]ethynyl]pyridin-2-yl]methanol 880250-71-5P, N-[3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyridin-2-yl]thiophen-2-yl]ethynyl]phenyl]methanesulfonamide 880250-72-6P, N-tert-Butyl-8-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride 880250-73-7P, 2-[5-(Pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine 880250-74-8P, N-tert-Butyl-2-[5-[(3-chlorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-

alpyridin-3-amine 880250-75-9P, N-tert-Butyl-2-[5-[(2,3-difluorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine  
880250-76-0P, N-tert-Butyl-7-chloro-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyridin-3-amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazo[1,2-a]pyridin-3- amines and related compds. as mGluR5 receptor modulators)

IT 880250-77-1P 880250-78-2P, [2-(5-Bromothiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl] (1-phenylethyl)amine 880250-79-3P, [2-(5-Bromothiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl] (1,1,3,3-tetramethylbutyl)amine 880250-80-6P, [2-(5-Bromothiophen-2-yl)imidazo[1,2-a]pyridin-3-yl] (1,1,3,3-tetramethylbutyl)amine 880250-82-8P 880250-83-9P 880250-86-2P 880250-87-3P 880250-88-4P 880250-89-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazo[1,2-a]pyridin-3- amines and related compds. as mGluR5 receptor modulators)


IT 880250-84-0P, N-tert-Butyl-2-[5-[(6-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of imidazo[1,2-a]pyridin-3- amines and related compds. as mGluR5 receptor modulators)

RN 880250-84-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(6-methyl-2-pyridinyl)ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)



IT 880238-42-6P, Cyclopentyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880239-39-4P 880240-65-3P, (4-Methoxybenzyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880240-79-9P, tert-Butyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880241-88-3P, (3-Methoxybenzyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880242-57-9P, (1-Phenylethyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880244-30-4P, (3-Methoxyphenyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880245-97-6P, tert-Butyl [2-(4-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880246-11-7P, [2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl] (1,1,3,3-tetramethylbutyl)amine 880246-23-1P, Butyl [2-(4-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine 880246-48-0P, [2-(5-Pyridinylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl] (1,1,3,3-tetramethylbutyl)amine 880246-61-7P 880247-03-0P 880247-16-5P, Dimethyl [2-(5-

phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-ylamine  
**880247-31-4P**, Methyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine **880247-45-0P**, N-[2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]acetamide **880247-59-6P**, Ethyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine **880247-73-4P**, Propyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine **880247-82-5P**, Butyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine **880247-83-6P**, (2-Methylpropyl) [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine **880247-84-7P**, Pentyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine **880247-85-8P 880247-86-9P**, Benzyl [2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]amine **880247-87-0P**, [2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-ylamino]acetic acid methyl ester **880247-88-1P 880247-89-2P 880247-90-5P**, N-[2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]benzamide **880247-91-6P**, [2-(5-Phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]pyridin-3-ylmethanamine **880247-92-7P**, 2,2-Dimethyl-N-[2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]propionamide **880247-93-8P**, 3-Methoxy-N-[2-(5-phenylethynylthiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl]benzamide **880247-94-9P 880247-95-0P 880247-96-1P**, Methyl 2-[5-(phenylethynyl)thiophen-2-yl]-3-(2,4,4-trimethylpentan-2-ylamino)imidazo[1,2-a]pyrazine-8-carboxylate **880247-98-3P**, 2-[5-[(6-Methylpyridin-2-yl)ethynyl]thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrazin-3-amine **880247-99-4P**, N-Cyclohexyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-00-0P**, 2-[5-(Phenylethynyl)thiophen-2-yl]-3-(piperidin-1-yl)imidazo[1,2-a]pyrazine **880248-01-1P**, N-tert-Butyl-N-methyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-03-3P**, N-tert-Butyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-05-5P**, N,N-Diethyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-07-7P**, N-tert-Butyl-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-10-2P**, N-Methyl-2-[5-(phenylethynyl)thiophen-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-11-3P**, 2-[5-(Phenylethynyl)thiophen-2-yl]-3-(pyrrolidin-1-yl)imidazo[1,2-a]pyrazine Hydrochloride **880248-12-4P**, N-tert-Butyl-2-[5-[(4-fluorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-16-8P**, N-tert-Butyl-2-[5-[(3-fluorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-17-9P**, N-tert-Butyl-2-[5-[(2-fluorophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-18-0P**, Methyl 3-(tert-butylamino)-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazine-8-carboxylate **880248-19-1P**, N-tert-Butyl-2-[5-(pyrazin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-20-4P**, 2-[5-[(4-Aminophenyl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine **880248-21-5P**, N-Isopropyl-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-22-6P**, N-tert-Butyl-2-[5-(thiophen-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-23-7P**, N-tert-Butyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine **880248-24-8P**, N-tert-Butyl-2-[5-[(2-methoxyphenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-25-9P**, N-tert-Butyl-2-[5-[(3-methoxyphenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-26-0P**,

N-tert-Butyl-2-[5-[(4-methoxyphenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-28-2P**,  
 N-tert-Butyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine **880248-29-3P**, N-tert-Butyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyrazin-3-amine **880248-30-6P**,  
 N-tert-Butyl-2-[2-methyl-6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-amine **880248-31-7P**, N-tert-Butyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-32-8P**,  
 3-(tert-Butylamino)-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazine-8-carboxylic acid **880248-33-9P**, 4-[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]phenol Hydrochloride **880248-34-0P**, 3-[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]phenol **880248-35-1P**, 2-[5-[(3-Aminophenyl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-36-2P**,  
 2-[5-[(2-Aminophenyl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-38-4P**,  
 N-tert-Butyl-2-[6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-amine **880248-39-5P**, N-tert-Butyl-2-[5-(pyridin-4-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-40-8P**, 2-[5-[(6-Aminopyridin-3-yl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-41-9P**,  
 N-tert-Butyl-2-[5-(pyrimidin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-42-0P**,  
 N-tert-Butyl-2-[5-[(4-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-43-1P**,  
 N-tert-Butyl-2-[5-[(5-methylpyridin-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-45-3P**,  
 N-tert-Butyl-2-[5-(thiazol-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-46-4P**, 2-[5-(Pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-47-5P**,  
 N-tert-Butyl-2-[5-[(5-methylthiophen-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-48-6P**,  
 2-[5-[(6-Aminopyridin-2-yl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-49-7P**,  
 N-tert-Butyl-2-[5-[(3-methylthiophen-2-yl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-50-0P**,  
 N-tert-Butyl-2-[4-(phenylethynyl)thiazol-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-51-1P**, N-tert-Butyl-2-[5-(m-tolylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-52-2P**,  
 3-[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]benzonitrile Hydrochloride **880248-54-4P**,  
 N-tert-Butyl-2-[6-(phenylethynyl)pyridin-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-55-5P**, N-tert-Butyl-N-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-56-6P**, 4-[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]benzonitrile Hydrochloride **880248-57-7P**,  
 2-[5-[(1H-Indol-6-yl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-58-8P**,  
 N-tert-Butyl-2-[2-(phenylethynyl)thiazol-5-yl]imidazo[1,2-a]pyrazin-3-amine **880248-59-9P** **880248-60-2P**, 2-[5-[(3-(1H-Pyrrol-1-yl)phenyl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-61-3P**, 2-[5-[(1H-Indol-4-yl)ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-62-4P**, N-tert-Butyl-2-[5-[(3-nitrophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-63-5P**, N-tert-Butyl-2-[5-[(4-nitrophenyl)ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-64-6P**, N-tert-Butyl-2-[5-(thiazol-4-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride

**880248-65-7P**, 2-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]phenol **880248-66-8P**,  
 2-[5-[[3-(Aminomethyl)phenyl]ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine **880248-67-9P**,  
 2-[5-(Biphenyl-3-ylethynyl)thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-68-0P**,  
 N-tert-Butyl-2-[5-(thiophen-3-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-69-1P**,  
 N-tert-Butyl-2-[5-[[3-(dimethylamino)phenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-70-4P**,  
 N-tert-Butyl-2-[5-[[6-methylpyridin-2-yl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-71-5P**,  
 N-tert-Butyl-2-[5-[[3-fluoropyridin-2-yl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-72-6P**,  
 N-tert-Butyl-2-[5-[[3-(methylamino)phenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-73-7P**,  
 N-tert-Butyl-2-[5-(p-tolylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-74-8P**, N-tert-Butyl-2-[5-(o-tolylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-75-9P**,  
 N-tert-Butyl-2-[4-methyl-5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-76-0P**,  
 N-tert-Butyl-2-[4-methyl-5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-77-1P**,  
 N-tert-Butyl-2-[5-[[6-fluoropyridin-2-yl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-78-2P**, N-tert-Butyl-2-[5-[[2-nitrophenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-79-3P**, N-tert-Butyl-8-chloro-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-80-6P**,  
 N-tert-Butyl-2-[5-[[6-methoxypyridin-2-yl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-81-7P**,  
 N-tert-Butyl-2-[5-[[5-fluoropyridin-2-yl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-82-8P**,  
**880248-83-9P**, N-tert-Butyl-2-[5-[[5-methoxypyridin-3-yl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-84-0P**, 5-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]nicotinonitrile Hydrochloride **880248-85-1P**, N-tert-Butyl-2-[5-[[3-(methylthio)phenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-86-2P**, Methyl 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]benzoate **880248-87-3P**, N-tert-Butyl-2-[5-[[3,5-difluoropyridin-2-yl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-88-4P**, N-tert-Butyl-2-[5-(phenylethynyl)thiazol-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-89-5P**,  
 N-tert-Butyl-2-[2-(pyridin-4-ylethynyl)thiazol-5-yl]imidazo[1,2-a]pyrazin-3-amine **880248-90-8P**, 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]benzaldehyde **880248-91-9P**,  
 3-[[5-[3-(tert-Butylamino)imidazo[1,2-a]pyrazin-2-yl]thiophen-2-yl]ethynyl]-4-fluorobenzonitrile **880248-92-0P**,  
 N-tert-Butyl-2-[5-[[3-(trifluoromethyl)phenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-93-1P**,  
 N-tert-Butyl-2-[2-(pyridin-2-ylethynyl)thiazol-5-yl]imidazo[1,2-a]pyrazin-3-amine **880248-94-2P**, N-tert-Butyl-2-[3-methyl-5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-95-3P**, N-tert-Butyl-2-[3-methyl-5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-96-4P**, N-tert-Butyl-2-[5-[[3-vinylphenyl]ethynyl]thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880248-97-5P**,  
 2-[5-[[1H-Imidazol-4-yl]ethynyl]thiophen-2-yl]-N-tert-butylimidazo[1,2-a]pyrazin-3-amine Hydrochloride **880248-98-6P**,  
 N-tert-Butyl-2-[5-[[3-methylpyridin-2-yl]ethynyl]thiophen-2-yl]imidazo[1,2-




a]pyrazin-3-amine **880248-99-7P**, N,N-Dimethyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-12-7P**, N-(2-Methylhexan-2-yl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-13-8P**, N-Phenethyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-14-9P**, N-(3-Methoxyphenethyl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-15-0P**, 2-[4-(Phenylethynyl)thiophen-2-yl]-N-[2-(thiophen-2-yl)ethyl]imidazo[1,2-a]pyrazin-3-amine **880249-17-2P**, N-(2-Methylpentan-2-yl)-2-[5-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-18-3P**, N-(Cyclohexylmethyl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-19-4P**, N-(2-Methoxybenzyl)-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-24-1P**, N-Cyclopentyl-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-25-2P**, N-(1-Phenylethyl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-26-3P**, N-(2-Methylpentan-2-yl)-2-[4-(phenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-28-5P**, N-Cyclopentyl-2-[5-(phenylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-50-3P**, N-Cyclohexyl-2-[3-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine **880249-51-4P**, 2-[3-(Pyridin-2-ylethynyl)phenyl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrazin-3-amine **880249-52-5P**, N-Cyclopentyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine **880249-54-7P**, N-4-Fluorophenyl-2-[4-(pyridin-2-ylethynyl)phenyl]imidazo[1,2-a]pyrazin-3-amine **880249-55-8P**, N-Cyclopentyl-2-[2-methyl-6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-amine **880249-56-9P**, N-Cyclohexyl-2-[2-methyl-6-(phenylethynyl)pyridin-3-yl]imidazo[1,2-a]pyrazin-3-amine **880249-57-0P**, N-Cyclopentyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-59-2P**, N-Cyclohexyl-2-[5-(pyridin-2-ylethynyl)furan-2-yl]imidazo[1,2-a]pyrazin-3-amine **880249-60-5P**, 2-[5-(Pyridin-2-ylethynyl)furan-2-yl]-N-(2,4,4-trimethylpentan-2-yl)imidazo[1,2-a]pyrazin-3-amine **880249-61-6P**, N-Cyclopentyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyrazin-3-amine **880249-63-8P**, N-Cyclohexyl-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyrazin-3-amine **880249-64-9P**, N-(4-Fluorophenyl)-2-[3-[(6-methylpyridin-2-yl)ethynyl]phenyl]imidazo[1,2-a]pyrazin-3-amine **880250-34-0P**, N-Methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine **880250-44-2P**, tert-Butyl[2-[5-(3-trifluoromethoxyphenylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-yl]amine **880250-72-6P**, N-tert-Butyl-8-methyl-2-[5-(pyridin-2-ylethynyl)thiophen-2-yl]imidazo[1,2-a]pyrazin-3-amine Hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazo[1,2-a]pyridin-3-amines and related compds. as mGluR5 receptor modulators)


RN 880238-42-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-cyclopentyl-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880239-39-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclohexylmethyl)-2-[5-(1-propynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880240-65-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-[(4-methoxyphenyl)methyl]-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880240-79-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880241-88-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-[(3-methoxyphenyl)methyl]-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880242-57-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1-phenylethyl)-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880244-30-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(3-methoxyphenyl)-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 880245-97-6 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[4-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 880246-11-7 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-(phenylethynyl)-2-thienyl]-N-(1,1,3,3-

tetramethylbutyl) - (9CI) (CA INDEX NAME)




RN 880246-23-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine N-butyl-2-[4-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880246-48-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine 2-[5-(2-pyridinyl)-2-thienyl]-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 880246-61-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine 2-[5-(4-pyridinylethynyl)-2-thienyl]-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 880247-03-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine 2-[5-(2-pyridinylethynyl)-2-thienyl]-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 880247-16-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-dimethyl-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880247-31-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-methyl-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880247-45-0 CAPLUS

CN Acetamide, N-[2-[5-(phenylethynyl)-2-thienyl]imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)



RN 880247-59-6 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-ethyl-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)

NH<sub>Et</sub>

RN 880247-73-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 1-[5-(phenylethynyl)-2-thienyl]-N-propyl-  
(9CI) (CA INDEX NAME)


NHPr-n



RN 880247-82-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 1-butyl-2-[5-(phenylethynyl)-2-thienyl]-  
(9CI) (CA INDEX NAME)


NHBu-n




RN 880247-83-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 1-(2-methylpropyl)-2-[5-(phenylethynyl)-2-thienyl]-  
(9CI) (CA INDEX NAME)

NHBu-i




RN 880247-84-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 1-pentyl-2-[5-(phenylethynyl)-2-thienyl]-  
(9CI) (CA INDEX NAME)Me-(CH<sub>2</sub>)<sub>4</sub>-NH


RN 880247-85-8 CAPLUS

CN Glycine, N-(2-methoxy-2-oxoethyl)-N-[2-[5-(phenylethynyl)-2-thienyl]imidazo[1,2-a]pyrazin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 880247-86-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-(phenylethynyl)-2-thienyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 880247-87-0 CAPLUS

CN Glycine, N-[2-[5-(phenylethynyl)-2-thienyl]imidazo[1,2-a]pyrazin-3-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 880247-88-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(4-pyridinylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880247-89-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(2-pyridinylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880247-90-5 CAPLUS

CN Benzamide, N-[2-[5-(phenylethynyl)-2-thienyl]imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 880247-91-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-methyl-2-[5-(phenylethynyl)-2-thienyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 880247-92-7 CAPLUS


CN Propanamide, 2,2-dimethyl-N-[2-[5-(phenylethynyl)-2-thienyl]imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)



RN 880247-93-8 CAPLUS




CN Benzamide, 3-methoxy-N-[2-5-(phenylethynyl)-2-thienyl]imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




RN 880247-94-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(3-pyridinylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880247-95-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880247-96-1 CAPLUS

CN Imidazo[1,2-a]pyrazine-8-carboxylic acid, 2-[5-(phenylethynyl)-2-thienyl]-3-[(1,1,3,3-tetramethylbutyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 880247-98-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-[(6-methyl-2-pyridinyl)ethynyl]-2-thienyl]-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 880247-99-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-cyclohexyl-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880248-00-0 CAPLUS

CN Imidazo[1,2-a]pyrazine, 2-[5-(phenylethynyl)-2-thienyl]-3-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 880248-01-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-N-methyl-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 880248-03-3 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(2-phenylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-05-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-diethyl-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880248-07-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(phenylethynyl)-2-furanyl]- (9CI) (CA INDEX NAME)



RN 880248-10-2 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-methyl-2-[5-(phenylethynyl)-2-thienyl]-N-(1,1,3,3-tetramethylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-11-3 CAPLUS


CN Imidazo[1,2-a]pyrazine, 2-[5-(phenylethynyl)-2-thienyl]-3-(1-pyrrolidiny)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-12-4 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(4-fluorophenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-16-8 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(3-fluorophenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-17-9 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(3-fluorophenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-18-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-8-carboxylic acid, 3-[(1,1-dimethylethyl)amino]-2-[5-(phenylethynyl)-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 880248-19-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(pyrazinylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880248-20-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-[(4-aminophenyl)ethynyl]-2-thienyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 880248-21-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1-methylethyl)-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 880248-22-6 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(2-thienylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-23-7 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[3-(2-pyridinylethynyl)phenyl]- (9CI) (CA INDEX NAME)



RN 880248-24-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(2-methoxyphenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)


NAME)



● HCl

RN 880248-25-9 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(3-methoxyphenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-26-0 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(4-methoxyphenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-28-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[4-(2-pyridinylethynyl)phenyl]- (9CI) (CA INDEX NAME)




RN 880248-29-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[3-[(6-methyl-2-pyridinyl)ethynyl]phenyl]- (9CI) (CA INDEX NAME)




RN 880248-30-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[2-methyl-6-(phenylethynyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 880248-31-7 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(2-pyridinylethynyl)-2-furanyl]- (9CI) (CA INDEX NAME)



RN 880248-32-8 CAPLUS


CN Imidazo[1,2-a]pyrazine-8-carboxylic acid, 3-[(1,1-dimethylethyl)amino]-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)





RN 880248-33-9 CAPLUS


CN Phenol, 4-[[5-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-thienyl]ethynyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-34-0 CAPLUS

CN Phenol, 3-[[5-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-thienyl]ethynyl]- (9CI) (CA INDEX NAME)



RN 880248-35-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-[(3-aminophenyl)ethynyl]-2-thienyl]-N-(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 880248-36-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-[(2-aminophenyl)ethynyl]-2-thienyl]-N-


(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-38-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[6-(phenylethynyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 880248-39-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(4-phenylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-40-8 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-[(6-amino-3-pyridinyl)ethynyl]-2-thienyl]-N-(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-41-9 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1 dimethylethyl)-2-[5-(2-pyrimidinylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-42-0 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1 dimethylethyl)-2-[5-[(4-methyl-2-pyridinyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-43-1 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1 dimethylethyl)-2-[5-[(5-methyl-2-pyridinyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-45-3 CAPLJS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(2-thiazolyethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 880248-46-4 CAPLJS


CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-(2-pyridinyethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-47-5 CAPLJS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[[4-(methylthio)phenyl]ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 880248-48-6 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-[(6-amino-2-pyridinyl)ethynyl]-2-thienyl]-N-(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 880248-49-7 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(2-methylthio)phenyl]ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 880248-50-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[4-(phenylethynyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 880248-51-1 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(3-methylphenyl)ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 880248-52-2 CAPLUS


CN Benzonitrile, 3-[[5-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-thienyl]ethynyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-54-4 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[6-(phenylethynyl)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-55-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-N-methyl-2-[5-(2-pyridinylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 880248-56-6 CAPLUS


CN Benzonitrile, 4-[[5-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-thienyl]ethynyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-57-7 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(1H-indol-6-ylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-58-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[2-(phenylethynyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 880248-59-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[[3-(1H-pyrrol-1-yl)phenyl]ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880248-60-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[[3-(1H-pyrrol-1-yl)phenyl]ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 880248-61-3 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(1H-indol-4-ylethynyl)-2-thienyl], monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-62-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(3-nitrophenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-63-5 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(4-nitrophenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 880248-64-6 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(4-thiazolylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-65-7 CAPLUS

CN Phenol, 2-[[5-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-thienyl]ethynyl]- (9CI) (CA INDEX NAME)




RN 880248-66-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-[[3-(aminomethyl)phenyl]ethynyl]-2-thienyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 880248-67-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-([1,1'-biphenyl]-3-ylethynyl)-2-thienyl]-N-(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 880248-68-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(3-thienylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 880248-69-1 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-[[3-(dimethylamino)phenyl]ethynyl]-2-thienyl]-N-(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-70-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(6-methyl-2-pyridinyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-71-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(3-fluoro-2-pyridinyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-72-6 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(3-(methylamino)phenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-73-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(4-methylphenyl)ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)



FN 880248-74-8 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(2-methylphenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

FN 880248-75-9 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[4-methyl-5-(phenylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-76-0 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[4-methyl-5-(2-pyridinylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-77-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(6-fluoro-2-pyridinyl)ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880248-78-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(2-nitrophenyl)ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880248-79-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-chloro-N-(1,1-dimethylethyl)-2-[5-(2-pyridinylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880248-80-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(6-methoxy-2-pyridinyl)ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 880248-81-7 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(5-methoxy-2-pyridinyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-82-8 CAPLUS

CN Benzeneacetonitrile, 4-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-(phenylethynyl)- (9CI) (CA INDEX NAME)



RN 880248-83-9 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(5-methoxy-3-pyridinyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-84-0 CAPLUS


CN 3-Pyridinecarbonitrile, 5-[[5-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-thienyl]ethynyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-85-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[[3-(methylthio)phenyl]ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880248-86-2 CAPLUS

CN Benzoic acid, 3-[[5-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-thienyl]ethynyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 880248-87-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-[(3,5-difluoro-2-pyridinyl)ethynyl]-2-thienyl]-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 880248-88-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(phenylethynyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 880248-89-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[2-(4-pyridinylethynyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 880248-90-8 CAPLUS


CN Benzaldehyde, 3-[[5-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-thienyl]ethynyl]- (9CI) (CA INDEX NAME)






RN 880248-91-9 CAPLUS

CN Benzonitrile, 3-[[5-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]-2-thienyl]ethynyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 880248-92-0 CAPLUS


CN Imidazo[1,2-a]pyrazin-3 amine, N-(1,1-dimethylethyl)-2-[5-[[3-(trifluoromethyl)phenyl]ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-93-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3 amine, N-(1,1-dimethylethyl)-2-[2-(2-pyridinylethynyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 880248-94-2 CAPLUS


CN Imidazo[1,2-a]pyrazin-3 amine, N-(1,1-dimethylethyl)-2-[3-methyl-5-(phenylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 880248-95-3 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[3-methyl-5-(2-pyridinylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 880248-96-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(3-ethenylphenyl)ethynyl]-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 880248-97-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-(1H-imidazol-4-ylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


FN 880248-98-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[(3-methyl-2-pyridinyl)ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)




FN 880248-99-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-dimethyl-2-[5-(2-pyridinylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




FN 880249-12-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylpentyl)-2-[4-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




FN 880249-13-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(2-phenylethyl)-2-[4-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880249-14-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-[2-(3-methoxyphenyl)ethyl]-2-[4-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880243-15-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[2-(phenylethynyl)-2-thienyl]-N-[2-(2-thienylethyl)]- (9CI) (CA INDEX NAME)




RN 880243-17-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(2,1-dimethylbutyl)-2-[5-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880243-18-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclohexylmethyl)-2-[4-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880243-19-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-[(2-methoxyphenyl)methyl]-2-[5-(phenylethynyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 880249-24-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-cyclopentyl-2-[4-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880249-25-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1-phenylethyl)-2-[4-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880249-26-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylbutyl)-2-[4-(phenylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)





RN 880249-08-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-cyclopentyl-2-[5-(phenylethynyl)-furan-2-yl]- (9CI) (CA INDEX NAME)




RN 880249-00-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-cyclohexyl-2-[3-(2-pyridinylethynyl)phenyl]- (9CI) (CA INDEX NAME)




RN 880249-51-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-[3-(2-pyridinylethynyl)phenyl]-N-1,1,3,3-tetramethylbutyl- (9CI) (CA INDEX NAME)




RN 880249-52-5 CAPLUS

CN 2-midazo[1,2-a]pyrazin-3-amine, N-cyclopentyl-2-[4-(2-pyridinyneethynyl)phenyl] - (9CI) (CA INDEX NAME)




RN 880249-54-7 CAPLUS

CN 2-midazo[1,2-a]pyrazin-3-amine, N-(4-fluorophenyl)-2-[4-(2-pyridinyneethynyl)phenyl] - (9CI) (CA INDEX NAME)



RN 880249-55-8 CAPLUS


CN 2-midazo[1,2-a]pyrazin-3-amine, N-cyclopentyl-2-[2-methyl-6-(phenylethynyl)-3-pyridinyl] - (9CI) (CA INDEX NAME)



RN 880249-56-9 CAPLUS


CN 2-midazo[1,2-a]pyrazin-3-amine, N-cyclohexyl-2-[2-methyl-6-(phenylethynyl)-3-pyridinyl] - (9CI) (CA INDEX NAME)

3-pyridinyl]- (9CI) (CA INDEX NAME)





RN 880249-57 0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-cyclopentyl-2-[5-(2-pyridinylethynyl)-2-furanyl]- (9CI) (CA INDEX NAME)



RN 880249-59 2 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-cyclohexyl-2-[5-(2-pyridinylethynyl)-2-furanyl]- (9CI) (CA INDEX NAME)



RN 880249-60 5 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 2-[5-(2-pyridinylethynyl)-2-furanyl]-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)






RN 880249-61-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-cyclopentyl-2-[3-[(6-methyl-2-pyridinyl)ethynyl]phenyl]- (9CI) (CA INDEX NAME)




RN 880249-63-8 CAPLUS



CN Imidazo[1,2-a]pyrazin-3-amine, N-cyclohexyl-2-[3-[(6-methyl-2-pyridinyl)ethynyl]phenyl]- (9CI) (CA INDEX NAME)



RN 880249-64-9 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(4-fluorophenyl)-2-[3-[(6-methyl-2-pyridinyl)ethynyl]phenyl]- (9CI) (CA INDEX NAME)






RN 880250-34-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-methyl-2-[5-(2-pyridinylethynyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880250-44-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-[[3-(trifluoromethoxy)phenyl]ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 880250-72-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-8-methyl-2-[5-(2-pyridinylethynyl)-2-thienyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


IT 880250-77-1P 880250-78-2P, [2-(5-Bromothiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl] (1-phenylethyl)amine 880250-79-3P  
 [2-(5-Bromothiophen-2-yl)imidazo[1,2-a]pyrazin-3-yl] (1,1,3,3-tetramethylbutyl)amine 880250-82-8P 880250-83-9P  
 RL: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of imidazo[1,2-a]pyridin-3-amines and related compds. as mGluR5 receptor modulators)  
 RN 880250-77-1 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-(5-bromo-2-thienyl)-N-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 880250-78-2 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-(5-bromo-2-thienyl)-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 880250-79-3 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 2-(5-bromo-2-thienyl)-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)



RN 880250-82-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-[5-  
[(trimethylsilyl)ethynyl]-2-thienyl]- (9CI) (CA INDEX NAME)

RN 880250-83-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-(5-ethynyl-2-  
thienyl)- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L57 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1004749 CAPLUS

DOCUMENT NUMBER: 143:306338

TITLE: Preparation of imidazo[1,2-a]pyrazine derivatives as  
inhibitors of JNK kinasesINVENTOR(S): Birault, Veronique; Harris, Clifford John; Harrison,  
Stephen Anthony

PATENT ASSIGNEE(S): Biofocus Discovery Limited, UK

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085252	A1	20050915	WO 2005-GB842	20050304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CC, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SM,  
 SY, TJ, TM, TN, TR, TT, TZ, JA, UG, US, UZ, VC, VN, YU, ZI, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZI, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PT, PT,  
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GV, ML,  
 MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 2004-4889

A 2004-0304



GB 2004-26259

A 2004-1130

OTHER SOURCE(S):

MARPAT 143:3063:3

GI



AB Title compds. I [R1 = (un)substituted heteroaryl, arylalkyl, aryl, etc.; X = NHR2, NR2R3 or OR2; R2 and R3 independently = H, (un)substituted heteroarylalkyl, heteroaryloxy, etc.; Z = NC(O), C(O)N, NS(O)2, etc.; n = 0-1] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of JNK kinases. Thus, e.g., II was prepared by coupling of 6,8-dibromo-imidazo[1,2-a]pyrazine (preparation given) with trans-4-aminocyclohexanol hydrochloride and subsequent amidation with thiophene-2-acetamide. The activity of I was evaluated in JNK screening assays and it was revealed that selected compds. of the invention displayed IC50 values in the range of less than 1  $\mu$ M up to 10  $\mu$ M. I as inhibitor of JNK kinases should prove useful in the treatment of diseases such as but not limited to rheumatoid arthritis, multiple sclerosis and asthma. Pharmaceutical compns. comprising I are disclosed.

IC ICM C07D487-04

ICS A61K031-437; A61P035-00

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT **Mental and behavioral disorders**

(attention deficit disorder; preparation of imidazo[1,2-a]pyrazine derivs.

as inhibitors of JNK kinases)


IT **Alzheimer's disease**  
 Angiogenesis  
 Anti-**Alzheimer's** agents  
 Anti-ischemic agents  
 Antiasthmatics  
 Anticonvulsants  
 Antidiabetic agents  
 Antiobesity agents  
 Antiparkinsonian agents  
 Antirheumatic agents  
 Antitumor agents  
 Anxiety  
 Anxiolytics  
 Asthma  
 Atherosclerosis  
 Autoimmune disease  
 Cardiovascular agents  
 Cardiovascular system, disease  
 Diabetes mellitus  
 Epilepsy  
 Human  
 Inflammation  
 Ischemia  
 Learning disorders  
 Mammary gland, neoplasm  
 Memory disorders  
 Metabolic disorders  
 Multiple sclerosis  
 Neoplasm  
 Nervous system, disease  
 Obesity  
 Ovary, neoplasm  
 Pancreas, neoplasm  
 Parkinson's disease  
 Prostate gland, neoplasm  
 Psoriasis  
 Rheumatoid arthritis  
 Transplant rejection  
 (preparation of imidazo[1,2-a]pyrazine der vs. as inhibitors of JNK kinases)

IT **63744-22-9P 864546-04-3P 864546-05-4P 864546-06-5P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of imidazo[1,2-a]pyrazine der vs. as inhibitors of JNK kinases)


IT **63744-22-9P 864546-05-4P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of imidazo[1,2-a]pyrazine der vs. as inhibitors of JNK kinases)

RN 63744-22-9 CAPIUS

CN Imidazo[1,2-a]pyrazine, 6,8-dibromo- (9CI) ((A INDEX NAME))



RN 864546-01-4 CAPLUS  
 CN Carbamic acid, (6-bromoimidazo[1,2-a]pyrazin-8-yl)(cyclopropylmethyl)-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L57 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:1004722 CAPLUS  
 DOCUMENT NUMBER: 143:306320  
 TITLE: Preparation of diaryl-substituted triazole derivatives  
 as mGluR1 inhibitors  
 INVENTOR(S): Kawamoto, Hiroshi; Ito, Satoru; Satoh, Atsushi;  
 Nagatomi, Yasushi; Hirata, Yukari; Kimura, Toshifumi;  
 Suzuki, Gentaro; Sato, Akio; Ohta, Hisashi  
 PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd, Japan  
 SOURCE: PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085214	A1	20050915	WO 2005-JP4379	20050307
W: AE, AG, AL, AM, AT, AU, AZ, BA BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: FW, GH, GM, KE, LS, MW, MZ, NA SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE IS, IT, LT, LU, MC, NL, PL, PT, PO, SE, SI, SK, TR, BF, BJ, CF CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.: JP 2004-63243 A 20040305  
 OTHER SOURCE(S): MARPAT 143:306320  
 GI



I



II

- AB Title compds. represented by the formula I [wherein X1 = O, N or CR2; X2-X4, A1 = independently N or C; X5 = S or A4:A3; A2-A4 = independently CR4 or N; ring A = (hetero)cyclcyl or (hetero)aryl; R2 = H, alkyl, cyano, alkyloxy(carbonyl) or trialkylsilyl; R4 = H, halo, alkyl(oxy), etc.; R3 = halo, alkyl(oxy), cyano, etc.; and pharmaceutically acceptable salts thereof] were prepared as mGluR1 (metabotropic Glutamate receptor 1) inhibitors. For example, II was given in a multi-step synthesis starting from 5-bromoindane. II showed inhibition of mGluR1a with an IC50 value of 2.3 nM. Thus, I are useful for the prevention or treatment of convulsion, acute pains, inflammatory pains, chronic pains, brain disorders such as brain infarction or transient cerebral ischemic attack, mental function disorders such as **schizophrenia**, anxiety, drug dependence, Parkinson's disease, or gastrointestinal disorders (no data).
- IC ICM C07D249-06  
ICS A61K031-4192; A61K031-427; A61K031-436; A61K031-437; A61K031-4375; A61K031-4439; A61K031-4709; A61K031-4725; A61K031-496; A61K031-498; A61K031-517; A61K031-5377; A61P001-06; A61P009-10; A61P025-04; A61P025-16; A61P025-18; A61P025-22; A61P025-28
- CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1
- IT Analgesics  
Anticonvulsants  
Antiparkinsonian agents  
Antipsychotics  
Anxiety  
Anxiolytics  
Convulsion  
Digestive tract, disease  
Drug dependence  
Parkinson's disease  
**Schizophrenia**  
(preparation of diaryl-substituted triazole derivs. as mGluR1 inhibitors)
- IT 864863-68-3P 864363-69-4P 864863-70-7P 864863-71-8P 864863-72-9P  
864863-73-0P 864363-75-2P 864863-76-3P 864863-77-4P 864863-79-6P  
864863-80-9P 864363-81-0P 864863-82-1P 864863-83-2P 864863-84-3P  
864863-85-4P 864363-86-5P 864863-87-6P 864863-88-7P 864863-89-8P  
864863-92-3P 864363-93-4P 864863-96-7P 864863-97-8P 864863-98-9P  
864863-99-0P 864364-00-6P 864864-01-7P 864864-02-8P 864864-03-9P  
864864-04-0P 864364-05-1P 864864-06-2P 864864-07-3P 864864-08-4P  
864864-09-5P 864364-10-8P 864864-11-9P 864864-12-0P 864864-14-2P  
864864-15-3P 864364-16-4P 864864-18-6P 864864-20-0P 864864-23-3P  
864864-24-4P 864364-25-5P 864864-26-6P 864864-27-7P 864864-28-8P  
864864-29-9P 864364-30-2P 864864-31-3P 864864-32-4P 864864-33-5P  
864864-34-6P 864364-35-7P 864864-36-8P 864864-37-9P 864864-38-0P  
864864-39-1P 864364-40-4P 864864-41-5P 864864-42-6P 864864-43-7P



864864-44- P	864864-45-9P	864864-46-0P	864864-49-3P	864864-50-6P
864864-51- P	864864-52-8P	864864-54-0P	864864-55-1P	864864-56-2P
864864-57- P	864864-58-4P	864864-59-1P	864864-60-8P	864864-62-0P
864864-63- P	864864-64-2P	864864-65-1P	864864-66-4P	864864-67-5P
864864-69- P	864864-70-0P	864864-71- P	864864-73-3P	864864-74-4P
864864-76-1 P	864864-77-7P	864864-78-4P	864864-79-9P	864864-80-2P
864864-81-1 P	864864-82-4P	864864-83-1P	864864-85-7P	864864-86-8P
864864-87- P	864864-88-0P	864864-90-1P	864864-91-5P	864864-92-6P
864864-93-1 P	864864-94-8P	864864-95-0P	864864-97-1P	864864-99-3P
864865-00-1 P	864865-01-0P	864865-02-1P	864865-03-2P	864865-04-3P
864865-05-1 P	864865-06-5P	864865-08-1P	864865-09-8P	
864865-10-1P	864865-11-2P	864865-12-1P	864865-13-4P	
864865-14-1 P	864865-15-6P	864865-16-1P	864865-18-9P	864865-19-0P
864865-20-1 P	864865-21-4P	864865-22-1P	864865-23-6P	864865-25-8P
864865-26-1P	864865-27-0P	864865-28-1 P	864865-29-2P	864865-30-5P
864865-31-1 P	864865-32-7P	864865-33-8P	864865-34-9P	864865-35-0P
864865-36- P	864865-37-2P	864865-38-1P	864865-39-4P	864865-40-7P
864865-41-1 P	864865-42-9P	864865-43-0P	864865-44-1P	864865-45-2P
864865-46-1 P	864865-47-4P	864865-48-0P	864865-49-6P	864865-50-9P
864865-52-1 P	864865-53-2P	864865-54-1P	864865-55-4P	864865-56-5P
864865-57-1 P	864865-58-7P	864865-59-8P	864865-60-1P	864865-61-2P
864865-62-1 P	864865-63-4P	864865-64-1P	864865-65-6P	864865-66-7P
864865-67-1 P	864865-68-9P	864865-69-1P	864865-70-3P	864865-71-4P
864865-72-1 P	864865-73-6P	864865-74-1P	864865-75-8P	864865-76-9P
864865-77-1 P	864865-78-1P	864865-79-1P	864865-80-5P	864865-81-6P
864865-82-1 P	864865-84-9P	864865-86-1P	864865-87-2P	864865-88-3P
864865-89-1 P	864865-90-7P	864865-91-8P	864865-92-9P	864865-93-0P
864865-94- P	864865-95-2P	864865-97-1P	864865-98-5P	864865-99-6P
864873-71-1 P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaryl-substituted triazole derivs. as mGluR1 inhibitors)

IT	622-37-7P	1548-68-1P	2101-86-2P	3296-02-4P	3296-03-5P	3296-04-6P
	3296-07-9P	4113-72-8P	10296-29-4P	1656-92-5P	34598-49-7P	
	35774-47-1P	35774-48-2P	59128-04-0P	66768-57-8P	91229-55-9P	
	102284-85-1P	102934-51-0P	118078-62-0P	124783-03-5P	151895-74-8P	
	209971-43-1P	477716-88-4P	807343-17-1P	832114-33-7P	864866-09-1P	
	864866-10-1P	864866-11-5P	864866-12-1P	864866-13-7P	864866-14-8P	
	864866-15-1P	864866-16-0P	864866-17-1P	864866-18-2P	864866-19-3P	
	864866-20-1P	864866-21-7P	864866-22-8P	864866-23-9P	864866-24-0P	
	864866-25-1P	864866-26-2P	864866-27-8P	864866-28-4P	864866-29-5P	
	864866-30-8P	864866-31-9P	864866-32-0P	864866-33-1P	864866-34-2P	
	864866-35-1P	864866-36-4P	864866-37-5P	864866-38-6P	864866-39-7P	
	864866-40-1P	864866-41-1P	864866-42-1P	864866-43-3P	864866-44-4P	
	864866-45-1P	864866-46-6P	864866-47-1P	864866-48-8P	864866-49-9P	
	864866-50-1P	864866-51-3P	864866-52-4P	864866-53-5P	864866-54-6P	
	864866-55-1P	864866-56-8P	864866-57-9P	864866-58-0P	864866-59-1P	
	864866-60-4P	864866-61-5P	864866-62-6P	864866-63-7P	864866-64-8P	
	864866-65-1P	864866-66-0P	864866-67-1P	864866-68-2P	864866-69-3P	
	864866-70-1P	864866-71-7P	864866-72-8P	864866-73-9P	864866-74-0P	
	864866-75-1P	864866-76-2P	864866-77-3P	864866-78-4P	864866-79-5P	
	864866-80-8P	864866-81-9P	864866-82-0P	864866-83-1P	864866-84-2P	
	864866-85-1P	864866-86-4P	864866-87-5P	864866-88-6P	864866-89-7P	
	864866-90-1P	864866-91-1P	864866-92-1P	864866-93-3P	864866-94-4P	
	864866-95-1P	864866-96-6P	864866-97-1P	864866-98-8P	864866-99-9P	
	864867-00-1P	864867-01-6P	864867-02-1P	864867-03-8P	864867-04-9P	
	864867-05-1P	864867-06-1P	864867-07-1P	864867-08-3P	864867-09-4P	
	864867-10-1P	864867-11-8P	864867-12-1P	864867-13-0P	864867-14-1P	
	864867-15-1P	864867-16-3P	864867-17-4P	864867-18-5P	864867-19-6P	

864867-20-9P 864867-21-0P 864867-22-1P 864867-23-2P 864867-24-3P  
 864867-25-4P 864867-26-5P 864867-27-6P 864867-28-7P  
 864867-29-8P 864867-30-1P 864867-31-2P 864867-32-3P 864867-33-4P  
 864867-34-5P 864867-35-6P 864867-36-7P 864867-37-8P 864867-38-9P  
 864867-39-0P 864867-40-3P 864867-41-4P 864867-42-5P 864867-43-6P  
 864867-44-7P 864867-45-8P 864867-46-9P 864867-47-0P 864867-48-1P  
 864867-49-2P 864867-50-5P 864867-51-6P 864867-52-7P 864867-53-8P  
 864867-54-9P 864867-55-0P 864867-56-1P 864867-57-2P 864867-60-7P  
 864867-61-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of diaryl-substituted triazole derivs. as mGluR1 inhibitors)


IT 864865-10-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of diaryl-substituted triazole derivs. as mGluR1 inhibitors)

RN 864865-10-1 CAPLUS

CN Imidazo[1,2-a]pyrazine, 2-ethyl-6-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-  
 1,2,3-triazol-4-yl]- (9CI) (CA INDEX NAME)




IT 864867-26-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of diaryl-substituted triazole derivs. as mGluR1 inhibitors)

RN 864867-26-5 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-bromo-2-ethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:346791 CAPLUS

DOCUMENT NUMBER: 142:411376

TITLE: A preparation of imidazopyrazine derivatives, useful  
 as antiarrhythmics

INVENTOR(S): Plouvier, Bertrand M. C.; Fedida, David; Beatch,  
 Gregory N.; Chou, Doug Ta Hung; Yifru, Aregahegn S.;  
 Jung, Grace

PATENT ASSIGNEE(S): Cardiome Pharma Corporation, Can.

SOURCE: PCT Int. Appl., 100 pp.




DOCUMENT TYPE: CODEN: PIXXD2  
 LANGUAGE: Patent  
 FAMILY ACC. NUM. COUNT: 1 English  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200503483	A2	20050421	WO 2004-1B3601	20041008
WO 200503483	A3	20050714		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, CH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-510010P P 20031008  
 OTHER SOURCE(S): MARPAT 142:411376  
 GI



AB The inventor relates to a preparation of imidazopyrazine derivs. of formula I [wherein: R1, R2, R3, and R4 are independently selected from H, Br, Cl, F, NO2, CHF2, or (cyclo)alkyl, etc.; R5 is a substituted alkyl], useful as antiarrhythmics. For instance, imidazopyrazinone derivative II [IC50 (μM), ion-channels: Kv1.5 - 4.8, hERG - 100, H1Na - 340, Kv2.1 - 60] was prepared via amination of 1-phenyl-1-cyclopropylmethanol by imidazopyrazine derivative III with a yield of 42%.

IC ICM A61K

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT AIDS (disease)

(AIDS dementia complex, treatment of; preparation of imidazopyrazine derivs. useful as antiarrhythmics)

- IT **Mental and behavioral disorders**  
(AIDS dementia, treatment of; preparation of imidazopyrazine  
derivs. useful as antiarrhythmics)
- IT **Mental and behavioral disorders**  
(dementia, treatment of; preparation of imidazopyrazine derivs.  
useful as antiarrhythmics)
- IT **Mental and behavioral disorders**  
(depression, treatment of; preparation of imidazopyrazine derivs. useful as  
antiarrhythmics)
- IT Allergy inhibitors  
Analgesics  
Anti-Alzheimer's agents  
Anti-inflammatory agents  
Antiarrhythmics  
Antiasthmatics  
Anticonvulsants  
Antidepressants  
Antidiabetic agents  
Antihypertensives  
Antimigraine agents  
Antiparkinsonian agents  
Antitussives  
Anxiolytics  
Cardiovascular agents  
(preparation of imidazopyrazine derivs. useful as antiarrhythmics)
- IT Allergy  
Alopecia  
**Alzheimer's disease**  
Anxiety  
Arthritis  
Asthma  
Autoimmune disease  
Cardiovascular system, disease  
Central nervous system disease  
Convulsion  
Cough  
Cystic fibrosis  
Diabetes mellitus  
Digestive tract, disease  
Eye, disease  
Hypercholesterolemia  
Hypertension  
Hypotension  
Inflammation  
Insomnia  
Multiple sclerosis  
Muscle, disease  
Myasthenia gravis  
Paralysis  
Parkinson's disease  
Psoriasis  
Respiratory system, disease  
**Schizophrenia**  
Seizures  
Sexual disorders  
Transplant rejection  
Ulcer  
(treatment of; preparation of imidazopyrazine derivs. useful as  
antiarrhythmics)
- IT 609-13-2P, 2-Bromo-3-oxo-butyric acid ethyl ester 4544-43-8P,

2-Bromo-4,4,4-trifluoro-3-oxo-butyric acid ethyl ester 6863-73-6P,  
 2-Amino-3-chloropyrazine 23348-99-4P, 1-(4-Nitrophenyl)-  
 cyclopropanecarboxylic acid 23349-00-0P 85333-43-3P,  
 8-Chloro-2-methylimidazo[1,2-a]pyrazine 104462-06-8P,  
 2-(4-Methoxyphenyl)-7H-imidazo[1,2-a]pyrazin-8-one 110223-15-9P,  
 2-Amino-3-benzoyloxy pyrazine 112398-75-1P, N-Methyl-5-chloroindole  
 408328-42-7P, 1-(4-Nitrophenyl)-cyclopropanecarbonitrile  
 611240-68-7P, 8-Chloro-2-trifluoromethylimidazo[1,2-a]pyrazine  
 850406-38-1P, 2-Methyl-7H-imidazo[1,2-a]pyrazin-8-one 850406-39-2P  
 , 8-Chloro-2-isopropylimidazo[1,2-a]pyrazine 850406-40-5P,  
 8-Bromo-2-isopropylimidazo[1,2-a]pyrazine 850406-41-6P,  
 2-Isopropyl-7H-imidazo[1,2-a]pyrazin-8-one hydrochloride  
 850406-42-7P, 8-Bromo-2-trifluoromethylimidazo[1,2-a]pyrazine  
 850406-43-8P, 2-Trifluoromethyl-7H-imidazo[1,2-a]pyrazin-8-one  
 hydrochloride 850406-44-9P, 2-Methyl-8-oxo-7,8-dihydro-imidazo[1,2-  
 a]pyrazine-3-carboxylic acid ethyl ester 850406-45-0P,  
 8-Oxo-2-trifluoromethyl-7,8-dihydro-imidazo[1,2-a]pyrazine-3-carboxylic  
 acid ethyl ester 850406-46-1P, 1-(4-Trifluoromethylphenyl)-1-  
 hydroxymethylcyclopropane 850406-47-2P, 1-(3,5-  
 Bis(trifluoromethyl)phenyl)-1-hydroxymethylcyclopropane 850406-48-3P,  
 [1-(5-Chloro-1-methyl-1H-indol-3-yl)cyclopropyl]methanol 850406-49-4P,  
 1-Methyl-5-chloro-3-[(dimethylamino)methyl]indole 850406-50-7P  
 850406-51-8P, [1-Methyl-5-chloroindol-3-yl]acetonitrile 850406-52-9P,  
 [1-(5-Chloro-1-methyl-1H-indol-3-yl)cyclopropyl]cyanide 850406-53-0P  
 850406-54-1P, 2-(5-Chloro-1-methyl-1H-indol-3-yl)acetic acid  
 850406-55-2P, 2-(5-Chloro-1-methyl-1H-indol-3-yl)ethanol 850406-56-3P,  
 3-(5-Chloroindol-1-yl)propan-1-ol 850406-57-4P, 1-[(3-tert-  
 Butyldimethylsilyloxy)propyl]-5-chloro-1H-indole  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)


(preparation of imidazopyrazine derivs. useful as antiarrhythmics)

IT 85333-43-3P, 8-Chloro-2-methylimidazo[1,2-a]pyrazine  
 611240-68-7P, 8-Chloro-2-trifluoromethylimidazo[1,2-a]pyrazine  
 850406-39-2P, 8-Chloro-2-isopropylimidazo[1,2-a]pyrazine  
 850406-40-5P, 8-Bromo-2-isopropylimidazo[1,2-a]pyrazine  
 850406-42-7P, 8-Bromo-2-trifluoromethylimidazo[1,2-a]pyrazine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(preparation of imidazopyrazine derivs. useful as antiarrhythmics)


RN 85333-43-3 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-2-methyl- (9CI) (CA INDEX NAME)




RN 611240-68-7 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 850406-39-2 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 850406-40-5 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-bromo-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 850406-42-7 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-bromo-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L57 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:34601 CAPLUS

DOCUMENT NUMBER: 142:134621

TITLE: Preparation of aryl-substituted 8-aminoarylimidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions

INVENTOR(S): Sun, Connie Li; Liang, Congxin; Huang, Ping; Harris, G. Davis; Guan, Huiping

PATENT ASSIGNEE(S): Sugen, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 119 pp., Cont.-in-part of U.S. Ser. No. 781,928.



CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005009832	A1	20050113	US 2004-845586	20040514
US 2004220189	A1	20041104	US 2004-781928	20040220
PRIORITY APPLN. INFO.:			US 2003-448114P	P 20030220
			US 2003-508860P	P 20031007
			US 2004-781928	A2 20040220

OTHER SOURCE(S): MARPAT 142:134621  
 GI



AB The title compds. I [wherein R1, R2 = H, (cyclo)alkyl, (hetero)aryl, etc.; R3, R4 = H, halo, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; R5 = H, halo, (un)substituted (hetero)aryl; wherein at least one of R4 and R5 = (hetero)aryl; R6 = H; or pharmaceutically acceptable salts and prodrugs thereof] were prepared as protein kinase (PK) inhibitors. For example, amination of 3,5-dibromoimidazo[1,2-a]pyrazine with methylamine in THF afforded (3-bromoimidazo[1,2-a]pyrazin-8-yl)methylamine (50%), which was coupled with phenylboronic acid in THF to give II (63%). Various assays which may be used to determine the level of activity of compds. I against one or more PKs (such as GST-Flk1 receptor tyrosine kinase, fibroblast growth factor type 1 receptors (FGFR1), and platelet-derived growth factor (PDGF) receptors) were described in detail (no data given). Thus, I and pharmaceutical compns. comprising these compds. are useful for treating disorders related to abnormal PK activity, such as cancer, diabetes, autoimmune disorders, inflammatory disorders, and cardiovascular disorders (no data).

IC ICM A61K031-498

ICS C07D487-04

INCL 514249000; 544350000

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT **Neuroglia**, neoplasm

(astrocytoma; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT **Neuroglia**, neoplasm

(glioblastoma; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT **Angiogenesis**

Angiogenesis inhibitors

Anti-inflammatory agents

Antiarthritics

Antidiabetic agents

Antirheumatic agents  
 Antitumor agents  
 Autoimmune disease  
 Bladder, neoplasm  
 Cardiovascular system, disease  
 Diabetes mellitus  
 Digestive tract, neoplasm  
 Fibrosis  
 Head and Neck, neoplasm  
 Head and Neck, neoplasm  
 Human  
 Immune disease  
 Immunomodulators  
 Inflammation  
 Lung, neoplasm  
 Mammary gland, neoplasm  
 Melanoma

**Neuroglia**, neoplasm  
 Osteoarthritis  
 Ovary, neoplasm  
 Prostate gland, neoplasm  
 Psoriasis  
 Rheumatoid arthritis

(preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT 274-79-3P, Imidazo[1,2-a]pyrazine 24241-18-7P,  
 (3,5-Dibromopyrazin-2-yl)amine 63744-21-8P, 3,5-  
 Dibromoimidazo[1,2-a]pyrazine 63744-22-9P, 6,8-  
 Dibromoimidazo[1,2-a]pyrazine 117718-82-8P, N-(3-Bromoimidazo[1,2-  
 a]pyrazin-8-yl)methylamine 117718-83-9P, N-(3-Bromoimidazo[1,2-a]pyrazin-  
 8-yl)ethylamine 117718-85-1P, N-(6-Bromoimidazo[1,2-a]pyrazin-8-  
 yl)methylamine 117718-89-5P, N-(Imidazo[1,2-a]pyrazin-8-yl)methylamine  
 117718-92-0P, (3-Bromoimidazo[1,2-a]pyrazin-8-yl)amine 210907-84-9P  
 690636-28-3P, 4-[2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-  
 yl)phenoxy]ethyl]morpholine 756520-70-4P, 4-[2-[3-(4,4,5,5-Tetramethyl-  
 [1,3,2]dioxaborolan-2-yl)phenoxy]ethyl]morpholine 787590-40-3P,  
 N-(3-Bromoimidazo[1,2-a]pyrazin-8-yl)butylamine 787590-41-4P,  
 N-(3-Bromoimidazo[1,2-a]pyrazin-8-yl)isopropylamine 787590-42-5P,  
 N-(3-Bromoimidazo[1,2-a]pyrazin-8-yl)(cyclopropyl)amine 787590-43-6P,  
 Benzyl(3-bromoimidazo[1,2-a]pyrazin-8-yl)amine 787590-44-7P,  
 (3-Bromoimidazo[1,2-a]pyrazin-8-yl)[2-(morpholin-4-yl)ethyl]amine  
 787590-45-8P, 2-[(3-Bromoimidazo[1,2-a]pyrazin-8-yl)amino]ethanol  
 787590-56-1P, (3-Bromoimidazo[1,2-a]pyrazin-5-yl)dimethylamine  
 787591-39-3P 787591-43-9P 787591-44-0P 787591-77-5P,  
 N-(3,5-Dibromoimidazo[1,2-a]pyrazin-8-yl)methylamine 787591-78-0P,  
 N-(5-Bromoimidazo[1,2-a]pyrazin-8-yl)methylamine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(intermediate; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT 787590-47-0P, (3-Phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-48-1P,  
 [3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-51-6P,  
 (3-Bromoimidazo[1,2-a]pyrazin-8-yl)(4-methoxyphenyl)amine  
 787590-55-0P, (3-Bromoimidazo[1,2-a]pyrazin-8-yl)dimethylamine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)

(kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT 673857-28-8P, (6-Phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-46-9P,



Methyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-49-2P,  
 N-[4-[8-[(4-Trifluoromethylbenzoyl)amino]imidazo[1,2-a]pyrazin-3-yl]phenyl]-4-trifluoromethylbenzamide 787590-50-5P, N-[4-(8-Aminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-4-trifluoromethylbenzamide  
 787590-52-7P, (4-Methoxyphenyl) (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
 787590-53-8P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol  
 787590-54-9P, Dimethyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
 787590-57-2P, Isopropyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
 787590-59-4P, 4-(8-Isopropylaminoimidazo[1,2-a]pyrazin-3-yl)phenol  
 787590-61-8P, Butyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
 787590-63-0P, Ethyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
 787590-65-2P, [2-(Morpholin-4-yl)ethyl] (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
 787590-67-4P, Benzyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
 787590-69-6P, 2-[(3-Phenylimidazo[1,2-a]pyrazin-8-yl)amino]ethanol  
 787590-70-9P, 1-Butyl-3-(3-phenylimidazo[1,2-a]pyrazin-8-yl)urea  
 787590-71-0P, N-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide  
 787590-72-1P, N-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]acetamide  
 787590-73-2P, 2,6-Dimethyl-4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol  
 787590-74-3P, [3-(4-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
 787590-75-4P, Cyclopropyl (3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
 787590-76-5P, N-[3-(4-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-77-6P, Methyl [3-(2-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
 787590-78-7P, Methyl [3-(3-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
 787590-79-8P, Methyl [3-(2-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
 787590-80-1P, N-[3-(Biphenyl-2-yl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-81-2P, N-[3-(2-Benzyloxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-82-3P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]ethanone  
 787590-83-4P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]ethanone  
 787590-84-5P, N-[3-(3-Isopropylphenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-85-6P, N-[3-(4-tert-Butylphenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-86-7P, N-[3-(4-Cyclohexylphenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-87-8P, N-[3-[3,5-Bis(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-89-0P, 3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)benzoic acid  
 787590-91-4P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)benzoic acid  
 787590-92-5P, 787590-93-6P, [4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]carbamate  
 787590-94-7P, Methyl [3-(4-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
 787590-95-8P, N-[3-(2,4-Difluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-96-9P, N-[3-(3,4-Dichlorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-98-1P, N-[3-(3-Fluoro-4-methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787590-99-2P, N-[3-(Biphenyl-4-yl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787591-00-8P, N-[3-(Biphenyl-3-yl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787591-01-9P, N-[3-(4-Benzyloxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787591-02-0P, Methyl [3-(naphthalen-1-yl)imidazo[1,2-a]pyrazin-8-yl]amine  
 787591-03-1P, N-[3-(2-Chlorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787591-04-2P, N-[3-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide  
 787591-05-3P, Methyl [3-(2-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
 787591-06-4P, Methyl [3-(3-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
 787591-07-5P, Cyclopropyl [3-[3-(2-(morpholin-4-yl)ethoxy)phenyl]imidazo[1,2-a]pyrazin-8-yl]amine  
 787591-08-6P, 3-(8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl)phenol  
 787591-09-7P, Methyl [3-(4-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine  
 787591-10-0P, N-[3-(2-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787591-11-1P, N-[3-(3,4-Difluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine  
 787591-12-2P, N-[3-(Benzodioxol-5-yl)imidazo[1,2-

a]pyrazin-8-yl)methylamine 787591-13-3P, N-[3-(3-Chlorophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-14-4P, N-[3-(4-Methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-15-5P, N-[3-(2-Methoxyphenyl)imidazo[1,2-a]pyrazin-3-yl)methylamine 787591-16-6P, Methyl[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-17-7P, N-[3-(4-Benzoyloxy-3-fluorophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-18-8P, N-[3-(4-Isopropylphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-19-9P, N-[3-[3,5-Bis(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazin-8-yl](cyclopropyl)amine 787591-20-2P, Cyclopropyl[3-[3,4-dichlorophenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-21-3P, 3-[4-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]benzoic acid 787591-22-4P, Methyl[3-[4-[2-(morpholin-4-yl)ethoxy]phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-23-5P, Cyclopropyl[3-[4-[2-(morpholin-4-yl)ethoxy]phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-24-6P, Cyclopropyl[3-(4-dimethylaminophenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-25-7P, Cyclopropyl[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-26-8P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]ethanone 787591-27-9P, 4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]carbamic acid benzyl ester 787591-28-0P, N-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide 787591-29-1P, N-[3-(3-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl](cyclopropyl)amine 787591-30-4P, N-[3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-31-5P, Methyl[3-(naphthalen-2-yl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-32-6P, 4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]benzoic acid 787591-33-7P, N-[3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl](cyclopropyl)amine 787591-34-8P, Methyl[3-[3-[2-(morpholin-4-yl)ethoxy]phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-36-0P, N-[3-(3-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-37-1P, 3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol 787591-38-2P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)-N-[2-(morpholin-4-yl)ethyl]benzamide 787591-40-6P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)-N-[3-(morpholin-4-yl)propyl]benzamide 787591-41-7P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)-N-[3-(pyrrolidin-1-yl)propyl]benzamide 787591-42-8P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(morpholin-4-yl)propyl]urea 787591-45-1P 787591-46-2P 787591-47-3P 787591-48-4P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(morpholin-4-yl)propyl]urea 787591-49-5P 787591-50-8P 787591-51-9P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea 787591-52-0P, 4-(Pyrrolidin-1-yl)piperidine-1-carboxylic acid N-[4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide 787591-54-2P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(morpholin-4-yl)ethyl]urea 787591-56-4P, 4-Hydroxypiperidine-1-carboxylic acid N-[4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide 787591-57-5P, 4-Hydroxypiperidine-1-carboxylic acid N-[3-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide 787591-58-6P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(morpholin-4-yl)ethyl]urea 787591-59-7P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea 787591-61-1P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea 787591-63-3P 787591-65-5P 787591-66-6P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea 787591-68-8P 787591-70-2P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea 787591-72-4P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[3-(morpholin-4-yl)propyl]urea 787591-74-6P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea 787591-75-7P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[2-(morpholin-4-yl)ethyl]urea 787591-76-8P, N-[5-(4-

Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-79-1P,  
 Methyl(5-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787591-81-5P,  
 Methyl[5-(thiophen-3-yl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-82-6P,  
 4-(8-Methylaminoimidazo[1,2-a]pyrazin-5-yl)phenol 787591-83-7P,  
 N-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-5-yl)phenyl]acetamide  
 787591-84-8P, N-[3,5-Bis(4-fluorophenyl)imidazo[1,2-a]pyrazin-8-  
 yl)methylamine 787591-85-9P, N-(3,5-Diphenylimidazo[1,2-a]pyrazin-8-  
 yl)methylamine 787591-86-0P, Methyl(6-phenylimidazo[1,2-a]pyrazin-8-  
 yl)amine 787591-87-1P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-6-yl)phenol  
 787591-88-2P, Dimethyl(3-phenylimidazo[1,2-a]pyrazin-5-yl)amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase  
 inhibitors for treatment of cancer and other conditions)

IT 75-31-0, Isopropylamine, reactions 76-09-5, Pinacol 98-80-6,  
 Phenylboronic acid 100-46-9, Benzylamine, reactions 104-94-9,  
 Anisidine 109-73-9, Butylamine, reactions 111-36-4, Butyl isocyanate  
 123-00-2, 4-(3-Aminopropyl)morpholine 123-75-1, Pyrrolidine, reactions  
 329-15-7, 4-(Trifluoromethyl)benzoyl chloride 543-27-1, Isobutyl  
 chloroformate 765-30-0, Cyclopropylamine 1423-26-3,  
 [3-(Trifluoromethyl)phenyl]boronic acid 1423-27-4, [2-  
 (Trifluoromethyl)phenyl]boronic acid 1765-93-1, 4-Fluorophenylboronic  
 acid 1993-03-9, 2-Fluorophenylboronic acid 2032-35-1,  
 Bromoacetaldehyde diethyl acetal 2038-03-1, [2-(Morpholin-4-  
 yl)ethyl]amine 3647-69-6, 4-(2-Chloroethyl)morpholine monohydrochloride  
 3900-89-8, 2-Chlorophenylboronic acid 4688-76-0, (2-Phenylphenyl)boronic  
 acid 5049-61-6, Aminopyrazine 5122-94-1, Biphenyl-4-ylboronic acid  
 5122-95-2, Biphenyl-3-ylboronic acid 5720-06-9, 2-Methoxyphenylboronic  
 acid 5720-07-0, 4-Methoxyphenylboronic acid 6165-68-0,  
 2-Thiopheneboronic acid 6165-69-1, Thiophen-3-ylboronic acid 7693-46-1  
 13922-41-3, Naphthalen-1-ylboronic acid 14047-29-1, 4-  
 Carboxyphenylboronic acid 16152-51-5, 4-Isopropylphenylboronic acid  
 16419-60-6, 2-Methylphenylboronic acid 16732-70-0 17596-79-1  
 25487-66-5, 3-Carboxyphenylboronic acid 28611-39-4, (4-  
 Dimethylaminophenyl)boronic acid 30418-59-8, 3-Aminophenylboronic acid  
 32316-92-0, Naphthalen-2-ylboronic acid 51067-38-0, 4-  
 Phenoxyphenylboronic acid 52488-36-5, 4-Bromoindole 63503-60-6,  
 3-Chlorophenylboronic acid 73852-19-4, [3,5-  
 Bis(trifluoromethyl)phenyl]boronic acid 78887-39-5, 3-  
 Acetylaminophenylboronic acid 87199-18-6, 3-Hydroxyphenylboronic acid  
 94839-07-3, 3,4-Methylenedioxyphenylboronic acid 108238-09-1,  
 2-Phenoxyphenylboronic acid 123324-71-0, 4-tert-Butylphenylboronic acid  
 128796-39-4, (4-Trifluoromethylphenyl)boronic acid 133057-83-7,  
 3-Fluoro-4-benzoyloxyphenylboronic acid 144025-03-6, (2,4-  
 Difluorophenyl)boronic acid 146631-00-7, 4-Benzoyloxyphenylboronic acid  
 149104-90-5, 4-Acetylphenylboronic acid 149507-26-6,  
 (3-Fluoro-4-methoxyphenyl)boronic acid 151169-75-4, (3,4-  
 Dichlorophenyl)boronic acid 168267-41-2, (3,4-Difluorophenyl)boronic  
 acid 175676-65-0, (2-Trifluoromethoxyphenyl)boronic acid 179113-90-7,  
 (3-Trifluoromethoxyphenyl)boronic acid 204841-19-0, 3-  
 Acetylphenylboronic acid 214360-60-8, N-[4-(4,4,5,5-Tetramethyl-  
 [1,3,2]dioxaborolan-2-yl)phenyl]acetamide 214360-73-3,  
 [4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)phenyl]amine  
 214360-76-6, 3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)phenol  
 216019-28-2, 3-Isopropylphenylboronic acid 269409-70-3,  
 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)phenol 269410-25-5,  
 2,6-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol  
 363186-06-5, [4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-  
 yl)phenyl]carbamic acid benzyl ester 374538-04-2, 4-

C/clohexylphenylboronic acid 787591-35-9, [3-[2-(Morpholin 4-y.)ethoxy]phenyl]boronic acid 25630-84-0

R.: RCT (Reactant); RACT (Reactant or reagent)

(preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT 338116-27-6P, 4-(4,4,5,5-Tetraethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole

736990-02-6P 825630-79-3P 25630-80-6P 825630-81-7P

825630-82-8P 825630-83-9P 82630-85-1P 825630-86-2P

R.: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT 274-79-3P, Imidazo[1,2-a]pyrazine 63744-21-8P,

3,5-Dibromoimidazo[1,2-a]pyrazine 63744-22-9P,

6,8-Dibromoimidazo[1,2-a]pyrazine 787590-56-1P,


(3-Bromoimidazo[1,2-a]pyrazin-5-yl)dimethylamine

R.: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)


RN 274-79-3 CAPLUS

CN Imidazo[1,2-a]pyrazine (8CI, 9CI) (CA INDEX NAME)




RN 63744-21-8 CAPLUS

CN Imidazo[1,2-a]pyrazine, 3,5-dibromo- (9CI) (CA INDEX NAME)




RN 63744-22-9 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6,8-dibromo- (9CI) (CA INDEX NAME)




RN 787590-56-1 CAPLUS


CN Imidazo[1,2-a]pyrazin-5-amine, 3-bromo-N,N-dimethyl- (9CI) CA INDEX NAME)




IT 787590-55-0P, (3-Bromoimidazo[1,2-a]pyrazin-8-yl)dimethylamine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses (kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions))  
 RN 787590-55-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 787590-54-9P, Dimethyl(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
 787591-88-2P, Dimethyl(3-phenylimidazo[1,2-a]pyrazin-5-yl)amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses (kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions))  
 RN 787590-54-9 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-8-amine, N,N-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 787591-88-2 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-5-amine, N,N-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)




IT 825530-84-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

RN 825530-84-0 CAPLUS

CN Carbamic acid, (3-bromoimidazo[1,2-a]pyrazin-8-yl)methyl-, 1,1 dimethylethyl ester (9CI) ((A INDEX NAME))




IT 825530-81-7P 825630-82-8P 825630-83-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)


RN 825530-81-7 CAPLUS

CN Carbamic acid, [3-(4-aminophenyl)imidazo[1,2-a]pyrazin-8-yl)methyl-, 1,1 dimethylethyl ester (9CI) ((A INDEX NAME))



RN 825530-82-8 CAPLUS


CN Carbamic acid, methyl[3-[4-[[[4-ritrophenoxy) carbonyl] amino]phenyl]imidazo[1,2-a]pyrazin-8-yl]-, 1,1-dimethylethyl ester (9CI) ((A INDEX NAME))



RII 825630-83-9 CAPLUS

CHI Carbamic acid, methyl [3-[4-[[[(2S)-2-phenylpropyl]amino]carbonyl]amino]phenyl]imidazo[1,2-a]pyrazine-8-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1074092 CAPLUS

DOCUMENT NUMBER: 142:49241

TITLE: Substituted imidazopyrazine and triazolopyrazine derivative GABAA receptor ligands, their preparation, pharmaceutical compositions, and therapeutic use

INVENTOR(S): Xu, Yuelian; Han, Bingsong; Xie, Linghong

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004107863	A1	20041216	WO 2004-US13778	20040503
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

CA 2524376 AA 20041216 CA 2004-2524376 20040503  
 EP 1619948 A1 20060202 EP 2004-751255 20040503

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.: US 2003-468073P P 20030505  
 WO 2004-US13778 W 20040503

OTHER SOURCE(S): MARPAT 142:49241

AB Imidazolopyrazine and triazolopyrazine derivs. (preparation described) are provided which may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. The compds. of the invention may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compns. and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

IC ICM A01N043-58  
 ICS A01N043-60; A61K031-495; A61K031-50; C07D471-00; C07D487-00;  
 C07D491-00; C07D495-00; C07D497-00

CC 1-11 (Pharmacology)  
 Section cross-reference(s): 9, 28, 63

IT **Mental and behavioral disorders**  
 (attention deficit disorder; imidazolopyrazine and triazolopyrazine derivative GABAA receptor ligands, preparation, pharmaceutical compns., and therapeutic use)

IT **Mental and behavioral disorders**  
 (depression; imidazolopyrazine and triazolopyrazine derivative GABAA receptor ligands, preparation, pharmaceutical compns., and therapeutic use)

IT **Alzheimer's disease**  
 Amnesia  
 Anti-Alzheimer's agents  
 Antidepressants  
 Anxiety  
 Anxiolytics  
 Cognition enhancers  
 Combination chemotherapy  
 Drug delivery systems  
 Human  
 Nervous system agents  
 Sleep disorders

(imidazolopyrazine and triazolopyrazine derivative GABAA receptor ligands, preparation, pharmaceutical compns., and therapeutic use)

IT 808138-65-0P 808138-67-2P 808138-69-4P 808138-75-2P  
 808138-77-4P 808138-85-4P 808138-87-6P 808138-89-8P  
 RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);  
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(imidazolopyrazine and triazolopyrazine derivative GABAA receptor ligands, preparation, pharmaceutical compns., and therapeutic use)

IT 808138-57-0  
 RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);  
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (imidazolopyrazine and triazolopyrazine derivative GABAA receptor ligands, preparation, pharmaceutical compns., and therapeutic use)




IT 808138-65-0P 808138-67-2P

RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);  
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(imidazolopyrazine and triazolopyrazine derivative GABA receptor ligands,  
preparation, pharmaceutical compns., and therapeutic use)


RN 808138-65-0 CAPLUS

CN Imidazo[1,2-a]pyrazine, 5-propyl-6-[[2-(2-pyridinyl)-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 808138-67-2 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-[[2-(3-fluoro-2-pyridinyl)-1H-imidazol-1-yl]methyl]-5-propyl- (9CI) (CA INDEX NAME)




IT 808138-57-0

RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);  
THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(imidazolopyrazine and triazolopyrazine derivative GABA receptor ligands,  
preparation, pharmaceutical compns., and therapeutic use)

RN 808138-57-0 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-[[2-(6-fluoro-2-pyridinyl)-1H-imidazol-1-yl]methyl]-5-propyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

1



THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:934327 CAPLJS  
 DOCUMENT NUMBER: 141:395578  
 TITLE: Preparation of aryl-substituted 8-aminoarylimidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions  
 INVENTOR(S): Sun, Connie Li; Liang, Congxin; Huang, Ping; Harris, G. Davis; Guan, Huiping  
 PATENT ASSIGNEE(S): Sugen, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 76 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004 20189	A1	20041104	US 2004-781928	20040220
US 2005 09832	A1	20050113	US 2004-845586	20040514
PRIORITY APP. INFO.:			US 2003-448114P	P 20030220
			US 2003-508860P	P 20031007
			US 2004-781928	A2 20040220

OTHER SOURCE(S): MARPAT 141:395578  
 GI



AB Title compds. I [wherein R1, R2 = independently H, acyl, carbamoyl, alkoxy, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; R3, R4 = independently H, halo, OH, acyl, carbamoyl, alkoxy, sulfamoyl, CN, NO2, NH2, (un)substituted (cyclo)alkyl, (hetero)aryl, etc.; R5 = H, halo, (un)substituted aryl; wherein at least one of R3, R4, and R5 = aryl; R6 = H; or pharmaceutically acceptable salts and prodrugs thereof] were prepared as protein kinase (PK) inhibitors. For example, amination of 3,5-dibromoimidazo[1,2-a]pyrazine with methylamine in THF afforded (3-bromoimidazo[1,2-a]pyrazin-8-yl)methylamine (50%), which was coupled with phenylboronic acid in THF to give II (63%). Nine exemplified compds. were tested and found active against GST-Flk1 receptor tyrosine kinase, fibroblast growth factor type 1 receptors (FGFR1), and platelet-derived growth factor (PDGF) receptors (no data). Thus, I and pharmaceutical compds. comprising these compds. are useful for treating disorders related to abnormal PK activity, such as cancer, diabetes, autoimmune disorders, inflammatory disorders, and cardiovascular disorders (no data).

IC ICM A6 K031-498

ICS C01D487-04

INCL 514249000; 544350000

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1, 63

IT Neuroglia, neoplasm  
(astrocytoma; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT Neuroglia, neoplasm  
(glioblastoma; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT Angiogenesis  
Angiogenesis inhibitors  
Anti-inflammatory agents  
Antiarthritics  
Antidiabetic agents  
Antirheumatic agents  
Antitumor agents  
Autoimmune disease  
Bladder, neoplasm  
Cardiovascular system, disease  
Diabetes mellitus  
Fibrosis  
Gastrointestinal agents  
Head and Neck, neoplasm  
Head and Neck, neoplasm  
Human  
Immune disease  
Immunomodulators  
Inflammation  
Lung, neoplasm  
Mammary gland, neoplasm  
Melanoma  
Neuroglia, neoplasm  
Osteoarthritis  
Ovary, neoplasm  
Prostate gland, neoplasm  
Psoriasis  
Rheumatoid arthritis  
(preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT 74-79-3P, Imidazo[1,2-a]pyrazine 24241-18-7P,  
3,5-Dibromopyrazin-2-yl)amine 63744-21-8P, 3,5-  
Dibromoimidazo[1,2-a]pyrazine 63744-22-9P, 6,8-  
Dibromoimidazo[1,2-a]pyrazine 117718-82-8P, N-(3-Bromoimidazo[1,2-  
a]pyrazin-8-yl)methylamine 117718-83-9P, N-(3-Bromoimidazo[1,2-a]pyrazin-  
8-yl)ethylamine 117718-85-1F, N-(6-Bromoimidazo[1,2-a]pyrazin-8-  
yl)methylamine 117718-89-5P, N-(Imidazo[1,2-a]pyrazin-8-yl)methylamine  
117718-92-0P, (3-Bromoimidazo[1,2-a]pyrazin-8-yl)amine 216907-84-9P  
690636-28-3P, 4-[2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-  
yl)phenoxy]ethyl]morpholine 756520-70-4P, 4-[2-[3-(4,4,5,5-Tetramethyl-  
[1,3,2]dioxaborolan-2-yl)phenoxy]ethyl]morpholine 787590-40-3P,  
N-(3-Bromoimidazo[1,2-a]pyrazin-8-yl)butylamine 787590-41-4P,  
N-(3-Bromoimidazo[1,2-a]pyrazin-8-yl)isopropylamine 787590-42-5P,  
N-(3-Bromoimidazo[1,2-a]pyrazin-8-yl)(cyclopropyl)amine 787590-43-6P,  
Benzyl (3-bromoimidazo[1,2-a]pyrazin-8-yl)amine 787590-44-7P,  
3-Bromoimidazo[1,2-a]pyrazin-8-yl) [2-(morpholin-4-yl)ethyl]amine  
787590-45-8P, 2-[(3-Bromoimidazo[1,2-a]pyrazin-8-yl)amino]ethanol  
787590-56-1P, (3-Bromoimidazo[1,2-a]pyrazin-5-yl)dimethylamine  
787591-39-3P 787591-43-9P 787591-44-0P 787591-77-9P,  
N-(3,5-Dibromoimidazo[1,2-a]pyrazin-8-yl)methylamine 787591-78-0P,  
N-(5-Bromoimidazo[1,2-a]pyrazin-8-yl)methylamine  
PL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
Reactant or reagent)  
(intermediate; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors

for treatment of cancer and other conditions)

IT 787590-47-0P, (3-Phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-48-1P, [3-(4-Amirophephenyl)imidazo[1,2-a]pyrazin-8-yl)amine 787590-51-6P, (3-Bromoiimidazo[1,2-a]pyrazin-8-yl)(4-methoxyphenyl)amine 787590-55-0P, (3-Bromoiimidazo[1,2-a]pyrazin-8-yl)dimethylamine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT 673857-28-8P, (6-Phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-46-1P, Methyl(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-49-2P, N-[4-[8-[(4-Trifluoromethylbenzoyl)amino]imidazo[1,2-a]pyrazin-3-yl]phenyl]-4-trifluoromethylbenzamide 787590-50-5P, N-[4-(8-Aminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-4-trifluoromethylbenzamide 787590-52-7P, (4-Methoxyphenyl)(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-53-8P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol 787590-54-9P, Dimethyl(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-57-2P, Isopropyl(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-59-4P, 4-(8-Isopropylaminoimidazo[1,2-a]pyrazin-3-yl)phenol 787590-61-8P, Butyl(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-63-0P, Ethyl(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-65-2P, [2-(Morpholin-4-yl)ethyl](3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-67-4P, Benzyl(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-69-6P, 2-[(3-Phenylimidazo[1,2-a]pyrazin-8-yl)amino]ethanol 787590-70-9P, 1-Butyl-3-(3-phenylimidazo[1,2-a]pyrazin-8-yl)urea 787590-71-0P, N-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide 787590-72-1P, N-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]acetamide 787590-73-2P, 2,6-Dimethyl-4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenol 787590-74-3P, [3-(4-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl)amine 787590-75-4P, Cyclopropyl(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787590-76-5P, N-[3-(4-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-77-6P, Methyl[3-(2-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-78-7P, Methyl[3-(3-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-79-8P, Methyl[3-(2-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-80-1P, N-[3-(Biphenyl-2-yl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-81-1P, N-[3-(2-Benzyloxyphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-82-3P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]ethanone 787590-83-4P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]ethanone 787590-84-5P, N-[3-(3-Isopropylphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-85-6P, N-[3-(4-tert-Butylphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-86-7P, N-[3-(4-Cyclohexylphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-87-8P, N-[3-[3,5-Bis(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-89-0P, 3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)benzoic acid 787590-91-4P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)benzoic acid 787590-92-5P 787590-93-6P, [4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]carbamic acid benzyl ester 787590-94-7P, Methyl[3-(4-trifluoromethylphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787590-95-8P, N-[3-(2,4-Difluorophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-96-9P, N-[3-(3,4-Dichlorophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-98-1P, N-[3-(3-Fluoro-4-methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787590-99-2P, N-[3-(Biphenyl-4-yl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-00-8P, N-[3-(Biphenyl-3-yl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-01-9P, N-[3-(4-Benzyloxyphenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine 787591-02-0P, Methyl[3-(naphthalen-1-yl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-03-1P, N-[3-(2-Chlorophenyl)imidazo[1,2-a]pyrazin-8-yl)methylamine

78 591-04-2P, N-[3-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl phenyl]acetamide 787591-05-3P, Methyl[3-(2-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-06-4P, Methyl[3-(3-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-07-5P, Cyclopropyl[3-[3-[2-(morpholin-4-yl ethoxy)phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-08-6P, 3-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenol 787591-09-7P, Methyl[3-(4-trifluoromethoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-10-0P, N-[3-(2-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-11-1P, N-[3-(3,4-Difluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-12-2P, N-[3-(Benzodioxol-5-yl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-13-3P, N-[3-(3-Chlorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-14-4P, N-[3-(4-Methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-15-5P, N-[3-(2-Methoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-16-6P, Methyl[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-17-7P, N-[3-(4-Benzoyloxy-3-fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-18-8P, N-[3-(4-Isopropylphenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-19-9P, N-[3-[3,5-Bis(trifluoromethyl)phenyl]imidazo[1,2-a]pyrazin-8-yl](cyclopropyl)amine 787591-20-2P, Cyclopropyl[3-(3,4-dichlorophenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-21-3P, 3-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]benzoic acid 787591-22-4P, Methyl[3-[4-[2-(morpholin-4-yl ethoxy)phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-23-5P, Cyclopropyl[3-[4-[2-(morpholin-4-yl ethoxy)phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-24-6P, Cyclopropyl[3-(4-dimethylaminophenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-25-7P, Cyclopropyl[3-(4-phenoxyphenyl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-26-8P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]ethanone 787591-27-9P, [4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]carbamic acid benzyl ester 787591-28-0P, N-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]acetamide 787591-29-1P, N-[3-(3-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl](cyclopropyl)amine 787591-30-4P, N-[3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-31-5P, Methyl[3-(naphthalen-2-yl)imidazo[1,2-a]pyrazin-8-yl]amine 787591-32-6P, 4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]benzoic acid 787591-33-7P, N-[3-(4-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl](cyclopropyl)amine 787591-34-8P, Methyl[3-[3-[2-(morpholin-4-yl ethoxy)phenyl]imidazo[1,2-a]pyrazin-8-yl]amine 787591-36-0P, N-[3-(3-Aminophenyl)imidazo[1,2-a]pyrazin-8-yl]methanamine 787591-37-1P, 3-[8-Methylaminoimidazo[1,2-a]pyrazin-3-yl]phenol 787591-38-2P, 4-[8-Methylaminoimidazo[1,2-a]pyrazin-3-yl]-N-[2-(morpholin-4-yl ethyl)]benzamide 787591-40-6P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)-N-[3-(morpholin-4-yl)propyl]benzamide 787591-41-7P, 4-[8-Methylaminoimidazo[1,2-a]pyrazin-3-yl]-N-[3-(pyrrolidin-1-yl)propyl]benzamide 787591-42-3P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(morpholin-4-yl)propyl]urea 787591-45-1P 787591-46-2P 787591-47-3P 787591-48-4P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(morpholin-4-yl)propyl]urea 787591-49-5P 787591-50-8P 787591-51-9P, 1-[1-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea 787591-52-0P, 4-Pyrrolidin-1-yl)piperidine-1-carboxylic acid N-[4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide 787591-54-2P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(morpholin-4-yl)ethyl]urea 787591-56-4P, 4-Hydroxypiperidine-1-carboxylic acid N-[4-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide 787591-57-5P, 4-Hydroxypiperidine-1-carboxylic acid N-[3-(8-methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]amide 787591-58-6P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(morpholin-4-yl)ethyl]urea 787591-59-7P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-

yl)ethyl]urea 787591-61-1P, 1-[3-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-1-[3-(pyrrolidin-1-yl)propyl]urea 787591-63-3P 787591-64-5P  
 787591-66-6P, 1-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-3-yl)phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea 787591-68-8P 787591-70-2P,  
 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[3-(pyrrolidin-1-yl)propyl]urea 787591-72-3P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[3-(morpholin-4-yl)propyl]urea 787591-74-6P, 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[2-(pyrrolidin-1-yl)ethyl]urea 787591-75-7P,  
 1-[4-[8-(Cyclopropylamino)imidazo[1,2-a]pyrazin-3-yl]phenyl]-3-[2-(morpholin-4-yl)ethyl]urea 787591-76-8P, N-[5-(4-Fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-79-1P,  
 Methyl(5-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787591-81-5P,  
 Methyl(5-(thiophen-3-yl)imidazo[1,2-a]pyrazin-8-yl)amine 787591-82-6P,  
 N-[4-(8-Methylaminoimidazo[1,2-a]pyrazin-5-yl)phenyl]acetamide 787591-84-8P, N-[3,5-Bis(4-fluorophenyl)imidazo[1,2-a]pyrazin-8-yl]methylamine 787591-85-9P, N-(3,5-Diphenylimidazo[1,2-a]pyrazin-8-yl)methylamine 787591-86-0P, Methyl(6-phenylimidazo[1,2-a]pyrazin-8-yl)amine 787591-87-1P, 4-(8-Methylaminoimidazo[1,2-a]pyrazin-6-yl)phenol 787591-88-2P, Dimethyl(3-phenylimidazo[1,2-a]pyrazin-5-yl)amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)

IT 274-79-3P, Imidazo[1,2-a]pyrazine 63744-21-8P,  
 3,5-Dibromimidazo[1,2-a]pyrazine 63744-22-9P,  
 6,8-Dibromimidazo[1,2-a]pyrazine 787590-66-1P,  
 (3-Bromimidazo[1,2-a]pyrazin-5-yl)dimethylamine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RCT (Reactant or reagent)

(intermediate; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)


RN 274-79-3 CAPLUS

CN Imidazo[1,2-a]pyrazine (8CI, 9CI) (CA INDEX NAME)




RN 63744-21-8 CAPLUS

CN Imidazo[1,2-a]pyrazine, 3,5-dibromo- (9CI) (CA INDEX NAME)




RN 63744-22-9 CAPLUS


CN Imidazo[1,2-a]pyrazine, 6,8-dibromo- (9CI) (CA INDEX NAME)




RN 78750-56-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-5-amine, 3-bromo-N,N-dimethyl- (9CI) (CA INDEX NAME)



IT 78750-55-0P, (3-Bromoimidazo[1,2-a]pyrazin-8-yl)dimethylamine  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(Kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)  
RN 78750-55-0 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, 3-bromo-N,N-dimethyl- (9CI) (CA INDEX NAME)




IT 78750-54-9P, Dimethyl(3-phenylimidazo[1,2-a]pyrazin-8-yl)amine  
78750-54-9P, Dimethyl(3-phenylimidazo[1,2-a]pyrazin-5-yl)amine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Kinase inhibitor; preparation of imidazo[1,2-a]pyrazines as kinase inhibitors for treatment of cancer and other conditions)  
RN 78750-54-9 CAPLUS  
CN Imidazo[1,2-a]pyrazin-8-amine, N,N-dimethyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 787591-88-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-5-amine, N,N-dimethyl 3-phenyl- (9CI) (CA INDEX NAME)



L57 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:696381 CAPLUS

DOCUMENT NUMBER: 141:225537

TITLE: Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity and their preparation, pharmaceutical compositions, and methods of use

INVENTOR(S): Currie, Kevin S.; Desimone, Robert W.; Pippin, Douglas A.; Darrow, James W.; Mitchell, Scott A.

PATENT ASSIGNEE(S): Cellular Genomics, Inc. USA

SOURCE: PCT Int. Appl., 106 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. CC INT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPL CATION NO.	DATE
-----	----	-----	-----	-----
WO 2004072080	A1	20040826	WO 2004-US3922	20040210
W:				
AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,				
BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,				
CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,				
ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,				
IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, LC,				
LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX,				
MZ, MZ, NA, NI				
RW:				
BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,				
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,				
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,				
GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,				
GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005054648	A1	20050310	US 2004-776002	20040210
US 2005054649	A1	20050310	US 2004-776631	20040210
PRIORITY APPLN. INFO.:			US 2003-446379P	P 20030210
OTHER SOURCE(S):		MARPAT 141:225537		



GI



AB The invention pertains to compds. I and all pharmaceutically acceptable forms thereof [wherein: R1 = H, halo, alkyl, alkoxy, (hetero)cycloalkyl(alkyl), sulfonamide, alkoxyalkyl, alkoxyalkoxy, (di)alkylamino(alkyl); or R1 = Ph or a benzo-fused 5- to 7-membered N/O/S heterocycloalkyl bearing 0-3 selected substituents; W = Ph or 5- or 6-membered N/O/S heteroaryl with 1-4 heteroatoms and 0-3 selected substituents; X = N or CH; R2 = (alkoxy)alkyl, (hetero)cycloalkyl(alkyl), (alkoxy)alkoxy; or R2 = phenyl(alkyl) or heteroaryl(alkyl) bearing 0-3 selected substituents; Z = (CR8R9)<sub>n</sub>, CONR10, NR10CO, or NR10CONR11; R8, R9 = H, alkyl, alkoxy, halo; n = 0-2; R10, R11 = H, alkyl, or Ph or heteroaryl with 0-3 selected substituents; R3 = H, alkyl; or R3 = (hetero)cycloalkyl(alkyl), Ph, or heteroaryl each bearing 0-3 selected substituents; or R3 = phenoxyphenyl with each ring bearing 0-3 selected substituents]. Addnl. compds. with a linking group between R1 and W are disclosed but neither prepared nor claimed. The compds. I are modulators of kinase activity and Hsp90 complex activity. Certain compds. I are highly active inhibitors of Hsp90 complex activity. The invention also provides pharmaceutical compns. containing one or more compound I, or a pharmaceutically acceptable form of such compds., and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and **neurodegenerative** diseases. The methods of treatment include administering a sufficient amount of a compound I or a form thereof to decrease the symptoms or slow the

progression of these diseases or disorders. The invention also encompasses methods of treating non-human patients, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to Hsp90 complex modulation. Methods of treatment include administering a compound I as a single active agent or administering a compound I in combination with one or more other therapeutic agents. The invention also includes a method for determining the presence of certain

kinases

or Hsp90 complex in a sample, comprising contacting the sample with a compound I, or form thereof, and detecting Hsp90 complex activity in the sample. Almost 50 compds. I were prepared in examples. For instance, compound II was prepared in 4 steps: (1) deprotection of BrCH<sub>2</sub>CH(OEt)<sub>2</sub> with HBr and cyclocondensation with 3,5-dibromo-2-aminopyrazine to give 6,8-dibromoimidazo[1,2-a]pyrazine; (2) aminolysis of the 8-bromo with 4-(p-tolyl)-1H-imidazole; (3) Suzuki coupling of the 6-bromo with 3-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>B(OH)<sub>2</sub>·HCl; and (4) carbamoylation of the amino group with 1-isocyanato-2-methylbenzene. In a tumor cell monolayer proliferation assay using MCF-7 or HCT-15 cells, compds. I had IC<sub>50</sub> values of 25 μM or less, with certain compds. having values of 10 μM or less.

IC ICM C07D487-04

ICS A61K031-4985; A61P035-02; A61P037-00; C02D241-00; C07D235-00

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

ST heteroarylphenylimidazopyrazine prepn modulator Hsp90 complex antitumor immunosuppressant **neuroprotectant** antiinflammatory; imidazopyrazine pyridinyl imidazolyl urea treatment cancer autoimmune **neurodegenerative** disease

IT Cytoprotective agents

(**neuroprotective**; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)

IT **746653-81-6P**, 1-[3-[8-(4-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea **746653-82-7P**, 1-(4-Chlorophenyl)-3-[3-[8-(4-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-83-8P**, 1-(2-Methylsulfanyphenyl)-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-84-9P**, 1-[3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea **746653-85-0P**, 1-(4-Chlorophenyl)-3-[3-[8-[4-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-86-1P**, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea **746653-87-2P**, 1-(4-Chlorophenyl)-3-[3-[8-(4-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-88-3P**, 1-o-Tolyl-3-[3-[8-(4-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-89-4P**, 1-(4-Chlorophenyl)-3-[3-[8-(4-methylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-90-7P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[4-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-91-8P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(4-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-92-9P**, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]urea **746653-93-0P**, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(morpholin-4-yl)methyl]phenyl]urea **746653-94-1P**, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(3-ethoxypropyl)amino]methyl]phenyl]urea **746653-95-2P**, 1-(4-Chlorophenyl)-3-[3-[8-(3-phenylpyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-96-3P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(3-phenylpyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746653-97-4P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-

yl]phenyl]urea 746653-98-5P, 4-Chloro-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746653-99-6P, 3-[(Morpholin-4-yl)methyl]-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-00-2P, 4-[(Morpholin-4-yl)methyl]-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-01-3P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-02-4P, 1-[3-[8-(2-p-Tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 746654-03-5P, 1-[4-[(Morpholin-4-yl)methyl]phenyl]-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-04-6P, 6-[4-[(Morpholin-4-yl)methyl]phenyl]-8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazine 746654-05-7P, 1-(4-Chlorophenyl)-3-[3-[8-(2-o-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-06-8P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-o-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-07-9P, 1-(4-Chlorophenyl)-3-[3-[8-(2-(2-methoxyphenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-08-0P, 1-(4-Chlorophenyl)-3-[3-[8-(2-(2-fluorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-09-1P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-(2-fluorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-10-4P, 1-[3-[8-(2-(2-Fluorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 746654-11-5P, 1-[3-[8-(2-(2-Methoxyphenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 746654-12-6P, 1-(4-Chlorophenyl)-3-[3-[8-(2-isopropylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-13-7P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-isopropylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-14-8P, 1-[3-[8-(4-Bromoimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea 746654-15-9P, 4-Fluoro-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-16-0P, 3-Methoxy-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-17-1P, 3-Methoxy-4-methyl-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-18-2P, N-[3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-19-3P, 2,6-Dimethyl-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-20-6P, 4-Fluoro-N-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-21-7P, 3-Methoxy-N-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-22-8P, 3-Methoxy-4-methyl-N-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-23-9P, 2-(4-Chlorophenyl)-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide 746654-24-0P, 2-(4-Chlorophenyl)-N-[3-[8-(2-(4-chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide 746654-25-1P, N-[3-[8-(2-(4-Chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-2-(3-trifluoromethylphenyl)acetamide 746654-26-2P, 1-[3-[8-(2-(4-Chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(morpholin-4-yl)methyl]phenyl]urea 746654-27-3P, 1-(4-Chlorobenzyl)-3-[3-[8-(2-(4-chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-28-4P, 1-[3-[8-(2-(4-Chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-(4-methylpiperazin-1-ylmethyl)phenyl]urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroarylphenylimidazopyrazines as


- modulators of Hsp90 complex activity)
- IT 63744-22-9P, 6,8-Dibromoimidazo[1,2-a]pyrazine 63744-23-0P  
 , 6,8-Dibromoimidazo[1,2-a]pyrazine hydrobromide 746654-29-5P,  
 6-Bromo-8-(4-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazine  
 746654-30-8P, 3-[8-(4-p-Tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine  
 RL: RCT (Reactant); SPN (Synthetic preparation) PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of heteroarylphenylimidazopyrazines as modulators  
 of Hsp90 complex activity)
- IT 614-68-6, 1-Isocyanato-2-methylbenzene 670-91-7, 4-p-Tolyl-1H-imidazole  
 2032-35-1, Bromoacetaldehyde diethyl acetal 2241-18-7,  
 3,5-Dibromo-2-aminopyrazine 25026-34-0, (4-Chlorophenyl)acetyl chloride  
 85006-23-1, 3-Aminophenylboronic acid hydrochloride 746654-31-9,  
 3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of heteroarylphenylimidazopyrazines as  
 modulators of Hsp90 complex activity)
- IT 746653-81-6P, 1-[3-[8-(4-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea 746653-82-7P, 1-(4-Chlorophenyl)-3-[3-[8-(4-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea  
 746653-83-8P, 1-(2-Methylsulfanylphenyl)-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746653-84-9P,  
 1-[3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea 746653-85-0P, 1-(4-Chlorophenyl)-3-[3-[8-[4-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea  
 746653-86-1P, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-o-tolylurea 746653-87-2P,  
 1-(4-Chlorophenyl)-3-[3-[8-(4-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746653-88-3P, 1-o-Tolyl-3-[3-[8-(4-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea  
 746653-89-4P, 1-(4-Chlorophenyl)-3-[3-[8-(4-methylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746653-90-7P,  
 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-[4-(4-chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746653-91-8P,  
 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(4-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746653-92-9P, 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]urea 746653-93-0P,  
 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(morpholin-4-yl)methyl]phenyl]urea 746653-94-1P,  
 1-[3-[8-[4-(4-Chlorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(3-ethoxypropyl)amino]methyl]phenyl]urea  
 746653-95-2P, 1-(4-Chlorophenyl)-3-[3-[8-(3-phenylpyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746653-96-3P,  
 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(3-phenylpyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746653-97-4P, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746653-98-5P, 4-Chloro-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746653-99-6P,  
 3-[(Morpholin-4-yl)methyl]-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-00-2P,  
 4-[(Morpholin-4-yl)methyl]-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide 746654-01-3P,  
 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-02-4P, 1-[3-[8-(2-p-Tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea 746654-03-5P, 1-[4-[(Morpholin-4-yl)methyl]phenyl]-3-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea 746654-04-6P, 6-[4-[(Morpholin-4-

yl)methyl]phenyl]-8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazine  
**746654-05-7P**, 1-(4-Chlorophenyl)-3-[3-[8-(2-o-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746654-06-8P**,  
 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-o-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746654-07-9P**, 1-(4-Chlorophenyl)-3-[3-[8-(2-methoxyphenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746654-08-0P**, 1-(4-Chlorophenyl)-3-[3-[8-(2-fluorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746654-09-1P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-fluorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746654-10-4P**, 1-[3-[8-(2-Fluorophenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea **746654-11-5P\*\***  
 \* , 1-[3-[8-(2-Methoxyphenyl)imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(3-trifluoromethylphenyl)urea **\*\*\*746654-12-6P**,  
 1-(4-Chlorophenyl)-3-[3-[8-(2-isopropylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746654-13-7P**, 1-(3-Chloro-4-fluorophenyl)-3-[3-[8-(2-isopropylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746654-14-8P**, 1-[3-[8-(4-Bromoimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(4-chlorophenyl)urea **746654-15-9P**,  
 4-Fluoro-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-16-0P**, 3-Methoxy-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-17-1P**, 3-Methoxy-4-methyl-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-18-2P**,  
 N-[3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-19-3P**, 2,6-Dimethyl-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-20-6P**,  
 4-Fluoro-N-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-21-7P**, 3-Methoxy-N-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-22-8P**, 3-Methoxy-4-methyl-N-[3-[8-(2-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]benzamide **746654-23-9P**,  
 2-(4-Chlorophenyl)-N-[3-[8-(2-phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide **746654-24-0P**, 2-(4-Chlorophenyl)-N-[3-[8-(2-(4-chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]acetamide **746654-25-1P**, N-[3-[8-(2-(4-Chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-2-(3-trifluoromethylphenyl)acetamide **746654-26-2P**, 1-[3-[8-(2-(4-Chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-[(morpholin-4-yl)methyl]phenyl]urea **746654-27-3P**, 1-(4-Chlorobenzyl)-3-[3-[8-(2-(4-chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]urea **746654-28-4P**, 1-[3-[8-(2-(4-Chlorophenyl)imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-[4-(4-methylpiperazin-1-ylmethyl)phenyl]urea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)


RN 746653-81-6 CAPLUS

CN Urea, N-(2-methylphenyl)-N'-[3-[8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746653-82-7 CAPLUS

CN Urea, N-(2-methylphenyl)-N'-(3-[8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 746653-83-8 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 746653-84-9 CAPLUS

CN Urea, N-(2-methylphenyl)-N'-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl)- (9CI) (CA INDEX NAME)




RN 746653-85-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746653-86-1 CAPLUS

CN Urea, N-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 746653-87-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[4-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-88-3 CAPLUS


CN Urea, N-(2-methylphenyl)-N'-[3-[8-[4-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746653-89-4 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(4-methyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)






RN 746653-90-7 CA PLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746653-91-8 CA PLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746653-92-9 CAPLUS

CN Urea, N-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 746653-93-0 CAPLUS

CN Urea, N-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746653-94-1 CAPLUS

CN Urea, N-[3-[8-[4-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-[[3-(ethoxypropyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 746653-95-2 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(3-phenyl-1H-pyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746653-96-3 CAPLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-(3-phenyl-1H-pyrazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RI 746653-97-4 CAPLUS

CI Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RI 746653-98-5 CAPLUS

CI Benzamide, 4-chloro-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RI 746653-99-6 CAPLUS

CI Benzamide, 3-(4-morpholinomethyl)-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RI 746654-00-2 CAPLUS

CI Benzamide, 4-(4-morpholinomethyl)-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-01-3 CAPLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-02-4 CAPLUS

CN Urea, N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-03-5 CAPLUS

CN Urea, N-[4-(4-morpholinylmethyl)phenyl]-N'-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-04-6 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-[4-(4-morpholinylmethyl)phenyl]-8-(2-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 746654-05-7 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[2-(2-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-06-8 CAPLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[2-(2-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-07-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[2-(2-methoxyphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-08-0 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[2-(2-fluorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-09-1 CAPLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[2-(2-fluorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-10-4 CAPLUS

CN Urea, N-[3-[8-[2-(2-fluorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 746654-11-5 CAPLUS


CN Urea, N-[3-[8-[2-(2-methoxyphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 746654-12-6 CAPLUS


CN Urea, N-(4-chlorophenyl)-N'-[3-[8-[2-(1-methylethyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)






RN 746654-13-7 CAPLUS

CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-[2-(1-methylethyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-14-8 CAPLUS

CN Urea, N-[3-[8-(4-bromo-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 746654-15-9 CAPLUS

CN Benzamide, 4-fluoro-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746,54-16-0 CAPLUS

CN Benzamide, 3-methoxy-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746,54-17-1 CAPLUS

CN Benzamide, 3-methoxy-4-methyl-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746,54-18-2 CAPLUS

CN Benzamide, N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-19-3 CAPLUS

CN Benzamide, 2,6-dimethyl-N-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-20-6 CAPLUS

CN Benzamide, 4-fluoro-N-[3-[3-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-21-7 CAPLUS

CN Benzamide, 3-methoxy-N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-22-8 CAPLUS

CN Benzaride, 3-methoxy-4-methyl-N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-23-9 CAPLUS

CN Benzeracetamide, 4-chloro-N-[3-[8-[2-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-24-0 CAPLUS

CN Benzeracetamide, 4-chloro-N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-25-1 CAPLUS

CN Benzeneacetamide, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 746654-26-2 CAPLUS

CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-27-3 CAPLUS

CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 746654-28-4 CAPLUS

CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



IT 63744-22-9P, 6,8-Dibromoimidazo[1,2-a]pyrazine 63744-23-0P

, 6,8-Dibromoimidazo[1,2-a]pyrazine hydrobromide 746654-29-5P,

6-Bromo-8-(4-p-tolylimidazol-1-yl)imidazo[1,2-a]pyrazine


746654-30-8P, 3-[8-(4-p-Tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)


RN 63744-22-9 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6,8-dibromo- (9CI) (CA INDEX NAME)



RN 63744-23-0 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6,8-dibromo-, hydrobromide (9CI) (CA INDEX NAME)




●> HBr

RN 46654-29-5 CAPLUS


CN imidazo[1,2-a]pyrazine, 6-bromo-8-[4-(4-methylphenyl)-1H-imidazol-1-yl]-  
(9CI) (CA INDEX NAME)

M:



RN 46654-30-8 CAPLUS

CN benzenamine, 3-[8-[4-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]- (9CI) (CA INDEX NAME)




IT 746654-31-9, 3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity

RN 746654-31-9 CAPLUS

CN Benzenamine, 3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]-(9CI) (CA INDEX NAME)



L57 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:267339 CAPLUS

DOCUMENT NUMBER: 140:303700

TITLE: Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors

INVENTOR(S): Paruch, Kamil; Guzi Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Gidjavallabhan, Viyyoor M.; Mallams, Alan K.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026377	A1	20040401	WO 2003-US29209	20030919
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CJ, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HK, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YJ, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BF, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499756	AA	20040401	CA 2003-2499756	20030919
US 2004063715	A1	20040401	US 2003-665005	20030919
US 6919341	B2	20050719		
AU 2003272476	A1	20040408	AU 2003-272476	20030919
EP 1543008	A1	20050622	EP 2003-754658	20030919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006507253	T2	20060302	JP 2004-537904	20030919
US 2005130980	A1	20050616	US 2005-47524	20050131
ZA 2005002375	A	20050927	ZA 2005-2375	20050322



PRIORITY APPLN. INFO.:

US 2002-412997P

P 20020923

US 2003-665005

A3 20030919


WO 2003-US29209

W 20030919

OTHER SOURCE(S):

MARPAT 140:303700

GI



AB In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. of formula I [R = H, halo, (un)substituted-aryl, -heteroaryl, -cycloalkyl, etc.; R1 = H, halo or alkyl; R2 = halo, (un)substituted-alkyl, -aryl, -arylalkyl, etc.; R3 = H, (un)substituted-aryl, -heteroaryl, -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing pharmaceutical

formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepared by condensation of 8-chloro-3-methylimidazo[1,2-a]pyrazine with 4-(aminomethyl)pyridine. I possessed excellent CDK inhibitory properties, e.g., II demonstrated an IC<sub>50</sub> value of 22.5  $\mu$ M.

IC ICM C07D487-04

ICS A61K031-495; A61P035-00

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

IT **Neuroglia, neoplasm**

(astrocytoma; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)

IT **Nerve, neoplasm**

(neuroblastoma; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)

IT **Antitumor agents**

Bladder, neoplasm

Drug delivery systems

Drug interactions

Esophagus, neoplasm

Gallbladder, neoplasm

Hodgkin's disease

Human

Kidney, neoplasm

Leukemia

Liver, neoplasm

Lung, neoplasm

Mammary gland, neoplasm

Melanoma  
 Myelodysplastic syndromes  
 Neuroglia, neoplasm  
 Ovary, neoplasm  
 Pancreas, neoplasm  
 Prostate gland, neoplasm  
 Skin, neoplasm  
 Stomach, neoplasm  
 Thyroid gland, neoplasm

(preparation of imidazopyrazines as cyclin dependent kinase inhibitors)

IT 63744-22-9P 108418-77-5P 108418-79-7P 117718-84-0P

676361-04-9P 676361-05-0P 676361-07-2P

676361-08-3P 676361-09-4P 676361-10-7P

676361-11-8P 676361-13-0P 676361-14-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)

IT 62-53-3, Aniline, reactions 70-11-1, Phenacyl bromide 91-00-9  
 100-46-9, Aminomethylbenzene, reactions 108-91-8, Cyclohexylamine,  
 reactions 109-85-3, 2-Methoxyethylamine 3731-51-9,  
 2-Aminomethylpyridine 3731-52-0, 3-(Aminomethyl)pyridine 3731-53-1,  
 4-(Aminomethyl)pyridine 10070-92-5, Pyridine-5-carboxaldehyde  
 13258-63-4, 4-(2-Aminoethyl)pyridine 20162-51-5 20173-24-4,  
 3-(2-Aminoethyl)pyridine 24241-18-7 51859-46-4 76537-38-7  
 177662-76-9, 4-Methylsulfonylaniline hydrochloride 387350-39-2  
 672324-65-1 673857-28-8 676361-15-2 676361-16-3  
 676361-17-4 676361-18-5 676361-19-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)


IT 63744-22-9P 676361-05-0P 676361-07-2P  
 676361-08-3P 676361-09-4P 676361-10-7P  
 676361-11-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)


RN 63744-22-9 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6,8-dibromo- (9CI) (CA INDEX NAME)




RN 676361-05-0 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-6-phenyl (9CI) (CA INDEX NAME)




RN 67636 -07-2 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-6-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 67636 -08-3 CAPLUS

CN Imidazo[1,2-a]pyrazine, 3-bromo-8-chloro-6-phenyl- (9CI) (CA INDEX NAME)




RN 67636 -09-4 CAPLUS

CN Imidazo[1,2-a]pyrazine, 3-bromo-8-chloro-6-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 67636 -10-7 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-3-iodo-6-phenyl- (9CI) (CA INDEX NAME)



RN 676361-11-8 C.APLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-6-(2-chlorophenyl)-3-iodo- (9CI) (CA INDEX NAME)




IT 76537-38-7 676361-15-2 676361-16-3  
676361-17-4 676361-18-5 676361-19-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(starting material; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)


RN 76537-38-7 C.APLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-3-methyl- (9CI) (CA INDEX NAME)




RN 676361-15-2 C.APLUS

CN Imidazo[1,2-a]pyrazine, 3,8-dichloro-6-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 676361-16-3 C.APLUS

CN Acetamide, N-[3-bromo-6-[2-(2-hydroxyethyl)-1-piperidinyl]imidazo[1,2-a]pyrazin-8-yl]-N-(3-pyridinylmethyl) (9CI) (CA INDEX NAME)




RN 676361-17-4 CAPLUS

CN Acetamide, N-[3-bromo-6-[(2-hydroxycyclohexyl)amino]imidazo[1,2-a]pyrazin-8-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 676361-18-5 CAPLUS

CN Acetamide, N-[3-bromo-6-[[2-(hydroxymethyl)cyclohexyl]amino]imidazo[1,2-a]pyrazin-8-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 676361-19-6 CAP. US

CN Acetamide, N- [3-bromo-6-[[1-(hydroxymethyl)-2-methylpropyl]amino]imidazo[1,2-a]pyrazin-8-yl]-N-(3-pyridinylmethyl)-  
(9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L57 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:267246 CAPLUS

DOCUMENT NUMBER: 140:303696

TITLE: Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors  
INVENTOR(S): Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026310	A1	20040401	WO 2003-US29456	20030919
WO 2004026310	C1	20050630		

W: AF, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CV, CC, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LI, LF, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, ON, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TK, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GF, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BF, KC, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, FI, FL, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BT, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


CA 2499874	AA	20040401	CA 2003-2499874	20030919
AU 2003275031	A1	20040408	AU 2003-275031	20030919
US 2004072835	A1	20040415	JS 2003-666424	20030919
EP 1542692	A1	20050622	EP 2003-759300	20030919

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006502838	T2	20060202	JP 2004-538213	20030919
ZA 2005002380	A	20050927	ZA 2005-2380	20050322

PRIORITY APPLN. INFO.: JS 2002-412906P P 20020923  
NO 2003-US29456 W 20030919

OTHER SOURCE(S): MARPAT 140:303696  
GI



AB In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. I [R = CF<sub>3</sub>, (un)substituted-alkyl, -heteroaryl, -heteroarylalkyl, -cycloalkyl, -heterocyclyl, etc.; R<sub>1</sub> = H, halo or alkyl; R<sub>2</sub> = H, halo, CN, cycloalkyl, heterocyclyl, alkynyl and CF<sub>3</sub>; R<sub>3</sub> = aryl (with exception of Ph), (un)substituted-heteroaryl (with exception of furyl), -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of preparing such compds., pharmaceutical compns. containing one or more such compds., methods of preparing pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepared by substitution of 8-chloro-6-methylimidzolo[1,2-a]pyrazine with 3-(aminomethyl)pyridine. Methods for performing assays with I are described (no data).

IC ICM A61K031-5025

ICS A61K031-407; A61K031-4406; A61K031-4427; C07D487-04

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

IT Neuroglia, neoplasm

(astrocytoma; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)

IT Nerve, neoplasm  
(**neuroblastoma**; preparation of imidazopyrazines as cyclin dependent kinase inhibitors)


IT Antitumor agents  
Bladder, neoplasm  
Drug delivery systems  
Drug interactions  
Esophagus, neoplasm  
Gallbladder, neoplasm  
Hodgkin's disease  
Human  
Kidney, neoplasm  
Leukemia  
Liver, neoplasm  
Lung, neoplasm  
Mammary gland, neoplasm  
Melanoma  
Myelodysplastic syndromes  
**Neuroglia**, neoplasm  
Ovary, neoplasm  
Pancreas, neoplasm  
Prostate gland, neoplasm  
Skin, neoplasm  
Stomach, neoplasm  
Thyroid gland, neoplasm  
(preparation of imidazopyrazines as cyclin dependent kinase inhibitors)

IT 3731-52-0, 3-(Amino methyl)pyridine 143591-86-0  
676132-60-8 676132-61-9 676132-62-0  
676132-63-1 676132-64-2 676132-65-3  
676132-66-4 676132-67-5 676132-68-6  
RL: RCT (Reactant) RACT (Reactant or reagent)  
(starting material; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors)

IT 143591-86-0 676132-60-8 676132-61-9  
676132-62-0 676132-63-1 676132-64-2  
676132-65-3 676132-66-4 676132-67-5  
676132-68-6  
RL: RCT (Reactant), RACT (Reactant or reagent)  
(starting material; preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors)

RN 143591-86-0 CAPLUS


CN Imidazo[1,2-a]pyrazine, 8-chloro-6-methyl- (9CI) (CA INDEX NAME)




RN 676132-60-8 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-6-(1,1-dimethyl-ethyl)- (9CI) (CA INDEX NAME)







RN 676132-61-9 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-chloro-6-ethyl- (9CI) (CA INDEX NAME)




RN 676132-62-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-chloro-6-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)



RN 676132-63-1 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-chloro-6-(phenyl methyl)- (9CI) (CA INDEX NAME)




RN 676132-64-2 CAPLUS  
 CN Acetamide, N-(3-bromo-6-methylimidazo[1,2-a]pyrazin-8-yl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 676132-65-3 CAPLUS

CN Acetamide, N-[3-bromo-6-(1,1-dimethylethyl)imidazo[1,2-a]pyrazin-8-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 676132-66-4 CAPLUS

CN Acetamide, N-(3-bromo-6-ethylimidazo[1,2-a]pyrazin-8-yl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 676132-67-5 CAPLUS

CN Acetamide, N-[3-bromo-6-(cyclohexylmethyl)imidazo[1,2-a]pyrazin-8-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 676132-68-6 (APLUS

CN Acetamide, N-(3-bromo-6-(phenylmethyl)imidazo[1,2-a]pyrazin-8-yl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L57 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:796660 CAPLUS

DOCUMENT NUMBER: 139:307796

TITLE: Preparation of aminoacyl imidazo- and triazolopyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

INVENTOR(S): Brockunier, Linda L.; Duffy, Joseph L.; Kim, Doo-seop; Parmee, Emma R.; Weber, Ann E.

PATENT ASSIGNEE(S): Merck &amp; Co., Inc., USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082817	A2	20031009	WO 2003-US8723	20030321
WO 2003082817	A3	20031218		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2478389 AA 20031009 CA 2003-2478389 20030321  
 AU 2003225916 A1 20031013 AU 2003-225916 20030321  
 EP 1490335 A2 20041229 EP 2003-745557 20030321  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LJ, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 US 2005107390 A1 20050519 US 2003-508898 20030321  
 JP 2005526811 T2 20050908 JP 2003-580285 20030321  
 PRIORITY APPLN. INFO.: US 2002-367410P P 20020325  
 WO 2003-US8723 W 20030321  
 OTHER SOURCE(S): MAR PAT 139:307796  
 GI




AB Title compds. I [Ar = (un)substituted Ph; X = N, (un)substituted CH<sub>2</sub>; R<sub>1</sub> = H, CN, (un)substituted alkyl, Ph, heterocyclic; R<sub>2</sub>, R<sub>3</sub> = H, CN, (un)substituted alkyl, Ph, naphthyl, CO<sub>2</sub>H, CONH<sub>2</sub>, cycloalkyl] were prepared for use as dipeptidyl peptidase-IV inhibitors in the treatment or prevention of diseases, such as diabetes and particularly type 2 diabetes. Thus, 6-benzyl-3-methyl 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine was prepared in 5 steps from 2-benzyloxirane and was acylated with (R)-3,4-F<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>CH(NHCO<sub>2</sub>CM<sub>2</sub>)CH<sub>2</sub>CO<sub>2</sub>H and deblocked to give the imidazopyrazine II.

IC ICM C07D211-36  
 ICS A61K031-495


CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference s): 1

IT Nerve, disease  
 (neuropathy; preparation of aminoacylimidazo- and triazolopyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes)


IT 19848-54-5P 20721-17-9P, 2-Hydroxy-5-methylpyrazine 59303-10-5P,  
 2-Chloro-5-methylpyrazine 132871-52-4P 161124-42-5P 476620-55-0P,  
 2-Bromo-4,5-difluorobenzyl alcohol 486459-98-7P 486459-99-8P  
 486460-00-8P 486460-02-0P 486460-03-1P 486460-04-2P 486460-05-3P  
 486460-06-4P 486460-07-5P 486460-08-6P 486460-09-7P 486460-24-6P  
 611240-46-1P 611240-47-2P 611240-48-3P 611240-49-4P 611240-50-7P  
 611240-51-8P 611240-52-9P 611240-53-0P 611240-54-1P 611240-55-2P  
 611240-56-3P 611240-57-4P 611240-58-5P 611240-59-6P 611240-60-9P  
 611240-61-0P 611240-62-1P 611240-63-2P 611240-64-3P 611240-65-4P  
 611240-66-5P 611240-67-6P **611240-68-7P 611240-69-8P**  
 611240-70-1P **611240-71-2P** 611240-72-3P 611240-73-4P  
 611240-74-5P 611240-75-6P 611240-76-7P 611240-77-8P 611240-78-9P  
 611240-81-4P 611240-83-6P 611240-84-7P 611240-85-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of aminoacylimidazo- and triazolopyrazines as dipeptidyl  
 peptidase inhibitors for the treatment or prevention of diabetes)  
 IT **611240-68-7P 611240-69-8P 611240-71-2P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of aminoacylimidazo- and triazolopyrazines as dipeptidyl  
 peptidase inhibitors for the treatment or prevention of diabetes)  
 RN 611240-68-7 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-chloro-2-(trifluoromethyl)- (9CI) (CA INDEX  
 NAME)



RN 611240-69-8 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-methyl-2-(trifluoromethyl)- (9CI) (CA INDEX  
 NAME)



RN 611240-71-2 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-(4-fluorophenyl)-2-(trifluoromethyl)- (9CI) (CA  
 INDEX NAME)



157 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003: 37761 CAPLUS  
 DOCUMENT NUMBER: 139:261331  
 TITLE: Preparation of 3-(tricyclic fused heteroaryl)  
 4-heteroaryl substituted 2,5-dioxo-1,2,3,4-tetrahydronaphthalenes as  
 GSK-3 $\beta$  kinase inhibitors  
 INVENTOR(S): Clayton, Joshua Ryan; Diefenbacher, Clive Gideon;  
 Engle, Thomas Albert; Furness, Kelly Wayne; Henry,  
 James Robert; Malhotra, Sushant; Marquart, Angela  
 Lynn; McLean, Johnathan Alexander; Mendel, David;  
 Burkholder, Timothy Paul; Li, Yihong; Reel, Jon Kevin  
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA; et al.  
 SOURCE: PCT Int. Appl., 161 pp.  
 CODEN PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076442	A1	20030918	WO 2003-US5050	20030304
W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IE, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MA, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, SC, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2477967	AA	20030918	CA 2003-2477967	20030304
AU 2003215325	A1	20030922	AU 2003-215325	20030304
EP 1483265	A1	20041208	EP 2003-711146	20030304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, MA, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008243	A	20050111	BR 2003-8243	20030304
US 2005090483	A1	20050428	US 2003-506459	20030304
CN 1639165	A	20050713	CN 2003-805292	20030304
JP 2005526072	T2	20050902	JP 2003-574659	20030304
PRIORITY APPLN. INFO.:			US 2002-362245P	P 20020305
			WO 2003-US5050	W 20030304

OTHER SOURCE(S): MARPAT 139:261331  
 CI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I; R1 = H, halo, alkyl; m = 0-4; R = (CH<sub>2</sub>)<sub>n</sub>, CHMe, CMe<sub>2</sub>, CH<sub>2</sub>Q1CH<sub>2</sub>, CHCHCHOHCH<sub>2</sub>; Q1 = CHOH, CO; n = 0-4; WXY = (CH<sub>2</sub>)<sub>3</sub>, (un)substituted CHNHCH<sub>2</sub>, NHCOCH<sub>2</sub>, etc.; Ar = benzofuryl, benzothienyl, indolyl, etc.), useful for treating GSK-3 $\beta$  mediated diseases such as diabetes and Alzheimer's disease, were prepared. Thus, treating 3-(6,7-dihydro-6H-1,4]diazepino[6,7,1-hj]indol-1-yl)-4-(imidazo[1,2-a]pyridin-3-yl)pyrrole-2,5-dione dihydrochloride (preparation given) with diethyl cyanocarbonimidate in the presence of Et<sub>3</sub>N in iso-PrOH followed by addition of morpholine afforded II. The exemplified compds. I exhibit IC<sub>50</sub> of  $\leq 0.2$   $\mu$ M against GSK-2 $\beta$ . Pharmaceutical composition comprising the compound I was claimed.

IC ICM C07D487-06  
ICS A61P025-08

CC 28-21 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s): 1, 63

ST tricyclic fused heteroaryl dioxopyrrole prepn GSK3beta protein kinase inhibitor; pyrroleione heteroaryl prepn GSK3beta inhibitor antidiabetic Alzheimer's disease

IT Anti-Alzheimer's agents  
Antidiabetic agents  
Human  
(preparation of 3-(tricyclic fused heteroaryl 4-heteroaryl substituted 2,5-dioxopyrroles as GSK-3 $\beta$  kinase inhibitors)

IT Alzheimer's disease  
Diabetes mellitus  
(treatment of; preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted 2,5-dioxopyrroles as GSK-3 $\beta$  kinase inhibitors)

IT 603263-19-0P 603263-27-0P 603263-35-0P 603263-43-0P 603263-51-0P  
603263-58-7P 603263-66-7P 603263-74-7P 603263-92-9P 603263-99-6P  
603264-05-7P 603264-12-6P 603264-20-6P 603264-27-3P 603264-33-1P  
603264-39-7P 603264-42-2P 603264-49-9P 603264-57-9P 603264-64-8P  
603264-72-8P 603264-82-0P 603264-88-6P 603264-95-5P 603265-03-8P  
603265-10-7P 603265-16-3P 603265-23-2P 603265-28-7P 603265-36-7P  
603265-45-8P 603265-52-7P 603265-58-3P 603265-64-1P 603265-72-1P  
603265-79-8P 603265-94-7P 603266-02-0P 603266-09-7P 603266-16-6P  
603266-23-5P 603266-31-5P 603266-38-2P 603266-47-3P 603266-55-3P  
603266-63-3P 603266-72-4P 603266-79-1P 603266-87-1P 603267-01-2P  
603267-08-9P 603267-17-0P 603267-24-9P 603267-32-9P 603267-47-6P  
603267-57-8P 603267-72-7P 603267-80-7P 603267-87-4P 603268-01-5P  
603268-07-1P 603268-14-0P 603268-28-6P 603268-35-5P 603268-42-4P  
603268-50-4P 603268-58-2P 603268-64-0P 603268-73-1P 603268-86-6P  
603268-92-4P 603268-97-9P 603269-09-6P 603269-15-4P 603269-24-5P  
603269-32-5P 603269-40-5P 603269-45-0P 603269-52-9P 603269-61-0P  
603269-69-8P 603269-77-8P 603269-92-7P 603270-04-8P 603270-12-8P  
603270-20-8P 603270-29-7P 603270-42-4P 603270-50-4P 603270-59-3P  
603270-67-3P 603270-73-1P 603270-80-0P 603270-87-7P 603270-95-7P  
603271-03-0P 603271-09-6P 603271-17-6P 603271-24-5P 603271-31-4P  
603271-39-2P 603271-47-2P 603271-54-1P 603271-61-0P 603271-67-6P  
603271-75-6P 603271-95-0P 603272-03-3P 603272-09-9P 603272-18-0P  
603272-26-0P 603272-35-1P 603272-42-0P 603272-51-1P  
603272-60-2P 603272-68-0P 603272-76-0P 603272-82-8P 603272-90-8P  
603272-98-6P 603273-06-9P 603273-14-9P 603273-21-8P 603273-28-5P  
603273-34-3P 603273-40-1P 603273-49-0P 603273-54-7P 603273-62-7P  
603273-69-4P 603273-77-4P 603273-82-1P 603273-91-2P 603273-98-9P  
603274-07-3P 603274-14-2P 603274-30-2P 603274-37-9P 603274-44-8P

603274-53-9P	603274-60-8P	603274-68-6P	603274-74-4P	603274-82-4P
603274-90-4P	603274-98-2P	603275-05-4P	603275-12-3P	603275-21-4P
603275-30-5P	603275-38-3P	603275-44-1P	603275-53-2P	603275-60-1P
603275-70-3P	603275-79-2P	603275-86-1P	603275-95-2P	603276-02-4P
603276-11-5P	603276-28-4P	603276-44-4P	603276-53-5P	603276-68-2P
603276-75-1P	603276-91-1P	603277-07-2P	603277-22-1P	603277-29-8P
603277-36-7P	603277-44-7P	603277-53-8P	603277-61-8P	603277-67-4P
603277-76-5P	603277-84-5P	603277-92-5P	603277-99-2P	603278-07-5P
603278-14-4P	603278-21-3P	603278-27-9P	603278-34-8P	603278-40-6P
603278-48-4P	603278-55-3P	603278-59-7P	603278-65-5P	603278-71-3P
603278-77-9P	603278-82-6P	603278-89-3P	603278-95-1P	603279-01-2P
603279-09-0P	603279-13-6P	603279-18-1P	603279-23-8P	603279-28-3P
603279-36-3P	603279-44-3P	603279-51-2P	603279-58-9P	603279-64-7P
603279-70-5P	603279-71-6P	603279-77-2P	603279-85-2P	603279-91-0P
603279-97-6P	603280-09-7P	603280-16-6P	603280-24-6P	603280-30-4P
603280-37-1P	603280-44-0P	603280-50-8P	603280-56-4P	603280-62-2P
603280-68-8P	603280-73-5P	603280-79-1P	603280-86-0P	603280-92-8P
603281-00-1P	603281-06-7P	603281-13-6P	603281-19-2P	603281-25-0P
603281-31-8P	603281-38-5P	603281-46-5P	603281-53-4P	603281-60-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted 2,5-dioxopyrroles as GSK-3 $\beta$  kinase inhibitors)

IT	603281-67-0P	603281-72-7P	603281-76-1P	603281-81-8P	603281-86-3P
	603281-90-9P	603281-95-4P	603282-02-6P	603282-16-2P	603282-21-9P
	603282-27-5P	603282-46-8P	603282-52-6P	603282-75-3P	603282-81-1P
	603282-88-8P	603282-94-6P	603283-00-7P	603283-06-3P	603283-13-2P
	603283-18-7P	603283-24-5P	603283-31-4P	603283-36-9P	603283-42-7P
	603283-44-9P	603283-50-7P	603283-55-2P	603283-62-1P	603283-71-2P
	603283-77-8P	603283-84-7P	603283-91-6P	603283-97-2P	603284-03-3P
	603284-08-8P	603284-13-5P	603284-19-1P	603284-27-1P	603284-33-9P
	603284-39-5P	603284-48-6P	603284-57-7P	603284-65-7P	603284-70-4P
	603284-75-9P	603284-80-6P	603284-87-3P	603284-92-0P	603284-95-3P
	603285-02-5P	603285-08-1P	603285-14-9P	603285-19-4P	603285-25-2P
	603285-32-1P	603285-39-8P	603285-44-5P	603285-50-3P	603285-56-9P
	603285-62-7P	603285-66-1P	603285-71-8P	603285-77-4P	603285-83-2P
	603285-90-1P	603285-96-7P	603286-09-5P	603286-16-4P	603286-22-2P
	603286-28-8P	603286-35-7P	603286-50-6P	603286-57-3P	603286-61-9P
	603286-68-6P	603286-76-6P	603286-82-4P	603286-89-1P	603286-95-9P
	603287-03-2P	603287-09-8P	603287-15-6P	603287-22-5P	603287-27-0P
	<b>603287-32-7P</b>	<b>603287-38-3P</b>	603287-46-3P	603287-52-1P	
	603287-58-7P	603287-64-5P	603287-70-3P	603287-77-0P	603287-83-8P
	603287-88-3P	603287-93-0P	603288-01-3P	603288-08-0P	603288-16-0P
	603288-22-8P	603288-29-5P	603288-32-0P	603288-37-5P	603288-43-3P
	603288-51-3P	603288-58-0P	603288-65-9P	603288-71-7P	603288-76-2P
	603288-81-9P	603288-89-7P	603288-96-6P	603289-03-8P	603289-09-4P
	603289-16-3P	603289-23-2P	603289-30-1P	603289-36-7P	603289-42-5P
	603289-44-7P	603289-51-6P	603289-58-3P	603289-63-0P	603289-74-3P
	603289-80-1P	603289-86-7P	603289-92-5P	603289-97-0P	603290-03-5P
	603290-10-4P	603290-16-0P	603290-24-0P	603290-30-8P	603290-36-4P
	603290-43-3P	603290-48-8P	603290-55-7P	603290-62-6P	603290-68-2P
	603290-74-0P	603290-80-8P	603290-85-3P	603290-92-2P	603290-98-8P
	603291-04-9P	603291-10-7P	603291-16-3P	603291-23-2P	603291-29-8P
	603291-36-7P	603291-43-6P	603291-51-6P	603291-57-2P	603291-62-9P
	603291-69-6P	603291-77-6P	603291-82-3P	603291-87-8P	603291-94-7P
	603291-99-2P	603292-05-3P	603292-11-1P	603292-16-6P	603292-20-2P
	603292-24-6P	603292-32-6P	603292-37-1P	603292-44-0P	603292-51-9P
	603292-56-4P	603292-62-2P	603292-68-8P	603292-72-4P	603292-78-0P
	603292-83-7P	603292-89-3P	603292-95-1P	603293-01-2P	603293-07-8P



603293-13-6P 60329 -20-5P 603293-29-4P 603293-42-1P 603293-48-7P  
 603293-59-0P 60329 -66-9P 603293-72-7P 603293-79-4P 603293-85-2P  
 603293-95-4P 60329 -00-4P 603294-06-0P 603294-12-8P 603294-19-5P  
 603294-27-5P 60329 -33-3P 603294-39-9P 603294-43-5P 603294-49-1P  
 603294-55-9P 60329 -61-7P 603294-69-5P 603294-76-4P 603294-81-1P  
 603294-87-7P 60329 -93-5P 603294-99-1P 603294-04-1P 603295-09-6P  
 603295-14-3P 60329 -18-7P 603295-24-5P 603295-30-3P 603295-35-8P  
 603295-41-6P 60329 -47-2P 603295-53-0P 603295-59-6P 603295-65-4P  
 603295-71-2P 60329 -76-7P 603295-82-5P 603295-88-1P 603295-93-8P  
 603295-98-3P 60329 -03-3P 603296-10-2P 603296-17-9P 603296-22-6P  
 603296-27-1P 60329 -30-6P 603296-33-9P 603296-39-5P 603296-45-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3 (tricyclic fused heteroaryl) 4-heteroaryl substituted 2,5-dioxopyrroles as GSK-3 $\beta$  kinase inhibitors)

IT 394-69-4P, 5-Fluoroquinoline 395-81-3P, 5-Fluoro-2-nitrobenzaldehyde  
 1701-57-1P, 2,3,4,5-Tetrahydro-1H-benzo[b]azepine 2343-23-9P  
 3349-64-2P 4424-80-0P, 1,3,4,5-Tetrahydrobenzo[b]azepin-2-one  
 5817-85-6P 5840-01-7P, 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline  
 10133-25-2P, Benzo[b]thiophene-4-carboxaldehyde 10134-91-5P,  
 Benzo[b]thiophene-7-carboxaldehyde 10167-97-2P, 2-Amino-5-methoxypyridine 17-81-50-9P, Benzo[b]thiophene-4-acetonitrile  
 17381-53-2P, Benzo[b]thiophene-7-acetonitrile 1955-60-8P 21801-85-4P  
 21801-86-5P, Imidazo[1,2-a]pyridine-3-acetamide 2250-48-2P  
 22780-71-8P, Benzo[b]thiophene-7-carbonitrile 2417-64-4P,  
 2-Amino-3-cyanopyridine 28740-75-2P 28740-77-4P 28740-85-4P  
 34784-04-8P, 5-Bromoquinoline 39597-67-6P, 1H-Indole-7-acetamide  
 59254-24-9P, 4-Methoxybenzofuran-7-carboxaldehyde 59611-52-8P,  
 6-Fluoro-1,2,3,4-tetrahydroquinoline 72995-16-5P 5-Chloro-1,2,3,4-tetrahydroquinoline 82199-98-2P, (1H-Indol-7-yl)acetonitrile  
 84548-94-7P 84549-03-1P, 7-Benzofuranacetonitrile 94239-08-4P,  
 7-Vinylindole 9848-31-2P 101820-69-3P 10190-09-1P 116476-45-0P  
 116939-11-8P 124730-53-6P, 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-carboxylic acid ethyl ester 124730-54-7P, 4,5,6,7-Tetrahydroazepino[3,2,1-hi]indole-1-carboxylic acid 124730-56-9P,  
 5,6-Dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1-carboxylic acid 133994-99-7P, 1-Methyl-1H-indole-4-carboxaldehyde 136117-93-6P  
 152712-40-8P, 4,5,6,7-Tetrahydroazepino[3,2,1-hi]indole-1-carboxylic acid ethyl ester 152712-44-2P 152712-45-3P, 2-Oxo-3-(2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)propionic acid ethyl ester 183611-01-0P  
 214894-99-2P 274910-19-9P 286836-72-4P 28712-32-8P 309976-26-9P,  
 5-Methyl-1H-indole-7-carboxaldehyde 345232-22-6P 1-(Pent-4-en-1-yl)-7-vinyl-1H-indole 345264-02-0P 345264-10-0P 345264-11-1P  
 345264-14-4P 345264-15-5P 345264-16-6P 345264-19-9P 345264-21-3P  
 345264-22-4P, N-Allyl-N-[(1H-indol-7-yl)methyl]amine 345264-23-5P  
 345264-24-6P 345264-25-7P 345264-26-8P 345264-43-9P 345264-44-0P  
 345264-51-9P 345264-52-0P, 1H-Indole-7-ethanol 345264-53-1P  
 345264-54-2P 345264-58-6P 345264-59-7P, 8-Chloro-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline 345264-60-0P 345264-61-1P,  
 5-Fluoro-1,2,3,4-tetrahydroquinoline 345264-62-2P, 7-Fluoro-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline 345264-63-3P 345264-64-4P,  
 8-Fluoro-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline 345264-65-5P  
 345264-90-6P 345264-91-0P 345334-99-8P 408355-39-5P 408356-52-5P,  
 1H-Indole-7-methanamine 470715-79-8P 555154-94-4P 555154-95-5P  
 555154-96-6P 555154-97-7P 555154-98-8P 555154-99-9P 555155-00-5P  
 555155-01-6P 555155-03-8P 555155-06-1P, 5-(Tetrahydropyranyloxy)benzofuran-7-carboxaldehyde 555155-07-2P,  
 4-Fluorobenzofuran-7-carboxaldehyde 555155-08-3P 5-Fluorobenzofuran-7-carboxaldehyde 555155-09-4P, 6-Fluorobenzofuran-7-carboxaldehyde

55155-10-7P, 4,5-Difluorobenzofuran-7-carboxaldehyde 555 55-11-8P,  
 ,6-Difluorobenzofuran-7-carboxaldehyde 555155-13-0P 56 337-71-9P  
 90417-55-3P 602299-23-0P, 7-Chloro-5,6-dihydro-4H-pyrrolo[3,2,1-  
 j]quinoline 602299-45-6P 502299-95-6P 603300-70-5P 603300-76-1P  
 03300-82-9P 603300-87-4P 503300-92-1P 603300-96-5P 603301-02-6P,  
 4-Bromo-5H-furo[3,2-c]pyridine-4-one 603301-06-0P, 4,7-Dihomofuro[3,2-  
 c]pyridine 603301-13-9P 603301-16-2P 603301-22-0P 603301-25-3P  
 03301-29-7P 603301-33-3P 503301-38-8P 603301-44-6P 603301-50-4P  
 03301-53-7P 603301-58-2P 503301-63-9P 603301-67-3P 603301-71-9P  
 03301-77-5P 603301-83-3P 503301-89-9P 603301-96-8P 603302-12-1P  
 03302-69-8P, Furo[3,2-c]pyridine-7-acetonitrile 603302-71-7P,  
 Furo[3,2-c]pyridine-7-carbonitrile 603302-86-9P, Furo[3,2-c]pyridine-7-  
 carboxylic acid 603302-91-6P, Furo[3,2-c]pyridine-7-methanol  
 03303-07-7P 603303-14-6P 503303-26-0P 603303-31-7P,  
 Benzo[b]thiophene-7-acetamide 603303-37-3P 603303-49-7P 603303-55-5P  
 03303-61-3P 603303-67-9P 503303-73-7P 603303-79-3P 603303-86-2P  
 03303-96-4P, 7-Benzofuranacetamide 603304-01-4P, Benzo[b]thiophene-4-  
 acetamide 603304-06-9P, Furo[3,2-c]pyridine-7-acetamide 603304-13-8P  
 03304-18-3P 603304-24-1P 503304-29-6P, 4-Benzofuranacetamide  
 03304-43-4P 603304-50-3P 603304-56-9P 603304-61-6P 603304-68-3P,  
 Imidazo[2,1-b]thiazole-3-acetamide 603304-73-0P 603304-79-6P  
 03304-86-5P 603304-95-6P 503305-00-6P 603305-06-2P 603305-12-0P  
 03305-28-8P 603305-34-6P 503305-40-4P 603305-46-0P 603305-53-9P  
 03305-64-2P 603305-70-0P 503305-76-6P 603305-83-5P,  
 Dihydro[3,2-b]pyridine-7-acetamide 603305-89-1P 603305-91-0P  
 03306-01-0P 603306-06-5P 503306-11-2P 603306-17-8P 603306-25-8P  
 03306-52-1P 603306-58-7P 503306-64-5P 603306-70-3P 603306-76-9P  
 03306-81-6P 603306-88-3P 503306-93-0P 603306-99-6P 603307-06-8P  
 03307-11-5P 603307-18-2P 503307-25-1P 603307-33-1P 603307-37-5P  
 03307-42-2P 603307-47-7P 503307-53-5P 603307-58-0P 603307-64-8P  
 03307-69-3P 603307-74-0P 503307-80-8P 603307-85-3P 603307-92-2P  
 03308-02-7P 603308-08-3P 503308-13-0P 603308-19-6P 603308-25-4P  
 03308-37-8P 603308-43-6P 503308-51-6P 603308-56-1P 603308-67-4P  
 03308-80-1P 603308-88-9P 503309-09-7P 603309-16-6P 603309-24-6P  
 03309-31-5P, Imidazo[1,2-a]pyrazine-3-acetamide 603309-31-2P  
 03309-44-0P, Imidazo[1,2-b]pyridazine-3-acetamide 603309-52-0P  
 03309-57-5P 603309-64-4P 503309-77-9P 603309-83-7P,  
 Imidazo[1,2-c]pyrimidine-3-acetamide 603309-90-6P 603310-96-2P  
 03310-02-7P 603310-08-3P 503310-14-1P

L: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 Reactant or reagent)

(preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted  
 2,5-dioxopyrroles as GSK-3 $\beta$  kinase inhibitors)


IT 603272-35-1P 603287-32-7P 603287-38-3P

L: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 Uses)

(preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted  
 2,5-dioxopyrroles as GSK-3 $\beta$  kinase inhibitors)

RN 03272-35-1 CAPLUS


CN H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyrazin-3-yl-4-(1,2,3,4-  
 tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl)-, dihydrochloride  
 9CI) (CA INDEX NAME)



● 2 HCl


RN 603287-32-7 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro 4-imidazo[1,2-a]pyrazin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 603287-38-3 CAPLUS

CN Pyrrolo[3,2,1-jk][1,4]benzodiazepine, 7-(2,5-dihydro 4-imidazo[1,2-a]pyrazin-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)



IT 60:309-31-5P, Imidazo[1,2-a]pyrazine-3-acetamide  
 RL RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of 3-(tricyclic fused heteroaryl) 4-heteroaryl substituted  
 2,5-dioxopyrroles as GSK-3 $\beta$  kinase inhibitors)  
 RN 60:309-31-5 CAPLUS  
 CN Imidazo[1,2-a]pyrazine-3-acetamide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L57 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:678814 CAPLUS

DOCUMENT NUMBER: 139:214613

TITLE: Preparation of N-(azabicyclic)arylamides or  
 therapeutic use as nicotinic acetylcholine receptor  
 agonists

INVENTOR(S): Rogers, Bruce N.; Piotrowski, David W.; Walker, Daniel  
 P.; Jacobson, Eric Jon; Acker, Brad A.; Wenska, Donn  
 G.; Groppi, Vincent E., Jr.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 167 pp.

CODEN: PIXX12

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY/CC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2003070732 A1 20030828 WO 2003-US2687 20030214  
W: AE, AG, AL, AM, AP, AU, AZ, BA, BB, BG, BR, BY BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ NO, NZ, OM, PH,  
PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TF, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE SI, SK, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE SN, TD, TG  
CA 2476681 AA 20030828 CA 2003-2476681 20030214  
AU 2003219690 A1 20030909 AU 2003-219690 20030214  
US 2003236264 A1 20031225 US 2003-366855 20030214  
US 6858613 B2 20050222  
EP 1476449 A1 20041117 EP 2003-715958 20030214  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
BR 2003007735 A 20050125 BR 2003-7735 20030214  
JP 2005523288 T2 20050804 JP 2003-569639 20030214  
US 2005215584 A1 20050929 US 2004-4365 20041203  
PRIORITY APPLN. INFO.:  
US 2002-357917P P 20020219  
US 2002-423157P P 20021101  
US 2003-366855 A1 20030214  
WO 2003-US2687 W 20030214  
THER SOURCE(S): MARPAT 139:214613  
I



.B N-(azabicyclic)arylamides such as RNR1C(:X)W [R = azabicyclic; R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central nervous system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la

Tourette's Syndrome, glaucoma, **neurodegeneration** associated with glaucoma, or symptoms associated with pain. Thus, the hydrochloride salt of amid I was prepared via a multistep synthetic sequence which included with an amidation reaction of pyrrolo[2,2-c]pyrimidine-3-carboxylic acid hydrochloride with (R)-(+)-3-aminopropylamine dihydrochloride using diethylphosphoric chloride and Et<sub>3</sub>N in THF. The prepared amides were assayed for human  $\alpha$ 7-5HT<sub>3</sub> receptor binding activity.

- IC ICM C07D519-00  
ICS A61K031-439; A61K031-4985; A61P025-18  
CC 31-4 (Alkaloids)  
Sect on cross-reference(s): 1, 27, 28, 63  
IT AIDS (disease)  
    (AIDS **dementia** complex, treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT **Mental and behavioral disorders**  
    (AIDS **dementia**, treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT **Mental and behavioral disorders**  
    (Parkinson's disease, treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT **Mental and behavioral disorders**  
    (Attention deficit disorder, treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT **Mental and behavioral disorders**  
    (**dementia**, treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT **Mental and behavioral disorders**  
    (Depression, treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT **Mental and behavioral disorders**  
    (Mood-affecting, treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT **Mental and behavioral disorders**  
    (Personality disorder, treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT **Mental and behavioral disorders**  
    (Psychosis, treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT **Alzheimer's disease**  
    Anorexia  
    Anxiety  
    Bulimia  
    Cognitive disorders  
    Drug dependence  
    Glaucoma (disease)  
    Parkinson's disease  
    **Schizophrenia**  
    Stress, animal  
    (treatment; preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)  
IT 588720-17-6P 588720-18-7P 588720-19-8P 588720-20-1P 588720-21-2P  
588720-22-3P 588720-23-4P 588720-24-5P 588720-25-6P 588720-32-5P  
588720-34-7P 588720-37-0P 588720-38-1P 588720-44-9P 588720-45-0P  
588720-46-1P 588720-49-4P 588720-50-7P 588720-51-8P 588720-54-1P  
588720-55-2P 588720-56-3P 588720-57-4P 588720-61-0P  
588720-64-3P 588720-65-4P 588720-69-8P 588720-70-1P  
588720-72-3P 588720-73-4P 588720-75-6P 588720-76-7P 588720-78-9P

588720-79-0P	588720-81-4F	588720-82-5P	588720-86-9	588720-87-0P
588720-88-1P	588720-89-2F	588720-92-7P	588720-93-8	588720-94-9P
588720-95-0P	588720-96-1F	588720-97-2P	588720-98-3	588720-99-4P
588721-00-0P	588721-01-1P	588721-02-2P	588721-03-3	588721-04-4P
588721-05-5P	588721-06-6P	588721-07-7P	588721-08-8	588721-09-9P
588721-10-2P	588721-11-3P	588721-12-4P	588721-13-5	588721-14-6P
588721-15-7P	588721-16-8P	588721-17-9P	588721-18-0	588721-19-1P
588721-20-4P	588721-21-5F	588721-22-6P	588721-23-7	588721-24-8P
588721-25-9P	588721-26-0P	588721-27-1P	588721-28-2	588721-29-3P
588721-30-6P	588721-31-7P	588721-32-8P	588721-33-9	588721-34-0P
588721-35-1P	588721-36-2P	588721-37-3P	588721-38-4	588721-39-5P
588721-40-8P	588721-41-9P	588721-42-0P	588721-43-1	588721-44-2P
588721-45-3P	588721-47-5P	588721-48-6P	588721-49-7	588721-50-0P
588721-51-1P	588721-52-2P	588721-53-3P	588721-54-4	588721-55-5P
588721-56-6P	588721-57-7P	588721-58-8P	588721-59-9	588721-60-2P
588721-61-3P	588721-62-4P	588721-63-5P	588721-64-6	588721-66-8P
588721-67-9P	588721-68-0P	588721-69-1P	588721-70-4	588721-71-5P
588721-72-6P	588721-73-7P	588721-74-8P	588721-75-9	588721-76-0P
588721-77-1P	588721-78-2P	588721-79-3P	588721-80-6	588721-81-7P
588721-82-8P	588721-83-9P	588721-84-0P	588721-85-1	588721-86-2P
588721-87-3P	588721-88-4P	588721-89-5P	588721-90-8	588721-91-9P
588721-92-0P	588721-93-1P	588721-94-2P	588721-96-4	588721-97-5P
588721-98-6P	588722-00-3P	588722-01-4P	588722-02-5	588722-04-7P
588722-05-8P	588722-06-9P	588722-08-1P	588722-09-2	588722-10-5P
588722-12-7P	588722-13-8P	588722-14-9P	588722-16-1	588722-17-2P
588722-18-3P	588722-19-4P	588722-20-7P	588722-21-8	588722-22-9P
588722-23-0P	588722-24-1P	588722-25-2P	588722-26-3	588722-27-4P
588722-28-5P	588722-29-6P	588722-30-9P	588722-31-0	588722-32-1P
588722-33-2P	588722-34-3P	588722-35-4P	588722-36-5	588722-37-6P
588722-38-7P	588722-39-8P	588722-40-1P	588722-41-2P	
588722-42-3P	588722-43-4P	588722-44-5P	588722-45-6	588722-46-7P
588722-47-8P	588722-48-9P	588722-49-0P	588722-50-3	588722-51-4P
588722-52-5P	588722-53-6P	588722-54-7P	588722-55-8	588722-56-9P
588722-57-0P	588722-58-1P	588722-59-2P	588722-60-5	588722-61-6P
588722-62-7P	588722-63-8P	588722-64-9P	588722-65-0	588722-66-1P
588722-67-2P	588722-68-3P	588722-69-4P	588722-70-7	588722-71-8P
588722-72-9P	588722-73-0P	588722-74-1P	588722-75-2	588722-76-3P
588722-77-4P	588722-78-5P	588722-79-6P	588722-80-9	588722-81-0P
588722-82-1P	588722-83-2P	588722-84-3P	588722-85-4	588722-86-5P
588722-87-6P	588722-88-7P	588722-89-8P	588722-90-1	588722-91-2P
588722-92-3P	588722-93-4P			

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of N-(azabicycyl)arylamides for therapeutic use as nicotinic  
acetylcholine receptor agonists)

IT	588722-94-5P	588722-95-6P	588722-96-7P	588722-97-8	588722-98-9P
	588722-99-0P	588723-00-6P	588723-01-7P	588723-02-8	588723-03-9P
	588723-04-0P	588723-05-1P	588723-06-2P	588723-07-3	588723-08-4P
	588723-09-5P	588723-10-8P	588723-11-9P	588723-12-0	588723-13-1P
	588723-14-2P	588723-15-3P	588723-16-4P	588723-17-5	588723-18-6P
	588723-19-7P	588723-20-0P	588723-21-1P	588723-22-2	588723-23-3P
	588723-24-4P	588723-25-5P	588723-26-6P	588723-27-7	588723-28-8P
	588723-29-9P	588723-30-2P	588723-31-3P	588723-32-4	588723-33-5P
	588723-34-6P	588723-35-7P	588723-36-8P	588723-37-9	588723-38-0P
	588723-39-1P	588723-40-4P	588723-41-5P	588723-42-6	588723-43-7P
	588723-44-8P	588723-45-9P	588723-46-0P	588723-47-1	588723-48-2P
	588723-49-3P	588723-50-6P	588723-51-7P	588723-52-8	588723-53-9P
	588723-54-0P	588723-55-1P	588723-56-2P	588723-57-3	588723-58-4P
	588723-59-5P	588723-60-8P	588723-61-9P	588723-62-0	588723-63-1P

588723 54-2P	588723-65-3P	588723 66-4P	588723-67-5P	588723-68-6P
588723 59-7P	588723-70-0P	588723 71-1P	588723-72-2P	588723-73-3P
<b>588723 74-4P</b>	588723-75-5P	588723 76-6P	588723-77-7P	
588723 78-8P	588723-79-9P	588723 80-2P	588723-81-3P	588723-82-4P
588723 83-5P	588723-84-6P	588723 85-7P	588723-86-8P	588723-87-9P
588723 88-0P	588723-89-1P	588723 90-4P	588723-91-5P	588723-92-6P
588723 93-7P	588723-94-8P	588723 95-9P	588723-96-0P	588723-97-1P
588723 98-2P	588723-99-3P	588724 00-9P	588724-01-0P	588724-02-1P
588724 03-2P	588724-04-3P	588724 05-4P	588724-06-5P	588724-07-6P
588724 08-7P	588724-09-8P	588724 10-1P	588724-11-2P	
<b>588724 12-3P</b>	588724-13-4P	588724 14-5P	588724-15-6P	
588724 16-7P	588724-17-8P	588724 18-9P	588724-19-0P	588724-20-3P
588724 21-4P	588724-22-5P	588724 23-6P	588724-24-7P	588724-25-8P
588724 26-9P	588724-27-0P	588724 28-1P	588724-29-2P	588724-30-5P
588724 31-6P	588724-32-7P	588724 33-8P	588724-34-9P	588724-35-0P
588724 36-1P	588724-37-2P	588724 38-3P	588724-39-4P	588724-40-7P
588724 41-8P	588724-42-9P	588724 43-0P	588724-44-1P	588724-45-2P
588724 46-3P	588724-47-4P	588724 48-5P	588724-49-6P	588724-50-9P
588724 51-0P	588724-52-1P	588724 53-2P	588724-54-3P	588724-55-4P
588724 56-5P	588724-57-6P	588724 58-7P	588724-59-8P	588724-60-1P
588724 61-2P	588724-62-3P	588724 63-4P	588724-64-5P	588724-65-6P
588724 66-7P	588724-67-8P	588724 68-9P	588724-69-0P	588724-70-3P
588724 71-4P	588724-72-5P	588724 73-6P	588724-74-7P	588724-75-8P
588724 76-9P	588724-77-0P	588724 78-1P	588724-79-2P	588724-80-5P
588724 81-6P	588724-82-7P	588724 83-8P	588724-84-9P	588724-85-0P
588724 86-1P	588724-87-2P	588724 88-3P	588724-89-4P	588724-90-7P
588724 91-8P	588724-92-9P	588724 93-0P	588724-94-1P	588724-95-2P
588724 96-3P	588724-97-4P	588724 98-5P	588724-99-6P	588725-00-2P
588725 01-3P	588725-03-5P	588725 04-6P	588725-05-7P	588725-06-8P
588725 07-9P	588725-08-0P	588725 09-1P	588725-10-4P	588725-11-5P
588725 12-6P	588725-13-7P	588725 14-8P	588725-15-9P	588725-16-0P
588725 17-1P	588725-18-2P	588725 19-3P	588725-20-6P	588725-21-7P
588725 22-8P	588725-23-9P	588725 24-0P	588725-25-1P	588725-26-2P
588725 27-3P	588725-28-4P			

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(azabicyclyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)

IT 588725 29-5P	588725-30-8P	588725 31-9P	588725-32-0P	588725-33-1P
588725 34-2P	588725-35-3P	588725 36-4P	588725-37-5P	588725-38-6P
588725 39-7P	588725-40-0P	588725 41-1P	588725-42-2P	588725-43-3P
588725 44-4P	588725-45-5P	588725 46-6P	588725-47-7P	588725-48-8P
588725 49-9P	588725-50-2P	<b>588725-51-3P</b>	588725-52-4P	
588725 53-5P	588725-54-6P	588725 55-7P	588725-56-8P	588725-57-9P
588725 58-0P	588725-59-1P	588725 60-4P	588725-61-5P	588725-62-6P
588725 63-7P	588725-64-8P	588725 65-9P	588725-66-0P	588725-67-1P
588725 68-2P	588725-69-3P	588725 70-6P	588725-71-7P	588725-72-8P
588725 73-9P	588725-74-0P	588725 75-1P	588725-76-2P	588725-77-3P
588725 78-4P	588725-79-5P	588725 80-8P	588725-81-9P	588725-82-0P
588725 83-1P	588725-84-2P	588725 85-3P	588725-86-4P	588725-87-5P
588725 88-6P	<b>588725-89-7P</b>	588725-90-0P	588725-91-1P	
588725 92-2P	588725-93-3P	588725 94-4P	588725-95-5P	588725-96-6P
588725 97-7P	588725-98-8P	588725 99-9P	588726-00-5P	588726-01-6P
588726 02-7P	588726-03-8P	588726 04-9P	588726-05-0P	588726-06-1P
588726 07-2P	588726-08-3P	588726 09-4P	588726-10-7P	588726-11-8P
588726 12-9P	588726-13-0P	588726 14-1P	588726-15-2P	588726-16-3P
588726 17-4P	588726-18-5P	588726 19-6P	588726-20-9P	588726-21-0P
588726 22-1P	588726-23-2P	588726 24-3P	588726-25-4P	588726-26-5P
588726 27-6P	588726-28-7P	588726 29-8P	588726-30-1P	588726-31-2P



588726-32-3P 588726-33-4P 588726-34-5P 588726-35-6P 588726-36-7P  
 588726-37-8P 588726-38-9P 588726-39-0P 588726-40-3P 588726-41-4P  
 588726-42-5P 588726-43-6P 588726-44-7P 588726-45-8P 588726-46-9P  
 588726-47-0P 588726-48-1P 588726-49-2P 588726-50-5P 588726-51-6P  
 588726-52-7P 588726-53-8P 588726-54-9P 588726-55-0P 588726-56-1P  
 588726-57-2P 588726-58-3P 588726-59-4P 588726-60-7P 588726-61-8P  
 588726-62-9P 588726-63-0P 588726-64-1P 588726-65-2P 588726-66-3P  
 588726-67-4P 588726-68-5P 588726-69-6P 588726-70-9P 588726-71-0P  
 588726-72-1P 588726-73-2P 588726-74-3P 588726-75-4P 588726-76-5P  
 588726-77-6P 588726-78-7P 588726-79-8P 588726-80-1P  
 588726-81-2P 588726-82-3P 588726-84-5P 588726-85-6P 588726-86-7P  
 588726-87-8P 588726-88-9P 588726-89-0P 588726-90-3P 588726-91-4P  
 588726-92-5P 588726-93-6P 588726-94-7P 588726-95-8P 588726-96-9P  
 588726-97-0P 588726-98-1P 588726-99-2P 588727-00-8P 588727-01-9P  
 588727-81-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of N-(azabicycyl)arylamides for therapeutic use as nicotinic  
 acetylcholine receptor agonists)

IT 19005-93-7P, 1H-Indole-2-carboxaldehyde 21472-88-8P, Ethyl  
 5-hydroxy-6-oxo-1,2,3,6-tetrahydropyridine-4-carboxylate 21473-14-3P  
 21473-16-5P, exo-1-Azabicyclo[2.2.1]heptan-3-ol 21492-03-5P,  
 cis-4-(Hydroxymethyl)piperidine-3-ol 23680-40-2P, Methyl  
 3-bromo-2-propynoate 24621-0-3P, 1H-Indole-2-methanol 40789-79-5P,  
 2-(Benzoyloxy)-1-nitroethane 49668-89-5P, Methyl 6-methylnicotinate  
 1-oxide 56026-36-9P, Methyl 6-(hydroxymethyl)nicotinate 63362-34-5P,  
 Methyl 6-(acetyloxymethyl)nicotinate 66182-01-2P, Ethyl  
 indolizine-6-carboxylate 7414-62-3P, Ethyl 9H- $\beta$ -carboline-3-  
 carboxylate 94413-64-6P, Methyl 2-cyanoisonicotinate 94413-69-1P  
 107407-80-7P, Ethyl pyrrolo[1,2-c]pyrimidine-3-carboxylate 129975-13-9P,  
 trans-4-Nitro-1-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester  
 131489-60-6P, Ethyl (E)-4-(benzylamino)-2-butenate 13617-69-6P  
 139022-25-6P, Imidazo[1,2-a]pyridine-6-carboxylic acid 139183-87-2P,  
 Methyl 6-(aminomethyl)nicotinate 139183-89-4P, Methyl  
 imidazo[1,5-a]pyridine-6-carboxylate 144017-84-5P, trans-4-Amino-1-  
 (phenylmethyl)-3-pyrrolidineacetic acid ethyl ester 15356-63-3P,  
 (3R)-1-((S)-1-Phenethyl)-3-(cyanomethyl)pyrrolidine 153780-28-0P, Ethyl  
 pyrrolo[1,2-a]pyrazine-3-carboxylate 156571-65-2P, Ethyl  
 3-ethoxy-O-ethyl-N-(1H-indol-3-ylmethylene)-DL-serinate 173340-19-7P,  
 (3S)-1-((S)-1-Phenethyl)-5-oxo-3-pyrrolidinecarboxylic acid  
 173724-95-3P, (3S)-1-((S)-1-Phenethyl)-3-(hydroxymethyl)pyrrolidine  
 174676-79-0P, (3R)-Methyl 1-((S)-1-phenylethyl)pyrrolidine-3-acetate  
 181873-33-6P 191150-86-4P, Benzyl cis-3-hydroxy-4-[(4-  
 methylphenyl)sulfonyloxymethyl]piperidine-1-carboxylate 191150-87-5P,  
 Benzyl cis-3-hydroxy-4-(hydroxymethyl)piperidine-1-carboxylate  
 197080-73-2P 206989-54-0P, tert-Butyl 4-(2-oxopropyl)piperidine-1-  
 carboxylate 221128-29-6P 256935-76-9P, Imidazo[1,5-a]pyridine-6-  
 carboxylic acid 384831-56-5P, Methyl 6-(azidomethyl)nicotinate  
 473795-29-8P, trans-(tert-Butoxycarbonylamino)-4-(2-hydroxyethyl)-1-(N-  
 phenylmethyl)pyrrolidine 473795-30-1P, (+)-trans-3-(tert-  
 Butoxycarbonylamino)-4-(2-hydroxyethyl)-1-(phenylmethyl)pyrrolidine  
 473795-31-2P, (-)-trans-3-(tert-Butoxycarbonylamino)-4-(2-hydroxyethyl)-1-  
 (phenylmethyl)pyrrolidine 473795-32-3P, exo-3-(tert-Butoxycarbonylamino)-  
 1-azabicyclo[2.2.1]heptane 473795-33-4P 473795-35-6P,  
 endo-3-Azido-1-azabicyclo[2.2.1]heptane 473795-36-7P 473795-39-0P,  
 endo-1-Azabicyclo[3.2.1]octan-3-amine dihydrochloride 473795-46-9P,  
 1-Bromo-3-piperidin-4-ylacetate trifluoroacetate 478149-39-2P,  
 (2S,3R)-2-Methyl-1-azabicyclo[2.2.2]octan-3-amine dihydrochloride  
 500556-90-1P 500556-91-2P 500556-92-3P 500556-94-5P 500556-95-6P

508201-49-8P, (3S)-1-((S)-1-Phenethyl) 3-(chloromethyl)pyrrolidine  
 508201-51-3P, (5R)-1-Azabicyclo[3.2.1] octan-3-one hydrochloride  
 508201-54-5P, (5R)-3-Oxo-1-((1S)-1-phenylethyl)-1-azabicyclo[3.2.1]octane chloride  
 508201-56-7P, (3R,5R)-1-Azabicyclo[3.2.1]octan-3-amine dihydrochloride  
 508201-58-9P, 1-Azabicyclo[3.2.2]nonan-3-amine bis(4-methylbenzenesulfonate)  
 521278-15-9P 524011-82-3P, 1-Azabicyclo[3.2.1]octan-3-amine  
 588720-10-9P, Ethyl 7-chloropyrrolo[1,2-c]pyrimidine-3-carboxylate  
 588720-11-0P, Ethyl 6-chloropyrrolo[1,2-c]pyrimidine-3-carboxylate  
 588720-12-1P, Ethyl 6-bromopyrrolo[1,2-c]pyrimidine-3-carboxylate  
 588720-13-2P, Pyrrolo[1,2-c]pyrimidine-3-carboxylic acid hydrochloride  
 588720-14-3P 588720-15-4P 588720-15-5P 588720-29-0P,  
 Imidazo[3,5-a]pyridine-7-carboxylic acid 588720-36-9P, Methyl  
 6-(methylsulfonyloxymethyl)nicotinate 588720-40-5P, Ethyl  
 6-(prop-1-ynyl)nicotinate 588720-42-5P, Indolizine-6-carboxylic acid  
 588720-47-2P, Ethyl 3-ethoxy-O-ethyl-N-(1H-pyrrol-2-ylmethylene)-DL-pyrazine-3-carboxylic acid  
 588720-48-3P, Pyrrolo[1,2-a]pyrazine-3-carboxylic acid  
 588720-58-5P 588720-59-6P 588720-62-1P 588720-66-5P,  
 Ethyl 3-ethoxy-O-ethyl-N-(1H-imidazol-2-ylmethylene)-DL-serinate  
 588720-67-6P 588720-68-7P 588720-90-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(azabicyclic)aryl amides for therapeutic use as nicotinic acetylcholine receptor agonists)

IT 588720-64-3P 588720-65-4P 588722-40-1P  
 588723-74-4P 588724-12-3P 588725-51-3P  
 588725-89-7P 588726-79-8P


RL: PAC (Pharmacological activity); SP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(azabicyclic)aryl amides for therapeutic use as nicotinic acetylcholine receptor agonists)

RN 588720-64-3 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxamide, 1-((3R)-1-azabicyclo[2.2.2]oct-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 588720-65-4 CAPLUS


CN Imidazo[1,2-a]pyrazine-6-carboxamide, 1-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 588720-64-3

CMF C14 H17 N5 O

Absolute stereochemistry.




CN 2

CFN 87-69-4

CMF C4 H6 O6


Absolute stereochemistry.



RN 583722-40-1 CAPLUS

CN Indazo[1,2-a]pyrazine-6-carboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 583723-74-4 CAPLUS

CN Indazo[1,2-a]pyrazine-6-carboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 583724-12-3 CAPLUS


CN Imidazo[1,2-a]pyrazine-6-carboxamide, N-(3R)-1-azabicyclo[3.2.2]non-3-yl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 588725-51-3 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxamide, N-(2R)-7-azabicyclo[2.2.1]hept-5-yl-  
(9CI) (CA INDEX NAME)



RN 588725-89-7 CAPLUS


CN Imidazo[1,2-a]pyrazine-6-carboxamide, N-(2R)-7-azabicyclo[2.2.1]hept-6-yl-  
(9CI) (CA INDEX NAME)



RN 588726-79-8 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-  
2-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 588720-67-6P 588720-68-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of N-(azabicyclic)arylamides for therapeutic use as nicotinic  
acetylcholine receptor agonists)


RN 588720-67-6 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxylic acid, ethyl ester (9CI) (C, INDEX NAME)



RN 58870-68-7 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carboxylic acid, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THIS FORMAT

L57 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:58094 CAPLUS

DOCUMENT NUMBER: 138:106720

TITLE: Preparation of heteroaryl substituted fused bicyclic heteroaryl compounds as benzodiazepine-GABA<sub>A</sub> receptor ligands and probes

INVENTOR(s): Hutchison, Allen; Maynard, George; Albaugh, Pamela; Xie, Linghong; Yuan, Jun; Mitchell, Scott; Singh, Vinod; Ghosh, Manuka; Li, Guiying; Liu, Nian

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 141 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY AC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006471	A1	20030113	WO 2002-US22130	20020712
AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DI, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZI, ZM, ZW GH, GM, KE, LS, MW, MZ, SI, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CI, CG, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

CA 2453554	AA	20030123	CA 2002-2453554	20020712
US 2003207885	A1	20031106	US 2002-194852	20020712
US 6936617	B2	20050830		
EP 1406906	A1	20040414	EP 2002-749983	20020712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, IL, LV, FI, RO, MK, CY, AL, BG, CZ, EE				
BR 2002011124	A	20040629	BR 2002-11124	20020712
CN 1553916	A	20041208	CN 2002-816696	20020712
JP 2005505518	T2	20050224	JP 2003-512241	20020712
NZ 530992	A	20050624	NZ 2002-530992	20020712
US 2006014746	A1	20060119	US 2005-214345	20050829
PRIORITY APPLN. IN 'O.:			US 2001-305533P	P 20010713
			US 2002-194852	A3 20020712
			WO 2002-US22130	W 20020712

OTHER SOURCE(S): MARPAT 138:106720  
GI



AB This invention relates to heteroaryl substituted fused bicyclic heteroaromatic compounds, such as heteroaryl-substituted imidazopyridines, imidazopyrazines, imidazopyridazines, imidazopyrimidines, and imidazothiazoles, which may be described by I or II (variables defined below; e.g. 5-ethyl-6-[[2-(6-fluoro-pyridin-2-yl)imidazol-1-yl]methyl]imidazo[2,1-b]thiazole). The invention particularly relates to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. In a assay of GABAA receptor binding that tests the displacement of 3H-Flumazenyl from rat cortical tissue in 0.05M Tris HCl buffer at 4°, I or II exhibit  $K_i$  of 1-micromolar or less; preferred compounds exhibit  $K_i$  of 100 nanomolar or less; and more preferred compounds exhibit  $K_i$  of 10-nanomolar or less. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Processes for preparing I and II are disclosed but not claimed; 3 example preps. are included. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related I and II in combination with  $\geq 1$  other CNS agents to potentiate the effects of the other CNS agents. Addnl. this invention relates to the use of such compounds as probes for the localization of GABAA receptors in tissue sections (no data). For I: Z1 is N or CR1; Z2 is N or CR2; Z3 is N or CR3; Z4 is N or CR4; Z5 is N or C; Z6 is N or C; provided that no more than two of Z1-Z6 are N. R1, R2, R3, and R4 = (i) H, halogen, hydroxy, nitro, cyano, amino, haloalkyl, and haloalkoxy; (ii) alkyl, alkoxy, cycloalkyl, akenyl, alkynyl, (cycloalkyl)alkyl, -NH(R10), -N(R10)(R11), hydroxyalkyl, aminoalkyl, (R10)NHalkyl, (R10)(R11)Nalkyl, alkanoyl,

alkoxy carbonyl, alkylsulfonyl, (C1-6)alkylsulfinyl, alkylthio, mono- and dialkyl aminocarbonyl, heterocycloalkyl, aryl, and heteroaryl; (iii) -GRA (G is alkyl, -O-, -C(O)-, or -CH<sub>2</sub>-C(O)-, and RA is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl). (iv) -C(O)JRBRC (J is N, CH, or C-alkyl, and RB and RC = H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, aryl, arylalkyl, alkanoyl, heteroaryl, and mono and dialkylaminoalkyl, or RB and RC and the atom to which they are attached form a 4- to 10-membered monocyclic or bicyclic ring, comprising: a) 0-3 double bonds, and (b) 0-3 O, S, SO, SO<sub>2</sub>, or N-RD (RD is (1) hydrogen; or (2) Aryl, alkyl, cycloalkyl, heterocycloalkyl, or Arylalkyl (Aryl is aryl or heteroaryl)); and (v) -OC(O)RE, -C(O)NH<sub>2</sub>, -C(O)NRE, -C(O)NRERF, -S(O)nRE, -S(O)nNH<sub>2</sub>, -S(O)nNHRE, -S(O)nNREF, -NHC(O)RE, -C(:NRE)RF, -HC:N-OH, -HC:N(alkoxy), -HC:N(alkyl), -NR(C(O)RF, -NHS(O)nRE, and -NRES(O)nRF (n is 0-2; RE and RF = alkyl, cycloalkyl, heterocycloalkyl, alkoxy, mono- and dialkylamino, aryl, and heteroaryl). R<sub>5</sub> = ( ) H, halogen, cyano, or haloalkyl; (ii) alkyl, cycloalkyl, (cycloalkyl)alkyl, each of which comprises 0-3 double bonds and/or 0-3 triple bonds; or (iii) aryl, arylalkyl, heteroaryl, or heteroarylalkyl. Q = -C(R<sub>6</sub>)(R<sub>7</sub>), -N(alkyl)- or O (R<sub>6</sub> and R<sub>7</sub> = H, F, or alkyl); with the proviso that Q is not O when X<sub>2</sub> is H; X<sub>1</sub> and X<sub>2</sub> = N, C or CH; Y is N, C, -CH-, -CH<sub>2</sub>-, or absent; and W = aryl or heteroaryl. For II, see the claims

IC ICM C07D513-04

ICS C07D471-04; C07D487-04; A61K031-437; A61K031-5025; A61K031-519; A61K031-4985; A61P025-00; C07D13-04; C07D277-00; C07D235-00; C07D471-04; C07D235-00; C07D22-00; C07D487-04; C07D237-00; C07D235-00; C07D487-04; C07D23-00; C07D235-00

CC 28-17 Heterocyclic Compounds (More Than One Hetero Atom)

Section cross-reference(s): 1, 9

IT **Mental and behavioral disorders**

(attention deficit hyperactivity disorder; preparation of heteroaryl substituted fused bicyclic heteroaryl compds. as benzodiazepine-GABAA receptor ligands and probes with various therapeutic uses)

IT **Mental and behavioral disorders**

(depression; preparation of heteroaryl substituted fused bicyclic heteroaryl compds. as benzodiazepine-GABAA receptor ligands and probes with various therapeutic uses)

IT **Alzheimer's disease**

Anti-Alzheimer's agents

Antidepressants

Antipsychotics

Anxiolytics

Anxiolytics

Cognition enhancers

Memory disorders

**Schizophrenia**

Sleep disorders

(preparation of heteroaryl substituted fused bicyclic heteroaryl compds. as benzodiazepine-GABAA receptor ligands and probes with various therapeutic uses)

IT 488115-60-2P, 6-Chloro-3-propyl-2-[(2-phenylimidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-61-3P, 6-Chloro-2-[(2-(6-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-62-4P, 6-Chloro-2-[(2-(3-chlorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-63-5P, 7-Cyano-3-ethyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-64-6P, 7-Cyano-3-ethyl-2-[(2-(6-fluorophenyl)imidazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-65-7P, 3-Ethyl-2-[(2-phenylimidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-66-8P, 3-Ethyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-67-9P, 3-Ethyl-2-[(2-(6-

fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine  
 488115-68-0P, 7 Chloro-3-propyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-69-1P, 6-Chloro-3-propyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine  
 488115-70-4P, 7 Chloro-3-ethyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-71-5P, 7-Chloro-3-ethyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-72-6P,  
 3-Ethyl-6-fluoro-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-73-7P, 3-Ethyl-6-fluoro-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-74-8P,  
 3-Ethyl-6-fluoro-2-[(2-(3-chlorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-75-9P, 3-Ethyl-6-fluoro-2-[(2-(2,5-difluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-76-0P,  
 3-Ethyl-2-[(2-(3-cyanophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-77-1P, 6-Bromo-3-propyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-78-2P, 3-Ethyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)imidazo[1,2-a]pyridine 488115-79-3P, 6-Chloro-3-methyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-80-6P,  
 6-Chloro-3-methyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-82-8P, 6-Chloro-3-ethyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-83-9P,  
 6-Chloro-3-ethyl-2-[(2-(3-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-84-0P, 3-Cyano-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-85-1P, 3-Cyano-2-[(2-(3-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-86-2P, 3,6-Dimethyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-87-3P, 3,6-Dimethyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-88-4P, 3-Methyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-89-5P, 7-Ethyl-3-methyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-90-3P, 5-Ethyl-3-methyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-91-9P, 5-(1-Hydroxyethyl)-3-methyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-92-0P, 6-Chloro-3-methyl-2-[(2-(2,5-difluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-93-1P, 6-Chloro-3-methyl-2-[(2-(5-fluoro-2-methylphenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-94-2P, 3,5,7-Trimethyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-95-3P, 5,7-Trimethyl-2-[(2-(3-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-96-4P, 3-Methyl-6-(trifluoromethyl)-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-97-5P, 3-Methyl-6-(trifluoromethyl)-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-98-6P, 3-Bromo-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488115-99-7P, 3-Ethyl-6-(trifluoromethyl)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488116-00-3P, 3-Ethyl-6-(trifluoromethyl)-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488116-01-4P, 3,7-Diethyl-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488116-02-5P, 6-Acetyl-3-ethyl-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488116-03-5P, 6-Bromo-3-ethyl-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488116-04-7P, 3-Ethyl-6-(thiazol-2-yl)-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488116-05-3P, 3-Ethyl-6-(thiazol-2-yl)-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488116-06-9P, 3-Ethyl-6-(pyridin-2-yl)-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488116-07-0P, 3-Ethyl-6-(pyridin-4-yl)-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine



488116-0 -1P, 6-Cyano-3-ethyl-2-[(2-(imidazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488116-09-2P, 6-Chloro-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116 10-5P, 3-Bromo-6-chloro-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-11-6P, 6-Chloro-3-propyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-12-7P, 3-Bromo-6-chloro-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-13-8P, 3-Propyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-14-9P, 2-[(2-(6-Fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-15-0P, 3-Bromo-6-chloro-2-[(2-(6-chloropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-16-1P, 6-Chloro-3-propyl-2-[(2-(6-chloropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-17-2P, 6-Chloro-3-propyl-2-[(2-(3-cyanophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-18-3P, 6-Chloro-3-ethyl-2-[(2-(6-chloropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-19-4P, 3-Propyl-2-[(2-(6-chloropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-20-7P, 6-Chloro-3-methyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-21-8P, 6-Chloro-3-methyl-2-[(2-(4-chloropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-22-9P, 6-Chloro-3-methyl-2-[(2-(6-chloropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-23-0P, 3-Methyl-2-[(2-(6-chloropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-24-1P, 6-Chloro-3-ethyl-2-[(2-(6-chloropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-25-2P, 3-Ethyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-26-3P, 3-Methyl-2-[(2-(6-pyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-27-4P, 3-Ethyl-2-[(2-(6-pyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-28-5P, 6-Chloro-3-ethyl-2-[(2-(3-cyanophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-29-6P, 3-Propyl-2-[(2-(3-cyanophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-30-9P, 6-Chloro-3-propyl-2-[(2-(2-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-31-0P, 6-Chloro-3-ethyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-32-1P, 6-Chloro-3-propyl-2-[(2-(2-cyanophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-33-2P, 6-Chloro-3-propyl-2-[(2-(2-fluoropyridin-4-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-34-3P, 6-Chloro-3-propyl-2-[(2-(2-chloropyridin-3-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-35-4P, 3-Propyl-2-[(2-(pyridin-3-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-36-5P, 6-Chloro-3-ethyl-2-[(2-(2-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-37-6P, 6-Chloro-3-propyl-2-[(2-(3-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-38-7P, 6-Chloro-3-propyl-2-[(2-(2-(trifluoromethyl)phenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-39-8P, 6-Chloro-3-propyl-2-[(2-(2-chlorophenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-40-1P, 6-Chloro-3-methyl-2-[(2-(2-(trifluoromethyl)phenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-41-2P, 6-Chloro-3-propyl-2-[(2-(3-(methylsulfonyl)phenyl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-42-3P, 6-Chloro-3-propyl-2-[(2-(5-(trifluoromethyl)pyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-43-4P, 6-Chloro-3-propyl-2-[(2-(2-piperidinopyridin-3-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-44-5P, 6-Chloro-3-propyl-2-[(2-(6-(trifluoromethyl)pyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-45-6P, 6-Chloro-3-propyl-2-[(2-(6-cyanopyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-46-7P, 6-Chloro-3-propyl-2-[(2-(pyrazin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488116-47-8P, 6-Chloro-3-propyl-2-[(2-(5-fluoropyridin-3-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine



yl)methyl] midazo[1,2-a]pyrimidine 488116-87-6P, 3-Bromo-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine  
 488116-88-P, 3-Ethyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488116-89-8P, 3-Ethyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488116-90-1P,  
 3-Ethyl-2-[(2-(3-cyanophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488116-91-P, 3-Ethyl-2-[(2-(6-chloropyridin-2-yl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488116-92-3P, 3-Ethyl-2-[(2-(3-chlorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488116-93-4P,  
 3-Ethyl-2-[(2-(2-(trifluoromethyl)phenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488116-94-5P, 3-Ethyl-2-[(2-(2-chlorophenyl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488116-95-6P, 3-Ethyl-2-[(2-(2-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488116-96-7P,  
 3-Ethyl-2-[(2-(3-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488116-97-8P, 3-Ethyl-2-[(2-(2-fluoropyridin-4-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488116-98-9P, 3-Ethyl-2-[(2-(6-cyanopyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine  
 488116-99-P, 3-Ethyl-2-[(2-(5-(trifluoromethyl)pyridin-2-yl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488117-00-6P, 3-Bromo-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488117-01-7P,  
 3-Bromo-2-[(2-(6-(trifluoromethyl)pyridin-2-yl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488117-02-8P, 3-Bromo-2-[(2-(1,5-dimethylpyrazol-3-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine  
 488117-03-P, 3-Bromo-2-[(2-(3-(trifluoromethyl)phenyl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488117-04-0P, 3-Bromo-2-[(2-(4-methoxyphenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine  
 488117-05-P, 3-Bromo-2-[(2-(3-fluoro-5-(trifluoromethyl)phenyl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488117-06-2P, 3-Bromo-2-[(2-(3,5-difluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine  
 488117-07-P, 3-Bromo-2-[(2-(2-methylthiazol-4-yl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488117-09-5P,  
 3-Methyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488117-10-8P, 3-Methyl-2-[(2-(6-cyanopyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488117-11-9P, 3-Bromo-2-[(2-(6-cyanopyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine  
 488117-12-P, 3-Methyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488117-13-1P, 3-Ethyl-2-[(2-(6-(trifluoroethyl)pyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488117-14-2P, 3-Ethyl-2-[(2-(5-methylisoxazol-3-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine 488117-15-3P, 3-Ethyl-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine  
 488117-16-P, 3-Ethyl-2-[(2-(2,3-difluorophenyl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488117-17-5P, 3-Ethyl-2-[(2-(3,4-difluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine  
 488117-18-P, 3-Ethyl-7-methyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]midazo[1,2-a]pyrimidine 488117-19-7P, 3-Ethyl-2-[(2-(5-fluoro-2-methylphenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine  
 488117-20-P, 3-Ethyl-7-(trifluoromethyl)-2-[(2-(3-chloro-2,5-difluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrimidine  
 488117-21-P, 3-Ethyl-2-[(2-(2,5-difluorophenyl)imidazol-1-yl)methyl] midazo[1,2-a]pyrimidine 488117-22-2P, 3-Ethyl-2-[(2-(3-chloro-2,5-difluorophenyl)imidazol-1-yl)methyl]midazo[1,2-a]pyrimidine  
 488117-23-P, 3-Ethyl-2-[(2-(5-cyano-2-fluorophenyl)imidazol-1-yl)methyl]midazo[1,2-a]pyrimidine 488117-24-4P, 5-Methyl-3-propyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine  
 488117-25-P, 5-Methyl-3-propyl-2-[(2-(2-fluorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-26-6P, 5-Methyl-3-propyl-2-[(2-(4-fluorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine  
 488117-27-P, 5-Methyl-3-propyl-2-[(2-(2,5-difluorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-28-8P, 5-Methyl-3-propyl-2-

[(2-(3-chloro-4-fluorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-29-9P, 5-Methyl-3-propyl-2-[(2-(3-chlorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-30-2P, 5-Methyl-3-propyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-31-3P, 5-Methyl-3-propyl-2-[(2-(2,5-difluorophenyl)-4-methylimidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-32-4P, 3-Ethyl-7-methoxy-5-(4-fluorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-33-5P, 3-Ethyl-7-methoxy-5-methyl-2-[(2-(3-chlorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-34-6P, 3-Ethyl-7-methoxy-5-methyl-2-[(2-(2,5-difluorophenyl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-35-7P, 3-Ethyl-5-methyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]pyrazolo[1,5-a]pyrimidine 488117-36-8P, 3-Ethyl-6-(3-hydroxy-3-methylbutyl)-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-37-9P, 3-Ethyl-6-(3-hydroxy-3-methyl-1-butenyl)-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-38-0P, 3-Ethyl-6-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-39-1P, 3-Ethyl-6-(pyridin-2-yl)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-40-4P, 3-Ethyl-6-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-41-5P, 6-Chloro-3-ethyl-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-42-6P, 3-Ethyl-6-(3-methoxypropyl)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-43-7P, 3-Ethyl-6-fluoro-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-44-8P, 6-Bromo-3-ethyl-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-45-9P, 3-Ethyl-6-fluoro-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-46-0P, 3-Ethyl-6-(2-methylphenyl)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-47-1P, 3-Ethyl-6-(2-methoxyphenyl)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-48-2P, 3-Ethyl-6-(2-(trifluoromethyl)phenyl)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-49-3P, 3-Ethyl-6-(3-hydroxy-3-methylbutyl)-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyridine 488117-50-6P, 6-Acetyl-3-ethyl-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488117-51-7P, 3-Ethyl-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488117-52-8P, 3-Ethyl-6-(thiazol-2-yl)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488117-53-9P, 3-Ethyl-6-(trifluoromethyl)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488117-54-0P, 3-Ethyl-6-(2-isopropoxyethoxy)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488117-55-1P, 3-Ethyl-6-((tetrahydropyran-4-yl)oxy)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488117-56-2P, 6-(4-Chloro-2-methylphenoxy)-3-ethyl-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488117-57-3P, 3-Ethyl-6-((4-(trifluoromethyl)phenyl)methoxy)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488117-58-4P, 3-Ethyl-6-((tetrahydropyran-3-yl)oxy)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine 488117-59-5P, 3-Ethyl-6-(4-(trifluoromethoxy)phenoxy)-2-[(2-(pyrimidin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-b]pyridazine

RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate, receptor probe; preparation of heteroaryl substituted fused bicyclic heteroaryl compds. as benzodiazepine-ABAA receptor ligands and probes)


IT 488116-72-9P, 3-Chloro-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-73-0P, 3-Bromo-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-74-1P, 3-Bromo-2-[(2-(3-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-75-2P, 6-Bromo-3-chloro-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-76-3P, 3-Chloro-6-methyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-78-5P, 3-Chloro-6-methoxy-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-79-6P, 3-Chloro-6-methoxy-2-[(2-(6-methoxypyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-80-9P, 3-Chloro-6-(pyrrolidin-2-yl)-2-[(2-(6-pyrrolidinopyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-81-0P, 3,6-Dimethyl-2-[(2-(6-fluoropyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-82-1P, 6-Bromo-3-chloro-2-[(2-(thiazol-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-83-2P, 3-Bromo-2-[(2-(6-methoxypyridin-2-yl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine 488116-84-3P, 3-Chloro-6-methyl-2-[(2-(3-fluorophenyl)imidazol-1-yl)methyl]imidazo[1,2-a]pyrazine

RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate, receptor probe; preparation of heteroaryl substituted fused bicyclic heteroaryl compds. as benzodiazepine-GABAA receptor ligands and probes)


RN 488116-72-9 CAPLUS

CN Imidazo[1,2-a]pyrazine, 3-chloro-2-[[2-(6-fluoro-2-pyridinyl)-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 488116-73-0 CAPLUS


CN Imidazo[1,2-a]pyrazine, 3-bromo-2-[[2-(6-fluoro-2-pyridinyl)-1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 488116-74-1 CAPLUS


CN Imidazo[1,2-a]pyrazine, 3-bromo-2-[[2-(3-fluoro-2-pyridinyl)-1H-imidazol-1-

yl)methyl]- (9CI) (CA INDEX NAME)




RN 488116-75-2 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-bromo-3-chloro-2-[[2-(6-fluoro-2-pyridinyl)-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 488116-76-3 CAPLUS

CN Imidazo[1,2-a]pyrazine, 3-chloro-2-[[2-(6-fluoro-2-pyridinyl)-1H-imidazol-1-yl]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 488116-78-5 CAPLUS


CN Imidazo[1,2-a]pyrazine, 3-chloro-2-[[2-(6-fluoro-2-pyridinyl)-1H-imidazol-1-yl]methyl]-6-methoxy- (9CI) (CA INDEX NAME)



RN 488116-79-6 CAPLUS


CN Imidazo[1,2-a]pyrazine, 3-chloro-6-methoxy-2-[[2-(6-methoxy-2-pyridinyl)-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)

1H-imidazol-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 488116-80-9 C/ PLUS

CN Imidazo[1,2-a]pyrazine, 3-chloro-6-(1-pyrrolidynyl)-2-[[2-[6-(1-pyrrolidinyl)-2-pyridinyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 488116-81-0 C/ PLUS

CN Imidazo[1,2-a]pyrazine, 2-[[2-(6-fluoro-2-pyridinyl)-1H-imidazol-1-yl]methyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 488116-82-1 C/PLUS


Imidazo[1,2-a]pyrazine, 6-bromo-3-chloro-2-[2-(2-thiazolyl)-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)



RN 488116-83-2 CA PLUS


CN Imidazo[1,2-a]pyrazine, 3-bromo-2-[[2-(6-methoxy-2-pyridinyl)-1H-imidazol-

1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 488116-84-3 CAPLUS

CN Imidazo[1,2-a]pyrazine, 4-chloro-2-[[2-(3-fluorophenyl)-1H-imidazol-1-yl)methyl]-6-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCE AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L57 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003.42275 CAPLUS

DOCUMENT NUMBER: 138.06717

TITLE: Preparation of  $\beta$ -amino tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotriazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

INVENTOR(S): Edmondson, Scott D.; Fisher, Michael H.; Kim, Doo-seop; MacCoss, Malcolm; Parmee, Emma R. Weber, Ann E.; Xu, Jinyou

PATENT ASSIGNEE(S): Merck &amp; Co., Inc., USA

SOURCE: PCT Int. Appl., 69 pp.

CODE I: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO	DATE
WO 2003004498	A1	20030116	WO 2002-US2134	20020705
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, B, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, F, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, K, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, N, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, T, TR, TT, TZ, UA, UG, US, UZ, VN, W, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZI, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, I, IT, LU, MC, NL,				



PT, SE, SI, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TG

CA 2450740	AA	20030116	CA 2002 2450740	20020705
CA 2450740	C	20060214		
US 2003100563	A1	20030529	US 2002 189603	20020705
US 6699871	B2	20040302		
EP 1412357	A1	20040428	EP 2002 749813	20020705
EP 1412357	B1	20060322		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002010866	A	20040629	BR 2002 10866	20020705
CN 1524082	A	20040825	CN 2002 813558	20020705
JP 2004536115	T2	20041202	JP 2003 510665	20020705
JP 3762407	B2	20060405		
TW 226331	B1	20050111	TW 2002 91114990	20020705
NZ 529833	A	20050128	NZ 2002 529833	20020705
EP 1625847	A1	20060215	EP 2005 77584	20020705
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
ZA 2003009294	A	20040722	ZA 2003 9294	20031128
US 2004167133	A1	20040826	US 2003 481353	20031219
BG 108493	A	20050430	BG 2003 108493	20031222
PRIORITY APPLN. INFO.:			US 2001 303474P	P 20010706
			EP 2002 749813	A3 20020705
			WO 2002 US21349	W 20020705

OTHER SOURCE(S): MARPAT 138:106717  
GI



AB  $\beta$ -Amino tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotriazolo[4,3-a]pyrazines [e.g. I; wherein Ar = (substituted) phenyl; X = N, CR<sub>2</sub>; R<sub>1</sub>, R<sub>2</sub>, independently = H, CN, (branched) (substituted) (C1-C10)alkyl, (substituted) Ph, (saturated) 5- or 6-membered heterocycle, etc.] were prepared. For example, 7-[(R)-3-amino-4-(3,4-difluorophenyl)butanoyl]-2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine (II) was prepared in several steps. The prepared compounds are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and, thus, are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV

enzyme is involved, such as type 2 diabetes (no data).

IC ICM C07D487-04  
ICS A61K031-4985; A61P003 10

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross-reference(s) 1, 63


IR Nerve, disease  
(**neuropathy**, therapeutic agents; preparation of  $\beta$ -amino tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotriazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors)

IR 274-79-3P, Imidazo[1,2-a]pyrazine 91476-80-1P,  
5,6,7,8-Tetrahydroimidazo[1,2-a]pyrazine 109113-96-4P  
126069-70-3P 140910-77-6P 486459-98-7P 486459-99-1P 486460-00-8P  
486460-01-9P 486460-02-0P 486460-03-1P 486460-04-1P 486460-05-3P  
486460-06-4P 486460-07-5P 486460-08-6P 486460-09-1P 486460-10-0P  
486460-11-1P 486460-12-2P 486460-13-3P 486460-14-1P 486460-15-5P  
486460-16-6P 486460-17-7P 486460-18-8P 486460-19-1P 486460-20-2P  
486460-21-3P 486460-22-4P 486460-23-5P 486460-24-1P 486460-25-7P  
486460-26-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of  $\beta$ -amino tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotriazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors)

IR 274-79-3P, Imidazo[1,2-a]pyrazine 109113-96-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of  $\beta$ -amino tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotriazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors)


RI 274-79-3 CAPLUS

CI Imidazo[1,2-a]pyrazine (8C, 9CI) (CA INDEX NAME)



RI 109113-96-4 CAPLUS

CI Imidazo[1,2-a]pyrazine, 2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD FORMAT

LE7 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:6 5619 CAPLUS

DOCUMENT NUMBER: 137:16 548


TITLE: Preparation of bicyclic nitrogenous fused-ring compounds such as imidazopyrazines, etc., as corticotropin-releasing factor receptor antagonists

INVENTOR(S): Hibi, Shigeki; Takahashi, Yoshinori; Hoshino, Yorihiro; Kikuchi, Koichi; Soejima, Motohiro; Yoshiuchi, Tatsuya; Shin, Kogyoku; Cho, Mutsuko; Shibata, Hisashi; Ino, Mitsuhiro; Hirakawa, Tetsuya

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 245 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062800	A1	20020815	WO 2002-J11098	20020208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1364952	A1	20031126	EP 2002-711424	20020208
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004082781	A1	20040429	US 2003-411741	20030625
PRIORITY APPLN. INFO.:			JP 2001-31537	A 20010208
			JP 2001-133208	A 20010427
			WO 2002-J11098	W 20020208

OTHER SOURCE(S): MARPAT 137:169548  
 GI



AB The title compds. I [R1 represents hydrogen, C1-6 alkyl, C1-6 alkoxy, etc.; R2 represents halogeno, cyano, nitro, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, etc.; R3 represents an optionally substituted C6-14 aromatic hydrocarbon group or an optionally substituted, 5- to 14-membered aromatic heterocyclic group; and X, Y, and Z each independently represents nitrogen or CR4 (wherein R4 represents hydrogen, halogeno, cyano, nitro, optionally halogenated C1-6 alkyl, etc.), provided that at least two of X, Y, and Z represent CR4] are prepared. In an in vitro test for binding to the corticotropin-releasing factor receptor, compds. of this invention in vitro showed IC50 values of 10 nM to 5000 nM.

IC ICM C07D487-04

ICS C07D471-04; A61K031-4985; A61K031-5025; A61P031-5377; A61K031-437; A61K031-519; A61P043-00; A61P025-28; A61P003-14; A61P003-04; A61P003-10; A61P025-32; A61P025-30; A61P025-20; A61P025-06; A61P025-04; A61P009-10; A61P025-00; A61P021-02

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1

- IT **Mental and behavioral disorders**  
(autism; preparation and effect of bicyclic nitrogenous fused-ring compds. such as imidazopyrazines, with corticotropin-releasing factor receptor antagonist activity)
- IT **Mental and behavioral disorders**  
(bipolar disorder; preparation and effect of bicyclic nitrogenous fused-ring compds. such as imidazopyrazines, with corticotropin-releasing factor antagonist activity)
- IT **Mental and behavioral disorders**  
(depression; preparation and effect of bicyclic nitrogenous fused-ring compds. such as imidazopyrazines, with corticotropin-releasing factor receptor antagonist activity)
- IT Nausea  
(neurogenic; preparation and effect of bicyclic nitrogenous fused-ring compds. such as imidazopyrazines, with corticotropin-releasing factor receptor antagonist activity)
- IT **Mental and behavioral disorders**  
(phobia; preparation and effect of bicyclic nitrogenous fused-ring compds. such as imidazopyrazines, with corticotropin-releasing factor antagonist activity)
- IT **Alzheimer's disease**  
Anti-Alzheimer's agents  
Antidepressants  
Antidiarrheals  
Antiemetics  
Anxiety  
Anxiolytics  
Diarrhea  
Laxatives  
**Schizophrenia**  
Stress, animal  
(preparation and effect of bicyclic nitrogenous fused-ring compds. such as imidazopyrazines, with corticotropin-releasing factor receptor antagonist activity)
- IT **Mental and behavioral disorders**  
(senile psychosis; preparation and effect of bicyclic nitrogenous fused-ring compds. such as imidazopyrazines, with corticotropin-releasing factor receptor antagonist activity)
- IT 70233-10-2P, (E)-4-(2,4-Dimethylphenyl)-3-buten-2-one 446273-43-4P  
, 8-Chloro-2-ethylimidazo[1,2-a]pyrazine-3-carboxylic acid methyl ester 446273-45-6P, 5-Chloro-3-(2,4-dichlorophenyl)-2-pyrazinamine 446273-47-8P, 8-Bromo-2-ethyl-6-methylimidazo[1,2-a]pyrazine-3-carboxylic acid methyl ester 446273-49-0P 446273-51-4P  
, 1-(8-Chloro-2-ethylimidazo[1,2-a]pyrazin-3-yl)butyl ethyl ether 446273-53-6P, 1-(8-Chloro-2-ethylimidazo[1,2-a]pyrazin-3-yl)-1-butanol 446273-55-8P, 1-(8-Chloro-2-ethylimidazo[1,2-a]pyrazin-3-yl)-1-butanone 446273-58-1P, 446273-59-2P, 4-Bromo-6-chloro-3-pyridazinamine 446273-60-5P, 6-Chloro-4-(2,4-dimethylphenyl)-3-pyridazinamine 446273-61-6P, 4-(2,4-Dimethylphenyl)-3-pyridazinamine 446273-62-7P, 8-(2,4-Dimethylphenyl)-2-ethylimidazo[1,2-b]pyridazine-3-carboxylic acid methyl ester 446273-63-8P, 8-Bromo-6-methyl-2-(methylsulfanyl)imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester 446273-65-0P, 8-Bromo-6-methyl-2-(methylsulfanyl)imidazo[1,2-a]pyridine-3-carboxylic acid 446273-66-0P, tert-Butyl N-[8-bromo-6-methyl-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]carbamate 446273-67-2P, tert-Butyl N-[8-bromo-6-methyl-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylcarbamate 446273-68-3P, N-[8-Bromo-6-methyl-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine 446273-69-4P, N-[8-Bromo-6-methyl-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446273-70-7P 446273-71-8P, Ethyl

8-methoxy-2-(methylsulfanyl)imidazo[1,2-a]pyrazine-3-carboxylate  
**446273-72-9P**, Ethyl 8-chloro-2-(methylsulfanyl)imidazo[1,2-a]pyrazine-3-carboxylate **446273-73-0P**, tert-Butyl  
 N-[8-chloro-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]carbamate  
**446273-74-1P**, N-[8-Chloro-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446273-75-2P**, N-[8-Chloro-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine  
**446273-76-3P**, 6-Chloro-4-(4-methoxy-2-methylphenyl)-3-pyridazinamine  
**446273-77-4P**, 4-(4-Methoxy-2-methylphenyl)-3-pyridazinamine **446273-78-5P**  
**446273-79-6P**, 2-[(6-Chloro-4-pyrimidinyl)amino]-1-butanol **446273-80-9P**,  
 2-(4-Pyrimidinylamino)-1-butanol **446273-81-0P**, 2-[(5-Bromo-4-pyrimidinyl)amino]-1-butanol **446273-82-1P**, 8-Bromo-2-ethyl-2,3-dihydroimidazo[1,2-c]pyrimidine **446273-83-2P**, 8-Bromo-2-ethylimidazo[1,2-c]pyrimidine **446273-84-3P** **446273-85-4P** **446273-86-5P**,  
 1-(8-Bromo-2-ethylimidazo[1,2-c]pyrimidin-3-yl)butyl ethyl ether  
**446273-87-6P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446273-88-7P**,  
 1-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-1-butanone **446273-89-8P**, 4-(2,4-Dimethylphenyl)-6-methyl-3-pyridazinamine  
**446273-90-1P**, 8-(2,4-Dimethylphenyl)-2-ethyl-6-methylimidazo[1,2-b]pyridazine-3-carboxylic acid methyl ester **446273-91-2P**,  
 8-(2,4-Dimethylphenyl)-2-ethyl-6-methylimidazo[1,2-b]pyridazine-3-carboxylic acid **446273-92-3P**, tert-Butyl N-[8-(2,4-dimethylphenyl)-2-ethyl-6-methylimidazo[1,2-b]pyridazin-3-yl]carbamate **446273-93-4P**,  
 8-(2,4-Dimethylphenyl)-2-ethyl-6-methylimidazo[1,2-b]pyridazin-3-amine  
**446273-94-5P**, 8-(2,4-dimethylphenyl)-2-ethylimidazo[1,2-b]pyridazine-3-carboxylic acid **446273-95-6P**, tert-Butyl N-[8-(2,4-dimethylphenyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]carbamate **446273-96-7P**,  
 8-(2,4-Dimethylphenyl)-2-ethylimidazo[1,2-b]pyridazin-3-amine  
 RL: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of bicyclic nitrogenous fused-ring compds. such as imidazopyrazine; as corticotropin-releasing factor receptor antagonists)

IT **446274-02-8P**, N-[8-(2-Bromo-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine **446274-03-9P**, N,N-Dicyclopropylmethyl-N-[2-(methylsulfanyl)-8-(2,4,6-trimethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]amine **446274-04-0P** **446274-05-1P**,  
 N-Cyclopropylmethyl-N-isopropyl-N-[2-(methylsulfanyl)-8-(2,4,6-trimethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]amine **446274-06-2P**,  
 N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine  
**446274-07-3P**, N-Cyclopropylmethyl-N-isobutyl-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine  
**446274-08-4P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-isobutylamine **446274-09-5P**, N-Cyclopropylmethyl-N-[3-(4-methoxy-2,6-dimethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446274-10-8P**, N-Cyclopropylmethyl-N-[8-(4-methoxy-2-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine  
**446274-11-9P**, N-Cyclopropylmethyl-N-[8-(2-methoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine  
**446274-12-0P**, N-[8-(4-Chloro-2-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine **446274-13-1P**, N-Cyclopropylmethyl-N-[8-(2,4-dimethoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446274-14-2P**, 4-[3-[(Cyclopropylmethyl)(propyl)amino]-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-8-yl]-3-methylbenzonitrile  
**446274-15-3P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-

methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-(1-ethylpropyl)amine  
 446274-16-4P, N-(1-Ethylpropyl)-N-[8-(2-methoxy-4,6-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine  
 446274-17-5P, N-Cyclopropylmethyl-N-[8-(4-methyl-1,3-benzodioxol-5-yl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine  
 446274-18-6P, N-Cyclopropylmethyl-N-[8-(5-methyl-2,3-dihydro-1,4-benzodioxin-6-yl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine  
 446274-20-0P, N-Cyclopropylmethyl-N-[8-(2-methoxy-4-(trifluoromethyl)phenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine  
 446274-22-2P, N,N-Dimethoxy-4-(trifluoromethyl)phenylamine  
 446274-23-3P, N,N-Dimethoxy-2-(trifluoromethyl)phenylamine  
 446274-24-4P, N,N-Dimethoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine  
 446274-25-5P 446274-26-6P, N,N-Dimethoxy-2-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine  
 446274-27-7P, N,N-Dimethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine  
 446274-28-8P, N-[8-(2-Chloro-4-(trifluoromethoxy)phenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-bis(cyclopropylmethyl)amine  
 446274-29-9P, N,N-Dicyclopropylmethyl-N-[8-(4-dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine  
 446274-30-2P, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl](cyclopropylmethyl)amino]-1-ethanol  
 446274-32-4P 446274-33-5P 446274-34-6P, N,N-Bis(cyclopropylmethyl)-8-[6-(dimethylamino)-4-methyl-3-pyridyl]-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-amine  
 446274-35-7P, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-[3-(4-methyl-2-pyridyl)-2-(methylsulfanyl)propyl]amine  
 446274-36-8P 446274-37-9P, 1-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl](cyclopropylmethyl)amino]-2-propanol  
 446274-38-0P, 1-[8-(2-Chloro-4-(trifluoromethoxy)phenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl](cyclopropylmethyl)amino]-2-propanol  
 446274-39-1P 446274-40-4P 446274-41-5P, 2-[8-[2-Chloro-4-(trifluoromethoxy)phenyl]-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl](cyclopropylmethyl)amino]acetamide  
 446274-42-6P 446274-43-7P 446274-44-8P 446274-45-9P, N-[8-[2-Chloro-4-(trifluoromethoxy)phenyl]-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-furylmethyl)amine  
 446274-46-0P 446274-48-2P 446274-49-3P, N-[8-[2-Chloro-4-(trifluoromethoxy)phenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-morpholinoethyl)amine  
 446274-50-6P 446274-51-7P, N,N-Bis(cyclopropylmethyl)-8-[6-(dimethylamino)-2-methoxyphenyl]-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-amine  
 446274-53-9P, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine  
 446274-55-1P, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine  
 446274-57-3P 446274-59-5P, 4-[3-[Di(cyclopropylmethyl)amino]-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-8-yl]-3-methoxybenzonitrile  
 446274-61-9P, N,N-Bis(cyclopropylmethyl)-N-[8-(2-methoxy-4-(pyrrolidin-1-yl)phenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine  
 446274-63-1P, 6-Chloro-3-(1-ethoxybutyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazine  
 446274-65-3P, 8-(2-Chloro-4-methoxyphenyl)-3-(1-ethoxybutyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazine  
 446274-67-5P,

3-(1-Ethoxybutyl)-8-(2-(2-ethoxy-4,6-dimethylphenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyrazine 446274-69-7P  
 446274-71-1P 446274-75-4P 446274-77-7P  
 446274-78-8P, N-[8-(2-Chloro-4-methoxyphenyl)-2-methoxyimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine 446274-79-9P,  
 N-Cyclopropylmethyl-N-[8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446274-80-2P,  
 N-[2-Ethyl-8-(2-methoxy-4-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-81-3P, N-[2-Ethyl-8-(2-methoxy-4-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N-(1-ethylpropyl)amine 446274-82-4P, N-[8-(2,4-Dichlorophenyl)-2-ethyl-6-methoxyimidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-83-5P, N-[2-Ethyl-8-(4-methoxy-2-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N-isobutyl-N-propylamine 446274-84-6P, N-[8-(2,6-Dimethoxy-3-pyridyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-85-7P,  
 N-[8-(2,6-Dimethyl-3-pyridyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-86-8P, N-[2-Ethyl-8-(6-methoxy-2-methyl-3-pyridyl)imidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-87-9P,  
 N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-88-0P, N-[8-(4-Chlorophenyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-89-1P, N-[8-(2,4-Dimethoxy-6-methylphenyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-90-4P, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-91-5P, N-[2-Ethyl-8-(4-methoxy-2,6-dimethylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446274-92-6P 446274-93-7P 446274-94-8P, N,N-Dicyclopropylmethyl-N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-b]pyridazin-3-yl]amine 446274-95-9P, N-Cyclopropylmethyl-N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N-propylamine 446274-96-0P, N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N-isobutyl-N-propylamine 446274-97-1P, N-Cyclopropylmethyl-N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N-(3-fluoropropyl)amine 446274-98-2P, N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N-(3-fluoropropyl)-N-propylamine 446274-99-3P, 8-(4-Methoxy-2-methylphenyl)-2-(methylsulfonyl)imidazo[1,2-b]pyridazin-3-amine 446275-00-9P,  
 N-[8-(4-Methoxy-2-methylphenyl)-2-(methylsulfonyl)imidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine 446275-01-0P, N,N-Dicyclopropylmethyl-N-[8-(4-methoxy-2-methylphenyl)-2-(methylsulfonyl)imidazo[1,2-b]pyridazin-3-yl]amine 446275-02-1P, N-[8-(2,4-Dichlorophenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-04-3P, N-[8-(2-Methoxy-4,6-dimethylphenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-05-4P, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-06-5P, N-[8-(2,4-Dichlorophenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N-isobutylamine 446275-07-6P, N-[8-(2,4-Dichlorophenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N-isobutyl-N-propylamine 446275-08-7P, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N-isobutylamine 446275-09-8P, N-Butyl-N-[8-(2,4-dichlorophenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N-isobutylamine 446275-10-1P, N-[8-(2,4-Dichlorophenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N-isobutyl-N-(2-methoxyethyl)amine 446275-11-2P,  
 N-[8-(2,6-Dimethoxy-3-pyridyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-12-3P, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-13-4P, N-[8-(2,4-Dichlorophenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N-(3-fluoropropyl)-N-isobutylamine 446275-14-5P,  
 N-[8-(2,4-Dichlorophenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N-

(4-fluorobutyl)-N-isobutylamine 446275-15-6P, N-[8-(2,4-Dimethoxyphenyl)-pyridin-3-yl]-N,N-dipropylamine  
 2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-16-7P, N-[8-(2,6-Dimethylphenyl)-pyridin-3-yl]-N,N-dipropylamine  
 446275-17-8P, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-18-9P, N-[8-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine 446275-19-0P, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-20-3P, N-[8-(6-Methoxy-2-methyl-3-pyridyl)-pyridin-3-yl]-N,N-dipropylamine  
 446275-21-4P, N-[8-(2,4-Dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-(4-fluorobutyl)-N-propylamine  
 446275-22-5P, N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-(3-fluoropropyl)-N-propylamine  
 446275-23-6P, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-(3-fluoropropyl)-N-propylamine  
 446275-24-7P, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-(3-fluoropropyl)-N-propylamine  
 446275-25-8P, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-(3-fluoropropyl)-N-propylamine  
 446275-26-9P, N-[8-(2,4-Dimethoxy-6-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-27-0P, N-[8-(2,4-Dimethoxy-6-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-28-1P, N-[8-(2-Ethoxy-6-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-29-2P, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-30-5P, N-[8-(2-Chloro-6-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-31-6P, N-[8-Mesityl-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-32-7P, N-[8-(2-Methoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-33-8P, N-[8-(4-Ethyl-2,6-dimethoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-34-9P, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-35-0P, N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-36-1P, N-[8-(2,4-dimethoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-37-2P, N-[8-(2-Fluoro-4,6-dimethoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-38-3P, N-[8-(4-Chloro-2-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-39-4P, N-[2-(Methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-40-7P, N-[8-(2,4-Dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-41-8P, N-[8-(4-Methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-42-9P, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-43-0P, N-(2-Butynyl)-N-[8-(2,4-dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-44-1P, N-[8-(2,4-Dichloro-6-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-45-2P, N-[8-(2,4-Dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-ethyl-N-(4-Methoxy-2-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine  
 446275-46-3P, N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-47-4P, N-Cyclobutylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-48-5P, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-propylamine  
 446275-49-6P, N-[8-(4-Chloro-2-(trifluoromethyl)phenyl)-2-(methylsulfanyl)imidazo[1,2-



a]pyridin-3-yl]-N,N-dipropylamine 446275-50-9P, N-[8-[4-Chloro-2,6-dimethoxyphenyl]-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-51-0P, N-[8-[4-Chloro-2,6-dimethoxyphenyl]-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-cyclobutylmethyl-N-propylamine 446275-52-1, N-[8-[4-Methoxy-2-(trifluoromethyl)phenyl]-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-53-2P, N-[8-(4-Methyl-1,3-benzodioxol-5-yl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-54-3P, N-Butyl-N-cyclobutylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]amine 446275-55-4P, N-Cyclobutylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-ethylamine 446275-56-5P, N-[8-[2-Chloro-4-(trifluoromethoxy)phenyl]-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-57-6P, N-Cyclobutylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]amine 446275-58-7P, N-[8-(5-Methyl-2,3-dihydro-1,4-benzodioxin-6-yl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine 446275-61-2P, N-Cyclobutylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]-N-(3-fluoropropyl)amine 446275-62-3P, N,N-Bis(propyl)-8-[6-(dimethylamino)-4-methyl-3-pyridyl]-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-amine 446275-63-4P 446275-64-5P 446275-65-1P 446275-66-7P 446275-67-8P 446275-68-9P 446275-69-0P 446275-70-1P 446275-71-4P 446275-72-5P 446275-73-6P 446275-74-7P 446275-75-1P 446275-77-0P, N-Butyl-N-cyclobutylmethyl-N-[8-(2,4-dimethoxy-6-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]amine 446275-78-1P, N-Butyl-N-cyclobutylmethyl-N-[8-(2,4-dimethyl-6-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyridin-3-yl]amine 446275-79-2P, 8-(2,4-Dichlorophenyl)-3-methyl-2-(methylsulfanyl)imidazo[1,2-a]pyridine 446275-80-5P, 1-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-c]pyrimidin-3-yl]butyl ethyl ether 446275-82-7P, 8-(4-Chloro-4-methoxyphenyl)-3-(1-methoxybutyl)-2-ethylimidazo[1,2-c]pyrimidine 446275-83-8P, 3-(1-Ethoxybutyl)-2-ethyl-8-(6-methoxy-2-methyl-3-pyridyl)imidazo[1,2-c]pyrimidine 446278-20-2P 446278-22-4P 446278-24-6P 446278-25-7P 446278-27-9P 446278-29-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic nitrogenous fused-ring compds. such as imidazopyrazines, as corticotropin-releasing factor receptor antagonists)

74-88-4, Methyl iodide, reactions 75-15-0, Carbon disulfide, reactions 75-65-0, tert-Butyl alcohol, reactions 96-20-8, 2-Amino-1-butanol 105-36-2, Ethyl bromoacetate 107-08-4, Propane iodide 123-38-6, Propionaldehyde, reactions 124-63-0, Methanesulfonyl chloride 927-77-5, Propylmagnesium bromide 1193-21-1, 4,6-Dichloropyrimidine 1439-36-7 4774-10-1, 3-Methoxy-2-pyrazinamine 5469-69-2, 3-Amino-6-chloropyridazine 6863-73-6, 3-Chloro-2-aminopyrazine 15764-16-6, 2,4-Dimethylbenzaldehyde 17282-00-7, 3-Bromo-5-methyl-2-pyridinamine 26386-88-9, Diphenylphosphoryl azide 55499-44-0, 2,4-Dimethylbenzeneboronic acid 55793-97-0, 1-(2,4-Dimethylphenyl)-3-oxobutyl cyanide 68716-47-2, 2,4-Dichlorobenzeneboronic acid 74290-65-6, 3-Bromo-5-methyl-2-pyrazinamine 114192-09-5, Methyl 2-chloro-3-oxopentanoate 208399-66-0, 4-Methoxy-2-methylphenylboronic acid 355836-08-7, 4,6-Dimethyl-2-methoxybenzeneboronic acid 391954-17-9, 8-Chloro-2-ethylimidazo[1,2-a]pyrazine 446273-97-8, 3-(2,4-Dichlorophenyl)-2-pyrazinamine 446273-98-9, 3-Amino-4-bromo-6-chloropyridazine 446274-01-7, 8-(2,4-Dichlorophenyl)-2-methylimidazo[1,2-a]pyrazine

RL: F T (Reactant); RACT (Reactant or reagent)

(Reactant; preparation of bicyclic nitrogenous fused-ring compounds, such as indazopyrazines, as corticotropin-releasing factor receptor antagonists)

IT 39195 -04-4P, 1-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]butyl ethyl ether 446270-84-4P,  
8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazine-3-carboxylic acid methyl ester 446270-85-5P, tert-Butyl N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]carbamate 446270-87-7P,  
N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446270-88-8P 446270-89-9P, 6-Chloro-8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester 446270-90-2P, tert-Butyl N-[6-chloro-8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]carbamate 446270-91-3P, N-[6-chloro-8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446270-92-4P,  
N-[6-chloro-8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446270-93-5P, 8-(2,4-dichlorophenyl)-2-ethyl-6-methylimidazo[1,2-a]pyrazine-3-carboxylic acid methyl ester 446270-94-6P, tert-Butyl N-[8-(2,4-dichlorophenyl)-2-ethyl-6-methylimidazo[1,2-a]pyrazin-3-yl]carbamate 446270-95-7P,  
N-[8-(2,4-Dichlorophenyl)-2-ethyl-6-methylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446270-96-8P 446270-97-9P,  
8-(2,4-Dichlorophenyl)-2-methyl-3-retroimidazo[1,2-a]pyrazine 446270-98-0P, 8-(2,4-Dichlorophenyl)-2-methylimidazo[1,2-a]pyrazine-3-amine 446270-99-1P 446271-00-7P,  
N-[8-(2,4-Dichlorophenyl)-2-methylimidazo[1,2-a]pyrazin-3-yl]-N-ethylpropylamine 446271-01-8P 446271-02-9P,  
N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-ethylpropylamine hydrochloride 446271-04-1P  
446270-06-3P 446271-08-5P 446271-10-9P  
446270-12-1P 446271-14-3P 446271-16-5P  
446270-18-7P 446271-20-1P, N-[6-chloro-8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-22-3P, 3-Chloro-4-[6-chloro-8-(dipropylamino)-2-ethylimidazo[1,2-a]pyrazin-3-yl]benzonitrile 446271-24-5P,  
N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-30-3P, N-[8-(4-chlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-32-5P,  
N-[2-ethyl-8-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-34-7P, N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-35-8P, N-Cyclopropylmethyl-N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine 446271-37-0P, N-[2-Ethyl-6-methoxy-3-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-38-1P, N-[8-(2,6-Dimethoxy-3-pyridyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-39-2P,  
N-[2-ethyl-8-(6-methoxy-2-methyl-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-41-6P 446271-43-8P,  
N-[2-ethyl-8-(2,4,6-trimethyl-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-45-0P, N-[2-Ethyl-8-(3-methyl-2-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-47-2P,  
N-[2-Ethyl-8-(6-methoxy-2,4-dimethyl-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-49-4P, N-[2-Ethyl-8-(6-methyl-1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-53-0P, N-[2-Ethyl-8-(4-methoxy-2,5-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446271-55-2P, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-propylamine 446271-57-4P,

N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446271-59-6P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-propylamine **446271-61-0P**, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446271-63-2P**, **446271-65-4P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446271-66-5P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-ethyl-N-isobutylamine **446271-68-7P**, N-Butyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446271-70-1P**, N-Benzyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446271-72-3P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-(2-thienylmethyl)amine **446271-74-5P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-furylmethyl)-N-isobutylamine **446271-76-7P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-isopentylamine **446271-78-9P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-[3-(methylsulfanyl)propyl]amine **446271-80-3P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-pentylamine **446271-81-4P**, N-Cyclohexylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446271-82-5P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine **446271-84-7P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-ethyl-N-(3-fluoropropyl)amine **446271-86-8P**, N-Butyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine **446271-87-0P**, N-Benzyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine **446271-88-1P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-(2-thienylmethyl)amine **446271-89-2P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-(2-furylmethyl)amine **446271-90-5P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-isopentylamine **446271-91-6P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-[3-(methylsulfanyl)propyl]amine **446271-92-7P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-pentylamine **446271-93-8P**, N-Cyclohexylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine **446271-94-9P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-(4,4,4-trifluorobutyl)amine **446271-95-0P**, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine **446271-96-1P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-isobutylamine **446271-97-2P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-(4,4,4-trifluorobutyl)amine **446271-98-3P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentylamine **446271-99-4P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-ethyl-N-isopentylamine **446272-00-0P**, N-Butyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentylamine **446272-01-1P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentyl-N-(2-thienylmethyl)amine **446272-02-2P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisopentylamine **446272-03-3P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentyl-N-[3-(methylsulfanyl)propyl]amine **446272-04-4P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentyl-N-pentylamine **446272-05-5P** **446272-06-6P**,

N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentylamine **446272-07-7P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentyl-N-propylamine **446272-08-8P**, N-[8-(4-Chloro-2-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-09-9P**, N-[8-(4-Bromo-2-chlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-10-2P**, N-[8-(2,4-Dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-11-3P**, N-[8-(4-Bromo-2-fluorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-12-4P**, N-[8-(2-Bromo-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-13-5P**, N-(sec-butyl)-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446272-14-6P**, N-(sec-Butyl)-N-cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine **446272-15-7P**, N-Butyl-N-(sec-butyl)-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine **446272-16-8P**, N-(sec-butyl)-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-17-9P** **446272-18-0P** **446272-19-1P**, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine **446272-20-4P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine **446272-21-5P**, N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine **446272-22-6P** **446272-23-7P**, N-Butyl-N-[8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-24-8P** **446272-25-9P**, N-Butyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-26-0P**, N-Butyl-N-[2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-27-1P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-isobutylamine **446272-28-2P**, N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-29-3P** **446272-30-6P** **446272-31-7P**, 8-(2,4-Dichlorophenyl)-3-(dipropylamino)-2-ethylimidazo[1,2-a]pyrazin-6-yl cyanide **446272-32-8P** **446272-33-9P** **446272-34-0P** **446272-35-1P**, 3-(1-Ethoxybutyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazine **446272-36-2P**, 8-(2,4-Dimethoxy-6-methylphenyl)-3-(1-ethoxybutyl)-2-ethylimidazo[1,2-a]pyrazine **446272-37-3P**, 8-(2,6-Dimethoxy-4-methylphenyl)-3-(1-ethoxybutyl)-2-ethylimidazo[1,2-a]pyrazine **446272-38-4P**, 8-(2-Chloro-4-methoxyphenyl)-3-(1-ethoxybutyl)-2-ethylimidazo[1,2-a]pyrazine **446272-39-5P**, 4-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-4-heptanol **446272-40-8P** **446272-41-9P** **446272-42-0P** **446272-43-1P** **446272-44-2P**, 8-(2,4-Dimethoxyphenyl)-2-ethyl-3-(1-ethylpropyl)imidazo[1,2-a]pyrazine **446272-45-3P**, N-[8-(2,4-Dimethylphenyl)-2-ethyl-6-methylimidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine **446272-46-4P**, N-[8-(2,4-Dimethylphenyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine **446272-47-5P**, N-[8-(2,4-Dimethoxyphenyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine **446272-48-6P**, N-[8-(2,4-Dimethoxyphenyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]-N-isobutylamine **446272-49-7P**, N-Cyclopropylmethyl-N-[8-(2,4-Dimethoxyphenyl)-2-ethylimidazo[1,2-b]pyridazin-3-yl]-N-isobutylamine **446272-50-0P**, N-[2-Ethyl-8-(4-methoxy-2-methylphenyl)imidazo[1,2-b]pyridazin-3-yl]-N,N-dipropylamine **446272-51-1P**, N-[8-(2,4-Dichlorophenyl)-6-methyl-2-(methylsulfonyl)imidazo[1,2-a]pyridin-3-yl]-N,N-dipropylamine **446272-52-2P**, N,N-Dipropyl-8-(2,4-dichlorophenyl)-2-(methylsulfonyl)imidazo[1,2-a]pyrazin-3-amine **446272-53-3P** **446272-54-4P**, N-[8-(2,4-Dichloro-6-methylphenyl)-2-

ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446272-51-5P  
 446272-56-6P, N-[8-(2-Bromo-4-isopropylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446272-57-7P,  
 -[8-(2-Bromo-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446272-58-8P, N-[8-(2-Bromo-4,6-dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine  
 446272-59-9P, N-[8-(2,4-Dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446272-60-2P,  
 -[8-(2-Chloro-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446272-61-3P, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine  
 446272-62-4P 446272-63-5P, N-[8-(2-Chloro-4,6-dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine  
 446272-64-6P, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)amine hydrochloride  
 446272-65-7P, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)amine 446272-66-8P,  
 -[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)-N-propylamine 446272-67-9P, N-Butyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)amine  
 446272-68-0P, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)-N-pentylamine 446272-69-1P,  
 -[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-(2-methoxyethyl)amine 446272-70-4P, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methylbutyl)amine 446272-71-5P, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-(2-methylbutyl)amine  
 446272-72-6P, N-Cyclobutylmethyl-N-cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
 446272-73-7P, N-Cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446272-74-8P,  
 N-Cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine 446272-75-9P, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)-N-propylamine  
 446272-76-0P, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)amine  
 446272-77-1P, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)-N-isobutylamine 446272-78-2P  
 446272-79-3P 446272-80-6P, 3-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl](propyl)aminopropanenitrile  
 446272-81-7P 446272-82-8P, N-Butyl-N-cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
 446272-83-9P, N-Butyl-N-cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine 446272-84-0P\*  
 \* , N-Butyl-N-[8-(2-chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine \*\*\*446272-85-1P  
 446272-86-2P, N,N-Dicyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine 446272-87-3P  
 446272-88-4P, N,N-Dicyclopropylmethyl-N-[2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]amine 446272-89-5P,  
 -[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methylbutyl)amine 446272-90-8P,  
 N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methylbutyl)amine 446272-91-9P,  
 -[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methylbutyl)amine 446272-92-0P,  
 N-Cyclopropylmethyl-N-[2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-(2-methylbutyl)amine 446272-93-1P,  
 -[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine 446272-94-2P,

N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446272-95-3P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine **446272-96-4P**, N-Cyclopropylmethyl-N-[2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446272-97-5P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine **446272-98-6P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-isobutylamine **446272-99-7P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-propylamine **446273-00-3P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-propylamine **446273-01-4P**, N,N-Dicyclopropylmethyl-N-[8-(2,4-dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine **446273-02-5P 446273-03-6P 446273-04-7P**, N,N-Dicyclopropylmethyl-N-[8-(2,4-dichloro-6-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine **446273-05-8P**, N-[8-(2-Bromo-4,6-dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine **446273-06-9P**, N-[8-(2,4-Dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine **446273-07-0P 446273-08-1P 446273-09-2P 446273-10-5P 446273-11-6P**, N-[8-(2,4-Dichlorophenyl)-2-ethyl-6-methoxyimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446273-12-7P**, N-[6-Chloro-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446273-13-8P 446273-14-9P**, N-[6-Chloro-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine **446273-15-0P**, N-[6-Chloro-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine **446273-16-1P**, N-[6-Chloro-8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine **446273-17-2P**, N-[6-Chloro-8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-propylamine **446273-18-3P**, N-[6-Chloro-8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(1-ethylpropyl)amine **446273-19-4P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446273-20-7P**, N-[8-(2-Methoxy-4,6-dimethylphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446273-21-8P**, N-Isobutyl-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446273-22-9P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-propylamine **446273-23-0P**, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446273-24-1P**, N-[8-(2,4-Dimethoxyphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446273-25-2P**, N-[8-(2,4-Dimethoxy-6-methylphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446273-27-4P**, N,N-Dicyclopropylmethyl-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]amine **446273-29-6P 446273-31-0P**, N-Cyclopropylmethyl-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446273-33-2P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine **446273-35-4P**, N-Cyclopropylmethyl-N-(3-fluoropropyl)-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]amine **446273-37-6P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methanesulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine **446273-39-8P**,

N, -Dicyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine 446273-40-1P,

N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine

446273-41-2P, N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine 446273-42-3P, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine 446278-18-8P

RL PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target product; preparation of bicyclic nitrogenous fused ring compds. such as imidazopyrazines, as corticotropin-releasing factor receptor antagonists)

IT 446273-43-4P, 8-Chloro-2-ethylimidazo[1,2-a]pyrazine-3-carboxylic acid methyl ester 446273-47-8P, 8-Bromo-2-ethyl-6-methylimidazo[1,2-a]pyrazine-3-carboxylic acid methyl ester

446273-49-0P 446273-51-4P, 1-(8-Chloro-2-ethylimidazo[1,2-a]pyrazin-3-yl)butyl ethyl ether 446273-53-6P,

1-(8-Chloro-2-ethylimidazo[1,2-a]pyrazin-3-yl)-1-butanol 446273-55-8P, 1-(8-Chloro-2-ethylimidazo[1,2-a]pyrazin-3-yl)-1-butanone 446273-71-8P, Ethyl 8-methoxy-2-(methylsulfanyl)imidazo[1,2-a]pyrazine-3-carboxylate 446273-72-9P

, Ethyl 8-chloro-2-(methylsulfanyl)imidazo[1,2-a]pyrazine-3-carboxylate 446273-73-0P, tert-Butyl N-[8-chloro-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]carbamate 446273-74-1P, N-[8-Chloro-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine

446273-75-2P, N-[8-Chloro-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446273-87-6P, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446273-88-7P


, 1-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-1-butanone

RL RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of bicyclic nitrogenous fused-ring compds. such as imidazopyrazines, as corticotropin-releasing factor receptor antagonists)


RN 446273-43-4 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-carboxylic acid, 8-chloro-2-ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 446273-47-8 CAPLUS


CN Imidazo[1,2-a]pyrazine-3-carboxylic acid, 8-bromo-2-ethyl-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 446273-49-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazine-3-carboxaldehyde, 8-chloro-2-ethyl- (9CI) (CA  
 INDEX NAME)



RN 446273-51-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-chloro-3-(1-ethoxybutyl)-2-ethyl- (9CI) (CA  
 INDEX NAME)




RN 446273-53-6 CAPLUS  
 CN Imidazo[1,2-a]pyrazine-3-methanol, 8-chloro-2-ethyl- $\alpha$ -propyl- (9CI)  
 (CA INDEX NAME)



RN 446273-55-8 CAPLUS  
 CN 1-Butanone, 1-(8-chloro-2-ethylimidazo[1,2-a]pyrazin-3-yl)- (9CI) (CA  
 INDEX NAME)




INDE: NAME)




RN 4462 3-71-8 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-carboxylic acid, 8-methoxy-2-(methylthio)-, ethyl ester (9CI) (CA INDEX NAME)




RN 4462 3-72-9 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-carboxylic acid, 8-chloro-2-(methylthio)-, ethyl ester (9CI) (CA INDEX NAME)




RN 4462 3-73-0 CAPLUS


CN Carbanic acid, [8-chloro-2-(methylthio)imidazo[1,2-a]pyrazin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 446273-74-1 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-chloro-2-(ethylthio)-N-propyl- (9CI)  
(CA INDEX NAME)

RN 446273-75-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-chloro-2-(ethylthio)-N,N-dipropyl- (9CI)  
(CA INDEX NAME)


RN 446273-87-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 446273-88-7 CAPLUS

CN 1-Butanone, 1-(2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl)- (9CI) (CA INDEX NAME)



IT 446274-02-8P, N-[8-(2-Bromo-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine 446274-03-9P, N,N-Dicyclopropylmethyl-N-[2-(methylsulfanyl)-8-(2,4,6-trimethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]amine 446274-04-0P 446274-05-1P, N-Cyclopropylmethyl-N-isopropyl-N-[2-(methylsulfanyl)-8-(2,4,6-trimethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]amine 446274-06-2P, N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine 446274-07-3P, N-Cyclopropylmethyl-N-isobutyl-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine 446274-08-4P, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-isobutylamine 446274-09-5P, N-Cyclopropylmethyl-N-[8-(4-methoxy-2,6-dimethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446274-10-8P, N-Cyclopropylmethyl-N-[8-(4-methoxy-2-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446274-11-9P, N-Cyclopropylmethyl-N-[8-(2-methoxy-4-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446274-12-0P, N-[8-(4-Chloro-2-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine 446274-13-1P, N-Cyclopropylmethyl-N-[8-(2,4-dimethoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446274-14-2P, 4-[3-[(Cyclopropylmethyl)(propyl)amino]-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-8-yl]-3-methylbenzonitrile 446274-15-3P, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-(1-ethylpropyl)amine 446274-16-4P, N-(1-Ethylpropyl)-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine 446274-17-5P, N-Cyclopropylmethyl-N-[8-(4-methyl-1,3-benzodioxol-5-yl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446274-18-6P, N-Cyclopropylmethyl-N-[8-(5-methyl-2,3-dihydro-1,4-benzodioxin-6-yl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446274-20-0P, N-Cyclopropylmethyl-N-[8-(2-methoxy-4-(trifluoromethyl)phenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446274-22-2P, N,N-Dicyclopropylmethyl-N-[8-(2-methoxy-4-(trifluoromethyl)phenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine 446274-23-3P, N,N-Dicyclopropylmethyl-N-[8-(4-methoxy-2-(trifluoromethyl)phenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine 446274-24-4P, N,N-Dicyclopropylmethyl-N-[8-(2,4-dimethoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine 446274-25-5P 446274-26-6P, N,N-Dicyclopropylmethyl-N-[8-(4-methoxy-2-methylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine 446274-27-7P, N,N-Dicyclopropylmethyl-N-[8-(2-methoxy-4-


methylphenyl)-2-methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine  
**446274-28-8P**, N-8-(2-Chloro-4-(trifluoromethoxy)phenyl)-2-(  
 (methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl)-N,N-  
 bis(cyclopropylmethyl)amine **446274-29-9P**, N,N-  
 Dicyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-(  
 (methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl)]amine **446274-30-2P**  
**446274-31-3P**, 2-[8-(2-Chloro-4-methoxyphenyl)-2-(  
 (methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl)](cyclopropylmethyl)amino]-1-  
 ethanol **446274-32-4P** **446274-33-5P** **446274-34-6P**  
 , N,N-Bis(cyclopropylmethyl)-8-[6-(dimethylamino)-4-methyl-3-pyridyl]-2-(  
 (methylsulfanyl)imidazo[1,2-a]pyrazin-3-amine **446274-35-7P**,  
 N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-  
 yl]-N-cyclopropylmethyl-N-[3-(methylsulfanyl)propyl]amine  
**446274-36-8P** **446274-37-9P**, 1-[8-(2-Chloro-4-  
 methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-  
 yl](cyclopropylmethyl)amino]-2-propanol **446274-38-0P**,  
 1-[8-(2-Chloro-4-(trifluoromethoxy)phenyl)-2-(methylsulfanyl)imidazo[1,2-  
 a]pyrazin-3-yl](cyclopropylmethyl)amino]-2-propanol **446274-39-1P**  
**446274-40-4P** **446274-41-5P**, 2-[8-(2-Chloro-4-  
 (trifluoromethoxy)phenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-  
 yl](cyclopropylmethyl)amino]acetamide **446274-42-6P**  
**446274-43-7P** **446274-44-8P** **446274-45-9P**,  
 N-[8-(2-Chloro-4-(trifluoromethoxy)phenyl)-2-(methylsulfanyl)imidazo[1,2-  
 a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-furylmethyl)amine  
**446274-46-0P** **446274-48-2P** **446274-49-3P**,  
 N-[8-(2-Chloro-4-(trifluoromethoxy)phenyl)-2-(methylsulfanyl)imidazo[1,2-  
 a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-morpholinoethyl)amine  
**446274-50-6P** **446274-51-7P**, N,N-Bis(cyclopropylmethyl)-8-  
 [4-(dimethylamino)-2-methoxyphenyl]-2-(methylsulfanyl)imidazo[1,2-  
 a]pyrazin-3-amine **446274-53-9P**, N-[8-(2-Chloro-4-methoxyphenyl)-  
 2-(methylsulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-  
 propylamine **446274-55-1P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-(  
 (methylsulfonyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-  
 propylamine **446274-57-3P** **446274-59-5P**,  
 4-[3-[Di(cyclopropylmethyl)amino]-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-  
 8-yl]-3-methoxybenzonitrile **446274-61-9P**, N,N-  
 Bis(cyclopropylmethyl)-N-[8-(2-methoxy-4-(pyrrolidin-1-yl)phenyl)-2-(  
 (methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl)]amine **446274-63-1P**,  
 6-Chloro-3-(1-ethoxybutyl)-2-ethyl-8-(2-methoxy-4,6-  
 dimethylphenyl)imidazo[1,2-a]pyrazine **446274-65-3P**,  
 8-(2-Chloro-4-methoxyphenyl)-3-(1-ethoxybutyl)-2-(  
 (methylsulfanyl)imidazo[1,2-a]pyrazine **446274-67-5P**,  
 3-(1-Ethoxybutyl)-8-(2-methoxy-4,6-dimethylphenyl)-2-(  
 (methylsulfanyl)imidazo[1,2-a]pyrazine **446274-69-7P**  
**446274-71-1P** **446274-75-5P** **446274-77-7P**  
**446274-78-8P**, N-8-(2-Chloro-4-methoxyphenyl)-2-methoxyimidazo[1,2-  
 a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine **446274-79-9P**,  
 N-Cyclopropylmethyl-N-[2-methoxy-8-(2-methoxy-4,6-  
 dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine  
**446278-20-2P** **446278-22-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of bicyclic nitrogenous fused-ring compds. such as  
 imidazopyrazines, as corticotropin-releasing factor receptor  
 antagonists)


RN 446274-02-8 CAP US

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-bromo-4-methoxyphenyl)-N-  
 (cyclopropylmethyl)-N-(3-fluoropropyl)-2-(methylthio)- (9CI) (CA INDEX  
 NAME)




RN 446274-03 9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-2-(methylthio)-8-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 446274-04 0 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-6-methoxy-4-methylphenyl) N,N-bis(cyclopropylmethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 446274-05 1 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-N-(1-methylethyl)-2-(2-chloro-6-methoxy-4-methylphenyl)- (9CI) (CA INDEX NAME)

(methylthio)-8-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 446274-06-2 CAPLU

CN Imidazo[1,2-a]pyridine-3-amine, N-(cyclopropylmethyl)-8-(2,6-dimethoxy-4-methylphenyl)-N-(2-methylpropyl)-2-(methylthio) (9CI) (CA INDEX NAME)




RN 446274-07-3 CAPLU

CN Imidazo[1,2-a]pyridine-3-amine, N-(cyclopropylmethyl)-8-(2-methoxy-4,6-dimethylphenyl)-N-(2-methylpropyl)-2-(methylthio) (9CI) (CA INDEX NAME)




RN 446274-08-4 CAPLU

CN Imidazo[1,2-a]pyridine-3-amine, 8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-N-(2-methylpropyl)-2-(methylthio) (9CI) (CA INDEX NAME)




RN 446274-09-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(4-methoxy-2,6-dimethylphenyl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 446274-10-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(4-methoxy-2-methylphenyl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 446274-11-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2-methoxy-4-methylphenyl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 446274-12-0 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-amine, 8-(4-chloro-2-methoxyphenyl)-N-(cyclopropylmethyl)-N-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)



RN 446274-13-1 CAPLUS


CN Imidazo[1,2-a]pyrazine-3-amine, N-(cyclopropylmethyl)-8-(2,4-dimethoxyphenyl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)



RN 446274-14-2 CAPLUS


CN Benzonitrile, 4-[3-[(cyclopropylmethyl)propylamino]-2-(methylthio)imidazo[1,2-a]pyrazin-8-yl]-3-methyl- (9CI) (CA INDEX NAME)






RN 446274-15-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2-(methylthio)- (9CI) (CA INDEX NAME)





RN 446274-16-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(1-ethylpropyl)-8-(2-methoxy-4,6-dimethylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-17-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(4-methyl-1,3-benzodioxol-5-yl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 446274-18-6 CAPLUS

CN Imidazo[1,2-a]pyrazine-4-amine, N-(cyclopropylmethyl) 8-(2,3-dihydro-5-methyl-1,4-benzodioxin-6-yl)-2-(methylthio)-N-propyl (9CI) (CA INDEX NAME)




RN 446274-20-0 CAPLUS

CN Imidazo[1,2-a]pyrazine-4-amine, N-(cyclopropylmethyl) 8-[2-methoxy-4-(trifluoromethyl)phenyl]-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 446274-22-2 CAS US

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-[2-methoxy-4-(trifluoromethyl)phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-23-3 CAS US

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-[4-methoxy-2-(trifluoromethyl)phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-24-4 CAS US

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-(2,4-dimethoxyphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




N 446274-25-5 CAPLUS

N Imidazo[1,2-a]pyrazin-3-amine, 8-(4-chloro-2-methoxyphenyl)-N,N-bis(cyclopropylmethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




N 446274-26-6 CAPLUS

N Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-(4-methoxy-2-methylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-27-7 CAPLU ;

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-(2-methoxy-4-methylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-28-8 CAPLU ;

CN Imidazo[1,2-a]pyrazin-3-amine, 8-[2-chloro-4-(trifluoromethoxy)phenyl]-N,N-bis(cyclopropylmethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-29-9 CAPLU ;

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-30-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-bromo-4-methoxyphenyl)-N,N-bis(cyclopropylmethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-31-3 CAPLUS

CN Ethanol, 2-[[8-(2-chloro-4-methoxyphenyl)-2-(methylthio)imidazo[1,2-a]pyrazin-3-yl](cyclopropylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 446274-32-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4-methoxyphenyl)-N-(cyclobutylmethyl)-N-(cyclopropylmethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-33-5 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-amine, N,N-bis(cyclopropylmethyl)-2-ethyl-8-[2-methoxy-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 446274-34-6 CAPLUS


CN Imidazo[1,2-a]pyrazine-3-amine, N,N-bis(cyclopropylmethyl)-8-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 146274-35-7 CAPLUS  
 CN [imidazo[1,2-a]pyrazin-3-amine 8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-2-(methylthio)-N-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)



RN 146274-36-8 CAPLUS  
 CN [imidazo[1,2-a]pyrazin-3-amine 8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-2-(methylthio)-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 146274-37-9 CAPLUS  
 CN 2-Propanol, 1-[[8-(2-chloro-4-methoxyphenyl)-2-(methylthio)imidazo[1,2-a]pyrazin-3-yl](cyclopropylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 146274-38-0 CAPLUS




CN 2-Propanol, 1-[[8-[2-chloro-4-(trifluoromethoxy)phenyl]-2-(methylthio)imidazo[1,2-a]pyrazin-3-yl](cyclopropylmethyl)amino]- (9CI)  
(CA INDEX NAME)



RN 446274-39-1 CAPLUS  
CN Imidazo[1,2-a]pyrazin-3-amine, 8-[2-chloro-4-(trifluoromethoxy)phenyl]-N-(cyclopropylmethyl)-2-(methylthio)-N-(tetrahydro-2H-pyran-4-yl)- (9CI)  
(CA INDEX NAME)




RN 446274-40-4 CAPLUS  
CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-[6-(dimethylamino)-2,4-dimethyl-3-pyridinyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 4-5274-41-5 CAPLUS

CN Acetamide, 2-[[8-[2-chloro-4-(trifluoromethoxy)phenyl]-2-(methylthio)imidazo[1,2-a]pyrazin-3-yl](cyclopropylmethyl)amino] - (9CI)  
(CA INDEX NAME)

F<sub>3</sub>C-

RN 4-5274-42-6 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, -[2-chloro-4-(trifluoromethoxy)phenyl]-N-(cyclopropylethyl)-N-(cyclopropylmethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)

F<sub>3</sub>C-

RN 4-5274-43-7 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, -[4-bromo-2-methoxyphenyl]-N, 1-

bis(cyclopropylmethyl)-2-(methylthio)-(9CI) (CA INDEX NAME)




UN 446274-44-8 CAPLUS

UN 2-Furancarboxamide, N-[8-[2-chloro-4-(trifluoromethoxy)phenyl]-2-(methylthio)imidazo[1,2-a]pyrazin-3-yl]-(9CI) (CA INDEX NAME)




UN 446274-45-9 CAPLUS

UN Imidazo[1,2-a]pyrazin-3-amine, 8-[2-chloro-4-(trifluoromethoxy)phenyl]-N-(cyclopropylmethyl)-N-(2-furanylmethyl)-2-(methylthio) (9CI) (CA INDEX NAME)




RN 446 74-46-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N- 2-bromoethyl)-8-[2-chloro-4-(trifluoromethoxy)phenyl]-N-(cyclopropylmethyl)-2-(methylthio) (9CI) (CA INDEX NAME)




RN 446 74-48-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8- 2-chloro-4-(trifluoromethoxy)phenyl]-N-(cyclopropylmethyl)-2-(methylthio)-N-[2-(1-pyrrolidinyl)ethyl] (9CI) (CA INDEX NAME)




RN 446 74-49-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8- 2-chloro-4-(trifluoromethoxy)phenyl]-N-(cyclopropylmethyl)-2-(methylthio)-N-[2-(4-morpholinyl)ethyl] (9CI) (CA INDEX NAME)




RI 446274-50-6 CAPLUS

CI Imidazo[1,2-a]pyrazin-3-amine, 8-[2-chloro-4-(trifluoromethoxy)phenyl]-N-(cyclopropylmethyl)-2-(methylthio)-N-[2-(1H-pyrazol-1-yl)ethyl]- (9CI)  
(CA INDEX NAME)




RI 446274-51-7 CAPLUS

CI Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-[4-(dimethylamino)-2-methoxyphenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274 53-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-2-(methylsulfinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446274 55-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-2-(methylsulfonyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446274 57-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-[2-chloro-4-(methylsulfinyl)phenyl]-N-(cyclopropylmethyl)-2-(methylsulfinyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446274-59-5 CAPLUS

CN Benzonitrile, 4-[3-[(cyclopropylmethyl)amino]-2-(methylthio)imidazo[1,2-a]pyrazin-8-yl]-3-methoxy- (CI) (CA INDEX NAME)




RN 446274-61-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-4-[2-methoxy-4-(1-pyrrolidinyl)phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-63-1 CAPLUS

CN Imidazo[1,2-a]pyrazine, 6-chloro-3-(1-ethoxybutyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 446274-6 -3 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(2-chloro-4-methoxyphenyl)-3-(1-ethoxybutyl)-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 446274-6 -5 CAPLUS

CN Imidazo[1,2-a]pyrazine, 3-(1-ethoxybutyl)-8-(2-methoxy-4,6-dimethylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 446274-6 -7 CAPLUS



CN 1 Butanone, 1-[8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-, O-methyloxime, (1E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 4,6274-71-1 CAPLUS

CN 1 Butanone, 1-[8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-, O-methyloxime, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 4,6274-75-5 CAPLUS

CN 1 Butanone, 1-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methylthio)imidazo[1,2-a]pyrazin-3-yl]-, O-methyloxime, (1E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 446274-77- CAPLUS

CN 1-Butanone 1-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methylthio)imidazo 1,2-  
alpyrazin-3-yl]-, O-methyloxime, (1Z)- (CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 446274-78- CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4-methoxyphenyl)-N-  
(cyclopropylmethyl)-2-methoxy-N-propyl- (9CI) (CA INDEX NAME)

RN 446 74-79-9 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-2-methoxy-8-(2-methoxy-4,6-dimethylphenyl)-N-propyl- (9CI) (CA INDEX NAME)



RN 446 78-20-2 CAPLUS

CN 1-Etanone, 1-[8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl], oxime, (1Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 446 78-22-4 CAPLUS

CN 1-Etanone, 1-[8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl], oxime, (1E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



IT 391954-17-9, 3-Chloro-2-ethylimidazo[1,2-a]pyrazine  
 446274-01-7, 3-(2,4-Dichlorophenyl)-2-methylimidazo[1,2-a]pyrazine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant preparation of bicyclic nitrogenous fused-ring compds. such as  
 imidazopyrazines, as corticotropin-releasing factor receptor  
 antagonists)  
 RN 391954-17-9 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-chloro-2-ethyl- (9CI) (CA INDEX NAME)



RN 446274-01-7 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA INDEX NAME)



IT 391954-04-4P 1-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]butyl ethyl ether 446270-84-4P,  
 8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazine-3-carboxylic acid  
 methyl ester 446270-85-5P, tert-Butyl N-[8-(2,4-dichlorophenyl)-  
 2-ethylimidazo[1,2-a]pyrazin-3-yl]carbamate 446270-87-7P,  
 N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine  
 446270-88-8P 446270-89-9P, 6-Chloro-8-(2,4

dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazine-3-carboxylic acid ethyl ester **446270-90-2P**, tert-Butyl N-[6-chloro-8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]carbamate **446270-91-3P**, N-[6-Chloro-8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446270-92-4P**, N-[6-chloro-8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446270-93-5P**, 8-(2,4-dichlorophenyl)-2-ethyl-6-methylimidazo[1,2-a]pyrazine-3-carboxylic acid methyl ester **446270-94-6P**, tert-Butyl N-[8-(2,4-dichlorophenyl)-2-ethyl-6-methylimidazo[1,2-a]pyrazin-3-yl]carbamate **446270-95-7P**, N-[8-(2,4-Dichlorophenyl)-2-ethyl-6-methylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446270-96-8P 446270-97-9P**, 8-(2,4-Dichlorophenyl)-2-methyl-3-methylimidazo[1,2-a]pyrazine **446270-98-0P**, 8-(2,4-Dichlorophenyl)-2-methylimidazo[1,2-a]pyrazine-3-amine **446270-99-1P 446271-00-7P**, N-[8-(2,4-Dichlorophenyl)-2-methylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446271-01-8P 446271-02-9P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine hydrochloride **446271-04-1P 446271-06-3P 446271-08-5P 446271-10-9P 446271-12-1P 446271-14-3P 446271-16-5P 446271-18-7P 446271-20-1P**, N-[6-Chloro-8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-22-3P**, 3-Chloro-4-[6-chloro-8-(dipropylamino)-2-ethylimidazo[1,2-a]pyrazin-3-yl]benzonitrile **446271-24-5P**, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-30-3P**, N-[8-(4-Chlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-32-5P**, N-[2-Ethyl-8-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-34-7P**, N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-35-8P**, N-Cyclopropylmethyl-N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446271-37-0P**, N-[2-Ethyl-6-methoxy-4-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-38-1P**, N-[8-(2,6-Dimethoxy-3-pyridyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-39-2P**, N-[2-Ethyl-8-(6-methoxy-2-methyl-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-41-6P 446271-43-8P**, N-[2-Ethyl-8-(2,4,6-trimethyl-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-45-0P**, N-[2-Ethyl-8-(3-methyl-2-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-47-1P**, N-[2-Ethyl-8-(6-methoxy-2,4-dimethyl-3-pyridyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-49-4P**, N-[2-Ethyl-8-(6-methyl-1,3-benzodioxol-5-yl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-53-0P**, N-[2-Ethyl-8-(4-methoxy-2,5-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446271-55-2P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-propylamine **446271-57-4P**, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446271-59-6P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-propylamine **446271-61-0P**, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446271-63-2P 446271-65-4P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446271-66-5P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-ethyl-N-isobutylamine **446271-68-7P**, N-Butyl N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446271-70-1P**, N-Benzyloxy-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-

isobutylamine **446271-72-3P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-(2-thienylmethyl)amine  
**446271-74-5P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-furylmethyl)-N-isobutylamine **446271-76-7P**,  
N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-isopentylamine **446271-78-9P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-[3-(methylsulfanyl)propyl]amine **446271-80-3P**, N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-pentylamine **446271-81-4P**, N-Cyclohexylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine  
**446271-82-5P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine **446271-84-7P**,  
N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-ethyl-N-(3-fluoropropyl)amine **446271-85-8P**, N-Butyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine  
**446271-87-0P**, N-Benzyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine  
**446271-88-1P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-(2-thienylmethyl)amine  
**446271-89-2P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-(2-furylmethyl)amine  
**446271-90-5P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-isopentylamine **446271-91-6P**,  
N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-[3-(methylsulfanyl)propyl]amine **446271-92-7P**,  
N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-pentylamine **446271-93-8P**, N-Cyclohexylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine **446271-94-9P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-(4,4,4-trifluorobutyl)amine **446271-95-0P**, N-Cyclohexylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine  
**446271-96-1P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)-N-isobutylamine **446271-97-2P**,  
N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-(4,4,4-trifluorobutyl)amine **446271-98-3P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentylamine  
**446271-99-4P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-ethyl-N-isopentylamine **446272-00-0P**,  
N-Butyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentylamine **446272-01-1P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentyl-N-(2-thienylmethyl)amine  
**446272-02-2P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisopentylamine **446272-03-3P**,  
N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentyl-N-[3-(methylsulfanyl)propyl]amine **446272-04-4P**,  
N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentyl-N-pentylamine **446272-05-5P** **446272-06-6P**,  
N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentylamine **446272-07-7P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isopentyl-N-propylamine  
**446272-08-8P**, N-[8-(4-Chloro-2-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-09-9P**,  
N-[8-(4-Bromo-2-chlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-10-2P**, N-[8-(2,4-Dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-11-3P**,  
N-[8-(4-Bromo-2-fluorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-12-4P**, N-[8-(2-Bromo-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-13-5P**,

N-(sec-Butyl)-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine **446272-14-6P**, N-(sec-Butyl)-N-cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine **446272-15-7P**, N-Butyl-N-(sec-butyl)-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine **446272-16-8P**, N-(sec-Butyl)-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-17-9P** **446272-18-0P** **446272-19-1P**, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine **446272-20-4P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine **446272-21-5P**, N-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine **446272-22-6P** **446272-23-7P**, N-Butyl-N-[8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-24-8P** **446272-25-9P**, N-Butyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-26-0P**, N-Butyl-N-[2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-27-1P**, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-isobutylamine **446272-28-2P**, N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine **446272-29-3P** **446272-30-6P** **446272-31-7P**, 8-(2,4-Dichlorophenyl)-3-(dipropylamino)-2-ethylimidazo[1,2-a]pyrazin-6-yl cyanide **446272-32-8P** **446272-33-9P** **446272-34-0P** **446272-35-1P**, 3-(1-Ethoxybutyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazine **446272-36-2P**, 8-(2,4-Dimethoxy-6-methylphenyl)-3-(1-ethoxybutyl)-2-ethylimidazo[1,2-a]pyrazine **446272-37-3P**, 8-(2,6-Dimethoxy-4-methylphenyl)-3-(1-ethoxybutyl)-2-ethylimidazo[1,2-a]pyrazine **446272-38-4P**, 8-(2-Chloro-4-methoxyphenyl)-3-(1-ethoxybutyl)-2-ethylimidazo[1,2-a]pyrazine **446272-39-5P**, 4-[2-Ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-4-heptanol **446272-40-8P** **446272-41-9P** **446272-42-0P** **446272-43-1P** **446272-44-2P**, 8-(2,4-Dimethoxyphenyl)-2-ethyl-3-(1-ethylpropyl)imidazo[1,2-a]pyrazine **446272-52-2P**, N,N-Dipropyl-8-(2,4-dichlorophenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-amine **446272-53-3P** **446272-54-4P**, N-[8-(2,4-Dichloro-6-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-55-5P** **446272-56-6P**, N-[8-(2-Bromo-4-isopropylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-57-7P**, N-[8-(2-Bromo-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-58-8P**, N-[8-(2-Bromo-4,6-dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-59-9P**, N-[8-(2,4-Dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-60-2P**, N-[8-(2-Chloro-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-61-3P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-62-4P** **446272-63-5P**, N-[8-(2-Chloro-4,6-dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine **446272-64-6P**, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)amine hydrochloride **446272-65-7P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)amine **446272-66-8P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)-N-propylamine **446272-67-9P**, N-Butyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)amine **446272-68-0P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxyethyl)-N-pentylamine

**446272-69-1P**, N-[3-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-(2-methoxyethyl)amine  
**446272-70-4P**, N-Cyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxybutyl)amine  
**446272-71-5P**, N-[3-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-(2-methoxybutyl)amine  
**446272-72-6P**, N-Cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(2-methoxybutyl)amine  
**446272-73-7P**, N-Cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine  
**446272-74-8P**, N-Cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutylamine  
**446272-75-9P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)-N-propylamine  
**446272-76-0P**, N-Cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)amine  
**446272-77-1P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)-N-isobutylamine  
**446272-78-2P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)-N-propylamine  
**446272-79-3P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)-N-isobutylamine  
**446272-80-6P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)-N-propylamine  
**446272-81-7P**, N-[8-(2,4-Dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(4-fluorobutyl)-N-isobutylamine  
**446272-82-8P**, N-Butyl-N-cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446272-83-9P**, N-Butyl-N-cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446272-84-0P**, N-Butyl-N-cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446272-85-1P**, N-Butyl-N-cyclobutylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446272-86-2P**, N,N-Dicyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446272-87-3P**, N,N-Dicyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446272-88-4P**, N,N-Dicyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446272-89-5P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-90-8P**, N-Cyclopropylmethyl-N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-91-9P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-92-0P**, N-Cyclopropylmethyl-N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-93-1P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-94-2P**, N-Cyclopropylmethyl-N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-95-3P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-96-4P**, N-Cyclopropylmethyl-N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-97-5P**, N-Cyclopropylmethyl-N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-98-6P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446272-99-7P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446273-00-3P**, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(2-methoxy-4-methylphenyl)amine  
**446273-01-4P**, N,N-Dicyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446273-02-5P**, N,N-Dicyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446273-03-6P**, N,N-Dicyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446273-04-7P**, N,N-Dicyclopropylmethyl-N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]amine  
**446273-05-8P**, N-[8-(2-Bromo-4,6-dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-propylamine  
**446273-06-9P**, N-[8-(2,4-Dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine  
**446273-07-0P**, N-[8-(2,4-Dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine  
**446273-08-1P**, N-[8-(2,4-Dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine  
**446273-09-2P**, N-[8-(2,4-Dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine  
**446273-10-5P**, N-[8-(2,4-Dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine  
**446273-11-6P**, N-[8-(2,4-Dibromophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-diisobutylamine



N-[8-(2,4-dichlorophenyl)-2-ethyl-6-methoxyimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446273-12-7P, N-[6-Chloro-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446273-13-3P 446273-14-9P, N-[6-Chloro-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine 446273-15-0P, N-[6-Chloro-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine 446273-16-1P, N-[6-Chloro-8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine 446273-17-2P, N-[6-Chloro-8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine 446273-18-3P, N-[6-Chloro-8-(2-chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(1-ethylpropyl)amine 446273-19-4P, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446273-20-7P, N-[8-(2-Methoxy-4,6-dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446273-21-3P, N-Isobutyl-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446273-22-9P, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-isobutyl-N-propylamine 446273-23-0P, N-[8-(2,6-Dimethoxy-4-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446273-24-1P, N-[8-(2,4-Dimethoxyphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446273-25-2P, N-[8-(2,4-Dimethoxy-6-methylphenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N,N-dipropylamine 446273-27-4P, N,N-Dicyclopropylmethyl-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine 446273-29-5P 446273-31-0P, N-Cyclopropylmethyl-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446273-33-2P, N-[8-(2-Chloro-4-methoxyphenyl)-2-ethyl-N-cyclopropylmethyl-N-(3-fluoropropyl)-ethylsulfanyl]imidazo[1,2-a]pyrazin-3-yl]amine 446273-35-4P, N-Cyclopropylmethyl-N-[8-(2-methoxy-4,6-dimethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]amine 446273-37-6P, N-[8-(2-Chloro-4-methoxyphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylmethyl-N-(3-fluoropropyl)amine 446273-39-8P, N,N-Dicyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-ethylsulfanyl]imidazo[1,2-a]pyrazin-3-yl]amine 446273-40-1P, N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-methylphenyl)-2-ethylsulfanyl]imidazo[1,2-a]pyrazin-3-yl]-N-propylamine 446273-41-2P


, N-Cyclopropylmethyl-N-[8-(2,6-dimethoxy-4-ethylphenyl)-2-(methylsulfanyl)imidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)amine 446273-42-3P, N-[8-(2-Chloro-6-methoxy-4-methylphenyl)-2-ethyl-N-cyclopropylmethyl-N-(3-fluoropropyl)amine 446278-18-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target product; preparation of bicyclic nitrogenous fused-ring compounds such as imidazopyrazines, as corticotropin-releasing factor receptor antagonists)


RN 391954-04-1 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(2,4-dichlorophenyl)-3-(1-ethoxybutyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 446270-84-4 CAPLU:

CN Imidazo[1,2-a]pyrazine-3-carboxylic acid, 8-(2,4-dichlorophenyl)-2-ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 446270-85-5 CAPLU:

CN Carbamic acid, [8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 446270-87-7 CAPLU:

CN Imidazo[1,2-a]pyrazine-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-propyl-, methyl ester (9CI) (CA INDEX NAME)



RN 446270-88-8 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 446270-89-9 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-carboxylic acid, 6-chloro-8-(2,4-dichlorophenyl)-2-ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 446270-90-2 CAPLUS

CN Carbamic acid, [6-chloro-8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 446270-91-3 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-amine, 6-chloro-8-(2,4-dichlorophenyl)-2-ethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 446270-92-4 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-amine, 6-chloro-8-(2,4-dichlorophenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446270-93-5 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-carboxylic acid, 8-(2,4-dichlorophenyl)-2-ethyl-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 446270-94-6 ( \PLUS

CN Carbamic acid, [8-(2,4-dichlorophenyl)-2-ethyl-6-methylimidazo[1,2-a]pyrazin-3-yl]-, 1,1-dimethylethyl ester ( CI) (CA INDEX NAME)




RN 446270-95-7 ( \PLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-6-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 446270-96-8 ( \PLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-6-methyl-N,N-dipropyl-, morphohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 446270-97-9 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(2,4-dichlorophenyl)-2-methyl-1,3-nitro- (9CI)  
(CA INDEX NAME)




RN 446270-98-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-methyl- (9CI) (CA  
INDEX NAME)



RN 446270-99-1 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-methyl-N,N-  
dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 446271-00-7 CAF US

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-2-methyl- (9CI) (A INDEX NAME)



RN 446271-01-8 CAF US

CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-N,N-diethyl-8-(2,4,6-trimethylphenyl), monohydrochloride (9CI) (A INDEX NAME)




● HCl

RN 446271-02-9 CAF US

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(1-


ethylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

446271-04-1 CAPLUS

Imidazo[1,2-a]pyrazin-3-amine, N-butyl-8-(2,4-dichlorophenyl)-N,2-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

446271-06-3 CAPLUS


Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-N-(1-ethylpropyl)-8-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)





RN 446271-08-5 CAPLU:


CN Imidazo[1,2-a]pyridine-3-amine, 8-(2,4-dimethoxyphenyl)-2-ethyl-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446271-10-9 CAPLU:

CN Imidazo[1,2-a]pyridine-3-amine, 8-(2,4-dimethoxy-3-methylphenyl)-2-ethyl-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 446271-12-1 CAPLU:

CN Imidazo[1,2-a]pyridine-3-amine, 2-ethyl-N,N-dipropyl-8-(2,4,6-


trimethoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446271-14-3 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(4-methoxy-2,6-dimethylphenyl)-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446271-16-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(4-methoxy-2-methylphenyl)-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446271-18-7 CAPLUS


CN Imidazo[1,2-a]pyrazine 3-amine, 8-(2-chloro-4-methoxyphenyl)-2-ethyl-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446271-20-1 CAPLUS


CN Imidazo[1,2-a]pyrazine 3-amine, 6-chloro-8-(2-chloro-4-methoxyphenyl)-2-ethyl-N,N-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 446271-22-3 CAPLUS


CN Benzonitrile, 3-chloro-5-[6-chloro-3-(dipropylamino)-2-ethylimidazo[1,2-

lpyrazin-8-yl]- (9CI) (CA INDEX NAME)




RN 46271-24-5 CAPLUS

CN midazo[1,2-a]pyrazin-3-amine, 8-(2,6-dimethoxy-4-methylphenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 46271-30-3 CAPLUS

CN midazo[1,2-a]pyrazin-3-amine, 8-(4-chlorophenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 46271-32-5 CAPLUS

CN midazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(4-methoxyphenyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446271-34-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446271-35-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)-N-methylpropyl- (9CI) (CA INDEX NAME)




RN 446271-37-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-6-methoxy-8-(2-methoxy-4,6-dimethylphenyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 44-271-38-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,6-dimethoxy-3-pyridinyl)-N-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 44-271-39-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(6-methoxy-2-methylpyridinyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 44-271-41-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-[6-(dimethylamino)-4-methylpyridinyl]-2-methyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




N 446271-43-8 CAPLUS

N Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-N,N-dipropyl-8-(2,4,6-trimethyl-3-pyridinyl)- (9CI) (CA INDEX NAME)




N 446271-45-0 CAPLUS

N Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(3-methyl-2-pyridinyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




N 446271-47-2 CAPLUS

N Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(6-methoxy-2,4-dimethyl-3-pyridinyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446271-49-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(6-methyl-1,3-benzodioxol-5-yl)-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 446271-53-0 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(4-methoxy-2,5-dimethylphenyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 446271-55-2 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylpropyl)-N-propyl- (9CI) (CA INDEX NAME)






RN 446271-57-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 446271-59-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446271-61-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 446271 53-2 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N,N-bis(2-methylpropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● Cl


RN 446271 55-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446271 56-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-N,2-diethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 46271-68-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine N-butyl-8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 46271-70-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine 8-(2,4-dichlorophenyl)-2-ethyl-1-N-(2-methylpropyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 46271-72-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine 8-(2,4-dichlorophenyl)-2-ethyl-1-N-(2-methylpropyl)-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 446271-74-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(2-furanylmethyl)-N-(2-methylpropyl)- (9C) (CA INDEX NAME)




RN 446271-76-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-methylbutyl)-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446271-78-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylpropyl)-N-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)




RN 44-271-80-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 1-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 44-271-81-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 1-(cyclohexylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 44-271-82-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 1-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)- (9CI) (CA INDEX NAME)




RN 446271-84-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-N,2-diethyl-N-(3-fluoropropyl)- (9CI) (CA INDEX NAME)




RN 446271-85-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-butyl-8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)- (9CI) (CA INDEX NAME)




RN 446271-87-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 4462 1-88-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)-N-(2-thienylmethyl) (9CI) (CA INDEX NAME)




RN 4462 1-89-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)-N-(2-furanylmethyl) (9CI) (CA INDEX NAME)




RN 4462 1-90-5 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)-N-(3-methylbutyl) (9CI) (CA INDEX NAME)



RN 446271-91-6 APLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)-N-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)




RN 446271-92-7 APLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)-N-pentyl- (9CI) (CA INDEX NAME)




RN 446271-93-8 APLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclohexylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)- (9CI) (CA INDEX NAME)






RN 446271 94-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)-N-(4,4,4-trifluorobutyl)- (9CI) (CA INDEX NAME)




RN 446271 95-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)- (9CI) (CA INDEX NAME)




RN 446271 96-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-fluoropropyl)-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446271-97-2 CA LUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylpropyl)-N-(4,4,4-trifluorobutyl)- (9CI) (CA INDEX NAME)




RN 446271-98-3 CA LUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-methylbutyl)- (CI) (CA INDEX NAME)




RN 446271-99-4 CA LUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-N,2-diethyl-N-(3-methylbutyl)- (CI) (CA INDEX NAME)




RN 446272-0 -0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-butyl 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 446272-0 -1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-methylbutyl)-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 446272-0 -2 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N,N-bis(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 446272-03-3 CAPL 3  
 CN Imidazo[1,2-a]pyridine-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-methylbutyl)-N-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)



RN 446272-04-4 CAPL 3  
 CN Imidazo[1,2-a]pyridine-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-methylbutyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446272-05-5 CAPL 3  
 CN Imidazo[1,2-a]pyridine-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-methylbutyl)-N-(4-methyl-1,4-trifluorobutyl)- (9CI) (CA INDEX NAME)



Et

 $\text{V}-\text{CH}_2-\text{CH}_2-\text{CHMe}_2$ 
 $(\text{CH}_2)_3-\text{CF}_3$ 


RN 446272-06- CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



Et

 $\text{N}-\text{CH}_2-\text{CH}_2-\text{CHMe}_2$ 

RN 446272-07- CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(3-methylbutyl)-N-propyl- (9CI) (CA INDEX NAME)




Et

 $\text{V}-\text{CH}_2-\text{CH}_2-\text{CHMe}_2$ 


n-Pr

RN 446272-08- CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(4-chloro-2-methoxyphenyl)-2-ethyl-N-(3-methylbutyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446272-09-9 CAPLUS

CN Imidazo[1,2-a]pyrazine 1,3-dipropyl-2-ethyl-8-(4-bromo-2-chlorophenyl)- (9CI) (C INDEX NAME)




RN 446272-10-2 CAPLUS

CN Imidazo[1,2-a]pyrazine 1,3-dipropyl-2-ethyl-8-(2,4-dibromophenyl)- (9CI) (CA INDEX NAME)




RN 446272-11-3 CAPLUS

CN Imidazo[1,2-a]pyrazine 1,3-dipropyl-2-ethyl-8-(4-bromo-2-fluorophenyl)- (9CI) (C INDEX NAME)




RN 446272-12-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-bromo-4-fluorophenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446272-13-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(1-methylpropyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446272-14-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(1-methylpropyl) (9CI) (CA INDEX NAME)




RN 446272-15-7 CAPLUS

CN Imidazo[1,2-a]pyrazine derivative, N-butyl-8-(2,4-dichlorophenyl)-2-ethyl-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 446272-16-8 CAPLUS


CN Imidazo[1,2-a]pyrazine derivative, 8-(2,4-dichlorophenyl)-2-ethyl-N-(1-methylpropyl)-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 446272-17-9 CAPLUS




CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-[(tetrahydro-3-thienyl)methyl]- (9CI) (CA INDEX NAME)




RN 446272-18-0 C/ LUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-propyl-N-[(tetrahydro-3-thienyl)methyl]- (9CI) (CA INDEX NAME)




RN 446272-19-1 C/ LUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,6-dimethoxy-4-methylphenyl)-2-ethyl-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-20-4 C/ LUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4-methoxyphenyl)-2-ethyl-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-21-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-8-(2-methoxy-4,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-22-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 2-ethyl-N,N-bis(2-methylpropyl)-8-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 446272-23-7 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-butyl-8-(2-chloro-4-methoxyphenyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-24-8 CAPL S  
 CN Imidazo[1,2-a]pyridin-3-amine, N-butyl-2-ethyl 8-(2-methylpropyl)-8-(2,4,6-trimethylphenyl) (9CI) (CA INDEX NAME)



RN 446272-25-9 CAPL S  
 CN Imidazo[1,2-a]pyridin-3-amine, N-butyl-8-(2,6-dimethoxy-4-methylphenyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-26-0 CAPL S  
 CN Imidazo[1,2-a]pyridin-3-amine, N-butyl-2-ethyl 8-(2-methoxy-4,6-dimethylphenyl)-8-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-27-1 CAPLUS

CM Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-28-2 CAPLUS

CM Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,6-dimethoxy-4-methylphenyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-29-3 CAPLUS

CM Imidazo[1,2-a]pyrazin-3-amine, 6-bromo-8-(4-chlorophenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446272-30-6 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-amine, 6-bromo-8-(2,4-dichlorophenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446272-31-7 CAPLUS

CN Imidazo[1,2-a]pyrazine-6-carbonitrile, 8-(2,4-dichlorophenyl)-3-(dipropylamino)-2-ethyl- (9CI) (CA INDEX NAME)




RN 446272-32-8 CAPLUS


CN Imidazo[1,2-a]pyrazine-3-amine, 6-bromo-8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylpropyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446272-33-9 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-(methylethyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 446272-34-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-methoxy-4,6-dimethylphenyl)-2-(1-methylethyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446272-35-1 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 3-(1-methoxybutyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 446272-36-2 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(2,4-dimethoxy-6-methylphenyl)-3-(1-ethoxybutyl)-2-ethyl- (9CI) (CA 1 DEX NAME)




RN 446272-37-3 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(2,6-dimethoxy-4-methylphenyl)-3-(1-ethoxybutyl)-2-ethyl- (9CI) (CA 1 DEX NAME)




RN 446272-38-4 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(2-chloro-4-methoxyphenyl)-3-(1-ethoxybutyl)-2-ethyl- (9CI) (CA 1 DEX NAME)



RN 4 6272-39-5 CAPLUS


CN Imidazo[1,2-a]pyrazine-3-methanol, 2-ethyl-8-(2-methoxy-4-chlorophenyl)- $\alpha,\alpha$ -dipropyl- (9CI) (CA INDEX NAME)



RN 4 6272-40-8 CAPLUS

CN Imidazo[1,2-a]pyrazine, 2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)-3-[(1Z)-1-propenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 4 6272-41-9 CAPLUS




CN Imidazo[1,2-a]pyrazine, 2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)-3-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 446272-42-0 CAPLUS


CN Imidazo[1,2-a]pyrazine, 2-ethyl-3-[(1Z)-1-ethyl-1-propenyl]-8-(2-methoxy-4,6-dimethylphenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 446272-43-1 CAPLUS


CN Imidazo[1,2-a]pyrazine, 2-ethyl-3-(1-ethylpropyl)-8-(2-methoxy-4,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 446272-44-2 CAPLUS


CN Imidazo[1,2-a]pyrazine, 3-(2,4-dimethoxyphenyl)-2-ethyl-1-(1-ethylpropyl)-

(9C ) (CA INDEX NAME)




RN 446 72-52-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8 (2,4-dichlorophenyl)-2-(methythio)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 446 72-53-3 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8 (2,4-dichlorophenyl)-N-(2-methylpropyl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 446 72-54-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8 (2,4-dichloro-6-methylphenyl)-2-ethyl-N,N-diethyl- (9CI) (CA INDEX NAME)




R 446272-55-5 CAPLUS

C Imidazo[1,2-a]pyrazin-3-amine, 8-[2-chloro-4-(trifluoroethyl)phenyl]-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




R 446272-56-6 CAPLUS

C Imidazo[1,2-a]pyrazin-3-amine, 8-[2-bromo-4-(1-methylethyl)phenyl]-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




R 446272-57-7 CAPLUS

C Imidazo[1,2-a]pyrazin-3-amine, 8-(2-bromo-6-methoxy-4-nonylphenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 44627 -58-8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(4-bromo-6-methylphenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 44627 -59-9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(4-methylphenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 44627 -60-2 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(4-chloro-6-methylphenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446272-61-3 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-6-methoxy-4-methylphenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 446272-62-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-bromo-4-methylphenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446272-63-5 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4,6-dimethylphenyl)-2-ethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 446272 4-6 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methoxyethyl)-, monohydrochloride (9C) (CA INDEX NAME)



• HCl


RN 446272 5-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 446272 6-8 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methoxyethyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 46272-67-9 CAPLUS  
 CN midazo[1,2-a]pyrazin-3-amine N-butyl-8-(2,4-dichlorophenyl)-2-ethyl-N-(2-ethoxyethyl)- (9CI) (CA INDEX NAME)



RN 46272-68-0 CAPLUS  
 CN midazo[1,2-a]pyrazin-3-amine 8-(2,4-dichlorophenyl)-2-ethyl-N-(2-ethoxyethyl)-N-pentyl- (9CI) (CA INDEX NAME)




RN 46272-69-1 CAPLUS  
 CN midazo[1,2-a]pyrazin-3-amine 8-(2,4-dichlorophenyl)-2-ethyl-N-(2-ethoxyethyl)-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-70 4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)



RN 446272-71 5 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylbutyl)-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 446272-72 5 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclobutylmethyl)-N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl- (9CI) (CA INDEX NAME)






RN 446272-73-7 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 1-(cyclobutylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 446272-74-8 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 1-(cyclobutylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-75-9 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(4-fluorobutyl)-N-propyl- (9CI) (CA INDEX NAME)



RN 446272-76-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl-N-(4-fluorobutyl)- (9CI) (CA INDEX NAME)




RN 446272-77-1 CAPLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-N-(4-fluorobutyl)-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 4462 2-78-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl- (9CI) (C INDEX NAME)



RN 4462 2-79-3 CAPLUS


CN Butamide, N-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]-N-(3-fluoropropyl)- (9CI) (CA INDEX NAME)



RN 4462 2-80-6 CAPLUS


CN Propionitrile, 3-[[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-

yl]propylamin - (9CI) (CA INDEX NAME)




RN 446272-81-7 \PLUS

CN Propanenitril, 3-[(cyclopropylmethyl)(8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl)amino] - (9CI) (CA INDEX NAME)




RN 446272-82-8 \PLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-butyl-N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 446272-83-9 \PLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-butyl-N-(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 446272 84-0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-butyl-8-(2-chloro-6-methoxy-4-methylphenyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272 85-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-6-methoxy-4-methylphenyl)-N,N-bis(cyclopropylmethyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 446272 86-2 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-(2,6-dimethoxy-4-methylphenyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 446272-87-3 CAF US

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4-methoxyphenyl)-N,N-bis(cyclopropylmethyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 446272-88-4 CAF US

CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-2-ethyl-8-(2-methoxy-4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 446272-89 5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-6-methoxy-4-methylphenyl)-N-(cyclopropylmethyl)-2-ethyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)




RN 446272-90 8 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-8-(2,6-dimethoxy-4-methylphenyl)-2-ethyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)




RN 446272-91 9 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-2-ethyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)




RN 446272-92 0 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)




RN 446272-93-1 CAPLU

CN Imidazo[1,2-a]pyridine-3-amine, 8-(2-chloro-6-methoxy-4-methylphenyl)-N-(cyclopropylmethyl)-2-ethyl-N-propyl- (9CI) (CA INDEX NAME)



RN 446272-94-2 CAPLU


CN Imidazo[1,2-a]pyridine-3-amine, N-(cyclopropylmethyl)-8-(2,6-dimethoxy-4-methylphenyl)-2-ethyl-N-propyl- (9CI) (CA INDEX NAME)



RN 446272-95-3 CAPLU


CN Imidazo[1,2-a]pyridine-3-amine, 8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-2-ethyl-N-propyl- (9CI) (CA INDEX NAME)






RN 446272-96-4 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, N-(cyclopropylmethyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446272-97-5 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-6-methoxy-4-methylphenyl)-N-ethyl-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-98-6 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-chloro-6-methoxy-4-methylphenyl)-N-(cyclopropylmethyl)-2-ethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446272-99-7 CAPLUS

CN Imidazo[1,2-a]pyrazine 3-amine, 8-(2-chloro-4-methoxyphenyl)-2-ethyl-N-(3-fluoropropyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446273-00-3 CAPLUS

CN Imidazo[1,2-a]pyrazine 3-amine, 8-(2-chloro-6-methoxy-4-methylphenyl)-2-ethyl-N-(3-fluoropropyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446273-01-4 CAPLUS

CN Imidazo[1,2-a]pyrazine 3-amine, N,N-bis(cyclopropylmethyl)-8-(2,4-dibromophenyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 446273-02-5 (APLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-bromo-4-methoxy-4-methylphenyl)-N,N-bis(cyclopropylmethyl)-2-ethyl- (9CI) (CA INDEX NAME)



RN 446273-03-6 (APLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 8-(2-bromo-4-methoxyphenyl)-N,N-bis(cyclopropylmethyl)-2-ethyl- (9CI) (CA INDEX NAME)



RN 446273-04-7 (APLUS


CN Imidazo[1,2-a]pyrazin-3-amine, N,N-bis(cyclopropylmethyl)-8-(2,4-dichlorophenyl)-

6-methoxyphenyl)-2-ethyl-1- (9CI) (CA INDEX NAME)




RN 446273-05-8 CAPLUS

CN Imidazo[1,2-a]pyrazine-4-amine, 8-(2-bromo-4,6-dimethylphenyl)-N-(cyclopropylmethyl)-2-ethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 446273-06-9 CAPLUS

CN Imidazo[1,2-a]pyrazine-4-amine, 8-(2,4-dibromophenyl)-2-ethyl-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 446273-07-0 CAPLUS

CN Imidazo[1,2-a]pyrazine-4-amine, 8-[5-chloro-4-(2,5-diethyl-1H-pyrrol-1-yl)-2-methoxyphenyl]-N,N-bis(cyclopropylmethyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 446273-08-1 CAI US

CN Imidazo[1,2-a]pyrazin-3-amine, 8-(4-amino-5-chloro-2-methoxyphenyl)-N,N-bis(cyclopropylmethyl)-2-ethyl- (9CI) (CA IN EX NAME)




RN 446273-09-2 CAI US

CN Imidazo[1,2-a]pyrazin-3-amine, 8-[2-chloro-4-(trifluoromethoxy)phenyl]-N,N-bis(cyclopropylmethyl)-2-ethyl- (9CI) (CA IN EX NAME)




N 446273-10-5 CAPLUS

N Imidazo[1,2-a]pyrazin-3-ine, 8-[2-chloro-4-(trifluoromethyl)phenyl]-N,N-bis(cyclopropylmethyl)-2-ethyl- (9CI) (CA INDEX NAME)




N 446273-11-6 CAPLUS

N Imidazo[1,2-a]pyrazin-3-ine, 8-(2,4-dichlorophenyl)-N,N-dipropyl-2-ethyl-6-methoxy- (9CI) (CA INDEX NAME)




N 446273-12-7 CAPLUS

N Imidazo[1,2-a]pyrazin-3-ine, 6-chloro-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446273-13-8 CAPLUS

CN Imidazo[1,2-a]pyridine-3-amine, 6-chloro-N,N-bis(cyclopropylmethyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 446273-14-9 CAPLUS

CN Imidazo[1,2-a]pyridine-3-amine, 6-chloro-N-(cyclopropylmethyl)-2-ethyl-8-(2-methoxy-4,6-dimethylphenyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 446273-15-0 CAPLUS

CN Imidazo[1,2-a]pyridine-3-amine, 6-chloro-N-(cyclopropylmethyl)-2-ethyl-N-(3-fluoropropyl)-8-(2-methoxy-4,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 446273-16-1 CAPLUS

CN Imidazo[1,2-a]pyrazin-3-amine, 6-chloro-8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-2-ethyl-N-(3-fluoropropyl)- (9CI) (CA INDEX NAME)



RN 446273-17-2 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 6-chloro-8-(2-chloro-4-methoxyphenyl)-2-ethyl-N-(3-fluoropropyl)-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)



RN 446273-18-3 CAPLUS


CN Imidazo[1,2-a]pyrazin-3-amine, 6-chloro-8-(2-chloro-4-methoxyphenyl)-2-ethyl-N-(1-ethylpropyl)-N-(3-fluoropropyl)- (9CI) (CA INDEX NAME)






RN 446273-19-4 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-amine, 8-(2-chloro-4-methoxyphenyl)-2-(methylthio)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446273-20-7 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-amine, 8-(2-methoxy-4,6-dimethylphenyl)-2-(methylthio)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 446273-21-8 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-amine, 8-(2-methoxy-4,6-dimethylphenyl)-N-(2-methylpropyl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 146273-22-9 CAPLUS

CN 8-(2-chloro-4-methoxyphenyl)-2-(methylthio)-N,N-dipropyl-1H-imidazo[1,2-a]pyrazin-3-amine (9CI) (CA INDEX NAME)




RN 146273-23-0 CAPLUS

CN 8-(2,6-dimethoxy-4-methylphenyl)-2-(methylthio)-N,N-dipropyl-1H-imidazo[1,2-a]pyrazin-3-amine (9CI) (CA INDEX NAME)




RN 146273-24-1 CAPLUS

CN 8-(2,4-dimethoxyphenyl)-2-(methylthio)-N,N-dipropyl-1H-imidazo[1,2-a]pyrazin-3-amine (9CI) (CA INDEX NAME)




RN 446273-25-2 CAPLUS

CN Imidazo[1,2-a]pyrazine-4-amine, 8-(2,4-dimethoxy-6-methylphenyl)-2-(methylthio)-N,N-diisopropyl- (9CI) (CA INDEX NAME)



RN 446273-27-4 CAPLUS


CN Imidazo[1,2-a]pyrazine-4-amine, N,N-bis(cyclopropylmethyl)-8-(2-methoxy-4,6-dimethylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 446273-29-6 CAPLUS

CN Imidazo[1,2-a]pyrazine-4-amine, 8-(2-chloro-4-methoxyphenyl)-N,N-bis(cyclopropylmethyl)-2-(methylthio)- (9CI) (CA INDEX NAME)


4e



RN 4 273-31-0 CAPLUS

CN 1 1-diazo[1,2-a]pyrazin-3-amine, 1-(cyclopropylmethyl)-8-(2-methoxy-4,6-dimethylphenyl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)


;



RN 4 273-33-2 CAPLUS


CN 1 1-diazo[1,2-a]pyrazin-3-amine, 1-(2-chloro-4-methoxyphenyl)-1-(cyclopropylmethyl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)

4e




RN 4 273-35-4 CAPLUS


CN 1 1-diazo[1,2-a]pyrazin-3-amine, 1-(cyclopropylmethyl)-N-(3-fluoropropyl)-8-(2-methoxy-4,6-dimethylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




446273-37-6 CAPLUS  
 Imidazo[1,2-a]pyrazin-3-ine, 8-(2-chloro-4-methoxyphenyl)-N-(cyclopropylmethyl)-N-(3-fluoropropyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




446273-39-8 CAPLUS  
 Imidazo[1,2-a]pyrazin-3-ine, N,N-bis(cyclopropylmethyl)-8-(2,6-dimethoxy-4-methylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




446273-40-1 CAPLUS  
 Imidazo[1,2-a]pyrazin-3-ine, N-(cyclopropylmethyl)-8-(2,6-dimethoxy-4-methylphenyl)-2-(methylthio)-N-propyl- (9CI) (CA INDEX NAME)




RN 446 3-41-2 CAPLUS  
 CN Imi zo[1,2-a]pyrazin-3-amine, N- cyclopropylmethyl)-8-(2,6-di methoxy-4-  
 met lphenyl)-N-(3-fluoropropyl)-2-(methylthio)- (9CI) (CA IN: X NAME)



RN 446 3-42-3 CAPLUS  
 CN Imi zo[1,2-a]pyrazin-3-amine, 8- 2-chloro-6-methoxy-4-methylp nyl)-N-  
 (cy opropylmethyl)-N-(3-fluoropr oyl)-2-(methylthio)- (9CI) A INDEX  
 NAM.



RN 446 8-18-8 CAPLUS  
 CN Imi zo[1,2-a]pyrazin-3-amine, 8- 2-bromo-4,6-dimethylphenyl)-N-  
 bis cyclopropylmethyl)-2-ethyl- (CI) (CA INDEX NAME)



REFERENCE COUNT: 34 HERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

ANSWER 17 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

SESSION NUMBER: 2002:54712 CAPLUS

DOCUMENT NUMBER: 137:15267

TITLE: Method using pyrazine compounds and pyridine compounds for inhibiting JAK kinases compound preparation, and therapeutic use

INVENTOR(S): Burns, Christopher John; Wilks, Andrew Frederick

PATENT ASSIGNEE(S): Cytosol Pty. Ltd., Australia

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060492	A1	20020808	WO 2002-AU89	20020130
W:	AE, AG, AL, AM, AT	AU, AZ, BA, BB, BG, BR, BY, Z, CA, CH, CN,		
	CO, CR, CU, CZ, DE	DK, DM, DZ, EC, EE, ES, FI, B, GD, GE, GH,		
	GM, HR, HU, ID, IL	IN, IS, JP, KE, KG, KP, KR, Z, LC, LK, LR,		
	LS, LT, LU, LV, MA	MD, MG, MK, MN, MW, MX, MZ, O, NZ, OM, PH,		
	PL, PT, RO, RU, SD	SE, SG, SI, SK, SL, TJ, TM, N, TR, TT, TZ,		
	UA, UG, US, UZ, VN	YU, ZA, ZM, ZW		
RW:	GH, GM, KE, LS, MW	MZ, SD, SL, SZ, TZ, UG, ZM, W, AT, BE, CH,		
	CY, DE, DK, ES, FI	FR, GB, GR, IE, IT, LU, MC, L, PT, SE, TR,		
	BF, BJ, CF, CG, CI	CM, GA, GN, GQ, GW, ML, MR, E, SN, TD, TG		
CA 2436487	AA	20020808	CA 2002-2436487	20020130
EP 1363702	A1	20031126	EP 2002-715984	20020130
R:	AT, BE, CH, DE, DK	ES, FR, GB, GR, IT, LI, LU, L, SE, MC, PT,		
	IE, SI, LT, LV, FI	RO, MK, CY, AL, TR		
JP 2004528295	T2	20040916	JP 2002-560683	20020130
US 2004102455	A1	20040527	US 2003-470955	20030730
US 2006069084	A1	20060330	US 2005-223633	20050909
PRIORITY APPLN. INFO.:			AU 2001-2792	A 20010130
			AU 2001-2793	A 20010130
			WO 2002-AU89	W 20020130
			US 2003-470955	A3 20030730

OTHER SOURCE(S): MARPAT 137:150267

AB The invention provides methods of inhibiting JAK kinases involving the use of a group of compounds based either on a 2-amino-6-carba-disubstituted pyrazole scaffold or a 2-amino-6-carba-disubstituted pyridine scaffold. The invention also provides methods of treating JAK-associated disease

IC ICM : 1K031-435  
ICS : 1K031-443; A61K031-4436; A61K031-4439; A61K031-444; A61K031-496;  
: 1K031-497; A61K031-4985; A61K031-5377; A61K031-551; A61P031-12;  
: 1P011-02; A61P017-00; A61P017-00; A61P031-12; A61P035-00;  
: 1P035-02

CC 1-12 (pharmacology)  
Section cross-reference(s): 28

IT Allergic inhibitors

Alzheimer's disease

Anti-Alzheimer's agents

Antiallergics

Antihistamines

Antidiabetic agents

Antirheumatic agents

Antitumor agents

Antiviral agents

Autoimmune disease

Eczema

Hepatitis B virus

Hepatitis C virus

Human

Human immunodeficiency virus 1

Human herpesvirus 3

Human herpesvirus 4

Human immunodeficiency virus

Human papillomavirus

Rheumatic diseases

Rheumatoid arthritis

Sjogren's syndrome

(pyrazine compounds and pyridine compounds for inhibiting JAK kinases, compound preparation, and therapeutic use)

IT 445263-27-4 445263-28-5 445263-29-6 445263-30-9 445263-31-0  
445263-32-1 445263-33-2 445263-34-3 445263-35-4 445263-36-5  
445263-37-6 445263-38-7 445263-39-8 445263-40-1 445263-41-2  
445263-42-3 445263-43-4 445263-44-5 445263-45-6 445263-46-7  
445263-47-8 445263-48-9 445263-49-0 445263-50-3 445263-51-4  
445263-52-5 445263-54-7 445263-55-8 445263-56-9 445263-57-0  
445263-58-1 445263-59-2 445263-60-5 445263-61-6 445263-62-7  
445263-63-8 445263-64-9 445263-65-0 445263-66-1 445263-67-2  
445263-68-3 445263-69-4 445263-70-5 445263-71-8  
445263-72-9 445263-73-0 445263-74-1 445263-75-2 445263-76-3  
445263-77-4 445263-78-5 445263-79-6 445263-80-9 445263-81-0  
445263-82-1 445263-83-2 445263-84-3 445263-85-4 445263-86-5  
445263-87-6 445263-88-7 445263-89-8 445263-90-1 445263-91-2  
445263-92-3 445263-93-4 445263-94-5 445263-95-6  
445263-96-7 445263-97-8 445263-98-9 445263-99-0 445264-00-6  
445264-01-7 445264-02-8 445264-03-9 445264-04-0 445264-05-1  
445264-06-2 445264-07-3 445264-08-4 445264-09-5  
445264-10-8 445264-11-9 445264-12-0 445264-13-1  
445264-14-2 445264-15-3 445264-16-4 445264-17-5 445264-18-6  
445264-19-7 445264-20-0 445264-21-1 445264-22-2  
445264-23-3 445264-24-4 445264-25-5 445264-26-6 445264-27-7  
445264-28-8 445264-29-9 445264-30-2 445264-31-3 445264-32-4  
445264-33-5 445264-34-6 445264-35-7 445264-36-8 445264-37-9  
445264-38-0 445264-39-1 445264-40-4 445264-41-5 445264-42-6



445264-43-7 445264-44-8 445264-45-9 445264-46-0 445264-47-1  
445264-48-2 445264-49-3 445264-50-6 445264-51-7 445264-52-8  
445264-53-9 445264-54-0 445264-55-1 445264-56-2 445264-57-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(pyrazine compds. and pyrazine compds. for inhibiting C K kinases,  
compound preparation, and therapeutic use)


IT 445263-67-2 445263-70-7 445263-86-5  
445263-93-4 445264-07-3 445264-11-9  
445264-20-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(pyrazine compds. and pyrazine compds. for inhibiting C K kinases,  
compound preparation, and therapeutic use)


RN 445263-67-2 CAPLUS

CN Phenol, 4-[8-(4-morpholinyl)imidazo[1,2-a]pyrazin-6-yl]- (9CI) (CA INDEX  
NAME)




RN 445263-70-7 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(8-methoxy-4-methyl-1H-1,4-diazepin-1-yl)-6-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 445263-86-5 CAPLUS


CN Imidazo[1,2-a]pyrazine, 8-(8-methoxy-4-methyl-1H-1,4-diazepin-1-yl)-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 445263-9 -4 CAPLUS  
 CN Phenol, -[8-(4-morpholinyl)imidazo[1,2-a]pyrazin-6-yl]- (9CI) (CA INDEX NAME)




RN 445264-0 -3 CAPLUS  
 CN Benzoic acid, 4-[8-[4-(2-pyridinyl)-1-piperazinyl]imidazo[1,2-a]pyrazin-6-yl]- (9CI) (CA INDEX NAME)



RN 445264-1 -9 CAPLUS  
 CN Benzoic acid, 4-[8-[4-(4-(2-pyridinyl)-1-piperazinyl)imidazo[1,2-a]pyrazin-6-yl]-1-naphthol (9CI) (CA INDEX NAME)



RN 4 5264-20-0 CAPLUS

CN 2 idazo[1,2-a]pyrazine, 8-(4-methyl-1-piperazinyl)-6-(3-pyridinyl)- (9CI)  
(A INDEX NAME)REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L57 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:293441 CAPLUS

DOCUMENT NUMBER: 136:319426

TITLE: Imidazo[1,2-a]pyridine-, imidazo[1,2-a]pyrimidine and  
imidazo[1,2-a]pyrazine-3-yl-amine derivatives for  
nitric oxide synthase-inhibiting pharmaceuticalsINVENTOR(S): Sundermann, Bernd; Maul, Corinna; Hennig, J  
Hagen-Heinrich; Schneider, Johannes

PATENT ASSIGNEE(S): Gruenenthal GmbH, Germany

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXD02

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
W 2002030428	A1	20020418	WO 2001-EP11701	20011010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,				
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				

LT LU, LV, MA, MD, MG, MK, MN, W, MX, MZ, NO, NZ, PH, PL, F  
 RC RU, SD, SE, SG, SI, SK, SL, J, TM, TR, TT, TZ, UA, UG, U  
 UZ VN, YU, ZA, ZW, AM, AZ, BY, G, KZ, MD, RU, TJ, TM  
 RW: GH GM, KE, LS, MW, MZ, SD, SL, Z, TZ, UG, ZW, AT, BE, CH, C  
 DE DK, ES, FI, FR, GB, GR, IE, T, LU, MC, NL, PT, SE, TR, E  
 BJ CF, CG, CI, CM, GA, GN, GQ, W, ML, MR, NE, SN, TD, TG  
 DE 1005066 A1 20020418 2000-10050663 2000101  
 AU 2001091 B3 A5 20020422 2001-91893 2001101  
 CA 2425672 AA 20030411 2001-2425672 2001101  
 EP 1326613 A1 20030716 2001-972099 2001101  
 EP 1326613 B1 20040602  
 R: AT BE, CH, DE, DK, ES, FR, GB, R, IT, LI, LU, NL, SE, MC, P  
 IE SI, LT, LV, FI, RO, MK, CY, L, TR  
 JP 2004510 B0 T2 20040408 2002-533869 2001101  
 AT 268179 E 20040615 2001-972099 2001101  
 PT 1326613 T 20041029 2001-972099 2001101  
 ES 2220810 T3 20041216 2001-1972099 2001101  
 NZ 525779 A 20050128 2001-525779 2001101  
 US 2004023 B2 A1 20040205 2003-411402 2003041  
 PRIORITY APPLN. INFO.: 2000-10050663 A 2000101  
 2001-EP11701 W 2001101  
 OTHER SOURCE(S) MARPAT 136:319426  
 AB The title compds. are used for producing pharmaceuticals for inhibiting NO  
 synthase, or treating migraine and for treating septicemic shock,  
 multiple sclerosis, Parkinson's disease, Alzheimer's disease,  
 Huntington's chorea, inflammation, inflammatory pains, cerebral ischemia,  
 diabetes, meningitis, arteriosclerosis, and/or for wound healing. Thus  
 (5,7-dimethyl-2-(1,2-thiophen-3-yl-imidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-  
 tetramethylbutyl)amine-HCl showed 74% inhibition in the NO synthase assay.  
 Further, 1-(5,7-dimethyl-2-p-tolylimidazo[1,2-a]pyridin-3-yl)-(1,1,3,3-  
 tetramethylbutyl)amine-HCl was dissolved in 1-L water for use in injection  
 solns.  
 IC ICM A61K01-4985  
 ICS A61K01-519  
 CC 1-12 (Pharmacology)  
 Section cross-reference(s): 28, 63  
 IT Anti-Alzheimer's agents  
 Anti-inflammatory agents  
 Antiarteriosclerotics  
 Antidiabetic agents  
 Antimigraine agents  
 Antiparkinsonian agents  
 Meningitis  
 Multiple sclerosis  
 Wound healing  
 (imidazopyridine- and imidazopyrimidine and imidazopyrazineamine  
 derivs. for nitric oxide synthase-inhibiting pharmaceuticals)  
 IT 334899-24-P 334899-25-1P 334899-27-P 334899-29-5P 334899-30-3P  
 334905-14-P 334974-67-3P 334974-68-P 334974-69-5P 334974-70-3P  
 334974-71-P 334974-72-0P 334974-73-P 334974-74-2P 334974-75-3P  
 334974-76-P 334974-77-5P 334974-78-P 334974-79-7P 334974-80-0P  
 334974-81-P 334974-82-2P 334974-83-P 334974-87-7P 334974-91-3P  
 334975-02-P 412358-86-2P 412358-87-P 412358-88-4P 412358-89-3P  
 412358-90-P 412358-91-9P 412358-92-P 412358-93-1P 412358-94-2P  
 412358-95-P 412358-96-4P 412358-97-P 412358-98-6P 412358-99-7P  
 412359-00-P 412359-01-4P 412359-02-P 412359-03-6P 412359-04-7P  
 412359-05-P 412359-06-9P 412359-07-P 412359-08-1P 412359-09-2P  
 412359-10-P 412359-11-6P 412359-12-P 412359-13-8P 412359-14-9P  
 412359-15-P 412359-16-1P 412359-17-P 412359-18-3P 412359-19-4P  
 412359-20-P 412359-21-8P 412359-22-P 412359-23-0P 412359-24-1P

412 59-25-2P	412359-26-3P	412 59-27-4P	412359-28-5P	41 359-29-6P
412 59-30-9P	412359-31-0P	412 59-32-1P	412359-33-2P	41 359-34-3P
412 59-35-4P	412359-36-5P	412 59-37-6P	412359-38-7P	41 359-39-8P
412 59-40-1P	412359-41-2P	412 59-42-3P	412359-43-4P	41 359-44-5P
412 59-45-6P	412359-46-7P	412 59-47-8P	412359-48-9P	41 359-49-0P
412 59-50-3P	412359-51-4P	412 59-52-5P	412359-53-6P	41 359-54-7P
412 59-55-8P	412359-56-9P	412 59-57-0P	412359-58-1P	41 359-59-2P
412 59-60-5P	412359-61-6P	412 59-62-7P	412359-63-8P	41 359-64-9P
412 59-65-0P	412359-66-1P	412 59-67-2P	412359-68-3P	41 359-69-4P
412 59-70-7P	412359-71-8P	412 59-72-9P	412359-73-0P	41 359-74-1P
412 59-75-2P	<b>412359-76-3P</b>	412359-77-4P	412359-78-5P	
412 59-79-6P	412359-80-9P	412 59-81-0P	<b>412359-82-1P</b>	
412 59-83-2P	412359-84-3P	412 59-85-4P	412359-86-5P	41 359-87-6P
412 59-88-7P	412359-89-8P	412 59-90-1P	412359-91-2P	41 359-92-3P
412 59-93-4P	412359-94-5P	412 59-95-6P	412359-96-7P	41 359-97-8P
<b>412 59-98-9P</b>	412359-99-0P	412 60-00-0P	412360-01-1P	
412 60-02-2P	412360-03-3P	412 60-04-4P	412360-05-5P	41 360-06-6P
412 60-07-7P	412360-08-8P	412 60-09-9P	412360-10-2P	41 360-11-3P
412 60-12-4P	412360-13-5P	412 60-14-6P	<b>412360-15-7P</b>	
412 60-16-8P	412360-17-9P	412 60-18-0P	412360-19-1P	41 360-20-4P
412 60-21-5P	412360-22-6P	412 60-23-7P	412360-24-8P	41 360-25-9P
412 60-26-0P	412360-27-1P	412 60-28-2P	412360-29-3P	41 360-30-6P
412 60-31-7P	412360-32-8P	412 60-33-9P	412360-34-0P	41 360-35-1P
412 60-36-2P	412360-37-3P	412 60-38-4P	412360-39-5P	41 360-40-8P
412 60-41-9P	412360-42-0P	412 60-43-1P	412360-44-2P	41 360-45-3P
412 60-46-4P	412360-47-5P	412 60-48-6P	412360-49-7P	41 360-50-0P
412 60-51-1P	412360-52-2P	412 60-53-3P	412360-54-4P	41 360-55-5P
412 60-56-6P	412360-57-7P	412 60-58-8P	412360-59-9P	41 360-60-2P
412 60-61-3P	412360-62-4P	412 60-63-5P	412360-64-6P	41 360-65-7P
412 60-66-8P	<b>412360-67-9P</b>	412360-68-0P	412360-69-1P	
412 60-70-4P	412360-71-5P	412 60-72-6P	412360-73-7P	41 360-74-8P
412 60-75-9P	412360-76-0P	412 60-77-1P	412360-78-2P	41 360-79-3P
412 60-80-6P	412360-81-7P	412 60-82-8P	412360-83-9P	41 360-84-0P
412 60-85-1P	412360-86-2P	412 60-87-3P	412360-88-4P	41 360-89-5P
412 60-90-8P	412360-91-9P	412 60-92-0P	412360-93-1P	


RL: PAC (Pharmacological activity ; SPN (Synthetic preparation ; THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation) USES  
(Uses)

imidazopyridine- and imidazopyrimidine and imidazopyrazine nine  
derivs. for nitric oxide synthase-inhibiting pharmaceuticals


IT	412 60-94-2P	<b>412360-95-3P</b>	412360-96-4P	<b>412360-97-5P</b>	
	412 60-98-6P	412360-99-7P	412 61-00-3P	412361-01-4P	41 361-02-5P
	412 61-03-6P	412361-04-7P	412 61-05-8P	412361-06-9P	41 361-07-0P
	412 61-08-1P	412361-09-2P	412 61-10-5P	412361-11-6P	41 361-12-7P
	412 61-13-8P	412361-14-9P	412 61-15-0P	412361-16-1P	41 361-17-2P
	412 61-18-3P	412361-19-4P	412 61-20-7P	412361-21-8P	41 361-22-9P
	412 61-23-0P	412361-24-1P	412 61-25-2P	412361-26-3P	41 361-27-4P
	412 61-28-5P	412361-29-6P	412 61-30-9P	412361-31-0P	41 361-32-1P
	412 61-33-2P	412361-34-3P	412 61-35-4P	412361-36-5P	41 361-37-6P
	<b>412 61-38-7P</b>	412361-39-8P	412 61-40-1P	412361-41-2P	
	412 61-42-3P	412361-43-4P	412 61-44-5P	<b>412361-45-6P</b>	
	412 61-46-7P	412361-47-8P	412 61-48-9P	412361-49-0P	41 361-50-3P
	412 61-51-4P	412361-52-5P	412 61-53-6P	412361-54-7P	41 361-55-8P
	412 61-56-9P	412361-57-0P	412 61-58-1P	412361-59-2P	
	<b>412 61-60-5P</b>	412361-61-6P	412 61-62-7P	412361-63-8P	
	412 61-64-9P	412361-65-0P	412 61-66-1P	412361-67-2P	41 361-68-3P
	412 61-69-4P	412361-70-7P	412 61-71-8P	412361-72-9P	41 361-73-0P
	412 61-74-1P	412361-75-2P	412 61-76-3P	412361-77-4P	41 361-78-5P
	412 61-79-6P	412361-80-9P	412 61-81-0P	412361-82-1P	41 361-83-2P

RL: PAC (Pharmacological activity ; SPN (Synthetic preparation ; THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (imidazopyridine- and imidazopyrimidine- and imidazopyrazineamine  
 derivs. f nitric oxide synthase-inhibiting pharmaceuticals)  
 IT 412359-76-3P 412359-82-1P 412359-98-9P  
 412360-15-7P 412360-67-9P 412360-95-3P  
 412360-97-5P 412361-38-7P 412361-45-6P  
 412361-60-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (imidazopyridine- and imidazopyrimidine- and imidazopyrazineamine  
 derivs. f nitric oxide synthase-inhibiting pharmaceuticals)  
 RN 412359-76-3 APLUS  
 CN 2-Thiophenecarboxylic acid, 5-[3-(butylamino)imidazo[1,2-a]pyrazin-2-yl]  
 (9CI) (CA INDEX NAME)




RN 412359-82-1 APLUS  
 CN 2-Thiophenecarboxylic acid, 5-[3-[(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]- (9CI) (CA INDEX NAME)



RN 412359-98-9 APLUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-butyl-2-[(dimethylamino)-1-naphthalenyl] (9CI) (CA INDEX NAME)




RN 412360-15-7 APLUS  
 CN 2-Thiophenecarboxylic acid, 5-[3-[acetyl(1,1-dimethylethyl)amino]imidazo[1,2-a]pyrazin-2-yl]- (9CI) (CA INDEX NAME)




RN 412367 67-9 CAPLUS

CN 2-Thienecarboxylic acid, 5-[3-[acetyl(1,1,3,3-tetramethylbutyl)amino]imidazo[1,2-a]pyrazin-2-yl]- (9CI) (CA INDEX NAME)




RN 41236 95-3 CAPLUS

CN Acetamide, N-(1,1-dimethylethyl)-N-[2-[5-(methylthio)-2-thienyl]imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)



RN 41236 97-5 CAPLUS


CN Acetamide, N-[2-[5-(methylthio)-2-thienyl]imidazo[1,2-a]pyrazin-3-yl]-N-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 412367 38-7 CAPLUS

CN Glycine, N-acetyl-N-[2-(2-methylphenyl)imidazo[1,2-a]pyrazin-3-yl]-,


methyl ester ( I) (CA INDEX NAME)



RN 412361-45-6 C LUS  
 CN Acetamide, N-benzyl-N-[2-(3,4,5-trimethoxyphenyl)imidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)



RN 412361-60-5 C LUS  
 CN Imidazo[1,2-a]pyrazin-3-amine, N-(1,1-dimethylethyl)-2-(4-nitrophenyl)-, hydrochloride (CI) (CA INDEX NAME)



●x HCl

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L57 ANSWER 19 OF 2. CAPLUS COPYRIGHT 2006 ACS 1 STN  
 ACCESSION NUMBER: 2002:107321 CAPLUS  
 DOCUMENT NUMBER: 136:167373  
 TITLE: Preparation of imidazoly derivatives as agonists or antagonists of somatostatin receptors  
 INVENTOR(S): Thuriéau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gellon, Thomas D.; Morgan, Barry A.; Moinet, Christophe Philippe; Bigg, Dennis  
 PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.  
 SOURCE: PCT Int. Appl., 369 pp.



CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002/0140	A2	20020207	WO 2001-US23959	2001/031
WO 2002/0140	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, MD, RU, TJ, TM			
RW:	EH, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2417044	AA	20020207	CA 2001-2417204	2001/031
EP 1305044	A2	20030502	EP 2001-957342	2001/031
R:	AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, DE, SI, LT, LV, FI, RO, MK, AL, TR			
JP 2004/8613	T2	20040624	JP 2002-516272	2001/031
NZ 52377	A	20040924	NZ 2001-523774	2001/031
NO 2003/0473	A	20030130	NO 2003-473	2003/030
PRIORITY APPLICATION INFO.:			US 2000-222584P	P 2000/001
			WO 2001-US23959	W 2001/031

OTHER SOURCE: MARPAT 136:16737  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT \*

AB Imidazole derivs. I [R1 = H, (CH2)mC(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo[b]thiophene, P naphthyl, etc.; m = 0-6; R2 = H, alkyl; R3 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mE(CH2)mZ2; E = O, S, CO, etc.; Z2 = H, alkyl, etc.; R4 = H, (CH2)mA1; A1 = C(:Y)NX1X2; C(:Y)X2; C(:N)X2, X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.], which are useful as agonists or antagonists of somatostatin receptors (no data) and for inhibiting the proliferation of Helicobacter pylori, were prepared. Thus, activating 2-furancarboxylic acid with carbonyl imidazole followed by addition of 2-[(1S)-2-amino-2-(indol-3-yl)ethyl]-1-phenyl-1H-imidazole afforded 94% the title compound V. Compds. I are effective at 0.01-10.0 mg/kg/day.

IC ICM C02233-54  
 ICS C02403-06; A61P005-02

CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1

IT Nerve, disease  
 (diabetic neuropathy; preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)

IT 167983-81-4P 175531-38-1P 252279-1-1P 252279-15-5P 252292-10-9P  
 252292-11-0P 252292-72-1P 252292-13-2P 252292-74-3P 252292-15-4P  
 252292-16-6P 252292-78-7P 252292-80-1P 252292-81-2P  
 252292-82-3P 252292-83-4P 252292-84-5P 252292-85-6P 252292-86-7P

252292-87-8P	2	292-88-9P	252292-89-0P	2	292-90-3P	252292-91-4P
252292-92-5P	2	292-93-6P	252292-94-7P	2	292-95-8P	252292-96-9P
252292-97-0P	2	292-98-1P	252292-99-2P	2	293-00-8P	252293-01-9P
252293-02-0P	2	293-03-1P	252293-04-2P	2	293-05-3P	252293-06-4P
252293-07-5P	2	293-08-6P	252293-09-7P	2	293-10-0P	252293-11-1P
252293-12-2P	2	293-13-3P	252293-14-4P	2	293-15-5P	252293-16-6P
252293-17-7P	2	293-18-8P	252293-19-9P	2	293-20-2P	252293-21-3P
252293-22-4P	2	293-23-5P	252293-24-6P	2	293-25-7P	252293-26-8P
252293-27-9P	2	293-28-0P	252293-29-1P	2	293-30-4P	252293-32-6P
252293-35-9P	2	293-37-1P	252293-38-2P	2	293-39-3P	252293-40-6P
252293-41-7P	2	293-42-8P	252293-43-9P	2	293-44-0P	252293-46-2P
252293-47-3P	2	293-48-4P	252293-49-5P	2	293-50-8P	252293-51-9P
252293-52-0P	2	293-53-1P	252293-54-2P	2	293-55-3P	252293-56-4P
252293-57-5P	2	293-58-6P	252293-59-7P	2	293-60-0P	252293-61-1P
252293-62-2P	2	293-63-3P	252293-64-4P	2	293-65-5P	252293-66-6P
252293-67-7P	2	293-68-8P	252293-69-9P	2	293-70-2P	252293-71-3P
252293-72-4P	2	293-73-5P	252293-74-6P	2	293-75-7P	252293-76-8P
252293-77-9P	2	293-78-0P	252293-80-4P	2	293-81-5P	252293-82-6P
252293-83-7P	2	293-84-8P	252293-85-9P	2	293-86-0P	252293-87-1P
252293-88-2P	2	293-89-3P	252293-90-6P	2	293-91-7P	252293-92-8P
252293-93-9P	2	293-94-0P	252293-95-1P	2	293-96-2P	252293-97-3P
252293-98-4P	2	293-99-5P	252294-00-1P	2	294-01-2P	252294-03-4P
252294-04-5P	2	294-05-6P	252294-06-7P	2	294-07-8P	252294-08-9P
252294-09-0P	2	294-10-3P	252294-12-5P	2	294-14-7P	252294-16-9P
252294-18-1P	2	294-20-5P	252294-22-7P	2	294-23-8P	252294-24-9P
252294-25-0P	2	294-26-1P	252294-27-2P	2	294-28-3P	252294-29-4P
252294-30-7P	2	294-31-8P	252294-32-9P	2	294-33-0P	252294-34-1P
252294-35-2P	2	294-36-3P	252294-37-4P	2	294-39-6P	252294-40-9P
252294-41-0P	2	294-42-1P	252294-43-2P	2	294-44-3P	252294-45-4P
252294-46-5P	2	294-47-6P	252294-48-7P	2	294-49-8P	252294-50-1P
252294-51-2P	2	294-52-3P	252294-53-4P	2	294-54-5P	252294-55-6P
252294-56-7P	2	294-57-8P	252294-59-0P	2	294-60-3P	252294-61-4P
252294-62-5P	2	294-63-6P	252294-64-7P	2	294-65-8P	252294-66-9P
252294-67-0P	2	294-68-1P	252294-69-2P	2	294-70-5P	252294-71-6P
252294-72-7P	2	294-73-8P	252294-74-9P	2	294-75-0P	252294-76-1P
252294-77-2P	2	294-78-3P	252294-79-4P	2	294-80-7P	252294-81-8P

252294-82-9P 252294-83-0P 252294-85-2P

252294-87-4P 252294-88-5P 252294-89-6P 252294-90-9P

252294-91-0P	2	294-92-1P	252294-93-2P	2	294-94-3P	252294-95-4P
252294-96-5P	2	294-97-6P	252294-98-7P	2	294-99-8P	252295-00-4P
252295-01-5P	2	295-02-6P	252295-03-7P	2	295-04-8P	252295-05-9P
252295-06-0P	2	295-07-1P	252295-08-2P	2	295-09-3P	252295-10-6P
252295-11-7P	2	295-12-8P	252295-13-9P	2	295-14-0P	252295-15-1P
252295-17-3P	2	295-18-4P	252295-19-5P			

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PR (Preparation); USES (Uses)

(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)

IT	252295-20-8P	2	295-21-9P	252295-22-0P	2	295-23-1P	252295-24-2P
	252295-26-4P	2	295-27-5P	252295-28-6P	2	295-29-7P	252295-30-0P
	252295-31-1P	2	295-32-2P	252295-33-3P	2	295-34-4P	252295-35-5P
	252295-36-6P	2	295-37-7P	252295-38-8P	2	295-39-9P	252295-40-2P
	252295-42-4P	2	295-44-6P	252295-45-7P	2	295-46-8P	252295-47-9P
	252295-48-0P	2	295-49-1P	252295-51-5P	2	295-52-6P	252295-53-7P
	252295-54-8P	2	295-55-9P	252295-56-0P	2	295-57-1P	252295-58-2P
	252295-59-3P	2	295-61-7P	252295-62-8P	2	295-63-9P	252295-64-0P
	252295-65-1P	2	295-66-2P	252295-67-3P	2	295-70-8P	252295-71-9P
	252295-72-0P	2	295-73-1P	252295-74-2P	2	295-75-3P	252295-76-4P
	252295-77-5P	2	295-78-6P	252295-79-7P	2	295-80-0P	252295-81-1P

252295-82 P 252295-84-4P 252295-85-5P 252295-86-6P 252295-87-7P  
 252295-88-8P 252295-89-9P 252295-90-10P 252295-91-3P 252295-92-4P  
 252295-93-5P 252295-94-6P 252295-95-7P 252295-96-8P 252295-97-9P  
 252295-98-10P 252295-99-11P 252296-00-12P 252296-01-8P 252296-02-9P  
 252296-03-10P 252296-04-11P 252296-05-12P 252296-06-3P 252296-07-4P  
 252296-08-5P 252296-09-6P 252296-10-7P 252296-11-0P 252296-12-1P  
 252296-13-2P 252296-14-3P 252296-15-4P 252296-16-5P 252296-17-6P  
 252296-18-7P 252296-19-8P 252296-20-1P  
 252296-21-2P 252296-22-3P 252296-23-4P  
 252296-24-5P 252296-25-6P 252296-27-8P  
 252296-28-9P 252296-29-0P 252296-30-3P  
 252296-31-4P 252296-32-5P 252296-33-6P  
 252296-34-7P 252296-35-8P 252296-36-9P  
 252296-38-1P 252296-39-2P 252296-40-5P  
 252296-41-6P 252296-42-7P 252296-43-8P  
 252296-44-9P 252296-45-0P 252296-46-1P  
 252296-47-2P 252296-48-3P 252296-49-4P  
 252296-50-5P 252296-51-8P 252296-52-9P  
 252296-53-10P 252296-54-11P 252296-55-2P  
 252296-56-3P 252296-57-4P 252296-58-5P  
 252296-59-6P 252296-60-9P 252296-61-10P 252296-62-1P  
 252296-63-11P 252296-64-3P 252296-65-4P 252296-66-5P 252296-67-6P  
 252296-69-7P 252296-71-2P 252296-72-3P 252296-73-4P 252296-74-5P  
 252296-75-6P 252296-76-7P 252296-77-8P 252296-78-9P 252296-79-10P  
 252296-80-11P 252296-81-4P 252296-82-5P 252296-83-6P 252296-84-7P  
 252296-85-8P 252296-86-9P 252296-87-10P 252296-88-1P 252296-89-2P  
 252296-90-3P 252296-91-6P 252296-92-7P 252296-93-8P 252296-94-9P  
 252296-95-10P 252296-96-11P 252296-97-12P 252296-98-3P 252296-99-4P  
 252297-00-5P 252297-01-1P 252297-02-2P 252297-03-3P 252297-04-4P  
 252297-06-5P 252297-07-7P 252297-08-8P 252297-09-9P 252297-10-10P  
 252297-11-11P 252297-12-4P 252297-13-5P 252297-14-6P 252297-15-7P  
 252297-16-8P 252297-18-0P 252297-20-1P 252297-21-5P 252297-22-6P  
 252297-23-7P 252297-24-8P 252297-25-9P 252297-26-0P 252297-27-1P  
 252297-28-2P 252297-29-3P 252297-30-4P 252297-31-7P 252297-32-8P  
 252297-33-9P 252297-34-0P 252297-35-1P 252297-36-2P 252297-37-3P  
 252297-38-4P 252297-39-5P 252297-40-6P 252297-42-0P 252297-43-1P  
 252297-44-2P 252297-45-3P 252297-46-4P 252297-47-5P 252297-48-6P  
 252297-49-7P 252297-50-0P 252297-51-1P 252297-52-2P 252297-53-3P  
 252297-54-4P 252297-55-5P 252297-56-6P 252297-57-7P 252297-58-8P  
 252297-59-9P 252297-60-2P 252297-61-3P 252297-62-4P 252297-63-5P  
 252297-64-6P 252297-65-7P 252297-66-8P 252297-67-9P 252297-68-10P  
 252297-69-11P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of imidazolyl derivs. as agonists or antagonists of  
 somatostatin receptors)

IT 252292-78-7P 252294-83-0P 252294-85-2P  
 252294-87-4P 252294-88-5P 252296-18-7P  
 252296-19-8P 252296-20-1P 252296-21-2P  
 252296-22-3P 252296-23-4P 252296-24-5P  
 252296-25-6P 252296-27-8P 252296-28-9P  
 252296-29-0P 252296-30-3P 252296-31-4P  
 252296-32-5P 252296-33-6P 252296-34-7P  
 252296-35-8P 252296-36-9P 252296-38-1P  
 252296-39-2P 252296-40-5P 252296-41-6P  
 252296-42-7P 252296-43-8P 252296-44-9P  
 252296-45-0P 252296-46-1P 252296-47-2P  
 252296-48-3P 252296-49-4P 252296-50-7P  
 252296-51-8P 252296-52-9P 252296-53-0P

252296-54-1P 252296-55-2P 252296-56-3P


252296-57-4P 252296-58-5P 252296-59-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); IOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of midazolyl derivs. as agonist or antagonists of somatostatin receptors)


RN 252292-78-7 CAPLU

CN Imidazo[1,2-a]pyrazine-8-butanamine, 2,6-diphenyl (9CI) (CA INDEX NAME)




RN 252294-83-0 CAPLU

CN Imidazo[1,2-a]pyrazine-2-acetamide, N,8-bis(4-aminobutyl)- $\alpha,\alpha$ -dimethyl-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 252294-85-2 CAPLU

CN Imidazo[1,2-a]pyrazine-2-acetamide, N,8-bis(4-aminobutyl)-6-(4-chloro-3-nitrophenyl)- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




RN 252294-87-4 CAPLU


CN Imidazo[1,2-a]pyrazine-2-acetamide, N,8-bis(4-aminobutyl)-6-benzo[b]thien-3-yl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




RN 252294-88-5 CAPLUS  
 CN Imidazo[1,2-b]pyrazine-2-acetamide, N,8-bis(4-aminobutyl)-α,α-dimethyl-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 252296-18-7 CAPLUS  
 CN Imidazo[1,2-b]pyrazine-2-acetamide, 8-(4-aminobutyl)-N-(2-furanylmethyl)-α,α-dimethyl-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 252296-19-8 CAPLUS  
 CN Imidazo[1,2-b]pyrazine-2-acetamide, 8-(4-aminobutyl)-N-(2-furanylmethyl)-α,α-dimethyl-6-(4-chloro-3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 252296-20-1 CAPLUS  
 CN Imidazo[1,2-b]pyrazine-2-acetamide, 8-(4-aminobutyl)-N-[2-(1H-indol-3-yl)ethyl]-α,α-dimethyl-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)

NAME)




RN 252296-21-2 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)-6-(4-chloro-3-nitrophenyl)-N-[2-(1H-indol-3-yl)ethyl]- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




RN 252296-22-3 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)-N-[2-(1H-indol-3-yl)ethyl]- $\alpha,\alpha$ -dimethyl-6-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 252296-23-4 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-acetamide, N,8-bis(4-aminobutyl)-α,α-dimethyl-6-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 252296-24-5 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-acetamide, N,8-bis(4-aminobutyl)-α,α-dimethyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252296-25-6 CAPLUS


CN Imidazo[1,2-a]pyrazine-2-acetamide, N,8-bis(4-aminobutyl)-6-(4-chlorophenyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 252296-27-8 CAPLUS  
 CN Imidazo[1,2-a]pyrazine- acetamide, 8-(4-aminobutyl)- -(diphenylmethyl)-  
 $\alpha,\alpha$ -dimethyl-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 252296-28-9 CAPLUS  
 CN Imidazo[1,2-a]pyrazine- acetamide, 8-(4-aminobutyl)- -(4-chloro-3-  
 nitrophenyl)-N-(diphenylmethyl)- $\alpha,\alpha$ -dimethyl- (9CI) CA INDEX  
 NAME)




RN 252296-29-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazine- acetamide, 8-(4-aminobutyl)- -cyclohexyl-  
 $\alpha,\alpha$ -dimethyl-6-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 252296-30-3 CAPLUS  
 CN Imidazo[1,2-a]pyrazine- acetamide, 8-(4-aminobutyl)- -(4-chloro-3-  
 nitrophenyl)-N-cyclohexyl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)







RN 252296-31-4 CAP JS

CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-amino-2-chlorophenylethyl)-N-cyclohexyl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

RN 252296-32-5 CAP JS


CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-amino-2-phenylethyl)-N-cyclohexyl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

RN 252296-33-6 CAP JS

CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-amino-2-phenylethyl)-6-benzo[b]thien-3-yl-N-cyclohexyl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)


RN 252296-34-7 CAP JS

CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-amino-2-nitrophenyl)-N-cyclohexyl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




FN 252296-35-8 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-carboxamide, 8-(4-aminobutyl)-6-(4-chlorophenyl)-N-cyclohexyl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




FN 252296-36-9 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-carboxamide, 8-(4-aminobutyl)-N-cyclohexyl-6-(3,4-dichlorophenyl)- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)



FN 252296-38-1 CAPLUS


CN Imidazo[1,2-a]pyrazine-2-carboxamide, 8-(4-aminobutyl)-N-cyclohexyl-6-(2,3-dihydro-1,4-benzodioxin-6-yl)- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




FN 252296-39-2 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-carboxamide, 8-(4-aminobutyl)-6-(4-bromophenyl)-N-cyclohexyl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)


cyclohexyl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




RN 252296-40-5 CAPLU  
CN Imidazo[1,2-a]pyridine-2-acetamide, 8-(4-aminobutyl)-N-butyl- $\alpha,\alpha$ -dimethyl-6-(3-bromophenyl)- (9CI) (CA INDEX NAME)



RN 252296-41-6 CAPLU  
CN Imidazo[1,2-a]pyridine-2-acetamide, 8-(4-aminobutyl)-N-butyl-6-(4-chloro-3-nitrophenyl)- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




RN 252296-42-7 CAPLU  
CN Imidazo[1,2-a]pyridine-2-acetamide, 8-(4-aminobutyl)-N-butyl- $\alpha,\alpha$ -dimethyl-6-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 252296-43-8 CAPLU  
CN Imidazo[1,2-a]pyridine-2-acetamide, 8-(4-aminobutyl)-N-butyl-

$\alpha,\alpha$ -dimethyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252296-44-9 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)-6-benzyl-N-butyl- $\alpha,\alpha$ -dimethyl- (9CI) (CA INDEX NAME)




RN 252296-45-0 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)-N-butyl- $\alpha,\alpha$ -dimethyl-6-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 252296-46-1 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)-N-butyl- $\alpha,\alpha$ -dimethyl-6-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 252296-47-2 CAPLUS

CN Imidazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)-N-butyl- $\alpha,\alpha$ -dimethyl-6-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)




RN 252296-48-3 CAPLUS

CN Imidazo[1,2-a]pyrazi: -2-acetamide, 8-(4-aminobuty -N-butyl-6-(2,3-  
 dihydro-1,4-benzodio n-6-yl)- $\alpha,\alpha$ -dimethyl- (9CI) .CA INDEX  
 NAME)




RN 252296-49-4 CAPLUS

CN Imidazo[1,2-a]pyrazi: -2-acetamide, 8-(4-aminobuty -6-(4-bromophenyl)-N-  
 butyl- $\alpha,\alpha$ -dimethyl- CI) (CA INDEX NAME)




RN 252296-50-7 CAPLUS

CN Imidazo[1,2-a]pyrazi: -2-acetamide, 8-(4-aminobuty - $\alpha,\alpha$ -  
 dimethyl-6-(3-nitrop nyl)-N-[2-(2-pyridinyl)ethyl (9CI) (CA INDEX  
 NAME)




RN 252296-51-8 CAPLUS


CN idazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)-6-(4-chlorophenyl)- $\alpha,\alpha$ -dimethyl-N-[2-(2-pyridinyl)ethyl]- (9CI) 'A  
(INDEX NAME)




RN 2296-52-9 CAPLUS  
CN idazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)- $\alpha,\alpha$ -methyl-6-(2-phenylethyl)-N-[2-(2-pyridinyl)ethyl]- (9CI) CA INDEX  
(ME)



RN 2296-53-0 CAPLUS  
CN idazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)- $\alpha,\alpha$ -methyl-6-(phenylmethyl)-N-[2-(2-pyridinyl)ethyl]- (9CI) 'A INDEX NAME)




RN 2296-54-1 CAPLUS  
CN idazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)-6-benz[b]thien-3-yl- $\alpha,\alpha$ -dimethyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 2296-55-2 CAPLUS  
CN idazo[1,2-a]pyrazine-2-acetamide, 8-(4-aminobutyl)- $\alpha,\alpha$ -methyl-6-(4-nitrophenyl)-N-[2-(2-pyridinyl)ethyl]- (9CI) CA INDEX


NAME)




RN 252296-56-3 CAPLUS

CN Imidazo[1,2-a]pyrazine-8-yl- $\alpha,\alpha$ -dimethyl-N-[2-(2-pyridinyl)ethyl]-acetamide, 8-(4-aminobutyl)-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

RN 252296-57-4 CAPLUS


CN Imidazo[1,2-a]pyrazine-8-yl- $\alpha,\alpha$ -dimethyl-N-[2-(2-pyridinyl)ethyl]-acetamide, 8-(4-aminobutyl)-4-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

RN 252296-58-5 CAPLUS

CN Imidazo[1,2-a]pyrazine-8-yl- $\alpha,\alpha$ -dimethyl-N-[2-(2-pyridinyl)ethyl]-acetamide, 8-(4-aminobutyl)-4-(2,3-dihydro-1,4-benzodioxin-6-yl)- (9CI) (CA INDEX NAME)

RN 252296-59-6 CAPLUS

CN Imidazo[1,2-a]pyrazine-8-yl- $\alpha,\alpha$ -dimethyl-N-[2-(2-pyridinyl)ethyl]-acetamide, 8-(4-aminobutyl)-4-(4-bromophenyl)- (9CI) (CA INDEX NAME)



L57 AN. ER 20 OF 22 CAPLUS COPYRIGHT © 2006 ACS on STN

ACCESSION NUMBER: 2002:72101 CAPLUS

DOCUMENT NUMBER: 136:134786

TITLE: Preparation of imidazo[1,2-a]pyrazines for the treatment of neurological disorders

INVENTOR(S): Bakthavatchalam, Rajagopal; Wilde, Richard G.; Gilligan, Paul J.

PATENT SIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. App., 48 pp.

CODEN: PIXXD

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY C. NUM. COUNT: 1


PATENT FORMATION:

PAT NO.	KIND	DATE	APPLICATION NO.	ATE
WO 002006286	A2	20020124	WO 2001-US22076	0010713
WO 002006286	A3	20020113		
W:	AE, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, BZ, C			CH, CN, CO, CR, CU, CZ, DE, DK, DZ, EC, EE, ES, FI, GB, G
	GM, HR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, L			LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NO, N
	RO, RU, SD, SE, SG, SI, SL, TJ, TM, TR, TT, TZ, U			UG, UZ, VN, YU, ZA, ZW, AM, AZ, KG, KZ, MD, RU, TJ, TM
RW:	GH, GM, KE, LS, MW, MZ, SL, SZ, TZ, UG, ZW, AT, B			CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, S
	BJ, CF, CG, CI, CM, GA, GW, ML, MR, NE, SN, TD, T			TR, BF,
CA 419626	AA	20020124	CA 2001-2419626	0010713
US 002049208	A1	20020125	US 2001-905097	0010713
US 589952	B2	20030108		
EP 301511	A2	20030116	EP 2001-954675	0010713
R:	AT, BE, CH, DE, DK, ES, GB, GR, IT, LI, LU, NL, S			MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, TR
JP 004532792	T2	20041128	JP 2002-512188	0010713
US 003220342	A1	20031127	US 2003-427234	0030501
PRIORITY APPLN. INFO.:			US 2000-218339P	P 0000714
			US 2001-905097	A1 0010713
			WO 2001-US22076	W 0010713

OTHER SOURCE(S): MARPAT 136:134786

GI







The title compds. [I; X = CHR5, NR5, O, S, SOn, a bond n = 0-2; D = (un)substituted (hetero)alkyl; R1 = alkyl, alkenyl, cycloalkyl, etc.; R2 = alkyl, cycloalkyl; R3 and R4 = H, alkyl, cycloalkyl, etc.; R5 = H, alkyl, cycloalkyl], useful in the treatment of various neurological and psychol. disorders, e.g., anxiety and depression, treatable by antagonizing CRF receptors, were prepared. E.g., a multi-step synthesis of I [X = a bond; R1 = CHMeOH; R2 = Et; R3, R4 = H; D = 2,4-dichlorophenyl], was given.

ICM C07D487-04  
 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
 Section cross-reference(s): 1  
 Antidepressants  
 Anxiolytics  
 (preparation of imidazo[1,2-a]pyrazines for the treatment of neurological disorders)  
 Corticotropin releasing factor receptors  
 RL: BSU (Biological study unclassified); BIOL (Biological study)  
 (preparation of imidazo[1,2-a]pyrazines for the treatment of neurological disorders)  
 391954-00-0P 391954-03-3P 391954-14-6P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of imidazo[1,2-a]pyrazines for the treatment of neurological disorders)  
 391954-01-1P 391954-02-2P 391954-04-4P  
 391954-05-5P 391954-06-6P 391954-07-7P  
 391954-08-8P 391954-09-9P 391954-10-2P  
 391954-11-3P 391954-12-4P 391954-13-5P  
 391954-15-7P 391954-16-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazo[1,2-a]pyrazines for the treatment of neurological disorders)  
 107-08-4, 1-Iodopropane 123-38-6, Propionaldehyde, reactions 816-40-0,  
 1-Bromo-2-butanone 2234-32-4, Propylmagnesium chloride 4858-85-9,  
 2,3-Dichloropyrazine 1040-91-7, Benzyl isocyanide 8716-47-2,  
 2,4-Dichlorobenzeneboronic acid  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of imidazo[1,2-a]pyrazines for the treatment of neurological disorders)  
 6863-73-6P 391954-17-9P 391954-18-0P  
 391954-19-1P 391954-20-4P 391954-21-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of imidazo[1,2-a]pyrazines for the treatment of neurological disorders)


IT 391954-00-0P 391954-03-3P 391954-14-6P  
 RL: C (Pharmacological activity); RCT (Reactant); SPN (Synthesis preparation); THU (Therapeutic use); BIOL (Biological study); P (Preparation); RACT (Reactant or agent); USES (Uses)  
 (Preparation of imidazo[1,2-a]pyrazines for the treatment of neuro disorders)  
 RN 391954-00-0 CAPLUS  
 CN Imidazo[1,2-a]pyrazine-3-methanol, 8-(2,4-dichlorophenyl)-2-ethyl- $\alpha$ -methoxy- (9CI) (CA INDEX NAME)



RN 391954-03-3 CAPLUS  
 CN Imidazo[1,2-a]pyrazine-3-methanol, 8-(2,4-dichlorophenyl)-2-ethyl- $\alpha$ -propoxy- (9CI) (CA INDEX NAME)



RN 391954-14-6 CAPLUS  
 CN 1-Butanone, 1-[8-(2,4-dichlorophenyl)-2-ethylimidazo[1,2-a]pyrazin-3-yl]- (9CI) (CA INDEX NAME)




IT 391954-01-1P 391954-02-2P 3 1954-04-4P  
 391954-05-5P 391954-06-6P 3 1954-07-7P  
 391954-08-8P 391954-09-9P 3 1954-10-2P  
 391954-11-3P 391954-12-4P 3 1954-13-5P  
 391954-15-7P 391954-16-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazo[1,2-a]pyrazines for the treatment of neurological disorders)


RN 391954-01-1 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(2,4-dichlorophenyl)-2-ethyl-3-(1-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 391954-02-2 CAPLUS


CN Imidazo[1,2-a]pyrazine-3-methanol, 8-(2,4-dichlorophenyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 391954- 4-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-(2,4-dichlorophenyl)-3-(1-ethoxybutyl)-1H-ethyl-  
 (9CI) CA INDEX NAME)



RN 391954- 5-5 CAPLUS  
 CN Imidazo[1,2-a]pyrazine-3-methanol, 8-(2,4-dichlorophenyl)-2-ethyl-1-propyl-  
 (9CI) (CA INDEX NAME)




RN 391954- 6-6 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-(2,4-dichlorophenyl)-3-(1-ethoxybutyl)-1H-methyl-  
 (9CI) CA INDEX NAME)




RN 91954-07-7 CAPLUS

CN 8-(2-chloro-4-methoxyphenyl)-2-ethyl-1H-imidazo[1,2-a]pyrazine-3-methanol (9CI) (CA INDEX NAME)




RN 91954-08-8 CAPLUS

CN 8-(2-chloro-4-methoxyphenyl)-2-ethyl-1H-imidazo[1,2-a]pyrazine-3-ol (9CI) (CA INDEX NAME)




RN 91954-09-9 CAPLUS

CN 8-[2-chloro-4-(difluoromethoxy)phenyl]-2-ethyl-1H-imidazo[1,2-a]pyrazine-3-ol (9CI) (CA INDEX NAME)




RN 391954-102 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-methanol, 8-[2-chloro-4-(difluoromethoxy)phenyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 391954-103 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-[2-chloro-4-(difluoromethoxy)phenyl]-3-(1-ethoxybutyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 391954-104 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-[4-(difluoromethoxy)-2,6-dimethylphenyl]-3-(1-ethoxybutyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 39 054-13-5 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-methanol, 8-[4-(difluoromethoxy)-2-methylphenyl]-2-ethyl-3-(1-(n-propyl)-2-ethoxyethyl)- (9CI) (CA INDEX NAME)




RN 39 054-15-7 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(2,4-dichlorophenyl)-2-ethyl-3-(1-methyl-2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 39 054-16-8 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-amine, 8-(2,4-dichlorophenyl)-2-ethyl-3-(1-phenylmethyl)-N-propyl- (9CI) (CA INDEX NAME)



t

Pr-n

(2-Ph

IT 391954-17-9 391954-18-0P 391954-19-1P


391954-20-4 391954-21-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant reagent)

(preparation of imidazo[1,2-a]pyrazine for the treatment of neuroleptic disorders)


RN 391954-17-9 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-chloro-2-ethyl (9CI) (CA INDEX NAME)



RN 391954-18-0 CAPLUS

CN Imidazo[1,2-a]pyrazine, 8-(2,4-dichlorophenyl)-2-ethyl- (9CI) (CA INDEX NAME)




t


RN 391954-19-0 CAPLUS

CN Imidazo[1,2-a]pyrazine-3-carboxaldehyde, 8-(2,4-dichlorophenyl)-2-ethyl- (9CI) (CA INDEX NAME)






RN 3919 1-20-4 CAPLUS

CN Imidazole[1,2-a]pyrazin-3-amine, 8-chloro-2-ethyl-N-(phenylmethyl) (9CI)  
(CA INDEX NAME)

RN 3919 1-21-5 CAPLUS

CN Imidazole[1,2-a]pyrazin-3-amine, 8-chloro-2-ethyl-N-(phenylmethyl)-N-propyl- (9CI)  
(CA INDEX NAME)

L57 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:462224 PLUS

DOCUMENT NUMBER: 125:114694

TITLE: Preparation of arylpiperazines as neurokinin antagonists

INVENTOR(s): Chiang, Yuan-Ching P.; Finke, Paul E.; Maccoss, Malcolm; Meurer, Laura C.; Miller, Daniel J.; Mills, Sander G.; Roehrig, Albert J.; Shah, Shrek K.

PATENT ASSIGNER(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl. 158 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. (JNT): 1  
PATENT INFORMATION

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9610568	A1	19960411	WO 95-US12341	19950926
W: AM, BB, BG, BR, BY, CA, CN, CZ, DE, FI, GE, HU, IS, JP, KG, KR, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SK, TJ, TM, TT, UA, UG, US, JZ				
RW: KE, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TG				
US 5607936	A	19970304	US 94-316013	19940930
CA 2199621	AA	19960411	CA 95-2199621	19950926
AU 9536429	A1	19960426	AU 95-36429	19950926
AU 702832	B2	19990304		
EP 783498	A1	19970716	EP 95-933964	19950926
R: AT, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10508297	T2	19980818	JP 95-511993	19950926
PRIORITY APPLN. IN O.:			US 94-316013	A2 19940930
			WO 95-US12341	W 19950926
OTHER SOURCE(S):	MARPAT 125:114694			
GI				



AB Title compds. [I; R = (un)substituted (hetero)aryl; R<sub>1</sub> = (un)substituted alk(en)yl; R<sub>2</sub> = null, quaternizing (phenyl) alkyl, O; R<sub>8</sub>, R<sub>9</sub> = H, halo, CF<sub>3</sub>, alkoxy, etc.] were prepared. Thus, (S)-3,5-bis(2-methyl-2-butenoxy)phenylpiperazine 2-3,5 was reductively condensed with N-[2-(acetylamino)ethyl]phenylpiperazine to give title compound (S)-II. Data for ligand displacement by I from NK-1, NK-2, and NK-3 receptors in vitro were given.

IC ICM C07D295-5  
ICS C07D403-4; A61K031-495

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))  
Section cross reference(s): 1

ST arylpiperazine prepn **neurokinin** antagonist

IT Respiratory tract  
(disease, treatment; preparation of aryl piperazines as **neurokinin** antagonist)

IT 33507-63-0, Substance P 86933-74-6, **Neurokinin A**  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(mediated diseases; treatment; preparation of arylpiperazines as **neurokinin** antagonists)

IT	179249-56-0P	179249-57-1P	179249-58-2P	179249-59-3P	179249-60-6P
	179249-61-7P	179249-62-8P	179249-63-9P	179249-64-0P	179249-65-1P
	179249-66-2P	179249-67-3P	179249-68-4P	179249-69-5P	179249-70-8P
	179249-71-9P	179249-72-0P	179249-73-1P	179249-74-2P	179249-75-3P
	179249-76-4P	179249-77-5P	179249-78-6P	179249-79-7P	
	179249-80-0P	179249-81-1P	179249-82-2P	179249-83-3P	179249-84-4P
	179249-85-5P	179249-86-6P	179249-87-7P	179249-88-8P	179249-89-9P
	179249-90-2P	179249-91-3P	179249-92-4P	179249-93-5P	179249-94-6P
	179249-95-7P	179249-96-8P	179249-97-9P	179249-98-0P	179249-99-1P
	179250-00-1P	179250-01-2P	179250-02-3P	179250-03-4P	179250-04-5P
	179250-05-6P	179250-06-7P	179250-07-8P	179250-08-9P	179250-09-0P
	179250-10-3P	179250-11-4P	179250-12-5P	179250-13-6P	179250-14-7P
	179250-15-8P	179250-16-9P	179250-17-0P	179250-18-1P	179250-19-2P
	179250-20-5P	179250-21-6P	179250-22-7P	179250-23-8P	179465-13-5P
	179465-14-6P	179465-15-7P	179465-16-8P	179465-17-9P	179465-18-0P
	179465-19-1P	179465-20-4P	179465-21-5P	179465-22-6P	

RL: BA (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylpiperazines as **neurokinin** antagonists)

IT	288-32-1, Imidazole, reactions	394-47-8, 2-Fluorobenzonitrile
	446-52-1, 2-Fluorobenzaldehyde	499-06-9, 3,5-Dimethylbenzoic acid
	725-89-1, 3,5-Bis(trifluoromethyl)benzoic acid	2905-62-6, 3,5-Dichlorobenzoyl chloride
	13058-77-0, 8-Chloro-1,7-naphthyridine	39512-11-1, 1-(2-Methylphenyl)piperazine
	52341-91-0, 57260-71-1, tert-Butyl piperazine-1-carboxylate	74803-32-0, 84400-99-7, 7-Chlorofuro[2,3-c]pyridine
	90719-82-7, (S)-4-Benzyl-2-oxazolidinone	117299-2-4, 121371-44-6, 147643-17-0, 161622-05-5, 3-Fluoro-5-trifluoromethylbenzoic acid
	179250-64-7, 179250-65-8, 179250-66-9, 179250-62-5, 179250-63-6	

RL: RC (Reactant); RACT (Reactant or reagent)

(preparation of arylpiperazines as **neurokinin** antagonists)

IT	59215-06-2P	164329-19-5P	164329-21-9P	167484-59-5P	167485-03-4P
	174855-03-9P	174855-57-3P	174855-59-5P	179250-24-9P	179250-25-0P
	179250-26-1P	179250-27-2P	179250-28-3P	179250-29-4P	179250-30-7P
	179250-31-8P	179250-32-9P	179250-33-0P	179250-34-1P	179250-35-2P
	179250-36-3P	179250-37-4P	179250-38-5P	179250-39-6P	179250-40-9P
	179250-41-0P	179250-42-1P	179250-43-2P	179250-44-3P	179250-45-4P
	179250-46-5P	179250-47-6P	179250-48-7P	179250-49-8P	179250-50-1P
	179250-51-2P	179250-52-3P	179250-53-4P	179250-54-5P	179250-55-6P
	179250-56-7P	179250-57-8P	179250-58-9P	179250-59-0P	179250-60-3P
	179250-61-4P				

RL: RC (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of arylpiperazines as **neurokinin** antagonists)

IT	179249-76-4P
RL:	BA (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylpiperazines as **neurokinin** antagonists)


RN	179249-76-4 CAPLUS
CN	Benzamide, N-[(2S)-2-(3,4-dichlorophenyl)-4-[4-(6-methylimidazo[1,2-a]pyridin-8-yl)-1-piperazinyl]butyl] N,3,5-trimethyl- (9CI) (CA 10 INDEX NAME)

Absolute stereochemistry.



L57 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2006 ACS o STN  
 ACCESSION NUMBER: 1988:631072 CAPLUS  
 DOCUMENT NUMBER: 109:231072  
 TITLE: 8-Alkylaminoimidazo[1,2-a]pyrazine derivatives, their preparation, and their application in therapy  
 INVENTOR(S): Sablayrolles, Claire; Bonnot, Pierre Antoine; Cros, Gerard; Chapat, Jean Pier ; Boucard, Maurice  
 PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemie Fabrik G.m.b.H., Fed. Rep. Ger.  
 SOURCE: PCT Int. Appl., 41 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNTRY: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLIC. NO.	ION NO.	DATE
WO 8804298	A1	19880616	WO 198	EP756	19871204
W: JP, US					
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, S					
FR 2607813	A1	19880610	FR 198	17164	19861205
FR 2607813	B1	19890331			
EP 348392	A1	19900103	EP 198	900690	19871204
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, N				SE	
JP 02501575	T2	19900531	JP 198	500907	19871204
US 5028605	A	19910702	US 198	364428	19890602
PRIORITY APPLN. INFO			FR 198	17164	A 19861205
			WO 198	EP756	W 19871204
OTHER SOURCE(S):		CASREACT 109:231072; MARP		109:231072	
GI					



AB The title compds. [I; R1,R2 = H, CF3, NO, NO2, cyano, halo, C1-5 alkyl, alkoxy, acyl, (substituted) Ph, carbamoyl, cycloalkyl, acyl, alkyl, amino, alkoxy, (substituted) C1-5 alkyl, acyl, furfuryl; R3R4 = (CH2)5, CH2CH2OCH2CH2, CH2CH2SCH2CH3; Y, Z = H, halo, CO2H, cyano, C1-5 alkyl, alkoxy, CF3, amino] and their pharmaceutically compatible salts were prepared as antispasmodics, uterine relaxants, bronchodilators, cardiac analeptics, and **neurosedatives**. Imidazo[1,2-a]pyrazine (preparation from amino pyrazine, given), in HOAc was treated with Br in HOAc and the product 5-dibromoimidazo[1,2-a]pyrazine was stirred with aqueous NaOH to give 3-bromo-8-methylaminoimidazo[1,2-a]pyrazine. I had ED50's 13-14 times greater than theophylline (II) for antispasmodic activity in the duodenum.

IC ICM C07D487-04

ICS A61D031-495

ICI C07D487-04, C07D241-00, C07D235-00

CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1

IT 117617-73-9P

RL: SPN (Synthetic preparation); FORM (Formation, nonpreparative); EP (Preparation)

(formation of, in preparation of drug)

IT 63744-22-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and amination of)

IT 87597-34-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and amination of, in preparation of drug)

IT 117702-80-9P 117718-73-7P 117718-74-8P

117718-75-9P 117718-76-0P 117718-77-1P 117718-78-2P 117718-79-3P

117718-80-6P 117718-81-7P 117718-82-8P 117718-83-9P

117718-84-0P 117718-85-1P 117718-86-2P 117718-87-3P 117718-88-4P,

Imidazo[1,2-a]pyrazin-8-amine 117718-89-5P 117718-90-8P

117718-91-9P 117718-92-0P 117718-93-1P 117718-94-2P

117718-95-3P 117718-96-4P 117718-97-5P 117718-98-6P

117718-99-7P 117719-00-3P 117719-01-4P 117719-02-5P

117719-03-6P 117719-04-7P 117719-05-8P 117719-06-9P 117719-07-0P

117719-08-1P 117736-91-1P 117736-92-2P 117736-93-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as drug)

IT 274-79-3P Imidazo[1,2-a]pyrazine 55635-63-7P

63744-24-1P 77112-52-8P 87597-29-3P

87597-32-3P 89641-34-9P, 2-Amino-5-bromo-3-dimethylaminopyrazine

117718-99-1P 117719-09-2P 117719-19-4P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of as drug intermediate)

IT 13134-31-1, 2,3-Diaminopyrazine 14399-37-2, 2-Amino-3,6-dichloropyrazine  
 55635-63-7, 2-Amino-5-bromo-3-methylaminopyrazine 84996-40-7  
 87597-21-5 8912 58-0, 2,3-Diamino-5-bromopyrazine 90674-84-3,  
 2-Amino-5-bromo-3-iperidylpyrazine 117719-10, 2-Amino-5-bromo-3-  
 ethylaminopyrazine 117719-11-6, 2-Amino-3-propylaminopyrazine  
 117719-12-7, 2-Amino-5-bromo-3-propylaminopyrazine 117719-13-8,  
 2-Amino-5-bromo-3-butylaminopyrazine 117719-15-0, 2-Amino-5-bromo-3-sec-  
 117719-16-1, 2-Amino-3-morpholinylpyrazine 117719-17-2,  
 2-Amino-5-bromo-3-morpholinylpyrazine 117719-18-3  
 RL: RCT (Reactant or reagent) RACT (Reactant or reagent)  
 (reaction of, preparation of drug)

IT 117617-73-9P  
 RL: SPN (Synthetic preparation); FORM (Formation nonpreparative); PREP  
 (Preparation)  
 (formation of, in preparation of drug)


RN 117617-73-9 CAPL  
 CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, triethyl ester (9CI)  
 (CA INDEX NAME)



## 3 ( D1-C1 )


IT 63744-22-9P  
 RL: RCT (Reactant or reagent) SPN (Synthetic preparation) PREP (Preparation); RACT  
 (preparation of amination of)

RN 63744-22-9 CAPLU  
 CN Imidazo[1,2-a]pyrazine, 6,8-dibromo- (9CI) (CA INDEX NAME)



IT 87597-34-0P  
 RL: RCT (Reactant or reagent) SPN (Synthetic preparation) PREP (Preparation); RACT  
 (preparation of amination of, in preparation of drug)

RN 87597-34-0 CAPLU  
 CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, 3,5,6-trichloro-, ethyl ester (9CI) (CA INDEX NAME)




IT 117702-86- 117718-73-7P 117718-74-8P  
 117718-80- 117718-91-9P 117718-93-1P  
 117718-97- 117719-01-4P 117719-02-5P  
 117736-92-

RL: BAC (Biological activity or effector except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as drug)


RN 117702-86- CAPLUS

CN Imidazo[1,2-a]pyrazine-8-amine, 6-bromo-2-chloromethyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 117718-73- CAPLUS

CN Imidazo[1,2-a]pyrazine-2-carboxylic acid 6-bromo-8-(1-piperidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 117718-74- CAPLUS


CN Imidazo[1,2-a]pyrazine-2-carboxylic acid 6-bromo-8-(4-morpholinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 117718-80-6 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 3,6-dibromo-8-(4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 117718-91-9 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 8-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 117718-93-1 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 6-bromo-8-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 117718-97-5 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 3,6-dibromo-8-(4-morpholinyl)- (9CI) (CA INDEX NAME)




NAME)




RN 117719-01-4 APLUS  
 CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, 8-(1-piperidinyl)-, ethyl ester  
 (9CI) (CA INDEX NAME)




RN 117719-02-5 APLUS  
 CN Imidazo[1,2-a]pyrazine-2-carboxylic acid, 8-(4-morpholinyl)-, ethyl ester  
 (9CI) (CA INDEX NAME)




RN 117736-92-2 APLUS  
 CN Imidazo[1,2-a]pyrazine-2-carbonitrile, 6-bromo-8-(4-morpholinyl)- (9CI)  
 (CA INDEX NAME)




IT 274-79-3P, Imidazo[1,2-a]pyrazine 63744-24-1P  
 77112-52-8P 87597-29-3 87597-32-8P  
 117718-93-1P 117719-09 2P 117719-19-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as drug intermediate)  
 RN 274-79-3 CAPLUS  
 CN Imidazo[1,2-a]pyrazine (8CI, 9CI) (CA INDEX NAME)




RN 63744-24-1 CAPLUS  
 CN Imidazo[1,2-a]pyrazine 3,6,8-tribromo- (9CI) (CA INDEX NAME)



RN 77112-52-8 CAPLUS  
 CN Imidazo[1,2-a]pyrazine 3-carboxylic acid, ethyl ester (9CI) (CA INDEX NAME)




RN 87597-29-3 CAPLUS  
 CN Imidazo[1,2-a]pyrazine 3-carboxamide, 6,8-dibromo- (9CI) (CA INDEX NAME)




RN 87597-32-8 CAF US

CN Imidazo[1,2-a]pyrazine-2-carbonitrile, 6,8-dibromo- (9CI) (CA INDEX NAME)




RN 117718-93-1 CA LUS

CN Imidazo[1,2-a]pyrazine, 6-bromo-8-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 117719-09-2 CA LUS

CN Imidazo[1,2-a]pyrazine, 6,8-dibromo-2-phenyl- (9CI) (CA INDEX NAME)



RN 117719-19-4 CA LUS

CN Imidazo[1,2-a]pyrazine, 5,8-dichloro- (9CI) (CA INDEX NAME)




T 87597-21-5

RL: RCT (Reactant); RACT Reactant or reagent)  
(reaction of, in preparation of drug)

N 87597-21-5 CAPLUS

N Imidazo[1,2-a]pyrazine-2-carboxylic acid, 6,8-dibromo ethyl ester (9CI)  
(CA INDEX NAME)



>